VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 4 (1-14 febrero / 2023)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Resumen de la información publicada por la OMS sobre vacunas en desarrollo contra la COVID-19, a nivel mundial.
- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS SiViFinlay VaCyT

Resumen de la información publicada por la OMS sobre vacunas en desarrollo contra la COVID-19, a nivel mundial

Última actualización por la OMS: 7 de febrero de 2023.

Fuente de información utilizada: World Health Organization | R&DBlueprint Powering research to prevent epidemics

178 Vacunas en evaluación clínica y 199 en evaluación preclínica



Vacunas en evaluación clínica por plataforma

Platform		Candidate vaccines (no. and %)	
PS	Protein subunit	57	32%
VVnr	Viral Vector (non-replicating)	24	14%
DNA	DNA	17	10%
IV	Inactivated Virus	22	12%
RNA	RNA	41	23%
VVr	Viral Vector (replicating)	4	2%
VLP	Virus Like Particle	7	4%
VVr + APC	VVr + Antigen Presenting Cell	2	1%
LAV	Live Attenuated Virus	2	1%
VVnr + APC	VVnr + Antigen Presenting Cell	1	1%
BacAg-SpV	Bacterial antigen-spore expression vector	1	1%
		178	

Vacunas en evaluación clínica por vía de administración

Oral		**5**	**3%**
Injectable		**160**	**90%**
SC	Sub cutaneous	5	3%
ID	Intra dermal	9	5%
IM	Intra muscular	146	82%
IN	Intra nasal	15	8%
AE	Aerosol	1	1%
IH	Inhaled	2	1%
TBD / No Data (ND)		**13**	**7%**

Número de dosis de las vacunas en evaluación clínica

Number of doses & schedule	Candidate vaccines (no. and %)	
1 dose	43	24%
Day 0	43	
2 doses	100	56%
Day 0 + 14	8	
Day 0 + 21	36	
Day 0 + 28	56	
3 doses	2	1%
Day 0 + 28 + 56	2	
TBD / No Data (ND)	33	19%

Vacunas mucosales en evaluación clínica

Desarrollador de la vacuna/fabricante/país	Plataforma de la vacuna	Vía de administración	Fase
University of Oxford/Reino Unido	Vector viral no replicativo	Intranasal	1
CanSino Biological Inc./Beijing Institute of Biotechnology/China	Vector viral no replicativo	Inhalación	4
CanSino Biological Inc./China	Vector viral no replicativo	Intranasal	3
Vaxart/Estados Unidos	Vector viral no replicativo	Oral	2
Univ. Hong Kong, Xiamen Univ./Beiging Wantai Biol. Pharm./China	Vector viral replicativo	Intranasal	3
Symvivo/Canadá	ADN	Oral	1
ImmunityBio, Inc./Estados Unidos	Vector viral no replicativo	Oral y Sublingual	1/2
Codagenix/Serum Institute of India	Virus vivo atenuado	Intranasal	3
Center for Genetic Engineering and Biotechnology (CIGB)/Cuba	Subunidad proteica	Intranasal	1/2
Razi Vaccine and Serum Research Institute/India	Subunidad proteica	Intranasal	3
Bharat Biotech International Limited/India	Vector viral no replicativo	Intranasal	3
Meissa Vaccines, Inc./Estados Unidos	Virus vivo atenuado	Intranasal	1
Laboratorio Avi-Mex/México	Virus inactivado	Intranasal	2/3
USSF + VaxForm/Estados Unidos	Subunidad proteica	Oral	1
CyanVac LLC/Estados Unidos	Vector viral no replicativo	Intranasal	1
DreamTec Research Limited/Hong Kong	BacAg-SpV	Oral	NA
Sean Liu, Icahn School of Medicine at Mount Sinai	Vector viral replicativo	Intranasal	2/3
Hannover Medical School/Alemania	Vector viral no replicativo	Inhalación	1
ACM Biolabs/Singapur	Subunidad proteica	Intranasal	1
Intravacc B.V/Holanda	Vector viral no replicativo	Intranasal	1
McMaster University/Canadá	Vector viral no replicativo	Aerosol	1
Research Institute of Influenza	Vector viral no replicativo	Intranasal	1/2

Vacunas en fase 4 de evaluación clínica

Candidatos vacunales más avanzados/fabricante/país	Plataforma de la vacuna
Sinovac/China	Virus Inactivado
Sinopharm/Beijing Institute of Biological Products/China (2)	Virus Inactivado
University of Oxford/AstraZeneca/Reino Unido	Vector viral no replicativo
CanSino Biological Inc./Beijing Institute Biotechnology/China (IM e IH)	Vector viral no replicativo
Janssen Pharmaceutical Companies/Estados Unidos	Vector viral no replicativo
Moderna/NIAID/Estados Unidos	ARN
Pfizer/BioNTech Fosun Pharma/Estados Unidos	ARN
Medigen Vaccine Biol./Dynavax/NIAID/Taiwán/EE.UU	Subunidad proteica

Vacunas en fase 3 de evaluación clínica

Candidatos vacunales más avanzados/fabricante/país	Plataforma de la vacuna
Gamaleya Research Institute/Rusia	Vector viral no replicativo
Novavax/Estados Unidos	Subunidad proteica
Anhui Zhifei Longcom Biopharmac./Inst. Microbiol, Chin Acad Sci/China	Subunidad proteica
CureVac AG/Alemania	ARN
Institute of Medical Biology/Chinese Academy of Medical Sciences	Virus inactivado
Research Institute for Biological Safety Problems, Kazakhstan	Virus inactivado
Inovio Pharmac. + Intern. Vacc Inst. + Advaccine Biopharm Co., Ltd	ADN
Zydus Cadila Healthcare Ltd./India	ADN
Bharat Biotech International Limited/India	Virus Inactivado
Sanofi Pasteur + GSK/Francia/Gran Bretaña	Subunidad proteica
Shenzhen Kangtai Biological Products Co., Ltd./China	Virus Inactivado
Clover Biopharmaceuticals Inc./GSK/Dynavax/China/Reino Unido/EE.UU	Subunidad proteica
Vaxine Pty Ltd. + CinnaGen Co./Australia, Irán	Subunidad proteica
Instituto Finlay de Vacunas/Cuba	Subunidad proteica
Federal Budget Res Inst State Res Cent Virol Biotechnol "Vector"/Rusia	Subunidad proteica
West China Hospital + Sichuan University/China	Subunidad proteica
Vaxxinity/EE.UU	Subunidad proteica
Univ. Hong Kong, Xiamen Univ. & Beijing Wantai Biological Pharm./China	Vector viral replicativo
Acad Milit Sci (AMS) Walvax Biotechnol, Suzhou Abogen Biosci/China	ARN
Medicago Inc./Canadá	Partícula similar a virus
Codagenix/Serum Institute of India	Virus vivo atenuado
Center for Genetic Engineering and Biotechnology (CIGB)/Cuba	Subunidad proteica
Valneva, National Institute for Health Research, Reino Unido	Virus inactivado
Biological E. Limited/India	Subunidad proteica
Nanogen Pharmaceutical Biotechnology/Vietnam	Subunidad proteica
Shionogi/Japón	Subunidad proteica
Erciyes University/Turquía	Virus inactivado
SK Bioscience Co., Ltd./CEPI/Corea del Sur/Noruega	Subunidad proteica
Razi Vaccine and Serum Research Institute/Irán, India	Subunidad proteica
Bharat Biotech International Limited/India	Vector viral no replicativo (IN)
Providence Therapeutics/Canadá	ARN
POP Biotechnologies and EuBiologics Co.,Ltd/EEUU, Corea del Sur	Subunidad proteica
Jiangsu Rec-Biotechnology/China	Subunidad proteica
Radboud University/Holanda	Partícula similar a virus
Arcturus Therapeutics, Inc./Estados Unidos	ARN
Livzon Pharmaceutical/China	Subunidad proteica
National Vaccine and Serum Institute, China; Beijing Zhong Sheng Heng Yi	Subunidad proteica
KM Biologics Co., Ltd./Japón	Virus inactivado
Shanghai East Hospital and Stemirna Therapeutics/China	ARN
Bagheiat-allah University of Medical Sciences/AmitisGen/Irán	Subunidad proteica
Laboratorios Hipra, S.A./España	Subunidad proteica
Sinocelltech Ltd./China	Subunidad proteica
Chumakov Federal Scientific Center for Research/Rusia	Virus Inactivado
Yantai Patronus Biotech Co., Ltd.	Partícula similar a virus
Airlangga University/Indonesia	Virus Inactivado
PT Bio Farma/Indonesia	Subunidad proteica
AIM Vaccine and Liverna Therapeutics/China	ARN
China National Biotec Group Company Limited	Virus inactivado

Noticias en la Web

Software detecta contagios de variantes de COVID-19

1 feb. VICOS fue desarrollado por investigadores del Ministerio de Ciencia, Tecnología e Innovación de la Nación, en Argentina.



Un grupo de investigadores de Argentina desarrollaron un software de código abierto llamado "VICOS" (Vigilancia de CoInfección Viral) que permite identificar si una persona se ha contagiado con más de una variante de COVID-19.

El software fue utilizado para analizar mil 97 secuencias de SARS-CoV-2 en muestras clínicas obtenidas entre marzo de 2020 y agosto de 2021, donde los investigadores encontraron poblaciones mixtas de SARS-CoV-2 en el 2 por ciento de las muestras. Es decir, detectaron 23 casos de personas con coronavirus con dos variantes de COVID-19.

"Detectamos 23 casos de coinfecciones por SARS-CoV-2. El estudio detallado de los resultados de VICOS junto con un análisis filogenético adicional reveló 3 casos de coinfecciones por dos virus del mismo linaje, dos casos por virus de diferentes linajes genéticos, 13 eran compatibles tanto con la coinfección como con la evolución intrahuésped, y 5 casos probablemente eran una producto de la contaminación del laboratorio", detalla el informe publicado en la revista *Virus Research*.

La infección simultánea por dos linajes diferentes del SARS-CoV-2 surgió por primera vez poco después del inicio de la pandemia en una mujer portuguesa de 17 años, que pese a tener un buen estado de salud, desarrolló una enfermedad grave por COVID-19.

Por otra parte, las superinfecciones por coronavirus suelen aparecer como una excreción viral prolongada y a condiciones subyacentes del huésped como la inmunosupresión.

En el software, tanto en la coinfección como en la superinfección, la identificación de las poblaciones mixtas de los patógenos es más fácil cuando la divergencia viral es alta sin embargo, puede ser difícil detectarse en entornos de baja heterogeneidad genética.

"La identificación de coinfecciones por SARS-CoV-2 es más importante teniendo en cuenta la aparición de variantes virales con potencial escape inmunitario y mayor transmisibilidad, que la OMS ha denominado variantes de preocupación o variantes de interés, y la posibilidad de recombinación viral entre ellas", señalaron los investigadores en la publicación.

Los investigadores concluyeron que VICOS es una herramienta novedosa, rápida y útil para los laboratorios que realizan secuenciación genómica para vigilancia epidemiológica.

Fuente: El Financiero. Disponible en https://bit.ly/3xwr0xn

Vaccine Makers Kept $1.4 Billion in Prepayments for Canceled Covid Shots for the World's Poor

Feb 1. Separately, Johnson & Johnson is demanding additional payment for unwanted shots, confidential documents show.

As global demand for Covid-19 vaccines dries up, the program responsible for vaccinating the world's poor has been urgently negotiating to try to get out of its deals with pharmaceutical companies for shots it no longer needs.

Drug companies have so far declined to refund $1.4 billion in advance payments for now-canceled doses, according to confidential documents obtained by The New York Times.

Gavi, the international immunization organization that bought the shots on behalf of the global Covid vaccination program, Covax, has said little publicly about the costs of canceling the orders. But Gavi financial documents show the organization has been trying to stanch the financial damage. If it cannot strike a more favorable agreement with another company, Johnson & Johnson, it could have to pay still more.

Gavi is a Geneva-based nongovernmental organization that uses funds from donors including the U.S. government and the Bill and Melinda Gates Foundation to provide childhood immunizations to lower-income nations. Early in the pandemic, it was charged with buying Covid vaccinations for the developing world — armed with one of the largest-ever mobilizations of humanitarian funding — and began negotiations with the vaccine makers.

Those negotiations went badly at the outset. The companies initially shut the organization out of the market, prioritizing high-income countries that were able to pay more to lock up the first doses. Gavi eventually reached deals with nine manufacturers.

But the shots did not begin to reach developing countries in significant numbers until late 2021. By the time Gavi had a steady flow of supply, demand had begun to decline: countries with frail health systems struggled to deliver the shots, and the dominance of the milder Omicron variant sapped people's motivation to be vaccinated. Now, Covax is winding down far short of the World Health Organization's goal of vaccinating 70 percent of the population of each country.

The vaccine makers have brought in more than $13 billion from the shots that have been distributed through Covax. Under the contracts, the companies are not obligated to return the prepayments Gavi gave them to reserve vaccines that were ultimately canceled.

But in light of how many vaccine doses Gavi has had to cancel, some public health experts criticized the companies' actions.

Covid vaccine manufacturers "have a special responsibility" because their products are a societal good and most were developed with public funding, said Thomas Frieden, the chief executive of the global health nonprofit Resolve to Save Lives and a former director of the United States Centers for Disease Control and Prevention.

"That's a lot of money that could do a lot of good," he said.

He added that other large global health programs have budgets roughly equal to the amount the vaccine makers are holding on to. "The entire polio eradication effort costs about $1 billion a year, and that's a huge infrastructure," he said.

Gavi has reached settlements with Moderna, the Serum Institute of India and several Chinese manufacturers to cancel unneeded doses, surrendering $700 million in prepayments, the documents show.

Another drug company, Novavax, is refusing to refund another $700 million in advance payments for shots it never delivered.

Gavi and Johnson & Johnson are locked in a bitter dispute over payment for shots that Gavi told the company months ago it would not need, but which the company produced anyway. Johnson & Johnson is now demanding that Gavi pay an additional, undisclosed amount for them.

Gavi had an indirect supply relationship with Pfizer; the Biden administration purchased a billion shots from it to donate through Covax. The United States last year revised its deal with the company, converting an order for 400 million doses into future options. The company said it did not charge any fees to change the order.

The terms of Gavi's deals were kept secret because they were with private companies. There has been no public accounting of how much drug companies have earned from canceled vaccines.

The documents say that the manufacturers collectively made $13.8 billion in revenue on the vaccines that were distributed through Covax. Almost 1.9 billion doses have now been shipped, to 146 countries. More than half were purchased directly by Gavi and the rest were donated by high-income countries.

Gavi's settlements with Moderna and Serum took into account that the manufacturers had already incurred costs such as those for raw ingredients, according to the documents.

In a deal to cancel more than 200 million doses reached late last year, Gavi agreed to allow Moderna to keep an advance payment it had made. In exchange, Gavi was released from having to make any additional payments for the doses, meaning they were canceled at a cost "substantially lower" than expected, according to the documents. Moderna also issued Gavi a credit for $58 million for future products, which is good until 2030.

Gavi also made concessions to exit its deal with the Serum Institute of India. Gavi canceled 145 million doses by allowing the company to keep money Gavi had paid in advance, in order to cover the cost of materials that had already been procured. Serum also gave Gavi a credit note of an undisclosed amount that the organization can use to procure the many routine immunizations it buys from Serum each year.

Moderna and Serum declined to comment on the terms.

Gavi and Johnson & Johnson are at odds over 150 million Covid vaccine doses that Gavi ordered but has been trying to cancel for months.

Gavi had been expecting a significant share of those doses to be distributed by the end of 2021, but Johnson & Johnson had delivered fewer than 4 million doses by then. (Gavi's contract with the company did not require it to finish deliveries by that deadline.) When the company was finally ready to ramp up its deliveries last year, demand had plummeted.

Gavi's administrators alerted the company by mid-2022 that they would not need those doses and requested that it stop making new shots for Covax, according to the documents.

Johnson & Johnson nevertheless continued to make the shots and sought to deliver them by late 2022, according to the documents. Now, as stipulated in the contract, the company wants Gavi to make additional payment and accept the vaccines.

Gavi has proposed that the dispute go to mediation, but the company has "until now refused to engage in meaningful negotiations," the documents say. Some of the disputed vaccines have expiration dates as early as mid-2023.

Jake Sargent, a spokesman for Johnson & Johnson, said the company had made the ordered doses available to Covax and kept Gavi informed about production details.

In negotiations with Novavax, Gavi is seeking a refund for $700 million it spent on advance payments for shots.

Gavi had been expecting Novavax deliveries to begin as soon as summer 2021, but the company bungled its vaccine production. As a consequence, Gavi did not proceed with placing the orders for the vaccines it had originally reserved. Novavax said this was a breach of contract and canceled the deal, keeping the $700 million.

The dispute is unresolved. In a statement, the company said it is hoping to negotiate a new deal to supply its vaccine to Gavi.

Some of the vaccine contracts that Gavi entered into were completely fulfilled. In one case, AstraZeneca issued Gavi a refund when final production costs were lower than expected.

Had some vaccine manufacturers not been willing to renegotiate their contracts with Gavi, the costs to the organization could have been much higher. Gavi would have been on the hook for $2.3 billion for the doses it wanted to cancel, the documents show, but it saved $1.6 billion by exiting those contracts.

A spokesman for Gavi, Olly Cann, said the organization had made no new payments related to canceled doses. He said the surrendered advance payments represented a fraction of what Gavi would have paid for finished doses.

Dr. Seth Berkley, Gavi's chief executive, declined to comment for this article. But in an interview in December about the future of the global Covid vaccination program, he said Gavi was paying less per dose than what it had initially planned for vaccine purchases and substantially less than high-income countries paid for their shots.

Donations for Covid shots substantially inflated Gavi's budget, and the lost prepayments for canceled Covid vaccines do not threaten its regular childhood-vaccination work.

The contracts that Gavi has been trying to downsize were negotiated in the uncertain early months of the pandemic, in some cases before the vaccines had been shown to work.

"In a pandemic, I would want to err on the side of buying too many doses, rather than err on the side of not having enough doses, particularly given the fact that countries felt that there weren't enough doses at the beginning," Dr. Berkley said.

Wealthy countries, who ordered many more doses than they needed, have tried to offload their own surpluses onto Covax, which has struggled to absorb them.

Covax began deliveries to developing countries in 2021, but the early pace was glacial. When the program finally had vaccines, the shots presented challenges that weak health systems were ill-equipped to manage.

Frustrated by the erratic supply, some public health agencies did little to create demand for the vaccines, while a tide of misinformation discouraged people from seeking them out. Sub-Saharan Africa remains the world's least-vaccinated region, but reported Covid death rates in the region have been comparatively low, which has further eroded interest in the shots.

"We have so many offers of donations but we don't take them, because we don't want to have them expire here," said Dr. Andrew Mulwa, who oversees the Covid response at Kenya's health ministry. "We wonder, do we need to continue to spend money administering Covid-19 vaccines when we have other glaring disparities?"

Gavi is sitting on a stockpile of vaccines and expects millions more in donations from high-income countries that are seeking to shed their own oversupply. The organization anticipates a maximum demand of 450 million doses this year — half of what Covax shipped in 2022.

Fuente: The New York Times. Disponible en https://bit.ly/3WXSKoE

Adverse effects rare after bivalent COVID-19 vaccine jabs: HSA report

Feb 2. Adverse effects after the bivalent COVID-19 vaccine shots are rare, according to a Health Sciences Authority (HSA) safety update released.

The authority received 59 and 11 adverse event reports for the Moderna/Spikevax COVID-19 bivalent vaccine and Pfizer-BioNTech/Comirnaty COVID-19 bivalent vaccine respectively.

More than 482,600 doses of the Moderna bivalent vaccine have been administered since it was rolled out in Singapore on Oct 14 last year, while more than 202,300 Pfizer-BioNTech bivalent jabs have been given since Dec 12, 2022.



This means the HSA saw an adverse event reporting rate of 0.012 per cent for the Moderna bivalent vaccine and a smaller 0.005 per cent for the Pfizer-BioNTech bivalent vaccine.

The adverse events reported for the bivalent mRNA vaccines were similar to those that took the monovalent vaccine. The non-serious adverse events include allergic reactions such as a rash, eyelid swelling, fever, giddiness,

chest discomfort or an increase in blood pressure.

There were also six serious adverse events reported for the Moderna bivalent vaccine and two such events for the Pfizer-BioNTech bivalent vaccine.

These include serious allergic reactions, anaphylaxis, myocarditis, hypotension with tachycardia – fast heartbeat – and hearing loss, said HSA.

An adverse event is classified as serious when it resulted in hospitalisation, a significant reduction in functioning level, a life-threatening illness or death.

The serious adverse events reporting rates for the two bivalent vaccines are similar, at 0.001 per cent.

HSA's latest update covers the period from the roll-out of the vaccines on Dec 30, 2020, to Dec 31, 2022. This is the first HSA safety update to include data on the bivalent shots.

Including the monovalent mRNA vaccines, more than 10.5 million primary doses, 4.6 million first booster doses and 1.2 million second booster shots have been administered in Singapore as of Dec 31, 2022.

The reporting rates of adverse and serious adverse events for the mRNA vaccines remained rare, at 0.11 per cent (17,741 reports) and 0.007 per cent (1,119 reports) respectively.

There were 173 serious adverse event reports (0.004 per cent) for the first booster jab and 17 such reports (0.001 per cent) for the second booster shot.

ADVERSE EVENTS IN CHILDREN

The Moderna vaccine was rolled out on Oct 25 last year as a primary vaccine for children aged six months to four years, while the Pfizer-BioNTech jab was also made available as a booster for children aged five years to 11 years.

As of Dec 31, 2022, more than 16,000 doses of the Moderna vaccine have been administered to children aged six months to four years, and more than 81,000 Pfizer-BioNTech booster jabs have been given to children aged five years to 11 years.

Serious adverse events after COVID-19 vaccination in children aged six months to 11 years are rare, said HSA.

There were eight adverse event reports after children aged six months to four years who took the Moderna jab, including five serious events that included fever, vomiting, fits, and Kawasaki disease – the swelling of blood vessels.

There were 173 serious adverse event reports (0.004 per cent) for the first booster jab and 17 such reports (0.001 per cent) for the second booster shot.

ADVERSE EVENTS IN CHILDREN

The Moderna vaccine was rolled out on Oct 25 last year as a primary vaccine for children aged six months to four years, while the Pfizer-BioNTech jab was also made available as a booster for children aged five years to 11 years.

As of Dec 31, 2022, more than 16,000 doses of the Moderna vaccine have been administered to children aged six months to four years, and more than 81,000 Pfizer-BioNTech booster jabs have been given to

children aged five years to 11 years.

Serious adverse events after COVID-19 vaccination in children aged six months to 11 years are rare, said HSA.

There were eight adverse event reports after children aged six months to four years who took the Moderna jab, including five serious events that included fever, vomiting, fits, and Kawasaki disease – the swelling of blood vessels.

"Febrile seizures and Kawasaki disease are rare events that have been reported following childhood vaccination and can be associated with childhood illnesses. All the children have recovered or were recovering at the time of report," said HSA.

There were 26 adverse event reports from the Pfizer-BioNTech booster jab for children aged five years to 11 years – a reporting rate of 0.03 per cent. This was lower than the adverse event reporting rate for the primary vaccination series in this age group, which stood at 0.15 per cent.

There were also two serious adverse events, with one describing myocarditis – the inflammation of heart muscles – and the other was a drop in platelet count.

Both children were recovering at the time of the report, said HSA.

There have also been overseas cases of myocarditis reported with the booster doses of the mRNA COVID-19 vaccines in this age group, said HSA, adding that incidence remains rare and is generally lower compared to adolescents and adults.

It said that it is closely monitoring the adverse events and assessing them in the context of their background rate.

"Based on our assessment of current local and overseas data, no new safety signals have been identified with the use of the vaccines in this age group," HSA added.

OTHER VACCINES

More than 40,800 doses of the Nuvaxovid vaccine have been administered as of Dec 31, 2022, with a serious adverse event reporting rate of 0.02 per cent.

About 722,400 doses of the Sinovac-CoronaVac and Sinopharm inactivated vaccines have also been given, with a serious adverse reporting rate of 0.006 per cent.

The benefits of getting vaccinated with the mRNA, Nuxaxovid or inactivated vaccines "continue to outweigh the known risks", said HSA.

"Vaccination has been demonstrated to be the most effective way to reduce deaths and severe illness from COVID-19 infection and has enabled Singapore to ease most of the safe management measures," it added.

Fuente: Chanel News Asia. Disponible en https://bit.ly/4102QZz

Iran FM reaffirms Tehran's support for Cuba

Feb 5. Amirabdollahian, sat down with Cuban President Miguel Díaz-Canel for talks on issues of mutual interest and international topics in Havana on Saturday.

During the talks, Amirabdollahian pointed to the friendly and historical relations between Iran and Cuba and said the Islamic Republic is determined to promote and expand bilateral cooperation.

He thanked Cuba for cooperating with Iran in producing a joint vaccine in the Islamic Republic.

For his part, the Cuban president praised Iran's history and culture as well as the country's progress and scientific and technological achievements despite the sanctions in place against the Islamic Republic.

He expressed willingness for increasing contacts and exchanges between the two countries.

The Cuban president said the developments in the Latin American region provide new opportunities for promoting multilateralism and said Cuba is determined to cooperate with friendly countries and remove the relevant obstacles despite all the sanctions.

"The US government thinks only about its own interests and does not care about others. We have paid a heavy price for our political independence and we will safeguard it," the president added.

Amirabdollahian also in a meeting with his Cuban counterpart Bruno Rodríguez Parrilla once again condemned foreign meddling in the domestic affairs of Cuba and the US's incitement of riots in the country on July 11, 2022.

"America and some Western countries pursue the simultaneous policies of imposing sanctions and interference through encouraging and fueling riots in independent countries," he added.

For his part, the Cuban foreign minister described ties with the Islamic Republic as a priority for his country, condemning unilateral sanctions and foreign interference in the internal affairs of other countries.

Iranian Foreign Minister Hossein Amirabdollahian has reaffirmed Iran's support for Cuba in different spheres, calling for the promotion of bilateral ties between the two countries.

Fuente: Iran Front Page. Disponible en https://bit.ly/3xrc1Vt

The safety profile and the actual known adverse effects of COVID-19 vaccines in at-risk and healthy individuals

Feb 7. In a recent study published in *Pathogens*, researchers discussed the safety of coronavirus disease 2019 (COVID-19) vaccines in healthy people and patients with autoimmunity or cardiac issues.

Background

The COVID-19 pandemic has been a serious global public health challenge. Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed worldwide. According to the World Health Organization, more than 300 vaccines are under various preclinical and clinical development phases. Importantly, vaccines cannot effectively inhibit SARS-CoV-2 transmission due to the high variability of the virus, impeding the herd immunity goal.

Moreover, there is evidence of reduced effectiveness against the Omicron variant, even after a fourth dose. Several individuals develop inflammatory cardiomyopathy, thrombosis, neurologic problems, and other rare conditions after COVID-19 vaccination. These events may increase with the administration of repeated vaccine boosters. As such, researchers in the present study reviewed the safety of COVID-19 vaccines, especially in people with autoimmunity and cardiac issues.

COVID-19 vaccination in autoimmune and healthy individuals

Clinical evidence indicates an increase in autoimmunity symptoms following COVID-19 vaccination. A meta-analysis reported neurologic manifestations after the first SARS-CoV-2 vaccine dose in some patient subsets and also noted that more than half of these events occurred in individuals with a history of autoimmunity. mRNA and virus-vectored vaccines were reported to trigger multiple sclerosis (MS)-like episodes.

Another study reported adverse events after vaccination with Pfizer/AstraZeneca's vaccine in MS patients from Germany and the United Kingdom (UK). One research team observed rheumatoid arthritis (RA) flares developing 12 hours after the second vaccine dose in a 55-year-old individual, while another team identified new-onset RA within four weeks of vaccination.

Myocarditis and pericarditis risk after COVID-19 infection or vaccination

An increase in myocarditis/pericarditis incidence was initially reported after the introduction of COVID-19 vaccines, with approximately one in every 33,300 individuals at risk of cardiac inflammation. Moreover, the risk of myocarditis/pericarditis was further elevated among military personnel in the United States (US).

An Israeli study found no evidence of a higher risk of myocarditis/pericarditis after COVID-19 in non-vaccinated people. This contradicted the evidence from a study that reported an elevated incidence in hospitalized COVID-19 patients. An Italian study reported excess cases of myocarditis/pericarditis in young vaccinated individuals, with up to 12 cases per 100,000 people, while a US study estimated one myocarditis case in 6250 vaccinated subjects.

In addition, vaccine booster-associated myocarditis/pericarditis in males was reported in US universities, requiring hospitalization. Overall, data on myocarditis development post-COVID-19 vaccination can not be

ignored since the frequency of vaccine-associated myocarditis is not lower than that with COVID-19.

Safety of COVID-19 vaccines in individuals with autoimmunity and myocarditis history

Recently, a study revealed elevated blood troponin T levels after COVID-19 vaccination in all tested subjects with systemic lupus erythematosus (SLE), implying heart damage. Although the biomarker levels declined with time, the fact that all subjects exhibited higher levels is concerning, calling for caution in administering vaccines to these at-risk individuals with a history of myocarditis.

Notably, nearly half the SLE patients had been using immunosuppressants and immunomodulators at vaccination, which could have affected the inflammatory response to mRNA vaccines. SLE patients mount a lower antibody response than healthy patients after SARS-CoV-2 vaccination, even without immunosuppressants. It was suggested that autoreactive T cells show reduced activation following vaccination.

The constitutional domain of the British Isles Lupus Assessment Group (BILAG) index was significantly increased in SLE patients after receiving COVID-19 vaccines. Although no patient required a change of therapy, the researchers proposed regular surveillance of autoimmune patients. The risk/benefit ratio of continued administration of vaccines may need revision, given the increase in BILAG index, cardiac damage biomarkers, and the fact that COVID-19-induced myocarditis is not more common and riskier than vaccine-induced myocarditis.

Autoimmunity post-vaccination

There is evidence of the onset of autoimmune disorders after SARS-CoV-2 infection or vaccination. The viral spike protein's cellular receptor, angiotensin-converting enzyme 2 (ACE2), is targeted by autoantibodies during COVID-19. It is yet to be ascertained whether vaccination also triggers similar autoantibody responses.

Moreover, in silico findings suggest a potential cross-reactivity between the viral spike and human proteins, albeit some studies contradict this finding. Reports indicate myocardial inflammation in individuals with vaccine-related myocarditis and lymphocyte infiltrate, suggesting an autoimmune-like attack.

Conclusion

Taken together, the authors discussed COVID-19 vaccine safety and associated adverse events. The scientific community must determine whether the existing nucleic acid-based vaccines should be continued for at-risk individuals with autoimmunity when the long-term effects of vaccination are unclear (in these sub-populations). The development of COVID-19 vaccines using conventional technologies may be desirable for older adults and at-risk individuals.

Fuente: News Medical Life Sciences. Disponible en https://bit.ly/3k11sp3

CDC adds COVID-19 shots to list of routine vaccines for kids and adults

Feb 9. COVID-19 shots are included in new schedules of routinely recommended vaccines released by the US Centers for Disease Control and Prevention on Thursday. The immunization schedules summarize current vaccine recommendations for children, adolescents and adults, but do not set vaccine requirements for schools or workplaces.

Key changes to the schedules, published in the CDC's Morbidity and Mortality Weekly Report on Thursday,

include the addition of COVID-19 primary vaccine series and recommendations on booster dose vaccination; updated guidance on influenza and pneumococcal vaccines; and new vaccines for measles, mumps, and rubella (MMR) and for hepatitis B.

The schedule also recommends additional doses of MMR vaccine during a mumps outbreak and administering inactivated poliovirus vaccine in adults who are at an increased risk for exposure to the virus.

The proposed changes were recommended by the CDC's vaccine advisers, the Advisory Committee on Immunization Practices or ACIP, and signed off on by the CDC, which worked with physicians, nurses and pharmacists on the recommendation.

The biggest change, the report's authors told CNN, is incorporating Covid-19 vaccines into both schedules.

"This means COVID-19 vaccine is now presented as any other routinely recommended vaccine and is no longer presented in a special "call out" box as in previous years. This, in a sense, helps 'normalize' this vaccine and sends a powerful message to both healthcare providers and the general public that everyone ages 6 months and older should stay up to date with recommended COVID-19 vaccines (including a booster, when eligible), just as they would with any other routinely recommended vaccine," Dr. Neil Murthy and Dr. A. Patricia Wodi said in a statement.

However, including COVID-19 vaccines on the routine schedule does not mean vaccination will be required by schools. School-entry vaccination requirements are determined by state or local jurisdictions, and not by CDC.

The new recommendations also add the use of PCV15, a pneumococcal conjugate vaccine used to treat bacterial infection recently approved for use in children. Either PCV13 or the higher valent PCV15 may now be used based on the specific pediatric population.

The authors of the report include information on what to do in an outbreak of mumps. This comes amid the end of the measles outbreak in Columbus, Ohio, where all children infected were not fully vaccinated. The recommendations stated that an additional booster of the measles, mumps, and rubella vaccine is warranted in the case of a mumps outbreak.

"The vaccine for measles does not need a booster," said Dr. William Schaffner, a professor in the Division of Infectious Diseases at Vanderbilt University Medical Center, as he says the initial vaccine provides strong protection for life. "Mumps vaccine, however, does wane in its protection. And so if there's a mumps outbreak, then we would use MMR."

Similarly, the new recommendations provide clear guidance on the use of an additional poliovirus vaccine if new cases emerge, such as in New York City last year.

"There were lots of questions about whether an additional dose of polio vaccine was appropriate, and this just opens the door for the use of another dose of inactivated virus, that is injectable polio vaccine, in those circumstances where, for example, a local health department in concert with the CDC might recommend that," said Schaffner, who is a member of CDC's vaccine advisory committee.

Public health experts emphasize the importance of annual vaccinations as coverage among children has declined in recent years. In the 2021-2022 school year, vaccination coverage for kindergarteners fell to 93% for required vaccines -- dropping below the overall target of 95% that was set as an objective by the US

Department of Health and Human Services in the Healthy People project.

This dip in vaccination coverage has been attributed to health care disruptions related to the Covid-19 pandemic, experts say, and health care providers are working hard to get back to and surpass pre-pandemic levels.

“Why is that a matter of concern? Because it opens up opportunities for these viruses and other germs to be reintroduced into the United States, and to cause outbreaks of disease. The recently concluded measles outbreak in Ohio is an example, the introduction of the poliovirus into New York is an example, and we need to keep our guard up," said Schaffner.

Health care professionals urge families to make sure children are up to date with their vaccines.

"Vaccines are essential for the health of our whole society, including children and adolescents," said Dr. Sean O'Leary, chairman of the American Academy of Pediatrics Committee on Infectious Diseases and a vaccine adviser to the CDC. "We all have a responsibility to ensure everyone can access vaccinations, both for their individual health as well as to prevent the spread of illnesses. These schedules provide a roadmap parents and pediatricians can follow to help children get the vaccines they need so their immune systems will be ready to recognize and resist diseases.”

Fuente: CNN Health. Disponible en https://cnn.it/3YX7K7O

Cuba’s Abdala vaccine is safe, effective and thermostable – CIGB

Feb 9. Cuba's COVID-19 Abdala vaccine proved to be stable, effective and functional after being stored for 15 days at 37 °C, the Center for Genetic Engineering and Biotechnology of Cuba (CIGB) reported Thursday.

“Abdala is a vaccine that requires no freezing process to be preserved, unlike other vaccines, since it can be stored from four to eight degrees Celsius. It has been proved Abdala vaccine is thermostable for 15 days at 37 °C without being affected.”

“It facilitates its distribution and a high vaccination coverage,” the CIGB tweeted.

CIGB highlighted that Abdala vaccine recently proved its safety, effectiveness to fight off the COVID-19 pandemic.

The Cuban Abdala vaccine is the first COVID-19 immunogen manufactured in Latin America and the Caribbean.

Since July 2021, the Cuban vaccine has been authorized for emergency use after proving 92.28% effectiveness in preventing symptomatic disease and 90% effectiveness in severe COVID-19 patients. It also showed a 99.15% rise in antibodies in volunteers aged three to 11 years and 98.28% in those aged 12 to 18 years.



The CIGB confirmed the increased antibody titers was fourfold or more from

"Abdala is a vaccine that requires no freezing process to be preserved, unlike other vaccines, since it can be stored from four to eight degrees Celsius. It has been proved Abdala vaccine is thermostable for 15 days at 37 °C without being affected."

"It facilitates its distribution and a high vaccination coverage," the CIGB tweeted.

CIGB highlighted that Abdala vaccine recently proved its safety, effectiveness to fight off the COVID-19 pandemic.

The Cuban Abdala vaccine is the first COVID-19 immunogen manufactured in Latin America and the Caribbean.

Since July 2021, the Cuban vaccine has been authorized for emergency use after proving 92.28% effectiveness in preventing symptomatic disease and 90% effectiveness in severe COVID-19 patients. It also showed a 99.15% rise in antibodies in volunteers aged three to 11 years and 98.28% in those aged 12 to 18 years.

The CIGB confirmed the increased antibody titers was fourfold or more from the first dose in these population groups.

Sonia Resik, senior researcher of the studies with this vaccine, praised that over 80% of adverse events reported in children were mild and the rest of indicators were comparable with data obtained in adults, ratifying its effectiveness.

Abdala vaccine, on the other hand, has maintained its safety, effectiveness and Immune response to COVID-19, ratifying its suitability for booster doses.

Cuba also has produced Soberana 02 and Soberana Plus vaccines (from the Finlay Vaccine Institute) to fight the COVID-19 pandemic and two vaccine candidates (Soberana 01 and Mambisa) in clinical trials with important results.

Fuente: Prensa Latina. Disponible en https://bit.ly/3YHKUBk

¿Cómo marcha el proyecto de vacuna de Cuba contra el virus del papiloma humano?

10 feb. Durante el presente año, científicos cubanos aspiran a lograr un candidato vacunal formulado contra el virus del papiloma humano (VPH), listo para evaluar en modelos animales, paso relevante con miras a contar con un inmunógeno efectivo para enfrentar este problema de salud.

Sobre la importancia de una futura vacuna, el director general del Centro Nacional de Investigaciones Científicas (CNIC), el doctor en Ciencias Julio Alfonso Rubí, afirmó que es una oportunidad de proteger a nuestra población femenina en lo fundamental, ante un problema de salud como lo es el cáncer cervicouterino y otras lesiones asociadas a la infección del VPH.

La meta, aunque ambiciosa, es llegar a vacunar a la población femenina, entre nueve y 15 años de edad, para el año 2030, precisó Alfonso Rubí.

"El proyecto de vacuna contra el VPH va más allá de enfrentar un problema de salud; tener la vacuna en la mano y ser nosotros los productores es una cuestión también de seguridad y soberanía", sentenció el doctor Alfonso Rubí.

En el mundo existen al menos cinco vacunas contra el VPH que están precalificadas; sin embargo, los precios de estas no son accesibles hoy a las posibilidades económicas de nuestro país, apuntó el científico.

Por su parte, Karen Marrero Domínguez, investigadora del CNIC a cargo del proyecto, aseveró que la propuesta está dirigida a la obtención de un candidato vacunal bivalente contra la infección de los VPH en sus genotipos 16 y 18.

El candidato vacunal en desarrollo está diseñado como una vacuna de subunidades, y emplea como antígeno la proteína mayoritaria de la envoltura de los VPH 16 y 18, denominada l1, dijo.

El Centro Nacional de Investigaciones Científicas, junto a otras entidades del grupo empresarial BioCubaFarma, asume el proyecto de vacuna contra el virus del papiloma humano. (Foto: Cortesía del CNIC)

"Esta proteína, cuando se produce en sistemas recombinantes, tiene la propiedad de autoensamblarse en partículas, que se parecen morfológica e inmunogénicamente a las envolturas del propio virus. Por eso es que se denominan partículas similares a virus", detalló.

Todas las vacunas desarrolladas hasta la fecha emplean estas nanoestructuras como ingrediente activo, y han demostrado que son capaces de inducir una respuesta inmune que protege, una vez que se inmuniza, contra la infección por estos virus, afirmó la investigadora.

Igualmente, expresó que los inmunógenos aprobados hasta la fecha incluyen la protección contra los genotipos 16 y 18, que, en conjunto, son los responsables del 70 por ciento del desarrollo del cáncer cervicouterino, razón por la cual el proyecto cubano también los emplea.

Marrero Domínguez explicó que el proyecto se ha dividido en tres etapas. La primera constituye el desarrollo y obtención de los sistemas de producción; en nuestro caso se emplea la bacteria Escherichia Coli como hospedero, y el establecimiento de las condiciones de purificación de las proteínas, y posteriormente el ensamblaje de estas partículas similares a virus, a partir de las proteínas purificadas.

"Ya están los antígenos a nivel de laboratorio estructuralmente correctos. ¿Qué nos está faltando hoy? Hacer la evaluación inmunogénica, es decir, de la capacidad que tienen estas estructuras de inducir esas respuestas en modelos animales", sostuvo la experta.

Como segunda etapa del proyecto, corresponde adaptar el proceso de obtención de estas partículas, que se han desarrollado en el laboratorio, a una escala mayor, para lo cual se trabajará con el Centro Nacional de Biopreparados, a fin de obtener cantidades mayores de estos antígenos, que permitan el desarrollo del candidato vacunal como tal, en una formulación lista para ensayo.

"Nuestro propósito es bastante ambicioso, y es contar, antes de que termine el año, con un candidato vacunal formulado, listo para comenzar la evaluación en modelos animales, en cuanto a toxicología y respuesta inmune", informó Marrero Domínguez.

En Cuba, el cáncer cervicouterino constituye la quinta causa de muerte en la mujer, y la segunda,

específicamente, entre 15 y 44 años de edad.

Estudios para la identificación del VPH en diferentes grupos poblacionales, realizados por investigadores del Instituto de Medicina Tropical Pedro Kourí y otras entidades médicas cubanas como el Hospital Clínico Quirúrgico Hermanos Ameijeiras, han evidenciado una elevada frecuencia de la infección por genotipos de VPH de alto riesgo oncogénico en mujeres cubanas, aun cuando presentaran una citología normal.

De acuerdo con la Organización Panamericana de la Salud (OPS) y la Organización Mundial de la Salud (OMS), el VPH es un virus frecuente, de transmisión sexual. Si no han sido vacunadas, la mayoría de las personas tendrán una infección por el VPH en algún momento de su vida.

El VPH es la infección viral más frecuente del aparato reproductor y es causa de diversos trastornos, tanto en los hombres como en las mujeres, incluidas ciertas lesiones precancerosas que pueden progresar a un cáncer y las verrugas genitales.

Aunque la mayor parte de las infecciones por el VPH no causan síntomas y desaparecen espontáneamente, la infección persistente por el VPH puede dar lugar a enfermedades. En las mujeres, la infección persistente por ciertos tipos de VPH específicos (los más frecuentes son el VPH-16 y el VPH-18) puede conducir a lesiones precancerosas que, si no se tratan, pueden progresar a un cáncer cervicouterino.

La infección por el VPH se asocia también a cánceres orofaríngeos y anogenitales, así como a otros trastornos tanto en hombres como en mujeres.

Fuente: Escambray. Disponible en https://bit.ly/3lLW75q

El primer medicamento chino anti-SARS-CoV-2 que inhibe la proteasa 3CL está listo para el mercado

12 feb. El día 11, el primer lote de Xiannuoxin, un medicamento por vía oral que combina una molécula pequeña anti-SARS-CoV-2 y ritonavir, fue suministrada a dos grandes hospitales de Nanjing. Simcere Pharmaceutical Group Limited, con sede en la Nueva Área Jiangbei de Nanjing, empezó su producción justo después de que el fármaco recibiera la aprobación condicional de la Administración Nacional de Productos Médicos de China, hace unas dos semanas.

El precio del fármaco es de 750 yuanes por caja, unos 110 dólares, menos de la mitad de lo que cuesta en China el Paxlovid de Pfizer. A principios de semana, el Xiannuoxin fue añadido a la lista nacional de reembolsos médicos. Los pacientes solo deberán pagar el 10 por ciento de su precio, es decir, unos 75 yuanes, u 11 dólares.

"Gracias a los datos clínicos, descubrimos que el Xiannuoxin es similar o superior, en materia de seguridad, a los fármacos por vía oral importados que inhiben la proteasa 3CL. Doce días después de recibir la aprobación, empezamos la producción en masa del medicamento y lo suministraremos a varias instituciones médicas. El fármaco será otra herramienta efeciva para combatir la siguiente fase de brotes de la COVID-19", dijo Ren Jinsheng, presidente y director general de Simcere Pharmaceutical Group Limited.

Fuente: CGTN. Disponible en https://bit.ly/3levLjY

U.S. government to buy 1.5 mln more Novavax COVID vaccine doses

Feb 13. The U.S. government has agreed to buy 1.5 million more doses of Novavax Inc (NVAX.O) COVID-19 vaccine, the company said on Monday, adding that the modified agreement includes funds for development of an updated vaccine by fall this year.

Sales of the company's vaccine have been hurt by a global supply glut and waning demand, with Novavax cutting its full-year revenue forecast for the shots twice last year.

The protein-based vaccine was expected to convince those skpetical of the new mRNA-based vaccines against the virus from rivals such as Pfizer Inc (PFE.N) and Moderna (MRNA.O).

The deal comes even as the United States plans to end its COVID-19 emergency declarations on May 11, nearly three years after it imposed sweeping measures to curb the spread of the pandemic.

Novavax did not provide financial details of the contract.

The U.S. Food and Drug Administration is also in the process of simplifying its COVID-19 vaccine policy as it considers whether to recommend that Americans get an annual booster shot for the virus.

Shares of the vaccine maker rose 3.2% before the bell on Monday after the Wall Street Journal first reported the news.

Fuente: Reuters. Disponible en https://reut.rs/3Z4M7CN

Artículos científicos publicados en Medline

Filters activated: Publication date from 2023/02/01 to 2023/02/14. "vaccine" (Title/Abstract) 948 records.

Does natural and hybrid immunity obviate the need for frequent **vaccine** boosters against SARS-CoV-2 in the endemic phase?
Pilz S, Ioannidis JPA. Eur J Clin Invest. 2023 Feb;53(2):e13906. doi: 10.1111/eci.13906. Epub 2022 Nov 24. PMID: 36366946

Best of drug and **vaccine** allergy 2022.
Banerji A. Ann Allergy Asthma Immunol. 2023 Feb;130(2):143-144. doi: 10.1016/j.anai.2022.09.034. Epub 2022 Dec 1. PMID: 36737153

RxLegal: Emergency Use Authorizations.
Gabay M, Vora N. Hosp Pharm. 2023 Feb;58(1):16-17. doi: 10.1177/00185787221130703. Epub 2022 Oct 21. PMID: 36644751

BNT162b2 mRNA Vaccination Against Coronavirus Disease 2019 is Associated With a Decreased Likelihood of Multisystem Inflammatory Syndrome in Children Aged 5-18 Years-United States, July 2021 - April 2022.
Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Orzel AO, Young CC, Boom JA, Sahni LC, Maddux AB, Bline KE, Kamidani S, Tarquinio KM, Chiotos K, Schuster JE, Cullimore ML, Heidemann SM, Hobbs CV, Nofziger RA, Pannaraj PS, Cameron MA, Walker TC, Schwartz SP, Michelson KN, Coates BM, Flori HR, Mack EH, Smallcomb L, Gertz SJ, Bhumbra SS, Bradford TT, Levy ER, Kong M, Irby K, Cvijanovich NZ, Zinter MS, Bowens C, Crandall H, Hume JR, Patel MM, Campbell AP, Randolph AG; Overcoming COVID-19 Investigators. Clin Infect Dis. 2023 Feb 8;76(3):e90-e100. doi: 10.1093/cid/ciac637. PMID: 35924406

Covid-19, **vaccine** decision and schizophrenia.
Samaâli S, Karoui M, Maaroufi A, Kamoun R, Nefzi H, Ben Salah K, Ellouze F. Encephale. 2023 Feb;49(1):95-96. doi: 10.1016/j.encep.2022.01.004. Epub 2022 Feb 7. PMID: 35221023

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 **vaccine** and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial.
Toledo-Romaní ME, García-Carmenate M, Valenzuela-Silva C, Baldoquín-Rodríguez W, Martínez-Pérez M, Rodríguez-González M, Paredes-Moreno B, Mendoza-Hernández I, González-Mujica Romero R, Samón-Tabio O, Velazco-Villares P, Bacallao-Castillo JP, Licea-Martín E, Rodríguez-Ortega M, Herrera-Marrero N, Caballero-González E, Egües-Torres L, Duartes-González R, García-Blanco S, Pérez-Cabrera S, Huete-Ferreira S, Idalmis-Cisnero K, Fonte-Galindo O, Meliá-Pérez D, Rojas-Remedios I, Doroud D, Gouya MM, Biglari A, Fernández-Castillo S, Climent-Ruiz Y, Valdes-Balbín Y, García-Rivera D, Van der Stuyft P, Verez-Bencomo V; SOBERANA Phase 3 team. Lancet Reg Health Am. 2023 Feb;18:100423. doi: 10.1016/j.lana.2022.100423. Epub 2022 Dec 31. PMID: 36618081

Therapeutic Vaccination for HPV-Mediated Cancers.
Yan F, Cowell LG, Tomkies A, Day AT. Curr Otorhinolaryngol Rep. 2023 Feb 1:1-18. doi: 10.1007/s40136-023-00443-8. Online ahead of print. PMID: 36743978

Toxoplasma gondii **vaccine** candidates: a concise review.
Mamaghani AJ, Fathollahi A, Arab-Mazar Z, Kohansal K, Fathollahi M, Spotin A, Bashiri H, Bozorgomid A. Ir J Med Sci. 2023 Feb;192(1):231-261. doi: 10.1007/s11845-022-02998-9. Epub 2022 Apr 8. PMID: 35394635

Religiosity and the Naturalness Bias in Drug and **Vaccine** Choices.
Meier BP, Dillard AJ, Fetterman AK, Ji LJ, Lappas CM. J Relig Health. 2023 Feb;62(1):702-719. doi: 10.1007/s10943-022-01694-3. Epub 2022 Nov 17. PMID: 36394691

Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review.
Capone F, Rossi M, Cruciani A, Motolese F, Pilato F, Di Lazzaro V. Neural Regen Res. 2023 Feb;18(2):284-288. doi: 10.4103/1673-5374.346539. PMID: 35900404

The ideal **vaccine** to prevent cardiovascular disease.
Fröbert O, Cajander S, Udell JA. Eur Heart J. 2023 Feb 14;44(7):621-623. doi: 10.1093/eurheartj/ehac826. PMID: 36638781

Esophagitis and SARS-CoV-2 **vaccine**: Correspondence.
Sriwijitalai W, Wiwanitkit V. Med Clin (Barc). 2023 Feb 10;160(3):137. doi: 10.1016/j.medcli.2022.07.020. Epub 2022 Sep 22. PMID: 36244857

A perspective on SARS-CoV-2 virus-like particles vaccines.
Gao X, Xia Y, Liu X, Xu Y, Lu P, Dong Z, Liu J, Liang G. Int Immunopharmacol. 2023 Feb;115:109650. doi: 10.1016/j.intimp.2022.109650. Epub 2023 Jan 11. PMID: 36649673

The conundrum of COVID-19 mRNA **vaccine**-induced anaphylaxis.
Khalid MB, Frischmeyer-Guerrerio PA. J Allergy Clin Immunol Glob. 2023 Feb;2(1):1-13. doi: 10.1016/j.jacig.2022.10.003. Epub 2022 Dec 13. PMID: 36532656

Correspondence to Recombinant Adjuvanted Zoster **Vaccine** and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults.
Chu WM, Lee YH, Wei JC. J Infect Dis. 2023 Feb 1;227(3):466. doi: 10.1093/infdis/jiac309. PMID: 35880589

Cell-free protein synthesis systems for **vaccine** design and production.
Hu VT, Kamat NP. Curr Opin Biotechnol. 2023 Feb;79:102888. doi: 10.1016/j.copbio.2022.102888. Epub 2023 Jan 13. PMID: 36641905

Predicting COVID-19 and seasonal influenza **vaccine** uptake: The impact of fear and vasovagal symptoms.
Kowalsky JM. Appl Psychol Health Well Being. 2023 Feb;15(1):293-314. doi: 10.1111/aphw.12380. Epub 2022 Jun 15. PMID: 35705510

BNT162b2 and mRNA-1273 **Vaccine** Effectiveness against SARS-CoV-2 and Variants in the Urban Underserved Population.

Weng CH, Zhou S, Saal A, Hafferty M, McGuire DC, Chan PA. R I Med J (2013). 2023 Feb 1;106(1):26-28. PMID: 36706204

Vaccines for prion diseases: a realistic goal?
Napper S, Schatzl HM. Cell Tissue Res. 2023 Feb 11:1-26. doi: 10.1007/s00441-023-03749-7. Online ahead of print. PMID: 36764940

Invited Commentary: Vaccines and Fertility-Why Worry?
Harville EW. Am J Epidemiol. 2023 Feb 1;192(2):154-157. doi: 10.1093/aje/kwac147. PMID: 35968679

COVID-19 outbreak data analysis and prediction.
Anandan R, Nalini T, Chiwhane S, Shanmuganathan M, Radhakrishnan P. Measur Sens. 2023 Feb;25:100585. doi: 10.1016/j.measen.2022.100585. Epub 2022 Dec 5. PMID: 36507366

Achieving herd immunity in South America.
Lucero-Prisno DE 3rd, Shomuyiwa DO, Vicente CR, Méndez MJG, Qaderi S, Lopez JC, Mogessie YG, Alacapa J, Chamlagai L, Ndayizeye R, Kinay P. Glob Health Res Policy. 2023 Feb 1;8(1):2. doi: 10.1186/s41256-023-00286-2. PMID: 36726143

COVID-19 **vaccine** acceptance in sub-Saharan African countries: A systematic review and meta-analysis.
Gudayu TW, Mengistie HT. Heliyon. 2023 Feb;9(2):e13037. doi: 10.1016/j.heliyon.2023.e13037. Epub 2023 Jan 18. PMID: 36686610

COVID-19 **vaccine** hesitancy among young adults in Canada.
Santavicca T, Ngov C, Frounfelker R, Miconi D, Levinsson A, Rousseau C. Can J Public Health. 2023 Feb;114(1):10-21. doi: 10.17269/s41997-022-00693-x. Epub 2022 Oct 7. PMID: 36207641

New **vaccine** against canine leishmaniosis.
[No authors listed] Vet Rec. 2023 Feb;192(3):108. doi: 10.1002/vetr.2696. PMID: 36734580

Persistent pruritus following COVID-19 vaccination.
Doyle C, Watchorn RE. Ir J Med Sci. 2023 Feb;192(1):185-186. doi: 10.1007/s11845-022-02959-2. Epub 2022 Feb 24. PMID: 35199304

A MAPS **Vaccine** Induces Multipronged Systemic and Tissue-Resident Cellular Responses and Protects Mice against Mycobacterium tuberculosis.
O'Hara JM, Wakabayashi S, Siddiqi N, Cheung E, Babunovic GH, Thompson CM, Lu YJ, Rubin EJ, Malley R, Zhang F. mBio. 2023 Feb 7:e0361122. doi: 10.1128/mbio.03611-22. Online ahead of print. PMID: 36749098

An overview on the treatments and prevention against COVID-19.
Panahi Y, Gorabi AM, Talaei S, Beiraghdar F, Akbarzadeh A, Tarhriz V, Mellatyar H. Virol J. 2023 Feb 8;20(1):23. doi: 10.1186/s12985-023-01973-9. PMID: 36755327

COVID-19 **Vaccine** Acceptance and Hesitancy Among Health Care Workers in Lebanon.
Youssef NJ, Tfaily NK, Moumneh MBM, Boutros CF, Elharake JA, Malik AA, McFadden SM, Galal B, Yildirim I, Khoshnood K, Omer SB, Memish ZA, Dbaibo GS. J Epidemiol Glob Health. 2023 Feb 3:1-12. doi: 10.1007/s44197-023-00086-4. Online ahead of print. PMID: 36735184

The 20-valent pneumococcal conjugate **vaccine** (PCV20): expected added value.
Janssens E, Flamaing J, Vandermeulen C, Peetermans WE, Desmet S, De Munter P. Acta Clin Belg. 2023 Feb;78(1):78-86. doi: 10.1080/17843286.2022.2039865. Epub 2022 Feb 16. PMID: 35171752

COVID-19 **vaccine** hesitancy and racial discrimination among US adults.
Willis DE, Montgomery BEE, Selig JP, Andersen JA, Shah SK, Li J, Reece S, Alik D, McElfish PA. Prev Med Rep. 2022 Nov 28;31:102074. doi: 10.1016/j.pmedr.2022.102074. eCollection 2023 Feb. PMID: 36466305

An mRNA universal **vaccine** for influenza.
Villanueva MT. Nat Rev Drug Discov. 2023 Feb;22(2):98. doi: 10.1038/d41573-023-00013-z. PMID: 36631700

Global state of education-related inequality in COVID-19 **vaccine** coverage, structural barriers, **vaccine** hesitancy, and **vaccine** refusal: findings from the Global COVID-19 Trends and Impact Survey.
Bergen N, Kirkby K, Fuertes CV, Schlotheuber A, Menning L, Mac Feely S, O'Brien K, Hosseinpoor AR. Lancet Glob Health. 2023 Feb;11(2):e207-e217. doi: 10.1016/S2214-109X(22)00520-4. Epub 2022 Dec 21. PMID: 36565702

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue **vaccine** (TAK-003) and an inactivated hepatitis a (HAV) virus **vaccine** in a dengue non-endemic country.
Tricou V, Eyre S, Ramjee M, Collini P, Mojares Z, Loeliger E, Mandaric S, Rauscher M, Brose M, Lefevre I, Folschweiller N, Wallace D. Vaccine. 2023 Feb 10;41(7):1398-1407. doi: 10.1016/j.vaccine.2023.01.007. Epub 2023 Jan 19. PMID: 36681529

COVID-19 **Vaccine**-Related Beliefs and Behaviors Among Patients With and Survivors of Hematologic Malignancies.
Akesson J, Weiss ES, Sae-Hau M, Gracia G, Lee M, Culp L, Connell B, Butterfield S, Conti RM. JCO Oncol Pract. 2023 Feb;19(2):e167-e175. doi: 10.1200/OP.22.00338. Epub 2022 Nov 9. PMID: 36351207

Management of patients with immediate reactions to COVID-19 vaccines.
Picard M, Stone CA Jr, Greenhawt M. J Allergy Clin Immunol. 2023 Feb;151(2):413-415. doi: 10.1016/j.jaci.2022.09.003. Epub 2022 Sep 9. PMID: 36089078

Experiences and perspectives of cancer stakeholders regarding COVID-19 vaccination.
Bartley N, Havard P, Butow P, Shaw J; COVID-19 Cancer Stakeholder Authorship Group. Asia Pac J Clin Oncol. 2023 Feb;19(1):234-242. doi: 10.1111/ajco.13808. Epub 2022 Jul 18. PMID: 35851752

Current state of, prospects for, and obstacles to mRNA **vaccine** development.
Aljabali AAA, Bashatwah RM, Obeid MA, Mishra V, Mishra Y, Serrano-Aroca Á, Lundstrom K, Tambuwala MM. Drug Discov Today. 2023 Feb;28(2):103458. doi: 10.1016/j.drudis.2022.103458. Epub 2022 Nov 24. PMID: 36427779

COVID-19 **Vaccine**-Associated Immune Thrombosis and Thrombocytopenia (VITT): Diagnostic Discrepancies and Global Implications.

Zidan A, Noureldin A, Kumar SA, Elsebaie A, Othman M. Semin Thromb Hemost. 2023 Feb;49(1):9-14. doi: 10.1055/s-0042-1759684. Epub 2023 Jan 5. PMID: 36603593

Factors Associated With COVID-19 Non-vaccination in Adolescents Hospitalized Without COVID-19.
Sahni LC, Price AM, Olson SM, Newhams MM, Pannaraj PS, Maddux AB, Halasa NB, Bline KE, Cameron MA, Schwartz SP, Walker TC, Irby K, Chiotos K, Nofziger RA, Mack EH, Smallcomb L, Bradford TT, Kamidani S, Tarquinio KM, Cvijanovich NZ, Schuster JE, Bhumbra SS, Levy ER, Hobbs CV, Cullimore ML, Coates BM, Heidemann SM, Gertz SJ, Kong M, Flori HR, Staat MA, Zinter MS, Hume JR, Chatani BM, Gaspers MG, Maamari M, Randolph AG, Patel MM, Boom JA. J Pediatric Infect Dis Soc. 2023 Feb 9;12(1):29-35. doi: 10.1093/jpids/piac113. PMID: 36309873

The race toward a universal influenza **vaccine**: Front runners and the future directions.
Hu L, Lao G, Liu R, Feng J, Long F, Peng T. Antiviral Res. 2023 Feb;210:105505. doi: 10.1016/j.antiviral.2022.105505. Epub 2022 Dec 24. PMID: 36574905

Harnessing sortase A transpeptidation for advanced targeted therapeutics and **vaccine** engineering.
Obeng EM, Fulcher AJ, Wagstaff KM. Biotechnol Adv. 2023 Feb 3;64:108108. doi: 10.1016/j.biotechadv.2023.108108. Online ahead of print. PMID: 36740026

Psychometric development of the COVID-19 **vaccine** misinformation scale and effects on **vaccine** hesitancy.
Bok S, Martin D, Acosta E, Shum J, Harvie J, Lee M. Prev Med Rep. 2023 Feb;31:102087. doi: 10.1016/j.pmedr.2022.102087. Epub 2022 Dec 6. PMID: 36505271

Temporal trends and determinants of COVID-19 **vaccine** coverage and series initiation during pregnancy in Ontario, Canada, December 2020 to December 2021: A population-based retrospective cohort study.
Fell DB, Török E, Sprague AE, Regan AK, Dhinsa T, Alton GD, Dimanlig-Cruz S, MacDonald SE, Buchan SA, Kwong JC, Wilson SE, Håberg SE, Gravel CA, Wilson K, Dunn SI, Shah PS, El-Chaâr D, Barrett J, Walker MC, Okun N, Dougan SD. Vaccine. 2023 Feb 3:S0264-410X(23)00114-7. doi: 10.1016/j.vaccine.2023.01.073. Online ahead of print. PMID: 36759282

Systemic lupus erythematosus myocarditis after COVID-19 vaccination.
Sogbe M, Blanco-Di Matteo A, Di Frisco IM, Bastidas JF, Salterain N, Gavira JJ. Reumatol Clin (Engl Ed). 2023 Feb;19(2):114-116. doi: 10.1016/j.reumae.2022.06.006. PMID: 36739118

Systemic lupus erythematosus myocarditis after COVID-19 vaccination.
Sogbe M, Blanco-Di Matteo A, Di Frisco IM, Bastidas JF, Salterain N, Gavira JJ. Reumatol Clin. 2023 Feb;19(2):114-116. doi: 10.1016/j.reuma.2022.06.003. Epub 2022 Jul 28. PMID: 36211224

A survey of mechanisms underlying current and potential COVID-19 vaccines.
Hebel C, Thomsen AR. APMIS. 2023 Feb;131(2):37-60. doi: 10.1111/apm.13284. Epub 2022 Dec 11. PMID: 36394112

Vaccine-Associated Uveitis after COVID-19 Vaccination: **Vaccine** Adverse Event Reporting System Database Analysis.
Singh RB, Parmar UPS, Kahale F, Agarwal A, Tsui E. Ophthalmology. 2023 Feb;130(2):179-186. doi: 10.1016/j.ophtha.2022.08.027. Epub 2022 Aug 31. PMID: 36055601

Potential health risks of mRNA-based **vaccine** therapy: A hypothesis.
Acevedo-Whitehouse K, Bruno R. Med Hypotheses. 2023 Feb;171:111015. doi: 10.1016/j.mehy.2023.111015. Epub 2023 Jan 25. PMID: 36718314

Effect of **vaccine** booster, **vaccine** type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
Fong CH, Zhang X, Chen LL, Poon RW, Chan BP, Zhao Y, Wong CK, Chan KH, Yuen KY, Hung IF, Yuen JKY, To KK. EBioMedicine. 2023 Feb;88:104446. doi: 10.1016/j.ebiom.2023.104446. Epub 2023 Jan 25. PMID: 36706582

Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis.
Taheri S. Int Urol Nephrol. 2023 Feb 1:1-12. doi: 10.1007/s11255-023-03471-x. Online ahead of print. PMID: 36723829

Emerging Options for the Prevention and Management of Clostridioides difficile Infection.
Gonzales-Luna AJ, Carlson TJ, Garey KW. Drugs. 2023 Feb;83(2):105-116. doi: 10.1007/s40265-022-01832-x. Epub 2023 Jan 16. PMID: 36645620

The patient perspective on **vaccine** uptake in adults with psoriasis and eczema.
Noe MH, Archila M, Barbieri JS, Goldman N, Lopez CG, Mostaghimi A, Scherer AM, Tan AJ, Perez-Chada LM, Asgari MM, Gelfand JM. Arch Dermatol Res. 2023 Feb 7:1-10. doi: 10.1007/s00403-023-02546-0. Online ahead of print. PMID: 36749390

Understanding COVID-19 **Vaccine** Confidence in People Living with HIV: A pan-Canadian Survey.
Costiniuk CT, Singer J, Needham J, Yang Y, Qian H, Chambers C, Burchell AN, Samji H, Colmegna I, Del Canto S, Godin GH, Habanyama M, Hui C, Kroch A, Mandarino E, Margolese S, Martin C, Owino M, Mohammadi T, Zhang W, Pelaez S, Kovacs C, Benko E, Vulesevic B, Cooper CL, Anis AH. AIDS Behav. 2023 Feb 4:1-13. doi: 10.1007/s10461-023-03991-8. Online ahead of print. PMID: 36738344

Communication is crucial: Lessons from COVID-19 vaccination and pregnancy.
Cole C, Tsakiroglou M, Waitt C. Br J Clin Pharmacol. 2023 Feb;89(2):582-593. doi: 10.1111/bcp.15578. Epub 2022 Nov 24. PMID: 36321589

Provider Confidence and Perceived Barriers when Recommending the Human Papillomavirus **Vaccine** to Parents.
Dickson T, Hirko KA, Ford S. J Cancer Educ. 2023 Feb 4. doi: 10.1007/s13187-022-02248-7. Online ahead of print. PMID: 36737584

Estimating Waning of **Vaccine** Effectiveness: A Simulation Study.
Nikas A, Ahmed H, Zarnitsyna VI. Clin Infect Dis. 2023 Feb 8;76(3):479-486. doi: 10.1093/cid/ciac725. PMID: 36056892

COVID **Vaccine** Hesitancy and Risk of a Traffic Crash.
Redelmeier DA, Wang J, Thiruchelvam D. Am J Med. 2023 Feb;136(2):153-162.e5. doi: 10.1016/j.amjmed.2022.11.002. Epub 2022 Dec 2. PMID: 36470796

COVID-19 **vaccine** uptake and hesitation among men and women preparing for pregnancy: a cross-section survey based on the theory of planned behavior.
Lei A, Xi C, Luo X, Pu Y, You H. BMC Public Health. 2023 Feb 2;23(1):227. doi: 10.1186/s12889-023-15171-3. PMID: 36732717

Profiles of COVID-19 **vaccine** hesitancy by race and ethnicity in eastern Pennsylvania.
Colvin KM, Camara KS, Adams LS, Sarpong AP, Fuller DG, Peck SE, Ramos AS, Acevedo AL, Badume MA, Briggs SA, Chukwurah TN, Davila-Gutierrez Z, Ewing JA, Frempong JO, Garrett AA, Grampp SJ, Gillespie JW, Herrera EJ, Horsford SME, Maddox EJ, Pelaez JC, Quartey OL, Rodriguez F, Vasquez LA, Piper BJ, Gowtham S. PLoS One. 2023 Feb 6;18(2):e0280245. doi: 10.1371/journal.pone.0280245. eCollection 2023. PMID: 36745588

A scrub typhus **vaccine** presents a challenging unmet need.
Walker DH, Mendell NL. NPJ Vaccines. 2023 Feb 9;8(1):11. doi: 10.1038/s41541-023-00605-1. PMID: 36759505

Tumor cell **vaccine** combined with Newcastle disease virus promote immunotherapy of lung cancer.
Wang H, Nan F, Zeng Z, Zhang X, Ke D, Zhang S, Zhou X, Niu D, Fan T, Jiang S, Zhang X, Wang B, Zhang W. J Med Virol. 2023 Feb 4. doi: 10.1002/jmv.28554. Online ahead of print. PMID: 36738232

Vaccine knowledge, attitudes, and recommendation practices among health care providers in New York State.
Fernandes A, Wang D, Domachowske JB, Suryadevara M. Hum Vaccin Immunother. 2023 Feb 7:2173914. doi: 10.1080/21645515.2023.2173914. Online ahead of print. PMID: 36749617

Morphea after SARS-CoV2 **vaccine**.
Paolino G, Di Nicola MR, Rizzo N, Mercuri SR. An Bras Dermatol. 2023 Feb 6:S0365-0596(23)00008-9. doi: 10.1016/j.abd.2022.04.010. Online ahead of print. PMID: 36754652

COVID-19 vaccination hesitancy in people affected by diabetes and strategies to increase **vaccine** compliance: A systematic narrative review and meta-analysis.
Bianchi FP, Stefanizzi P, Martinelli A, Brescia N, Tafuri S. Vaccine. 2023 Feb 10;41(7):1303-1309. doi: 10.1016/j.vaccine.2023.01.036. Epub 2023 Jan 20. PMID: 36690559

COVID-19 **vaccine** hesitancy among Nigerians living with non-communicable diseases: a qualitative study.
Ojewale LY, Mukumbang FC. BMJ Open. 2023 Feb 2;13(2):e065901. doi: 10.1136/bmjopen-2022-065901. PMID: 36731928

Formulation and Evaluation of Lipidized Imiquimod as an Effective Adjuvant.
Yin W, Deng B, Xu Z, Wang H, Ma F, Zhou M, Lu Y, Zhang J. ACS Infect Dis. 2023 Feb 10;9(2):378-387. doi: 10.1021/acsinfecdis.2c00583. Epub 2023 Jan 23. PMID: 36688646

Effectiveness and durability of BNT162b2 **vaccine** against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study.

Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Xie F, Ackerson BK, Valluri SR, Jodar L, McLaughlin JM. Lancet Respir Med. 2023 Feb;11(2):176-187. doi: 10.1016/S2213-2600(22)00354-X. Epub 2022 Oct 7. PMID: 36216013

Computational design of candidate multi-epitope **vaccine** against SARS-CoV-2 targeting structural (S and N) and non-structural (NSP3 and NSP12) proteins.
Ali Z, Cardoza JV, Basak S, Narsaria U, Singh VP, Isaac SP, França TCC, LaPlante SR, George SS. J Biomol Struct Dyn. 2023 Feb 6:1-20. doi: 10.1080/07391102.2023.2173297. Online ahead of print. PMID: 36744449

Political Partisanship, Trust, and Attitudes toward COVID-19 Vaccines in Indonesia.
Halimatusa'diyah I, Durriyah TL. J Health Polit Policy Law. 2023 Feb 1;48(1):35-61. doi: 10.1215/03616878-10171076. PMID: 36112927

Mandatory COVID-19 vaccination for healthcare workers: A discussion paper.
Maneze D, Salamonson Y, Grollman M, Montayre J, Ramjan L. Int J Nurs Stud. 2023 Feb;138:104389. doi: 10.1016/j.ijnurstu.2022.104389. Epub 2022 Nov 9. PMID: 36462385

Estimation of **vaccine** effectiveness using the screening method.
Farrington CP. Int J Epidemiol. 2023 Feb 8;52(1):14-21. doi: 10.1093/ije/dyac207. PMID: 36326585

Influence of biotic interventions on the immune response to vaccines in young and older adults.
Spacova I, Patusco R, Lebeer S, Jensen MG. Clin Nutr. 2023 Feb;42(2):216-226. doi: 10.1016/j.clnu.2023.01.001. Epub 2023 Jan 6. PMID: 36657219

An Update on Human Papillomavirus Vaccination in the United States.
Boitano TKL, Ketch PW, Scarinci IC, Huh WK. Obstet Gynecol. 2023 Feb 1;141(2):324-330. doi: 10.1097/AOG.0000000000005056. Epub 2023 Jan 4. PMID: 36649341

Monitoring the COVID-19 immunisation programme through a national immunisation Management system - England's experience.
Tessier E, Edelstein M, Tsang C, Kirsebom F, Gower C, Campbell CNJ, Ramsay M, White J, Andrews N, Lopez-Bernal J, Stowe J. Int J Med Inform. 2023 Feb;170:104974. doi: 10.1016/j.ijmedinf.2022.104974. Epub 2022 Dec 23. PMID: 36577202

Skin manifestations following anti-COVID-19 vaccination: A multicentricstudy from Turkey.
Oguz Topal I, Tokmak A, Kurmuş GI, Kalkan G, Demirseren DD, Tosun M, Emre S, Özkök Akbulut T, Kaya Özden H, Koska MC, Külcü Çakmak S, Kutlu Ö, Mutlu E, Gür Aksoy G, Topaloğlu Demir F, Karadağ AS. J Cosmet Dermatol. 2023 Feb;22(2):354-363. doi: 10.1111/jocd.15570. Epub 2022 Dec 27. PMID: 36575896

Evidence synthesis and pooled analysis of **vaccine** effectiveness for COVID-19 mRNA **vaccine** BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.
Kyaw MH, Spinardi J, Zhang L, Oh HML, Srivastava A. Hum Vaccin Immunother. 2023 Feb 1:2165856. doi: 10.1080/21645515.2023.2165856. Online ahead of print. PMID: 36727201

Acceptability of a Chikungunya Virus **Vaccine**, United States Virgin Islands.

Curren EJ, Ellis EM, Hennessey MJ, Delorey MJ, Fischer M, Staples JE. Am J Trop Med Hyg. 2022 Dec 26;108(2):363-365. doi: 10.4269/ajtmh.22-0429. Print 2023 Feb 1. PMID: 36572007

Safety and immunogenicity of an investigational respiratory syncytial virus **vaccine** (RSVPreF3) in mothers and their infants: a phase 2 randomized trial.
Bebia Z, Reyes O, Jeanfreau R, Kantele A, De Leon RG, García Sánchez M, Banooni P, Gardener GJ, Bartha Rasero JL, Encinas Pardilla MB, Langley JM, Di Leo CM, Botelho-Nevers E, Buttery J, Laurichesse H, Madhi SA, García AM, Stanley T, Barjat T, Griffith R, Castrejón-Alba MM, de Heusch M, Dieussaert I, Hercor M, Lese P, Qian H, Tullio AN, Henry O. J Infect Dis. 2023 Feb 1:jiad024. doi: 10.1093/infdis/jiad024. Online ahead of print. PMID: 36722147

Race, ethnicity, psychological factors, and COVID-19 **vaccine** hesitancy during the COVID-19 pandemic.
Yuan Y, Melde C, Zhang N, Pagidipati P. Psychol Health Med. 2023 Feb;28(2):427-438. doi: 10.1080/13548506.2022.2084123. Epub 2022 May 30. PMID: 35638115

Vaccine supply chain management: An intelligent system utilizing blockchain, IoT and machine learning.
Hu H, Xu J, Liu M, Lim MK. J Bus Res. 2023 Feb;156:113480. doi: 10.1016/j.jbusres.2022.113480. Epub 2022 Dec 2. PMID: 36506475

The Role of Information and Knowledge in COVID-19 Vaccination Among People With Intellectual and Developmental Disabilities and Their Families.
Lineberry S, Bogenschutz M, Dinora P, Ayers K. Intellect Dev Disabil. 2023 Feb 1;61(1):16-30. doi: 10.1352/1934-9556-61.1.16. PMID: 36706004

Host populations, challenges, and commercialization of cryptococcal vaccines.
Del Poeta M, Wormley FL Jr, Lin X. PLoS Pathog. 2023 Feb 9;19(2):e1011115. doi: 10.1371/journal.ppat.1011115. eCollection 2023 Feb. PMID: 36757929

The v-safe after vaccination health checker: Active **vaccine** safety monitoring during CDC's COVID-19 pandemic response.
Myers TR, Marquez PL, Gee JM, Hause AM, Panagiotakopoulos L, Zhang B, McCullum I, Licata C, Olson CK, Rahman S, Kennedy SB, Cardozo M, Patel CR, Maxwell L, Kallman JR, Shay DK, Shimabukuro TT. Vaccine. 2023 Feb 10;41(7):1310-1318. doi: 10.1016/j.vaccine.2022.12.031. Epub 2023 Jan 23. PMID: 36697313

COVID **vaccine**-associated myocarditis in an 8-year-old patient.
Mehta K, Cohen R, Kelly B, Grosse-Wortmann L. Cardiol Young. 2023 Feb;33(2):334-335. doi: 10.1017/S1047951122002116. Epub 2022 Jul 27. PMID: 35892184

Measles vaccination in Brazil: where have we been and where are we headed?
Sato APS, Boing AC, Almeida RLF, Xavier MO, Moreira RDS, Martinez EZ, Matijasevich A, Donalisio MR. Cien Saude Colet. 2023 Feb;28(2):351-362. doi: 10.1590/1413-81232023282.19172022. Epub 2022 Dec 1. PMID: 36651391

TTV viral load as a predictor of antibody response to SARS COV-2 vaccination.
Focosi D, Baj A, Azzi L, Novazzi F, Maggi F. J Heart Lung Transplant. 2023 Feb;42(2):143-144. doi: 10.1016/j.healun.2022.10.025. Epub 2022 Nov 6. PMID: 36424253

Imperfect **vaccine** can yield multiple Nash equilibria in vaccination games.
Augsburger IB, Galanthay GK, Tarosky JH, Rychtář J, Taylor D. Math Biosci. 2023 Feb;356:108967. doi: 10.1016/j.mbs.2023.108967. Epub 2023 Jan 14. PMID: 36649795

Perceptions about human papillomavirus **vaccine** and oropharyngeal cancers, and the role of dental care providers in human papillomavirus prevention among US adults.
Naavaal S, Demopoulos CA, Kelly A, Tranby E, Frantsve-Hawley J. J Am Dent Assoc. 2023 Feb 6:S0002-8177(22)00793-0. doi: 10.1016/j.adaj.2022.12.006. Online ahead of print. PMID: 36754721

Safety and immunogenicity of mRNA COVID-19 **vaccine** in inpatients with muscular dystrophy.
Saito T, Saito T, Hashimoto H, Ogata K, Kobayashi M, Takada H, Kuru S, Kimura T, Nakamura A, Matsumura T. Muscle Nerve. 2023 Feb;67(2):117-123. doi: 10.1002/mus.27761. Epub 2022 Dec 19. PMID: 36478587

Treatment, outcome and re-vaccination of patients with SARS-CoV-2 **vaccine**-associated immune thrombocytopenia.
Ruzicka M, Wurm S, Lindner L, Dreyling M, von Bergwelt-Baildon M, Boeck S, Giessen-Jung C, Milani V, Stemmler JH, Subklewe M, Weigert O, Spiekermann K. Infection. 2023 Feb;51(1):231-238. doi: 10.1007/s15010-022-01909-5. Epub 2022 Oct 4. PMID: 36195695

Coverage and Determinants of COVID-19 Vaccination Among Pregnant Women: An Experience From a Low-Income Country.
Nazzal Z, Mohammad A, Qub L, Masri H, Abdullah I, Qasrawi H, Maraqa B. Am J Health Promot. 2023 Feb;37(2):222-227. doi: 10.1177/08901171221111107. Epub 2022 Aug 19. PMID: 35985988

Effect of COVID-19 **Vaccine** Messaging Platforms in Emergency Departments on **Vaccine** Acceptance and Uptake: A Cluster Randomized Clinical Trial.
Rodriguez RM, Nichol G, Eucker SA, Chang AM, O'Laughlin KN, Pauley A, Rising KL, Eswaran V, Morse D, Li C, Patel A, Duber HC, Arreguin M, Shughart L, Glidden D; PROCOVAXED Study Network. JAMA Intern Med. 2023 Feb 1;183(2):115-123. doi: 10.1001/jamainternmed.2022.5909. PMID: 36574256

Compliant citizens, defiant rebels or neither? Exploring change and complexity in COVID-19 **vaccine** attitudes and decisions in Bradford, UK: Findings from a follow-up qualitative study.
Lockyer B, Moss RH, Endacott C, Islam S, Sheard L; Bradford Institute for Health Research Covid-19 Scientific Advisory Group. Health Expect. 2023 Feb;26(1):376-387. doi: 10.1111/hex.13667. Epub 2022 Dec 1. PMID: 36457270

Cytokines and cecal microbiome modulations conferred by a dual **vaccine** in Salmonella-infected layers.
Jan TR, Lin CS, Wang SY, Yang WY. Poult Sci. 2023 Feb;102(2):102373. doi: 10.1016/j.psj.2022.102373. Epub 2022 Dec 5. PMID: 36527813

Erythema nodosum at COVID-19 **vaccine** injection site.
Matsuoka A, Higashi Y, Kanekura T. J Dermatol. 2023 Feb;50(2):e83-e84. doi: 10.1111/1346-8138.16613. Epub 2022 Oct 25. PMID: 36282881

Immunogenicity of BA.5 Bivalent mRNA **Vaccine** Boosters.

Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, Gallup L, Rowe M, Schonberg E, Thai S, Barrett J, Borducchi EN, Bouffard E, Jacob-Dolan C, Mazurek CR, Mutoni A, Powers O, Sciacca M, Surve N, VanWyk H, Wu C, Barouch DH. N Engl J Med. 2023 Feb 9;388(6):565-567. doi: 10.1056/NEJMc2213948. Epub 2023 Jan 11. PMID: 36630611

Broad protection from a single flu **vaccine**.
Attwaters M. Nat Rev Microbiol. 2023 Feb;21(2):67. doi: 10.1038/s41579-022-00849-z. PMID: 36517547

The elusive goal of COVID-19 **vaccine** immunity.
Abu-Raddad LJ, Chemaitelly H. Lancet Respir Med. 2023 Feb;11(2):115-117. doi: 10.1016/S2213-2600(22)00394-0. Epub 2022 Oct 7. PMID: 36216010

Images in Vascular Medicine: SARS-CoV-2 **vaccine**-induced ulcerations.
Santoro M, Weinberg I. Vasc Med. 2023 Feb;28(1):85-86. doi: 10.1177/1358863X221131594. Epub 2022 Nov 16. PMID: 36382612

Surveillance of gynecologic cancer patients post-COVID-19 **vaccine**: Are CA-125 levels reliable?
Thayer E, Walsh L, Leung K, Korets S. Gynecol Oncol Rep. 2023 Feb;45:101140. doi: 10.1016/j.gore.2023.101140. Epub 2023 Jan 21. PMID: 36714374

Exosome-based delivery of VP1 protein conferred enhanced resistance of mice to CVB3-induced viral myocarditis.
Zhang C, Zhang Y, Li Y, Lu J, Xiong S, Yue Y. Virology. 2023 Feb;579:46-53. doi: 10.1016/j.virol.2022.12.015. Epub 2023 Jan 2. PMID: 36603532

Covid-19 **vaccine** hesitancy: Text mining, sentiment analysis and machine learning on COVID-19 vaccination Twitter dataset.
Qorib M, Oladunni T, Denis M, Ososanya E, Cotae P. Expert Syst Appl. 2023 Feb;212:118715. doi: 10.1016/j.eswa.2022.118715. Epub 2022 Sep 5. PMID: 36092862

T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
Schiavoni I, Palmieri A, Olivetta E, Leone P, Di Lonardo A, Mazzoli A, Cafariello C, Malara A, Palamara AT, Incalzi RA, Onder G, Stefanelli P, Fedele G; GeroCovid Vax CMI Study Group. J Am Med Dir Assoc. 2023 Feb;24(2):140-147.e2. doi: 10.1016/j.jamda.2022.11.024. Epub 2022 Dec 7. PMID: 36587928

Recommending COVID-19 vaccination for adolescents in primary care.
Thompson P, McCormick L, Huang Q, Gilkey MB, Dailey SA, Brewer NT. Fam Pract. 2023 Feb 9;40(1):1-8. doi: 10.1093/fampra/cmac056. PMID: 35652480

Preferences for Sexually Transmitted Infection and Cancer Vaccines in the United States and in China.
Wagner AL, Lu Y, Janusz CB, Pan SW, Glover B, Wu Z, Prosser LA. Value Health. 2023 Feb;26(2):261-268. doi: 10.1016/j.jval.2022.07.019. Epub 2022 Aug 31. PMID: 36055920

Voice Assistants' Responses to Questions About the COVID-19 **Vaccine**: National Cross-sectional Study.
Sossenheimer P, Hong G, Devon-Sand A, Lin S. JMIR Form Res. 2023 Feb 8;7:e43007. doi: 10.2196/43007. PMID: 36719815

Hendra Virus: An Update on Diagnosis, Vaccination, and Biosecurity Protocols for Horses.
Wang X, Wise JC, Stewart AJ. Vet Clin North Am Equine Pract. 2023 Feb 1:S0749-0739(22)00073-6. doi: 10.1016/j.cveq.2022.11.009. Online ahead of print. PMID: 36737284

A new **vaccine** supply chain network under COVID-19 conditions considering system dynamic: Artificial intelligence algorithms.
Kamran MA, Kia R, Goodarzian F, Ghasemi P. Socioecon Plann Sci. 2023 Feb;85:101378. doi: 10.1016/j.seps.2022.101378. Epub 2022 Aug 8. PMID: 35966449

Vaccine Inequities and the Legacies of Colonialism: Speculative Fiction's Challenge to Medicine.
Penner L, Sprague C. J Med Humanit. 2023 Feb 6:1-5. doi: 10.1007/s10912-023-09782-5. Online ahead of print. PMID: 36740657

pH-Sensitive and Biodegradable $Mn_3(PO_4)_2 \cdot 3H_2O$ Nanoparticles as an Adjuvant of Protein-Based Bivalent COVID-19 **Vaccine** to Induce Potent and Broad-Spectrum Immunity.
Zhou SH, Zhang RY, You ZW, Zou YK, Wen Y, Wang J, Ding D, Bian MM, Zhang ZM, Yuan H, Yang GF, Guo J. ACS Appl Mater Interfaces. 2023 Feb 7:acsami.2c19736. doi: 10.1021/acsami.2c19736. Online ahead of print. PMID: 36748861

Finding TB **vaccine** antigens: follow the TCRs.
Lichtman A. Sci Immunol. 2023 Feb 3;8(80):eadg8281. doi: 10.1126/sciimmunol.adg8281. Epub 2023 Feb 3. PMID: 36735772

Computational designing of a novel subunit **vaccine** for human cytomegalovirus by employing the immunoinformatics framework.
Moin AT, Singh G, Ahmed N, Saiara SA, Timofeev VI, Ahsan Faruqui N, Sharika Ahsan S, Tabassum A, Nebir SS, Andalib KMS, Araf Y, Ullah MA, Sarkar B, Islam NN, Zohora US. J Biomol Struct Dyn. 2023 Feb;41(3):833-855. doi: 10.1080/07391102.2021.2014969. Epub 2022 Jan 4. PMID: 36617426

SARS-CoV-2 **vaccine** alleviates disease burden and severity in liver transplant recipients even with low antibody titers.
Khalaileh A, Imam A, Jammal A, Hakimian D, Amer J, Shafrir A, Milgrom Y, Massarwa M, Hazou W, Khader M, Safadi R. Hepatol Commun. 2023 Feb 1;7(2):e0025. doi: 10.1097/HC9.0000000000000025. eCollection 2023 Feb 1. PMID: 36724131

Extracellular Vesicles as Next Generation Immunotherapeutics.
Greening DW, Xu R, Ale A, Hagemeyer CE, Chen W. Semin Cancer Biol. 2023 Feb 9:S1044-579X(23)00017-2. doi: 10.1016/j.semcancer.2023.02.002. Online ahead of print. PMID: 36773820

A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2.
Mao S, Li S, Zhang Y, Long L, Peng J, Cao Y, Mao JZ, Qi X, Xin Q, San G, Ding J, Jiang J, Bai X, Wang Q, Xu P, Xia H, Lu L, Xie L, Kong D, Zhu S, Xu W. Nano Today. 2023 Feb;48:101730. doi: 10.1016/j.nantod.2022.101730. Epub 2022 Dec 21. PMID: 36570700

Mobile **Vaccine** Clinics for Patients With Serious Mental Illness and Health Care Workers in Outpatient Mental Health Clinics.

Van Alphen MU, Lim C, Freudenreich O. Psychiatr Serv. 2023 Feb 8:appips20220460. doi: 10.1176/appi.ps.20220460. Online ahead of print. PMID: 36751907

Esophagitis and SARS-CoV-2 **vaccine**.
Sriwijitalai W, Wiwanitkit V. Med Clin (Engl Ed). 2023 Feb 10;160(3):137. doi: 10.1016/j.medcle.2022.07.023. Epub 2023 Feb 4. PMID: 36777492

Indiana Parental Perceptions of the Acceptability of General and HPV-Specific State **Vaccine** Requirements.
Walker KK, Kasting ML, Head KJ, Sturm L, Zimet GD. J Community Health. 2023 Feb 6:1-11. doi: 10.1007/s10900-023-01198-5. Online ahead of print. PMID: 36745356

The race to make a variant-proof COVID **vaccine**.
Fox D. Nature. 2023 Feb 1. doi: 10.1038/d41586-023-00282-z. Online ahead of print. PMID: 36725946

Towards an effective Staphylococcus **vaccine**: why have candidates failed and what is the next step?
Tsai CM, Caldera JR, Hajam IA, Liu GY. Expert Rev Vaccines. 2023 Feb 10. doi: 10.1080/14760584.2023.2179486. Online ahead of print. PMID: 36765453

Estimation of **Vaccine** Effectiveness of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-CoV-2 Omicron.
Wei Y, Jia KM, Zhao S, Hung CT, Mok CKP, Poon PKM, Man Leung EY, Wang MH, Yam CHK, Chow TY, Guo Z, Yeoh EK, Chong KC. JAMA Netw Open. 2023 Feb 1;6(2):e2254777. doi: 10.1001/jamanetworkopen.2022.54777. PMID: 36735253

Reactive arthritis after vaccination against SARS-CoV-2: A case series and a mini-review.
Wojturska W, Nowakowski J, Pilch W, Biernikowicz M, Korkosz M. Hum Vaccin Immunother. 2023 Feb 6:2173912. doi: 10.1080/21645515.2023.2173912. Online ahead of print. PMID: 36746791

Peptide-based **vaccine** targeting IL17A attenuates experimental spondyloarthritis in HLA-B27 transgenic rats.
Hayashi H, Sun J, Yanagida Y, Yoshida S, Baba S, Tenma A, Toyoura M, Kawabata S, Ehara T, Asaki R, Sakaguchi M, Tomioka H, Shimamura M, Morishita R, Rakugi H, Tomita T, Nakagami H. RMD Open. 2023 Feb;9(1):e002851. doi: 10.1136/rmdopen-2022-002851. PMID: 36737108

Preclinical toxicity assessment of a peptide-based antiPCSK9 **vaccine** in healthy mice.
Momtazi-Borojeni AA, Banach M, Tabatabaei SA, Sahebkar A. Biomed Pharmacother. 2023 Feb;158:114170. doi: 10.1016/j.biopha.2022.114170. Epub 2022 Dec 30. PMID: 36587555

Associations of race/ethnicity and socioeconomic factors with vaccination among US adults during the COVID-19 pandemic, January to March 2021.
Kim D. Prev Med Rep. 2023 Feb;31:102021. doi: 10.1016/j.pmedr.2022.102021. Epub 2022 Oct 13. PMID: 36267818

Developing a multiepitope **vaccine** for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis.

Jiang F, Liu Y, Xue Y, Cheng P, Wang J, Lian J, Gong W. Int Immunopharmacol. 2023 Feb;115:109728. doi: 10.1016/j.intimp.2023.109728. Epub 2023 Jan 11. PMID: 36652758

Identifying intervention strategies to improve HPV **vaccine** decision-making using behaviour change theory.
Marshall S, Fleming A, Sahm LJ, Moore AC. Vaccine. 2023 Feb 10;41(7):1368-1377. doi: 10.1016/j.vaccine.2023.01.025. Epub 2023 Jan 18. PMID: 36669967

COVID-19 **vaccine** hesitancy in care home staff: A survey of Liverpool care homes.
Tulloch JSP, Lawrenson K, Gordon AL, Ghebrehewet S, Ashton M, Peddie S, Parvulescu P. Vaccine. 2023 Feb 10;41(7):1290-1294. doi: 10.1016/j.vaccine.2023.01.009. Epub 2023 Jan 9. PMID: 36669970

Mendelian randomisation identifies priority groups for prophylactic EBV vaccination.
Muckian MD, Wilson JF, Taylor GS, Stagg HR, Pirastu N. BMC Infect Dis. 2023 Feb 3;23(1):65. doi: 10.1186/s12879-023-08031-3. PMID: 36737699

A Systematic Review and Meta-analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis.
Gao J, Feng L, Li Y, Lowe S, Guo Z, Bentley R, Xie C, Wu B, Xie P, Xia W, Ma S, Liu H, Guo X, Uy JPN, Zhou Q, Wazir H, Sun C. Am J Prev Med. 2023 Feb;64(2):275-284. doi: 10.1016/j.amepre.2022.09.002. Epub 2022 Sep 26. PMID: 36266115

COVID-19 **vaccine** hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey.
Scanlon B, Wyld D, Firman P, Nakagaki M, Durham J, Kennedy G, Moran P, Smith M, Gavin N. Aust Health Rev. 2023 Feb;47(1):110-118. doi: 10.1071/AH22142. PMID: 36476744

Serological response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination with a twelve-week interval.
Sheng WH, Chang SY, Hsieh MJ, Ieong SM, Chang SC. J Formos Med Assoc. 2023 Feb;122(2):187-191. doi: 10.1016/j.jfma.2022.07.010. Epub 2022 Aug 18. PMID: 35987747

Rotavirus **Vaccine** Impact since Its Introduction in the National Immunization Program of Argentina.
Marti SG, Gibbons L, Reidel S, Stupka J, Degiuseppe J, Argento F, Gómez JA. Infect Dis Ther. 2023 Feb;12(2):513-526. doi: 10.1007/s40121-022-00709-6. Epub 2022 Dec 15. PMID: 36520328

Creation of poxvirus expressing foot-and-mouth and peste des petits ruminant disease virus proteins.
Zhao Z, Huang C, Zhu X, Qi Z, Cao Y, Li P, Bao H, Sun P, Bai X, Fu Y, Li K, Zhang J, Ma X, Wang J, Yuan H, Li D, Liu Z, Zhang Q, Lu Z. Appl Microbiol Biotechnol. 2023 Feb;107(2-3):639-650. doi: 10.1007/s00253-022-12351-w. Epub 2022 Dec 31. PMID: 36586016

Receipt of COVID-19 and seasonal influenza vaccines in California (USA) during the 2021-2022 influenza season.
Andrejko KL, Myers JF, Openshaw J, Fukui N, Li S, Watt JP, Murray EL, Hoover C, Lewnard JA, Jain S, Pry JM; California COVID-19 Case-Control Study Team. Vaccine. 2023 Feb 3;41(6):1190-1197. doi: 10.1016/j.vaccine.2022.12.052. Epub 2022 Dec 23. PMID: 36585281

COVID-19 **vaccine** refusal associated with health literacy: findings from a population-based survey in Korea.
Song I, Lee SH. BMC Public Health. 2023 Feb 6;23(1):255. doi: 10.1186/s12889-023-15182-0. PMID: 36747179

A high-throughput sequencing approach identifies immunotherapeutic targets for bacterial meningitis in neonates.
Pons S, Frapy E, Sereme Y, Gaultier C, Lebreton F, Kropec A, Danilchanka O, Schlemmer L, Schrimpf C, Allain M, Angoulvant F, Lecuyer H, Bonacorsi S, Aschard H, Sokol H, Cywes-Bentley C, Mekalanos JJ, Guillard T, Pier GB, Roux D, Skurnik D. EBioMedicine. 2023 Feb;88:104439. doi: 10.1016/j.ebiom.2023.104439. Epub 2023 Jan 27. PMID: 36709579

Associations of maternal age, education, and marital status with HPV **vaccine** uptake and hesitancy among United States Youth: A cross-sectional analysis of the 2020 National Immunization Survey (NIS).
Elenwo C, Batioja K, Davis T, Greiner BH, Markey C, Hartwell M. J Pediatr Adolesc Gynecol. 2023 Feb 7:S1083-3188(23)00223-1. doi: 10.1016/j.jpag.2023.01.213. Online ahead of print. PMID: 36758721

Real-world uptake of COVID-19 vaccination among individuals expressing **vaccine** hesitancy: A registry-linkage study.
Andrejko KL, Myers JF, Fukui N, Nelson L, Zhao R, Openshaw J, Watt JP, Jain S, Lewnard JA, Pry JM; California COVID-19 Case-Control Study Team. Vaccine. 2023 Feb 1:S0264-410X(23)00108-1. doi: 10.1016/j.vaccine.2023.01.066. Online ahead of print. PMID: 36746740

Early Estimates of Bivalent mRNA Booster Dose **Vaccine** Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, Wiegand RE, Accorsi EK, Verani JR, Shang N, Derado G, Britton A, Smith ZR, Fleming-Dutra KE. MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1. PMID: 36730051

Factors of COVID-19 **Vaccine** Perception among Transport Drivers in Singapore: A Cross-Sectional Pilot Study.
Huizi Lim E, Fong NP, Pang J. Am J Trop Med Hyg. 2023 Feb 6:tpmd220510. doi: 10.4269/ajtmh.22-0510. Online ahead of print. PMID: 36746661

Antiviral and bivalent **vaccine** efficacy against an omicron XBB.1.5 isolate.
Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann PJ, Pekosz A, Kawaoka Y. Lancet Infect Dis. 2023 Feb 8:S1473-3099(23)00070-1. doi: 10.1016/S1473-3099(23)00070-1. Online ahead of print. PMID: 36773622

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
Xia S, Wang L, Jiao F, Yu X, Xu W, Huang Z, Li X, Wang Q, Zhu Y, Man Q, Jiang S, Lu L. Emerg Microbes Infect. 2023 Feb 7:2178241. doi: 10.1080/22221751.2023.2178241. Online ahead of print. PMID: 36748716

Serum biomarkers for nutritional status as predictors in COVID-19 patients before and after vaccination.
Vaz-Rodrigues R, Mazuecos L, Villar M, Urra JM, Gortázar C, de la Fuente J. J Funct Foods. 2023 Feb;101:105412. doi: 10.1016/j.jff.2023.105412. Epub 2023 Jan 10. PMID: 36644001

Pathogenesis of wild-type- and **vaccine**-based recombinant peste des petits ruminants virus (PPRV) expressing EGFP in experimentally infected domestic goats.
Schmitz KS, Eblé PL, van Gennip RGP, Maris-Veldhuis MA, de Vries RD, van Keulen LJM, de Swart RL, van Rijn PA. J Gen Virol. 2023 Feb;104(2). doi: 10.1099/jgv.0.001828. PMID: 36757863

Coronavirus Vaccination Hesitancy: Early Education to Counter **Vaccine** Hesitancy/Refusal.
Oyolu IO. J Nurse Pract. 2023 Mar;19(3):104517. doi: 10.1016/j.nurpra.2022.12.002. Epub 2023 Feb 2. PMID: 36748058

Framing of national HPV **vaccine** recommendations and willingness to recommend at ages 9-10.
Kahn BZ, Reiter PL, Kritikos KI, Gilkey MB, Queen TL, Brewer NT. Hum Vaccin Immunother. 2023 Feb 7:2172276. doi: 10.1080/21645515.2023.2172276. Online ahead of print. PMID: 36749614

Context and Considerations for the Development of Community-Informed Health Communication Messaging to Support Equitable Uptake of COVID-19 Vaccines Among Communities of Color in Washington, DC.
Kerrigan D, Mantsios A, Karver TS, Davis W, Taggart T, Calabrese SK, Mathews A, Robinson S, Ruffin R, Feaster-Bethea G, Quinteros-Grady L, Galvis C, Reyes R, Martinez Chio G, Tesfahun M, Lane A, Peeks S, Henderson KM, Harris KM. J Racial Ethn Health Disparities. 2023 Feb;10(1):395-409. doi: 10.1007/s40615-022-01231-8. Epub 2022 Feb 3. PMID: 35118609

Self-amplifying RNA **vaccine** protects mice against lethal Ebola virus infection.
Krähling V, Erbar S, Kupke A, Nogueira SS, Walzer KC, Berger H, Dietzel E, Halwe S, Rohde C, Sauerhering L, Aragão-Santiago L, Moreno Herrero J, Witzel S, Haas H, Becker S, Sahin U. Mol Ther. 2023 Feb 1;31(2):374-386. doi: 10.1016/j.ymthe.2022.10.011. Epub 2022 Oct 27. PMID: 36303436

mSphere of Influence: Pertussis Vaccination and Antibodies in Mothers and Infants.
Portillo S. mSphere. 2023 Feb 2:e0000923. doi: 10.1128/msphere.00009-23. Online ahead of print. PMID: 36728427

Efficient stabilization of therapeutic hepatitis B **vaccine** components by amino-acid formulation maintains its potential to break immune tolerance.
Sacherl J, Kosinska AD, Kemter K, Kächele M, Laumen SC, Kerth HA, Öz EA, Wolff LS, Su J, Essbauer S, Sutter G, Scholz M, Singethan K, Altrichter J, Protzer U. JHEP Rep. 2022 Oct 13;5(2):100603. doi: 10.1016/j.jhepr.2022.100603. eCollection 2023 Feb. PMID: 36714793

Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines.
Rohokale R, Guo Z. ACS Infect Dis. 2023 Feb 10;9(2):178-212. doi: 10.1021/acsinfecdis.2c00559. Epub 2023 Jan 27. PMID: 36706246

Long-term effects of Pfizer-BioNTech COVID-19 vaccinations on platelets.

Zhou Y, Nishikawa M, Kanno H, Yang R, Ibayashi Y, Xiao TH, Peterson W, Herbig M, Nitta N, Miyata S, Kanthi Y, Rohde GK, Moriya K, Yatomi Y, Goda K. Cytometry A. 2023 Feb;103(2):162-167. doi: 10.1002/cyto.a.24677. Epub 2022 Aug 8. PMID: 35938513

Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales.
Kerr S, Bedston S, Bradley DT, Joy M, Lowthian E, Mulholland RM, Akbari A, Hobbs FDR, Katikireddi SV, de Lusignan S, Rudan I, Torabi F, Tsang RSM, Lyons RA, Robertson C, Sheikh A. Int J Epidemiol. 2023 Feb 8;52(1):22-31. doi: 10.1093/ije/dyac199. PMID: 36272418

COVID-19 vaccination hesitancy and uptake: Perspectives from people released from the Federal Bureau of Prisons.
Kramer C, Song M, Sufrin CB, Eber GB, Rubenstein LS, Saloner B. Vaccine. 2023 Feb 10;41(7):1408-1417. doi: 10.1016/j.vaccine.2023.01.039. Epub 2023 Jan 21. PMID: 36690558

Primary prevention of cervical cancer in women: Human papillomavirus **vaccine**.
O'Neill AM, Dwyer R. Eur J Obstet Gynecol Reprod Biol. 2023 Feb;281:29-31. doi: 10.1016/j.ejogrb.2022.12.001. Epub 2022 Dec 5. PMID: 36529063

A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice.
Kuraoka M, Aschner CB, Windsor IW, Mahant AM, Garforth SJ, Kong SL, Achkar JM, Almo SC, Kelsoe G, Herold BC. J Clin Invest. 2023 Feb 1;133(3):e161968. doi: 10.1172/JCI161968. PMID: 36454639

Translational vaccinomics and structural filtration algorithm to device multiepitope **vaccine** for catastrophic monkeypox virus.
Singh S, Rao A, Kumar K, Mishra A, Prajapati VK. Comput Biol Med. 2023 Feb;153:106497. doi: 10.1016/j.compbiomed.2022.106497. Epub 2022 Dec 30. PMID: 36599210

Rapid Rollout and Initial Uptake of a Booster COVID-19 **Vaccine** Among Israel Defense Forces Soldiers.
Talmy T, Nitzan I. J Prev (2022). 2023 Feb;44(1):1-14. doi: 10.1007/s10935-022-00702-2. Epub 2022 Aug 16. PMID: 35972594

Guillain-Barré syndrome after COVID-19 vaccines: A Tunisian case series.
Berrim K, Lakhoua G, Zaiem A, Charfi O, Aouinti I, Kastalli S, Daghfous R, El Aidli S. Br J Clin Pharmacol. 2023 Feb;89(2):574-578. doi: 10.1111/bcp.15601. Epub 2022 Nov 29. PMID: 36398559

Antibody Response against **Vaccine** Antigens in Children after TCRαβ-Depleted Haploidentical Stem Cell Transplantation: Is It Similar to That in Recipients with Fully Matched Donors?
Kondolot M, Yilmaz E, Erdog Sahin N, Ozcan A, Kaynar L, Unal E, Karakukcu M. Transplant Cell Ther. 2023 Feb;29(2):128.e1-128.e9. doi: 10.1016/j.jtct.2022.10.019. Epub 2022 Oct 30. PMID: 36323399

Factors related to human papillomavirus **vaccine** uptake and intentions among adults aged 18-26 and 27-45 years in the United States: A cross-sectional study.
Arevalo M, Brownstein NC, Whiting J, Vadaparampil ST, Head KJ, Meade CD, Islam JY, Kasting ML, Gwede CK, Barrios-Monroy V, Christy SM. Cancer. 2023 Feb 9. doi: 10.1002/cncr.34680. Online ahead of print. PMID: 36759972

Employing an immunoinformatics approach revealed potent multi-epitope based subunit **vaccine** for lymphocytic choriomeningitis virus.
Waqas M, Aziz S, Bushra A, Halim SA, Ali A, Ullah S, Khalid A, Abdalla AN, Khan A, Al-Harrasi A. J Infect Public Health. 2023 Feb;16(2):214-232. doi: 10.1016/j.jiph.2022.12.023. Epub 2022 Dec 31. PMID: 36603375

SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders.
Khare S, Niharika, Singh A, Hussain I, Singh NB, Singh S. Appl Biochem Biotechnol. 2023 Feb;195(2):1541-1573. doi: 10.1007/s12010-022-04181-3. Epub 2022 Oct 12. PMID: 36222988

mRNA **vaccine** technology for a multivalent flu **vaccine**.
Kirby T. Lancet Infect Dis. 2023 Feb;23(2):157. doi: 10.1016/S1473-3099(23)00013-0. PMID: 36708722

SIBO: the trail of a new human pathology associated with multiple severe and disabling Covid-19 and long Covid symptoms or induced by the anti-Covid-19 **vaccine**.
Fajloun Z, Abi Khattar Z, Kovacic H, Legros C, Sabatier JM. Infect Disord Drug Targets. 2023 Feb 10. doi: 10.2174/1871526523666230210162334. Online ahead of print. PMID: 36762752

Portrait of an autologous cancer **vaccine**: Then and now.
Berd D. Hum Vaccin Immunother. 2023 Feb 8:2172925. doi: 10.1080/21645515.2023.2172925. Online ahead of print. PMID: 36755486

The Past Is so Present: Understanding COVID-19 **Vaccine** Hesitancy Among African American Adults Using Qualitative Data.
Majee W, Anakwe A, Onyeaka K, Harvey IS. J Racial Ethn Health Disparities. 2023 Feb;10(1):462-474. doi: 10.1007/s40615-022-01236-3. Epub 2022 Feb 19. PMID: 35182372

SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection.
Pušnik J, Monzon-Posadas WO, Zorn J, Peters K, Baum M, Proksch H, Schlüter CB, Alter G, Menting T, Streeck H. Nat Commun. 2023 Feb 2;14(1):572. doi: 10.1038/s41467-023-36250-4. PMID: 36732523

A PEG-lipid-free COVID-19 mRNA **vaccine** triggers robust immune responses in mice.
Li M, Huang Y, Wu J, Li S, Mei M, Chen H, Wang N, Wu W, Zhou B, Tan X, Li B. Mater Horiz. 2023 Feb 6;10(2):466-472. doi: 10.1039/d2mh01260j. PMID: 36468425

COVID-19 Booster Vaccination in the U.S. Military, August 2021-January 2022.
Winkler EL, Stahlman SL, Wells NY, Chauhan AV, Hiban KM, Costello AA, Mancuso JD. Am J Prev Med. 2023 Feb;64(2):270-274. doi: 10.1016/j.amepre.2022.07.017. Epub 2022 Aug 29. PMID: 36123230

Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan.
Miyazaki H, Watanabe D, Ito Y, Okamoto N, Tokunaga E, Ku Y, Ooi M, Hoshi N, Kodama Y. Dig Dis Sci. 2023 Feb;68(2):564-570. doi: 10.1007/s10620-022-07703-5. Epub 2022 Sep 30. PMID: 36178566

HIV **vaccine** candidate efficacy in female macaques mediated by cAMP-dependent efferocytosis and V2-specific ADCC.

Bissa M, Kim S, Galli V, Fourati S, Sarkis S, Arakelyan A, de Castro IS, Rahman MA, Fujiwara S, Vaccari M, Tomalka JA, Stamos JD, Schifanella L, Gorini G, Moles R, Gutowska A, Ferrari G, Lobanov A, Montefiori DC, Nelson GW, Cam MC, Chakhtoura M, Haddad EK, Doster MN, McKinnon K, Brown S, Venzon DJ, Choo-Wosoba H, Breed MW, Killoran KE, Kramer J, Margolis L, Sekaly RP, Hager GL, Franchini G. Nat Commun. 2023 Feb 2;14(1):575. doi: 10.1038/s41467-023-36109-8. PMID: 36732510

A longitudinal assessment of variability in COVID-19 **vaccine** hesitancy and psychosocial correlates in a national United States sample.
Shook NJ, Oosterhoff B, Sevi B. Vaccine. 2023 Feb 10;41(7):1390-1397. doi: 10.1016/j.vaccine.2022.12.065. Epub 2023 Jan 2. PMID: 36669969

HPV Infection and Vaccination: A Question and Answer Guide for School Nurses.
Robinson MS, England M, Luthy KE, Peterson NE. NASN Sch Nurse. 2023 Feb 9:1942602X221146758. doi: 10.1177/1942602X221146758. Online ahead of print. PMID: 36757046

Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study.
Hamada H, Futamura M, Ito H, Yamamoto R, Yata K, Iwatani Y, Inoue H, Fukatsu N, Nagai H, Hasegawa Y. Vaccine. 2023 Feb 1:S0264-410X(23)00082-8. doi: 10.1016/j.vaccine.2023.01.050. Online ahead of print. PMID: 36737319

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA **vaccine** against SARS-CoV-2.
Szubert AJ, Pollock KM, Cheeseman HM, Alagaratnam J, Bern H, Bird O, Boffito M, Byrne R, Cole T, Cosgrove CA, Faust SN, Fidler S, Galiza E, Hassanin H, Kalyan M, Libri V, McFarlane LR, Milinkovic A, O'Hara J, Owen DR, Owens D, Pacurar M, Rampling T, Skene S, Winston A, Woolley J, Yim YTN, Dunn DT, McCormack S, Shattock RJ; COVAC 1 Study Team. EClinicalMedicine. 2023 Jan 13;56:101823. doi: 10.1016/j.eclinm.2022.101823. eCollection 2023 Feb. PMID: 36684396

Vaccination and SARS-CoV-2 seroprevalence in blood donors: Correspondence.
Sookaromdee P, Wiwanitkit V. Transfus Clin Biol. 2023 Feb;30(1):22. doi: 10.1016/j.tracli.2022.08.150. Epub 2022 Sep 1. PMID: 36058546

Local infectious disease experience influences **vaccine** refusal rates: a natural experiment.
Angelopoulos K, Stewart G, Mancy R. Proc Biol Sci. 2023 Feb 8;290(1992):20221986. doi: 10.1098/rspb.2022.1986. Epub 2023 Feb 1. PMID: 36722077

Vaccine in Short Supply Amid Increased Cholera Outbreaks.
[No authors listed] Am J Nurs. 2023 Feb 1;123(2):17. doi: 10.1097/01.NAJ.0000919688.58866.9a. PMID: 36698348

Recombinant vesicular stomatitis virus-vectored **vaccine** induces long-lasting immunity against Nipah virus disease.
Woolsey C, Borisevich V, Fears AC, Agans KN, Deer DJ, Prasad AN, O'Toole R, Foster SL, Dobias NS, Geisbert JB, Fenton KA, Cross RW, Geisbert TW. J Clin Invest. 2023 Feb 1;133(3):e164946. doi: 10.1172/JCI164946. PMID: 36445779

COVID-19 **vaccine** inequity and Big Pharma: time to rethink our love affair?
Ali S, Jacub A, Stranges S. Can J Public Health. 2023 Feb;114(1):80-81. doi: 10.17269/s41997-022-00706-9. Epub 2022 Nov 15. PMID: 36380135 F

Cost-effectiveness of future lockdown policies against the COVID-19 pandemic.
Gandjour A. Health Serv Manage Res. 2023 Feb;36(1):51-62. doi: 10.1177/09514848221080687. Epub 2022 Apr 5. PMID: 35380480

Understanding Drivers of **Vaccine** Hesitancy During the COVID-19 Pandemic Among Older Adults in Jiangsu Province, China: Cross-sectional Survey.
Yang L, Ji L, Wang Q, Yang G, Xiu S, Cui T, Shi N, Zhu L, Xu X, Jin H, Zhen S. JMIR Form Res. 2023 Feb 7;7:e39994. doi: 10.2196/39994. PMID: 36693149

The Naturalness Bias Influences Drug and **Vaccine** Decisions across Cultures.
Ji LJ, Lappas CM, Wang XQ, Meier BP. Med Decis Making. 2023 Feb;43(2):252-262. doi: 10.1177/0272989X221140803. Epub 2022 Dec 10. PMID: 36495149

COVID-19 **vaccine** safety during pregnancy in women with systemic lupus erythematosus.
Giannopoulou N, Gupta L, Andreoli L, Lini D; COVAD Study Group; Nikiphorou E, Aggarwal R, Agarwal V, Parodis I. Autoimmun Rev. 2023 Feb 3;22(4):103292. doi: 10.1016/j.autrev.2023.103292. Online ahead of print. PMID: 36740090

Vaccine Preventable Diseases in Pediatric Palliative Care - A Multicenter Cross-Sectional Study.
Vaillant V, Tretiakova I, Berthold D, Scheer M, Kimmig A, Hagenguth A, Kaestner J, Meinhardt A, Kriwy P, Wolff J, Hauch H. J Pain Symptom Manage. 2023 Feb;65(2):101-110. doi: 10.1016/j.jpainsymman.2022.10.014. Epub 2022 Nov 2. PMID: 36334849

Are parents' willing to vaccinate their children against COVID-19? A qualitative study based on the Health Belief Model.
Rajeh MT, Farsi DJ, Farsi NJ, Mosli HH, Mosli MH. Hum Vaccin Immunother. 2023 Feb 8:2177068. doi: 10.1080/21645515.2023.2177068. Online ahead of print. PMID: 36755490

Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary.
Rieckmann P, Centonze D, Giovannoni G, Hua LH, Oreja-Guevara C, Selchen D, Sørensen PS, Vermersch P, Wiendl H, Salloukh H, Yamout B. Neurodegener Dis Manag. 2023 Feb;13(1):5-13. doi: 10.2217/nmt-2022-0027. Epub 2022 Oct 24. PMID: 36278394

Cell membrane-camouflaged liposomes and neopeptide-loaded liposomes with TLR agonist R848 provides a prime and boost strategy for efficient personalized cancer **vaccine** therapy.
Shi L, Gu H. Nanomedicine. 2023 Feb;48:102648. doi: 10.1016/j.nano.2022.102648. Epub 2022 Dec 27. PMID: 36584738

Investigating a Signal of Acquired Hemophilia Associated with COVID-19 Vaccination: A Systematic Case Review.
Franchini M, Cappello E, Valdiserra G, Bonaso M, Moretti U, Focosi D, Tuccori M. Semin Thromb Hemost. 2023 Feb;49(1):15-26. doi: 10.1055/s-0042-1754389. Epub 2022 Sep 2. PMID: 36055265

Bilateral Persistent Placoid Maculopathy Following COVID-19 Vaccines: Real or Coincidence?
Chean CS, Ali E, Kulkarni P, Kapoor B, Kumar P. Ocul Immunol Inflamm. 2023 Feb 3:1-6. doi: 10.1080/09273948.2023.2170889. Online ahead of print. PMID: 36737061

Vaccine certificates for international travelers in future pandemics.
Dal-Ré R, Becker SL, Launay O, Pavli A. Eur J Clin Microbiol Infect Dis. 2023 Feb;42(2):227-228. doi: 10.1007/s10096-022-04544-y. Epub 2022 Dec 23. PMID: 36562922 F

Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, McDonald TJ, Auckland C, Harries LW, Davies M, Michell S, Kok KB, Lamb CA, Smith PJ, Hart AL, Pollok RC, Lees CW, Boyton RJ, Altmann DM, Sebastian S, Powell N, Goodhand JR, Ahmad T. Gut. 2023 Feb;72(2):295-305. doi: 10.1136/gutjnl-2022-327570. Epub 2022 Jul 28. PMID: 35902214

New partnership to boost UK cancer **vaccine** research.
Samarasekera U. Lancet Oncol. 2023 Feb;24(2):132. doi: 10.1016/S1470-2045(23)00011-6. Epub 2023 Jan 12. PMID: 36642081

Culture-centric narratives of influenza vaccination among high-risk groups in Hong Kong.
Ka Lai Lee D, Jiang CL. Health Promot Int. 2023 Feb 1;38(1):daac184. doi: 10.1093/heapro/daac184. PMID: 36617294

[COVID-19 infections and effectiveness of the vaccination among healthcare workers].
Rojkovich B, Németh D, Dinya E, Nagy E, Török E, Lázár I, Perduk A, Géher P, Nagy G. Orv Hetil. 2023 Feb 5;164(5):163-171. doi: 10.1556/650.2023.32709. Print 2023 Feb 5. PMID: 36739547

Health Literacy Correlates to HPV Vaccination Among US Adults Ages 27-45.
Galvin AM, Garg A, Griner SB, Moore JD, Thompson EL. J Cancer Educ. 2023 Feb;38(1):349-356. doi: 10.1007/s13187-021-02123-x. Epub 2022 Jan 13. PMID: 35022987

Reaffirming a Positive Correlation Between Number of **Vaccine** Doses and Infant Mortality Rates: A Response to Critics.
Goldman GS, Miller NZ. Cureus. 2023 Feb 2;15(2):e34566. doi: 10.7759/cureus.34566. eCollection 2023 Feb. PMID: 36751569

Chikungunya Virus **Vaccine** Candidate Incorporating Synergistic Mutations Is Attenuated and Protects Against Virulent Virus Challenge.
Lentscher AJ, McAllister N, Griswold KA, Martin JL, Welsh OL, Sutherland DM, Silva LA, Dermody TS. J Infect Dis. 2023 Feb 1;227(3):457-465. doi: 10.1093/infdis/jiac066. PMID: 35196388

Perceptions, precautions, and **vaccine** acceptance related to monkeypox in the public in China: A cross-sectional survey.
Wang B, Peng X, Li Y, Fu L, Tian T, Liang B, Sun Y, Chen Y, Wu X, Liu Q, Lin YF, Meng X, Zou H. J Infect Public Health. 2023 Feb;16(2):163-170. doi: 10.1016/j.jiph.2022.12.010. Epub 2022 Dec 12. PMID: 36535136

Allergy to Omalizumab: Lessons from a Reaction to the Coronavirus 2019 **Vaccine**.
Matsumoto T, Sakurai Y, Fujiki T, Kusakabe Y, Nakayama E, Tanaka A, Yamamoto N, Aihara K, Yamaoka S, Mishima M. Intern Med. 2023 Feb 1. doi: 10.2169/internalmedicine.1169-22. Online ahead of print. PMID: 36725035

Pregnancy outcomes and **vaccine** effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
Villar J, Soto Conti CP, Gunier RB, Ariff S, Craik R, Cavoretto PI, Rauch S, Gandino S, Nieto R, Winsey A, Menis C, Rodriguez GB, Savasi V, Tug N, Deantoni S, Fabre M, Martinez de Tejada B, Rodriguez-Sibaja MJ, Livio S, Napolitano R, Maiz N, Sobrero H, Peterson A, Deruelle P, Giudice C, Teji JS, Casale RA, Salomon LJ, Prefumo F, Cheikh Ismail L, Gravett MG, Vale M, Hernández V, Sentilhes L, Easter SR, Capelli C, Marler E, Cáceres DM, Albornoz Crespo G, Ernawati E, Lipschuetz M, Takahashi K, Vecchiarelli C, Hubka T, Ikenoue S, Tavchioska G, Bako B, Ayede AI, Eskenazi B, Thornton JG, Bhutta ZA, Kennedy SH, Papageorghiou AT; INTERCOVID-2022 International Consortium. Lancet. 2023 Feb 11;401(10375):447-457. doi: 10.1016/S0140-6736(22)02467-9. Epub 2023 Jan 17. PMID: 36669520

Varicella in the Neonatal ICU due to the Varicella **Vaccine** Oka Strain.
Frantzis I, Messina M, Taylor JM, Aschheim K, Hu H, Hairston JC, Lauren CT, Gershon A, Feldstein N, Orange J, Saiman L. J Neonatal Perinatal Med. 2023 Feb 1. doi: 10.3233/NPM-221031. Online ahead of print. PMID: 36744349

Evaluating methods to create protein functionalized catanionic vesicles.
Zayka P, Parr B, Robichaud H, Hickey S, Topping A, Holt E, Watts DBE, Soto N, Stein DC, DeShong P, Hurley M. Soft Matter. 2023 Feb 1. doi: 10.1039/d2sm01205g. Online ahead of print. PMID: 36723251

Primary prevention of acute cardiovascular events by influenza vaccination: an observational study.
Davidson JA, Banerjee A, Douglas I, Leyrat C, Pebody R, McDonald HI, Herrett E, Forbes H, Smeeth L, Warren-Gash C. Eur Heart J. 2023 Feb 14;44(7):610-620. doi: 10.1093/eurheartj/ehac737. PMID: 36537199

Unlocking infodemics and mysteries in COVID-19 **vaccine** hesitancy: Nexus of conspiracy beliefs, digital informational support, psychological Well-being, and religious fatalism.
Hassan Raza S, Yousaf M, Zaman U, Waheed Khan S, Core R, Malik A. Vaccine. 2023 Feb 3:S0264-410X(23)00079-8. doi: 10.1016/j.vaccine.2023.01.047. Online ahead of print. PMID: 36754765

Relative effectiveness of COVID-19 vaccination and booster dose combinations among 18.9 million vaccinated adults during the early SARS-CoV-2 Omicron period - United States, January 1, 2022-March 31, 2022.
Kompaniyets L, Wiegand RE, Oyalowo AC, Bull-Otterson L, Egwuogu H, Thompson T, Kahihikolo K, Moore L, Jones-Jack N, El Kalach R, Srinivasan A, Messer A, Pilishvili T, Harris AM, Gundlapalli AV, Link-Gelles R, Boehmer TK. Clin Infect Dis. 2023 Feb 8:ciad063. doi: 10.1093/cid/ciad063. Online ahead of print. PMID: 36750643

The Negative Effect of Preexisting Immunity on Influenza **Vaccine** Responses Transcends the Impact of **Vaccine** Formulation Type and Vaccination History.
Moritzky SA, Richards KA, Glover MA, Krammer F, Chaves FA, Topham DJ, Branche A, Nayak JL, Sant AJ. J Infect Dis. 2023 Feb 1;227(3):381-390. doi: 10.1093/infdis/jiac068. PMID: 35199825

Thermostable negative-marker foot-and-mouth disease virus serotype O induces protective immunity in guinea pigs.
Ranjitha HB, Dhanesh VV, Hosamani M, Sreenivasa BP, Jabeen U, Biswal JK, Saravanan P, Sanyal A, Bhanuprakash V, Basagoudanavar SH. Appl Microbiol Biotechnol. 2023 Feb;107(4):1285-1297. doi: 10.1007/s00253-023-12359-w. Epub 2023 Jan 19. PMID: 36656322

Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus **vaccine**: a challenge study in macaques.
Marzi A, Fletcher P, Feldmann F, Saturday G, Hanley PW, Feldmann H. Lancet Microbe. 2023 Feb 2:S2666-5247(23)00001-0. doi: 10.1016/S2666-5247(23)00001-0. Online ahead of print. PMID: 36739878

The role of a single-shot higher-valency pneumococcal **vaccine** in overcoming challenges regarding invasive pneumococcal disease in Hong Kong.
Hui CKM, Hung IFN, Lam B, Lin AWC, So TMK, Wong ATY, Wong MCS. Hong Kong Med J. 2023 Feb 8. doi: 10.12809/hkmj235141. Online ahead of print. PMID: 36751099

A recombinant baculovirus vector **vaccine** (BacMCP) against the infectious spleen and kidney necrosis virus (ISKNV).
Zhu M, Shen Z, Gu Y, Tong X, Zhang Y, Pan J, Feng Y, Hu X, Wang Y, Cao G, Xue R, Gong C. J Fish Dis. 2023 Feb;46(2):165-176. doi: 10.1111/jfd.13731. Epub 2022 Nov 24. PMID: 36423261

New COVID-19 **vaccine** strategy would mimic flu's annual shots.
Couzin-Frankel J. Science. 2023 Feb 3;379(6631):425-426. doi: 10.1126/science.adg9446. Epub 2023 Feb 2. PMID: 36730399

Unilateral Grover-like Skin Eruption Following Pfizer COVID-19 **Vaccine**.
Dadrass F, Knabel M, Swan J. Am J Dermatopathol. 2023 Feb 7. doi: 10.1097/DAD.0000000000002365. Online ahead of print. PMID: 36749132

IgA Vasculitis Following COVID-19 Vaccination: A French Multicenter Case Series Including 12 Patients.
Ramdani Y, Bettuzzi T, Bouznad A, Delaitre L, Nassarmadji K, Didier K, Paul C, Liozon E, Tieu A, Richard-Colmant G, Terrier B, Moulis G, Lafaurie M, Pillebout E, Maillot F, Audemard-Verger A. J Rheumatol. 2023 Feb;50(2):252-257. doi: 10.3899/jrheum.220545. Epub 2022 Nov 1. PMID: 36319000

Waning immunity to inactive SARS-CoV-2 **vaccine** in healthcare workers: booster required.
Balkan İİ, Dinc HO, Can G, Karaali R, Ozbey D, Caglar B, Beytur AN, Keskin E, Budak B, Aydogan O, Mete B, Ergin S, Kocazeybek B, Saltoglu N. Ir J Med Sci. 2023 Feb;192(1):19-25. doi: 10.1007/s11845-022-02984-1. Epub 2022 Mar 28. PMID: 35344137

Recent advancement, immune responses, and mechanism of action of various vaccines against intracellular bacterial infections.
Ali A, Waris A, Khan MA, Asim M, Khan AU, Khan S, Zeb J. Life Sci. 2023 Feb 1;314:121332. doi: 10.1016/j.lfs.2022.121332. Epub 2022 Dec 28. PMID: 36584914

Characterization of a VRC01-like antibody lineage with immature V_L from an HIV-1 infected Chinese donor.
Hu Y, Li D, Yuan Z, Feng Y, Ren L, Hao Y, Wang S, Hu X, Liu Y, Hong K, Shao Y, Wang Z. Mol Immunol. 2023 Feb;154:11-23. doi: 10.1016/j.molimm.2022.12.011. Epub 2022 Dec 26. PMID: 36577292

Indolent cutaneous lymphoma with gamma/delta expression after COVID-19 vaccination.
Hobayan CG, Chung CG. JAAD Case Rep. 2023 Feb;32:74-76. doi: 10.1016/j.jdcr.2022.12.001. Epub 2022 Dec 13. PMID: 36530557

SARS-CoV-2 **vaccine** breakthrough infections in Virginia, January 17, 2021 - June 30, 2021.
Darby B, Alexander V, Murphy J. Vaccine. 2023 Feb 10;41(7):1295-1298. doi: 10.1016/j.vaccine.2023.01.041. Epub 2023 Jan 20. PMID: 36690560

Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
Epsi NJ, Richard SA, Lindholm DA, Mende K, Ganesan A, Huprikar N, Lalani T, Fries AC, Maves RC, Colombo RE, Larson DT, Smith A, Chi SW, Maldonado CJ, Ewers EC, Jones MU, Berjohn CM, Libraty DH, Edwards MS, English C, Rozman JS, Mody RM, Colombo CJ, Samuels EC, Nwachukwu P, Tso MS, Scher AI, Byrne C, Rusiecki J, Simons MP, Tribble D, Broder CC, Agan BK, Burgess TH, Laing ED, Pollett SD; Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential COVID-19 Cohort Study Group. Clin Infect Dis. 2023 Feb 8;76(3):e439-e449. doi: 10.1093/cid/ciac392. PMID: 35608504

Influenza During the 2010-2020 Decade in the United States: Seasonal Outbreaks and **Vaccine** Interventions.
Malosh RE, McGovern I, Monto AS. Clin Infect Dis. 2023 Feb 8;76(3):540-549. doi: 10.1093/cid/ciac653. PMID: 36219562

Commentary: Estimation of **vaccine** effectiveness using the screening method.
Flannery B, Andrews N, Feikin D, Patel MK. Int J Epidemiol. 2023 Feb 8;52(1):19-21. doi: 10.1093/ije/dyac013. PMID: 35138384

A qualitative study of behavioral and social drivers of COVID-19 **vaccine** confidence and uptake among unvaccinated Americans in the US April-May 2021.
Abad N, Messinger SD, Huang Q, Hendrich MA, Johanson N, Fisun H, Lewis Z, Wilhelm E, Baack B, Bonner KE, Kobau R, Brewer NT. PLoS One. 2023 Feb 10;18(2):e0281497. doi: 10.1371/journal.pone.0281497. eCollection 2023. PMID: 36763680

COVID-19 **vaccine** side effects in patients with and without atopic dermatitis.
Shin L, Shahsavari S, Laborada J, Lee C, Thyssen JP, Wu JJ. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e138-e140. doi: 10.1111/jdv.18710. Epub 2022 Nov 7. PMID: 36305461

A typology of **vaccine** hesitancies: Results from a study of community pharmacists administering COVID-19 vaccinations during the pandemic.
Gregory PAM, Gill M, Datta D, Austin Z. Res Social Adm Pharm. 2023 Feb;19(2):332-342. doi: 10.1016/j.sapharm.2022.09.016. Epub 2022 Oct 8. PMID: 36266175

COVID-19 **vaccine** for young children: Will parents accept it?
Curatola A, Ferretti S, Gatto A, Chiaretti A. Acta Paediatr. 2023 Feb;112(2):301-302. doi: 10.1111/apa.16601. Epub 2022 Dec 1. PMID: 36415084

Transdermal Transmission Blocking **Vaccine** for Malaria using a Solid-in-Oil Dispersion.
Tanaka K, Minamihata K, Wakabayashi R, Lee JM, Miyata T, Kusakabe T, Kamiya N, Goto M. J Pharm Sci. 2023 Feb;112(2):411-415. doi: 10.1016/j.xphs.2022.10.031. Epub 2022 Nov 10. PMID: 36334812

Immune-enhancing effects of Astragalus polysaccharides and Ganoderma lucidum polysaccharides on Vibrio harveyi flgJ DNA **vaccine** in grouper.
Lin G, Da F, Wan X, Huang Y, Yang S, Jian J, Cai S. J Fish Dis. 2023 Feb;46(2):147-156. doi: 10.1111/jfd.13728. Epub 2022 Nov 9. PMID: 36352832

Attenuated African swine fever virus through serial passaging of viruses in cell culture: a brief review on the knowledge gathered during 60 years of research.
Zhang X, Wang Z, Ge S, Zuo Y, Lu H, Lv Y, Han N, Cai Y, Wu X, Wang Z. Virus Genes. 2023 Feb;59(1):13-24. doi: 10.1007/s11262-022-01939-z. Epub 2022 Oct 14. PMID: 36229722

SARS-CoV-2 elicits non-sterilizing immunity and evades **vaccine**-induced immunity: implications for future vaccination strategies.
Beukenhorst AL, Koch CM, Hadjichrysanthou C, Alter G, de Wolf F, Anderson RM, Goudsmit J. Eur J Epidemiol. 2023 Feb 4:1-6. doi: 10.1007/s10654-023-00965-x. Online ahead of print. PMID: 36738380

Genetic analysis of infectious bronchitis virus (IBV) in vaccinated poultry populations over a period of 10 years.
Vermeulen CJ, Dijkman R, de Wit JJS, Bosch BJ, Heesterbeek JAPH, van Schaik G. Avian Pathol. 2023 Feb 6:1-34. doi: 10.1080/03079457.2023.2177140. Online ahead of print. PMID: 36745131

Streptococcus pyogenes **vaccine** candidates do not induce autoimmune responses in a rheumatic heart disease model.
Reynolds S, Rafeek RAM, Hamlin A, Lepletier A, Pandey M, Ketheesan N, Good MF. NPJ Vaccines. 2023 Feb 4;8(1):9. doi: 10.1038/s41541-023-00604-2. PMID: 36739443

Age-Stratified Model to Assess Health Outcomes of COVID-19 Vaccination Strategies, Ghana.
Ofori SK, Schwind JS, Sullivan KL, Chowell G, Cowling BJ, Fung IC. Emerg Infect Dis. 2023 Feb;29(2):360-370. doi: 10.3201/eid2902.221098. Epub 2023 Jan 10. PMID: 36626878

Active Postlicensure Safety Surveillance for Recombinant Zoster **Vaccine** Using Electronic Health Record Data.
Nelson JC, Ulloa-Pérez E, Yu O, Cook AJ, Jackson ML, Belongia EA, Daley MF, Harpaz R, Kharbanda EO, Klein NP, Naleway AL, Tseng HF, Weintraub ES, Duffy J, Yih WK, Jackson LA. Am J Epidemiol. 2023 Feb 1;192(2):205-216. doi: 10.1093/aje/kwac170. PMID: 36193854

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection.
Khoury DS, Schlub TE, Cromer D, Steain M, Fong Y, Gilbert PB, Subbarao K, Triccas JA, Kent SJ, Davenport MP. Emerg Infect Dis. 2023 Feb;29(2):381-388. doi: 10.3201/eid2902.221422. PMID: 36692375

Aluminum-based metal-organic framework nanoparticles as pulmonary **vaccine** adjuvants.
Stillman ZS, Decker GE, Dworzak MR, Bloch ED, Fromen CA. J Nanobiotechnology. 2023 Feb 3;21(1):39. doi: 10.1186/s12951-023-01782-w. PMID: 36737783

From Facebook to YouTube: The Potential Exposure to COVID-19 Anti-**Vaccine** Videos on Social Media.
Gruzd A, Abul-Fottouh D, Song MY, Saiphoo A. Soc Media Soc. 2023 Feb 1;9(1):20563051221150403. doi: 10.1177/20563051221150403. eCollection 2023 Jan-Mar. PMID: 36751363

Safety and immunogenicity following co-administration of Yellow fever **vaccine** with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.
Sandberg JT, Löfling M, Varnaitė R, Emgård J, Al-Tawil N, Lindquist L, Gredmark-Russ S, Klingström J, Loré K, Blom K, Ljunggren HG. PLoS Negl Trop Dis. 2023 Feb 9;17(2):e0010616. doi: 10.1371/journal.pntd.0010616. Online ahead of print. PMID: 36758067

Self-Boosting Vaccination Based on Pulsatile Antigen Release from Core-Shell Microparticles.
Di J, Wang J, Wang S, Ma M, Zhang H, Liu N, Zheng A, Gao X, Liu B, Gao J. Small. 2023 Feb 2:e2207892. doi: 10.1002/smll.202207892. Online ahead of print. PMID: 36732845

Exploring the ethical complexity of pediatric organ transplant candidates and COVID-19 vaccination: Tensions between autonomy and beneficence, children and parents.
Lara Carrion L, Bramstedt KA. Pediatr Transplant. 2023 Feb;27(1):e14408. doi: 10.1111/petr.14408. Epub 2022 Oct 9. PMID: 36210480

A mathematical model of protein subunits COVID-19 vaccines.
Gholami S, Korosec CS, Farhang-Sardroodi S, Dick DW, Craig M, Ghaemi MS, Ooi HK, Heffernan JM. Math Biosci. 2023 Feb 9:108970. doi: 10.1016/j.mbs.2023.108970. Online ahead of print. PMID: 36773843

Immunogenicity of SARS-CoV-2 **Vaccine** in Kidney Transplant Recipients: A Cross-Sectional Study in Korea.
Song SH, Chung KY, Jee Y, Chung HS, Kim K, Minn D, Kim SK. J Korean Med Sci. 2023 Feb 6;38(5):e22. doi: 10.3346/jkms.2023.38.e22. PMID: 36747360

Identifying COVID-19 **Vaccine** Deserts and Ways to Reduce Them: A Digital Tool to Support Public Health Decision-Making.
Weintraub RL, Miller K, Rader B, Rosenberg J, Srinath S, Woodbury SR, Schultheiss MD, Kansal M, Vispute S, Serghiou S, Flores G, Kumok A, Shekel T, Gabrilovich E, Ahmad I, Chiang ME, Brownstein JS. Am J Public Health. 2023 Feb 2:e1-e5. doi: 10.2105/AJPH.2022.307198. Online ahead of print. PMID: 36730873

Socioeconomic and demographic characteristics influencing the hesitancy and refusal of COVID-19 **vaccine** in Ghana.
Sampene AK, Li C, Oteng Agyeman F, Brenya R. Ther Adv Vaccines Immunother. 2023 Feb 9;11:25151355221149336. doi: 10.1177/25151355221149336. eCollection 2023. PMID: 36778098

A bivalent form of nanoparticle-based dengue **vaccine** stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells.
Seesen M, Jearanaiwitayakul T, Limthongkul J, Midoeng P, Sunintaboon P, Ubol S. Vaccine. 2023 Feb 3:S0264-410X(23)00096-8. doi: 10.1016/j.vaccine.2023.01.062. Online ahead of print. PMID: 36740559

Vaccine effectiveness estimates from an early-season influenza A(H3N2) epidemic, including unique genetic diversity with reassortment, Canada, 2022/23.

Skowronski DM, Chuang ES, Sabaiduc S, Kaweski SE, Kim S, Dickinson JA, Olsha R, Gubbay JB, Zelyas N, Charest H, Bastien N, Jassem AN, De Serres G. Euro Surveill. 2023 Feb;28(5):2300043. doi: 10.2807/1560-7917.ES.2023.28.5.2300043. PMID: 36729117

Maternal antibodies induced by a live attenuated **vaccine** protect neonatal mice from cytomegalovirus.
Le-Trilling VTK, Jagnjić A, Brizić I, Eilbrecht M, Wohlgemuth K, Rožmanić C, Herdman A, Hoffmann K, Westendorf AM, Hengel H, Jonjić S, Trilling M. NPJ Vaccines. 2023 Feb 3;8(1):8. doi: 10.1038/s41541-023-00602-4. PMID: 36737485

Reverse vaccinology approach to design a **vaccine** targeting membrane lipoproteins of *Salmonella typhi*.
Sharma S, Solanki V, Tiwari V. J Biomol Struct Dyn. 2023 Feb;41(3):954-969. doi: 10.1080/07391102.2021.2015443. Epub 2021 Dec 23. PMID: 34939517

Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: A modelling study.
You T, Zhao X, Hu S, Gao M, Liu Y, Zhang Y, Qiao Y, Jit M, Zhao F. EClinicalMedicine. 2022 Dec 26;56:101789. doi: 10.1016/j.eclinm.2022.101789. eCollection 2023 Feb. PMID: 36618898

Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2.
Agallou M, Koutsoni OS, Michail M, Zisimopoulou P, Tsitsilonis OE, Karagouni E. J Infect Dis. 2023 Feb 1;227(3):353-363. doi: 10.1093/infdis/jiac421. PMID: 36259394

Preclinical development of a **vaccine**-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens.
Cho H, Binder J, Weeratna R, Dermyer M, Dai S, Boccia A, Li W, Li S, Jooss K, Merson J, Hollingsworth RE. Cancer Immunol Immunother. 2023 Feb;72(2):287-300. doi: 10.1007/s00262-022-03245-x. Epub 2022 Jul 13. PMID: 35829790

COVID19 **vaccine** in myasthenia gravis patients: safety and possible predictors of disease exacerbation.
Trinchillo A, Esposito M, Habetswallner F, Tuccillo F, De Martino BM. Neurol Sci. 2023 Feb;44(2):447-450. doi: 10.1007/s10072-022-06584-w. Epub 2022 Dec 25. PMID: 36567408

Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-**vaccine** neutralizing antibodies.
Aijaz J, Kanani F, Naseer F. J Clin Virol Plus. 2023 Feb;3(1):100137. doi: 10.1016/j.jcvp.2023.100137. Epub 2023 Jan 11. PMID: 36644775

Strengthening polio **vaccine** demand in Ghana: Understanding the factors influencing uptake of the **vaccine** and the effectiveness of different message frames.
Lohiniva AL, Nurzhynska A, Mueed A, Ali A, Ahmed K, Ayiku P, Amo-Adjei J, Kawakatsu Y, Shetye M, Greiner K, McIntosh R. PLoS One. 2023 Feb 10;18(2):e0279809. doi: 10.1371/journal.pone.0279809. eCollection 2023. PMID: 36763581

The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipeline.
Frost I, Sati H, Garcia-Vello P, Hasso-Agopsowicz M, Lienhardt C, Gigante V, Beyer P. Lancet Microbe. 2023 Feb;4(2):e113-e125. doi: 10.1016/S2666-5247(22)00303-2. Epub 2022 Dec 14. PMID: 36528040

Effectiveness of a Meningococcal Group B **Vaccine** (4CMenB) in Children.
Castilla J, García Cenoz M, Abad R, Sánchez-Cambronero L, Lorusso N, Izquierdo C, Cañellas Llabrés S, Roig J, Malvar A, González Carril F, Boone ALD, Pérez Martín J, Rodríguez Recio MJ, Galmés A, Caballero A, García Rojas A, Juanas F, Nieto M, Viloria Raymundo LJ, Martínez Ochoa E, Rivas AI, Castrillejo D, Moreno Pérez D, Martínez A, Borràs E, Sánchez Gómez A, Pastor E, Nartallo V, Arteagoitia JM, Álvarez-Fernández B, García Pina R, Fernández Arribas S, Vanrell J, García Hernández S, Mendoza RM, Méndez M, López-Tercero MM, Fernández-Rodríguez Á, Blanco Á, Carrillo de Albornoz FJ, Ruiz Olivares J, Ruiz-Montero R, Limia A, Navarro-Alonso JA, Vázquez JA, Barricarte A. N Engl J Med. 2023 Feb 2;388(5):427-438. doi: 10.1056/NEJMoa2206433. PMID: 36724329

Proteomic analysis of exosome-like vesicles from Fasciola gigantica adult worm provides support for new **vaccine** targets against fascioliasis.
Sheng ZA, Wu CL, Wang DY, Zhong SH, Yang X, Rao GS, Peng H, Feng SW, Li J, Huang WY, Luo HL. Parasit Vectors. 2023 Feb 10;16(1):62. doi: 10.1186/s13071-023-05659-7. PMID: 36765398

Laser-assisted intradermal delivery of a microparticle **vaccine** for respiratory syncytial virus induces a robust immune response.
Menon I, Kang SM, Braz Gomes K, Uddin MN, D'Souza M. Vaccine. 2023 Feb 3;41(6):1209-1222. doi: 10.1016/j.vaccine.2023.01.002. Epub 2023 Jan 9. PMID: 36631361

Influence of the COVID-19 pandemic and social media on the behaviour of pregnant and lactating women towards vaccination: a scoping review.
De Brabandere L, Hendrickx G, Poels K, Daelemans W, Van Damme P, Maertens K. BMJ Open. 2023 Feb 10;13(2):e066367. doi: 10.1136/bmjopen-2022-066367. PMID: 36764726

Adeno-associated virus-based malaria booster **vaccine** following attenuated replication-competent vaccinia virus LC16m8Δ priming.
Hasyim AA, Iyori M, Mizuno T, Abe YI, Yamagoshi I, Yusuf Y, Syafira I, Sakamoto A, Yamamoto Y, Mizukami H, Shida H, Yoshida S. Parasitol Int. 2023 Feb;92:102652. doi: 10.1016/j.parint.2022.102652. Epub 2022 Aug 23. PMID: 36007703

Baculoviral COVID-19 Delta DNA **vaccine** cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice.
Jang Y, Cho H, Chun J, Park K, Nowakowska A, Kim J, Lee H, Lee C, Han Y, Lee HJ, Shin HY, Kim YB. Vaccine. 2023 Feb 3;41(6):1223-1231. doi: 10.1016/j.vaccine.2022.12.067. Epub 2023 Jan 6. PMID: 36631359

Co-administration of COVID-19 and influenza vaccines.
Didierlaurent AM, Lambert PH. Clin Microbiol Infect. 2023 Feb 9:S1198-743X(23)00056-3. doi: 10.1016/j.cmi.2023.02.003. Online ahead of print. PMID: 36773770

COVID-19 **vaccine** affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study.
Pan H, Tang Z, Teng J, Sun Y, Liu H, Cheng X, Su Y, Ye J, Hu Q, Chi H, Zhou Z, Jia J, Meng J, Wang M, Wang F, Chen X, Ma Y, Zhang H, You Y, Zhu D, Chen L, Yang C, Shi H, Liu T. Rheumatology (Oxford). 2023 Feb 1;62(2):829-834. doi: 10.1093/rheumatology/keac400. PMID: 35866674

Long-lasting T-cell response to SARS-CoV-2 antigens after vaccination-a prospective cohort study of HCWs working with COVID-19 patients.
Krifors A, Freyhult E, Rashid Teljebäck M, Wallin RPA, Winqvist O, Månsson E. Infect Dis (Lond). 2023 Feb;55(2):142-148. doi: 10.1080/23744235.2022.2142662. Epub 2022 Nov 11. PMID: 36369711

A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) **vaccine** seroprotection in patients receiving maintenance dialysis.
Manley HJ, Aweh G, Frament J, Ladik V, Lacson EK. Nephrol Dial Transplant. 2023 Feb 13;38(2):447-454. doi: 10.1093/ndt/gfac039. PMID: 35150277

Oral Vaccination with Engineered Probiotic Limosilactobacillus reuteri Has Protective Effects against Localized and Systemic Staphylococcus aureus Infection.
Pan N, Liu Y, Zhang H, Xu Y, Bao X, Sheng S, Liang Y, Liu B, Lyu Y, Li H, Ma F, Pan H, Wang X. Microbiol Spectr. 2023 Feb 1:e0367322. doi: 10.1128/spectrum.03673-22. Online ahead of print. PMID: 36723073

Recombinant protein subunit COVID-19 **vaccine**-induced Guillain-Barré Syndrome in an adolescent: A case report.
Rohilla R, Kakkar AK, Divyashree K, Mohindra R, Suri V. Br J Clin Pharmacol. 2023 Feb;89(2):556-560. doi: 10.1111/bcp.15466. Epub 2022 Aug 1. PMID: 35856283

Sterile Filtration of a Multi-Serotype Glycoconjugate **Vaccine** Drug Product.
Du Z, Gill K, Toprani V, Zydney AL. Biotechnol Bioeng. 2023 Feb 1. doi: 10.1002/bit.28342. Online ahead of print. PMID: 36726046

Novel sialoglycan linkage for constructing adjuvant-protein conjugate as potent **vaccine** for COVID-19.
Wen Y, Zhang RY, Wang J, Zhou SH, Peng XQ, Ding D, Zhang ZM, Wei HW, Guo J. J Control Release. 2023 Feb 8;355:238-247. doi: 10.1016/j.jconrel.2023.01.062. Online ahead of print. PMID: 36716860

Vaccination intention and uptake within the Black community in Appalachia.
Brumbaugh JT, Sokoto KC, Wright CD, Francis SE, Hubbard J, Alexander L, McNeil DW. Health Psychol. 2023 Feb 13. doi: 10.1037/hea0001264. Online ahead of print. PMID: 36780275

Serological response to COVID-19 **vaccine** and its predictors in patients with solid malignancies: A systematic review and meta-analysis of 16 cohort studies.
Chen D, Pan Y, Wang Y, Chen X, Zhang J, Zhang Y, Ding T, Yang Z, Lu T, Zheng Y, Wei J, Kong W, Li H, Yin X, Yang G, Zhang G, Wang X. J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.012. Epub 2022 Nov 26. PMID: 36574520

Surgically Derived Cancer Cell Membrane-Coated R837-Loaded Poly(2-Oxazoline) Nanoparticles for Prostate Cancer Immunotherapy.
Li S, Dong S, Wu J, Lv X, Yang N, Wei Q, Wang C, Chen J. ACS Appl Mater Interfaces. 2023 Feb 4. doi: 10.1021/acsami.2c22363. Online ahead of print. PMID: 36738473

Dosing of intravenous immunoglobulin in COVID-19 **vaccine**-induced immune thrombocytopenia and thrombosis.

Misbah SA, Pavord S, Foster M. J Clin Pathol. 2023 Feb;76(2):143-144. doi: 10.1136/jcp-2022-208377. Epub 2022 Sep 29. PMID: 36175122

Vaccination with a cocktail **vaccine** elicits significant protection against Sarcoptes scabiei in rabbits, whereas the multi-epitope **vaccine** offers limited protection.
Shen N, Wei W, Chen Y, Liu S, Xiong L, Xiao J, Gu X, Xie Y, Xu J, Jing B, Peng X, Yang G. Exp Parasitol. 2023 Feb;245:108442. doi: 10.1016/j.exppara.2022.108442. Epub 2022 Dec 9. PMID: 36509170

Cost-effectiveness of sub-national geographically targeted vaccination programs: A systematic review.
Getchell M, Mantaring EJ, Yee K, Pronyk P. Vaccine. 2023 Feb 11:S0264-410X(23)00132-9. doi: 10.1016/j.vaccine.2023.02.006. Online ahead of print. PMID: 36781333

Possible Mpox Protection from Smallpox **Vaccine**-Generated Antibodies among Older Adults.
Sanz-Muñoz I, Sánchez-dePrada L, Sánchez-Martínez J, Rojo-Rello S, Domínguez-Gil M, Hernán-García C, Fernández-Espinilla V, de Lejarazu-Leonardo RO, Castrodeza-Sanz J, Eiros JM. Emerg Infect Dis. 2023 Feb 2;29(3). doi: 10.3201/eid2903.221231. Online ahead of print. PMID: 36732061

Research Note: Effect of a live Salmonella Enteritidis **vaccine** against Salmonella Pullorum infection in breeder chickens.
Li P, Guo L, Luan Y, Zhao W, Cui L, Hao G, Sun S. Poult Sci. 2023 Feb;102(2):102308. doi: 10.1016/j.psj.2022.102308. Epub 2022 Nov 3. PMID: 36470026

Transarterial Embolization for Shoulder Injury Related to **Vaccine** COVID-19 Administration.
Fernández Martínez AM, Cuesta Marcos MT, Rodríguez Prieto J. Cardiovasc Intervent Radiol. 2023 Feb;46(2):292-294. doi: 10.1007/s00270-022-03319-4. Epub 2022 Nov 30. PMID: 36450993

Effects of the BTN162b2 mRNA COVID-19 **vaccine** in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
Fiorcari S, Atene CG, Maffei R, Mesini N, Debbia G, Colasante C, Pozzi S, Barbieri E, Maccaferri M, Leonardi G, Potenza L, Luppi M, Marasca R. Hematol Oncol. 2023 Feb;41(1):120-127. doi: 10.1002/hon.3077. Epub 2022 Sep 30. PMID: 36156278

A novel tool to eradicate an ancient scourge: the novel oral polio **vaccine** type 2 story.
Bandyopadhyay AS, Zipursky S. Lancet Infect Dis. 2023 Feb;23(2):e67-e71. doi: 10.1016/S1473-3099(22)00582-5. Epub 2022 Sep 23. PMID: 36162417

Immunogenicity and safety of a third dose of anti-SARS-CoV-2 BNT16b2 **vaccine** in liver transplant recipients.
Toniutto P, Cussigh A, Cmet S, Bitetto D, Fornasiere E, Fumolo E, Fabris M, D'Aurizio F, Fabris C, Grillone L, Sartor A, Curcio F, Falleti E. Liver Int. 2023 Feb;43(2):452-461. doi: 10.1111/liv.15331. Epub 2022 Dec 14. PMID: 35661561

Call out racism and inequity in reports on **vaccine** intentions.
Wilson RF, Kota KK, Sheats KJ, Luna-Pinto C, Owens C, Harrison DD, Razi S. Nat Hum Behav. 2023 Feb 8. doi: 10.1038/s41562-023-01532-w. Online ahead of print. PMID: 36755132

Nasal delivery of an immunotherapeutic **vaccine** in thermosensitive hydrogel against allergic asthma.

Zhong Y, Su C, Wu S, Miao C, Wang B. Int Immunopharmacol. 2023 Feb 2;116:109718. doi: 10.1016/j.intimp.2023.109718. Online ahead of print. PMID: 36738673

Hawman DW, Meade-White K, Leventhal S, Appelberg S, Ahlén G, Nikouyan N, Clancy C, Smith B, Hanley P, Lovaglio J, Mirazimi A, Sällberg M, Feldmann H. Mol Ther. 2023 Feb 1;31(2):387-397. doi: 10.1016/j.ymthe.2022.09.016. Epub 2022 Oct 3. PMID: 36184852

Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 **vaccine**.
Sheng WH, Ieong SM, Lin PH, Hsieh MJ, Yang HC, Pan CF, Chao TL, Chang SY, Chang SC. J Formos Med Assoc. 2023 Feb;122(2):121-131. doi: 10.1016/j.jfma.2022.09.004. Epub 2022 Sep 8. PMID: 36127206

A booster shot of **vaccine** against SARS-CoV-2 should be rigorously promoted and implemented in China.
Yin Y, Lin J, Yuan S, Tong S, Chen E, Zheng J, Wang W. J Infect. 2023 Feb;86(2):e49-e50. doi: 10.1016/j.jinf.2022.09.015. Epub 2022 Sep 25. PMID: 36170897

Primary diphtheria immunisation of adolescents and adults with low-dose **vaccine**, a survey of historic evidence from the literature.
Kahn F, Lepp T, Storsaeter J. Acta Paediatr. 2023 Feb;112(2):242-245. doi: 10.1111/apa.16589. Epub 2022 Nov 17. PMID: 36333877

COVID **vaccine**-associated myocarditis in an 8-year-old patient - ERRATUM.
Mehta K, Cohen R, Kelly B, Grosse-Wortmann L. Cardiol Young. 2023 Feb;33(2):336. doi: 10.1017/S1047951122002657. Epub 2022 Aug 9. PMID: 35942708

Working towards a comprehensive appraisal of **vaccine**-induced immunity against SARS-CoV-2 in IBD.
Otten AT, Bourgonje AR, Visschedijk MC. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):99-100. doi: 10.1016/S2468-1253(22)00404-6. Epub 2022 Dec 5. PMID: 36481042

Exploring staphylococcal superantigens to design a potential multi-epitope **vaccine** against *Staphylococcus aureus*: an *in-silico* reverse vaccinology approach.
Rahman S, Sarkar K, Das AK. J Biomol Struct Dyn. 2023 Feb 2:1-15. doi: 10.1080/07391102.2023.2171138. Online ahead of print. PMID: 36729064

Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial.
Boulware DR, Murray TA, Proper JL, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Siegel LK, Klatt NR, Odde DJ, Karger AB, Ingraham NE, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Lindberg S, Fricton R, Lee S, Zaman A, Saveraid HG, Tordsen WJ, Pullen MF, Sherwood NE, Huling JD, Bramante CT; COVID-OUT study team. Clin Infect Dis. 2023 Feb 8;76(3):e1-e9. doi: 10.1093/cid/ciac772. PMID: 36124697

Safety and Immunogenicity of a Chimeric Subunit **Vaccine** against Shiga Toxin-Producing *Escherichia coli* in Pregnant Cows.

Vidal RM, Montero DA, Del Canto F, Salazar JC, Arellano C, Alvarez A, Padola NL, Moscuzza H, Etcheverría A, Fernández D, Velez V, García M, Colello R, Sanz M, Oñate A. Int J Mol Sci. 2023 Feb 1;24(3):2771. doi: 10.3390/ijms24032771. PMID: 36769094

Infection preventionists' experiences during the second year of the COVID-19 pandemic: Findings from focus groups conducted with association for professionals in infection control & epidemiology (APIC) members.
Rebmann T, Alvino RT, Lugo KA, Holdsworth JE, Gomel A. Am J Infect Control. 2023 Feb;51(2):121-128. doi: 10.1016/j.ajic.2022.11.023. Epub 2022 Dec 1. PMID: 36463974

Immunogenicity Evaluation of Thermostable Microparticles Entrapping Receptor Binding Domain of SARS-CoV-2 by Single Point Administration.
Ahuja R, Srichandan S, Meena J, Biswal BK, Panda AK. J Pharm Sci. 2023 Feb 2:S0022-3549(23)00026-6. doi: 10.1016/j.xphs.2023.01.024. Online ahead of print. PMID: 36736778

The resurgence of polio: The effect of the Covid-19 pandemic on polio eradication.
Niaz F, Tariq S, Rana MS, Nashwan AJ, Fatima I, Afzal Y, Tariq R. Ethics Med Public Health. 2023 Feb;26:100858. doi: 10.1016/j.jemep.2022.100858. Epub 2022 Nov 24. PMID: 36471883

Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated **Vaccine** Candidate.
Patel SS, Rauscher M, Kudela M, Pang H. Clin Infect Dis. 2023 Feb 8;76(3):e1350-e1359. doi: 10.1093/cid/ciac418. PMID: 35639602

Genome sequences of BCG Pasteur ATCC 35734 and its derivative, the **vaccine** candidate BCGΔBCG1419c.
D'Auria G, Hodzhev Y, Aceves-Sánchez MJ, Moya A, Panaiotov S, Flores-Valdez MA. BMC Genomics. 2023 Feb 10;24(1):69. doi: 10.1186/s12864-023-09169-9. PMID: 36765273

Audiometry-Confirmed Sudden Sensorineural Hearing Loss Incidence among COVID-19 Patients and BNT162b2 **Vaccine** Recipients.
Cohen Michael O, Tamir SO, O'Rourke N, Marom T. Otol Neurotol. 2023 Feb 1;44(2):e68-e72. doi: 10.1097/MAO.0000000000003777. Epub 2022 Dec 21. PMID: 36624589

Liver injury with autoimmune features after vaccination against SARS-CoV-2: The verdict is still open.
Ferronato M, Lenzi M, Muratori L. Eur J Intern Med. 2023 Feb;108:108-110. doi: 10.1016/j.ejim.2022.09.029. Epub 2022 Oct 6. PMID: 36261309

A case of Anti-MDA5-Positive dermatomyositis after inactivated COVID-19 **vaccine**.
Yang L, Ye T, Liu H, Huang C, Tian W, Cai Y. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e127-e129. doi: 10.1111/jdv.18653. Epub 2022 Oct 31. PMID: 36222733

Exploring nurses' experiences of a tailored intervention to increase MMR **vaccine** acceptance in a Somali community in Stockholm, Sweden: a qualitative interview study.
Appelqvist E, Jama A, Kulane A, Roth A, Lindstrand A, Godoy-Ramirez K. BMJ Open. 2023 Feb 6;13(2):e067169. doi: 10.1136/bmjopen-2022-067169. PMID: 36746543

Experiencing herd immunity in virtual reality increases COVID-19 vaccination intention: Evidence from a large-scale field intervention study.
Plechatá A, Vandeweerdt C, Atchapero M, Luong T, Holz C, Betsch C, Dietermann B, Schultka Y, Böhm R, Makransky G. Comput Human Behav. 2023 Feb;139:107533. doi: 10.1016/j.chb.2022.107533. Epub 2022 Oct 17. PMID: 36277032

Various aspects of the relationship between vitiligo and the COVID-19 pandemic or SARS-CoV-2 vaccines: Clinical pearls for dermatologists.
Aryanian Z, Balighi K, Hatami P, Goodarzi A, Janbakhsh A, Afshar ZM. J Cosmet Dermatol. 2023 Feb 9. doi: 10.1111/jocd.15550. Online ahead of print. PMID: 36762373

Beta-glucan enhanced immune response to Newcastle disease **vaccine** and changed mRNA expression of spleen in chickens.
Cao L, Li J, Zhang J, Huang H, Gui F, Xu W, Zhang L, Bi S. Poult Sci. 2023 Feb;102(2):102414. doi: 10.1016/j.psj.2022.102414. Epub 2022 Dec 9. PMID: 36565635

Reverse vaccinology assisted design of a novel multi-epitope **vaccine** to target Wuchereria bancrofti cystatin: An immunoinformatics approach.
Das NC, Gupta PSS, Panda SK, Rana MK, Mukherjee S. Int Immunopharmacol. 2023 Feb;115:109639. doi: 10.1016/j.intimp.2022.109639. Epub 2022 Dec 29. PMID: 36586276

Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
Chiew CJ, Premikha M, Chong CY, Wei WE, Ong B, Lye DC, Heng D, Lee VJ, Tan KB. Lancet Infect Dis. 2023 Feb;23(2):177-182. doi: 10.1016/S1473-3099(22)00573-4. Epub 2022 Sep 28. PMID: 36182678

SARS-CoV-2 **vaccine** booster elicits robust prolonged maternal antibody responses and passive transfer to the offspring via the placenta and breastmilk.
Marshall NE, Blanton MB, Doratt BM, Malherbe DC, Rincon M, True H, McDonald T, Beauregard C, Adatorwovor R, Messaoudi I. Am J Obstet Gynecol MFM. 2023 Feb;5(2):100830. doi: 10.1016/j.ajogmf.2022.100830. Epub 2022 Nov 30. PMID: 36462615

Immunogenicity and Safety of Vaccines Against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study.
Baek YJ, Lee YJ, Park SR, Kim KH, Beom SH, Lee CK, Shin SJ, Rha SY, Kim S, Lee KH, Kim JH, Jeong SJ, Ku NS, Choi JY, Yeom JS, Jung M, Ahn JY. Cancer Res Treat. 2023 Feb 9. doi: 10.4143/crt.2022.1541. Online ahead of print. PMID: 36758955

Hepatitis E Virus Outbreak among Tigray War Refugees from Ethiopia, Sudan.
Ahmed A, Ali Y, Mohamed NS, Zinsstag J, Siddig EE, Khairy A. Emerg Infect Dis. 2023 Feb;29(2):460-461. doi: 10.3201/eid2902.221796. PMID: 36692354

Hepatitis E Virus Outbreak among Tigray War Refugees from Ethopia, Sudan.
Azman AS, Gignoux E, Nesbitt R, Rumunu J, Aggarwal R, Ciglenecki I. Emerg Infect Dis. 2023 Feb;29(2). doi: 10.3201/eid2902.221495. PMID: 36692343

Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons.
Prabhu M, Yang YJ, Johnston CD, Murphy EA, Ketas TJ, Diaz-Tapia R, Jurkiewicz M, Racine-Brzostek S, Mohammed I, Sukhu AC, Singh S, Forlenza K, Iyer S, Yee J, Eng D, Marks K, Zhao Z, Klasse PJ, Permar S, Moore JP, Riley LE. Am J Obstet Gynecol MFM. 2023 Feb;5(2):100796. doi: 10.1016/j.ajogmf.2022.100796. Epub 2022 Nov 2. PMID: 36334723

Vaccination or NPI? A conjoint analysis of German citizens' preferences in the context of the COVID-19 pandemic.
Bughin J, Cincera M, Kiepfer E, Reykowska D, Philippi F, Żyszkiewicz M, Ohme R, Frank D. Eur J Health Econ. 2023 Feb;24(1):39-52. doi: 10.1007/s10198-022-01450-0. Epub 2022 Apr 25. PMID: 35467175

Immune response of European sea bass (Dicentrarchus labrax L.) against combination of antigens from three different pathogens.
Valsamidis MA, White DM, Kokkoris GD, Bakopoulos V. Vet Immunol Immunopathol. 2023 Feb;256:110535. doi: 10.1016/j.vetimm.2022.110535. Epub 2022 Dec 23. PMID: 36621058

The Roles of Information Valence, Media Literacy and Perceived Information Quality on the Association Between Frequent Social Media Exposure and COVID-19 Vaccination Intention.
Xin M, Luo S, Wang S, Zhao J, Zhang G, Li L, Li L, Lau JT. Am J Health Promot. 2023 Feb;37(2):189-199. doi: 10.1177/08901171221121292. Epub 2022 Aug 16. PMID: 35972385

Generation of a high yield **vaccine** backbone for influenza B virus in embryonated chicken eggs.
Aslam S, Rajendran M, Kriti D, Kurland A, Johnson J, van Bakel H, Krammer F, García-Sastre A, Ayllon J. NPJ Vaccines. 2023 Feb 10;8(1):12. doi: 10.1038/s41541-023-00603-3. PMID: 36765053

A COVID-19 Vaccination Program to Promote Uptake and Equity for People Experiencing Homelessness in Los Angeles County.
Rosen AD, Senturia A, Howerton I, Kantrim EU, Evans V, Malluche T, Miller J, Gonzalez M, Robie B, Shover CL, Chang AH, Behforouz H, Nguyen A, Thomas EH. Am J Public Health. 2023 Feb;113(2):170-174. doi: 10.2105/AJPH.2022.307147. Epub 2022 Dec 1. PMID: 36455191

[The "Carmen de Bolívar event" in HPV vaccination in Colombia. Cause or outcome?].
Henríquez-Mendoza GM. Rev Salud Publica (Bogota). 2023 Feb 3;22(4):447-452. doi: 10.15446/rsap.V22n4.84173. PMID: 36753245

Preclinical evaluation of a COVID-19 **vaccine** candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.
Barreiro A, Prenafeta A, Bech-Sabat G, Roca M, Mur EP, March R, González-González L, Madrenas L, Corominas J, Fernández A, Moros A, Cañete M, Molas M, Pentinat-Pelegrin T, Panosa C, Moreno A, Molas EP, Vilarrassa EP, Palmada J, Garriga C, Cabañas TP, Iglesias-Fernández J, Vergara-Alert J, Lorca-Oró C, Roca N, Fernández-Bastit L, Rodon J, Pérez M, Segalés J, Pradenas E, Marfil S, Trinité B, Ortiz R, Clotet B, Blanco J, Pedroza JD, Carrasco RA, Salgado YR, Loubat-Casanovas J, Larripa SC, Prado JG, Barretina J, Sisteré-Oró M, Rica PC, Meyerhans A, Ferrer L. iScience. 2023 Feb 2:106126. doi: 10.1016/j.isci.2023.106126. Online ahead of print. PMID: 36748086

Optimal spatial evaluation of a pro rata **vaccine** distribution rule for COVID-19.

Castonguay FM, Blackwood JC, Howerton E, Shea K, Sims C, Sanchirico JN. Sci Rep. 2023 Feb 7;13(1):2194. doi: 10.1038/s41598-023-28697-8. PMID: 36750592

Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster **vaccine**, SCTV01C in adults previously vaccinated with inactivated **vaccine**: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial.
Hannawi S, Saifeldin L, Abuquta A, Alamadi A, Mahmoud SA, Li J, Chen Y, Xie L. J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.12.003. Epub 2022 Dec 9. PMID: 36509358

The Association Between Pediatric COVID-19 Vaccination and Socioeconomic Position: Nested Case-Control Study From the Pedianet Veneto Cohort.
Batzella E, Cantarutti A, Caranci N, Giaquinto C, Barbiellini Amidei C, Canova C. JMIR Public Health Surveill. 2023 Feb 1;9:e44234. doi: 10.2196/44234. PMID: 36645419

New HIV **Vaccine** Approach Safely Stimulated Rare Precursors to Broadly Neutralizing Antibodies.
Suran M. JAMA. 2023 Feb 1. doi: 10.1001/jama.2022.23242. Online ahead of print. PMID: 36723948

Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination.
Raccagni AR, Candela C, Mileto D, Bruzzesi E, Canetti D, Bertoni C, Castagna A, Nozza S. J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.12.001. Epub 2022 Dec 5. PMID: 36481365

Stability of hybrid versus **vaccine** immunity against BA.5 infection over 8 months.
Malato J, Ribeiro RM, Fernandes E, Leite PP, Casaca P, Antunes C, Fonseca VR, Gomes MC, Graca L. Lancet Infect Dis. 2023 Feb;23(2):148-150. doi: 10.1016/S1473-3099(22)00833-7. Epub 2023 Jan 5. PMID: 36620968

Assessment of COVID-19 **vaccine** take-up and its predictors among healthcare professionals in public hospitals, Addis Ababa, Ethiopia: Facility-based cross-sectional study.
Niguse S, Gebremariam S, Terefa DR, Biset Y, Mekasha E, Meskele K. Hum Vaccin Immunother. 2023 Feb 6:2171181. doi: 10.1080/21645515.2023.2171181. Online ahead of print. PMID: 36746745

Probiotic Therapy During Vaccination Alters Antibody Response to Simian-Human Immunodeficiency Virus Infection But Not to Commensals.
Wilson A, Manuzak JA, Liang H, Leda AR, Klatt N, Lynch RM. AIDS Res Hum Retroviruses. 2023 Feb 3. doi: 10.1089/AID.2022.0123. Online ahead of print. PMID: 36517984

Post-Marketing Safety Surveillance of a Childhood Pentavalent Diphtheria-Tetanus-Acellular Pertussis-Polio and Haemophilus influenzae Type B (DTaP-IPV//Hib) **Vaccine** in South Korea.
Yang K, Kim H, Ortiz E, Huoi C, Kang J. Infect Dis Ther. 2023 Feb;12(2):499-511. doi: 10.1007/s40121-022-00724-7. Epub 2022 Dec 15. PMID: 36520326

Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) **vaccine**: a prospective and retrospective cohort study.
Yechezkel M, Mofaz M, Painsky A, Patalon T, Gazit S, Shmueli E, Yamin D. Lancet Respir Med. 2023 Feb;11(2):139-150. doi: 10.1016/S2213-2600(22)00407-6. Epub 2022 Nov 18. PMID: 36410364

Bacillus Calmette-Guérin Tokyo-172 **vaccine** provides age-related neuroprotection in actively induced and spontaneous experimental autoimmune encephalomyelitis models.
Cossu D, Yokoyama K, Sakanishi T, Sechi LA, Hattori N. Clin Exp Immunol. 2023 Feb 6:uxad015. doi: 10.1093/cei/uxad015. Online ahead of print. PMID: 36745025

CD171 Multi-epitope peptide design based on immuno-informatics approach as a cancer **vaccine** candidate for glioblastoma.
Mohammadzadeh Hosseini Moghri SAH, Mahmoodi Chalbatani G, Ranjbar M, Raposo C, Abbasian A. J Biomol Struct Dyn. 2023 Feb;41(3):1028-1040. doi: 10.1080/07391102.2021.2020166. Epub 2022 Jan 4. PMID: 36617427

Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA **vaccine** development.
Wang F. Clin Transl Oncol. 2023 Feb 13. doi: 10.1007/s12094-023-03108-6. Online ahead of print. PMID: 36781600

Horizontal transmission of endemic viruses among rhesus macaques (Macaca mulatta): Implications for human cytomegalovirus **vaccine**/challenge design.
Yee JL, Strelow LI, White JA, Rosenthal AN, Barry PA. J Med Primatol. 2023 Feb;52(1):53-63. doi: 10.1111/jmp.12621. Epub 2022 Sep 23. PMID: 36151734

Coronavirus disease 2019 **vaccine** effectiveness among a population-based cohort of people with HIV.
Sookaromdee P, Wiwanitkit V. AIDS. 2023 Feb 1;37(2):365-366. doi: 10.1097/QAD.0000000000003439. PMID: 36541649

Does the BNT162b2 **Vaccine** Trigger Antimelanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease?
Mutoh T, Takahashi M, Nagai T, Kudo M. J Rheumatol. 2023 Feb;50(2):293-294. doi: 10.3899/jrheum.220730. Epub 2022 Oct 1. PMID: 36182114

Human papilloma virus **vaccine** for palmoplantar warts: A retrospective study of 18 patients.
Merio L, Chanal J, Jachiet M, Pourcher V, Arnault JP, Jouhet C, Milpied-Homsi B, Bourgault-Villada I, Aubin F, Caux F, Fouéré S, Vicaut E, Beylot-Barry M, Chosidow O; with the support of the GrIDIST. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e223-e225. doi: 10.1111/jdv.18523. Epub 2022 Sep 8. PMID: 35972053

Effective personalized neoantigen **vaccine** plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient.
Gao S, Wang J, Zhu Z, Fang J, Zhao Y, Liu Z, Qin H, Wei Y, Xu H, Dan X, Yang L, Xu Q. Immunotherapy. 2023 Feb;15(2):57-69. doi: 10.2217/imt-2021-0339. Epub 2023 Jan 18. PMID: 36651232

In silico formulation of a next-generation multiepitope **vaccine** for use as a prophylactic candidate against Crimean-Congo hemorrhagic fever.
Alam R, Samad A, Ahammad F, Nur SM, Alsaiari AA, Imon RR, Talukder MEK, Nain Z, Rahman MM, Mohammad F, Karpiński TM. BMC Med. 2023 Feb 1;21(1):36. doi: 10.1186/s12916-023-02750-9. PMID: 36726141

A stance dataset with aspect-based sentiment information from Indonesian COVID-19 vaccination-related tweets.
Purwitasari D, Putra CBP, Raharjo AB. Data Brief. 2023 Apr;47:108951. doi: 10.1016/j.dib.2023.108951. Epub 2023 Feb 4. PMID: 36776157

Preclinical developments in the delivery of protein antigens for vaccination.
Hendy DA, Haven A, Bachelder EM, Ainslie KM. Expert Opin Drug Deliv. 2023 Feb 10:1-18. doi: 10.1080/17425247.2023.2176844. Online ahead of print. PMID: 36731824

Prevention of Neisseria gonorrhoeae With Meningococcal B **Vaccine**: A Matched Cohort Study in Southern California.
Bruxvoort KJ, Lewnard JA, Chen LH, Tseng HF, Chang J, Veltman J, Marrazzo J, Qian L. Clin Infect Dis. 2023 Feb 8;76(3):e1341-e1349. doi: 10.1093/cid/ciac436. PMID: 35642527

Design of multi-epitope based **vaccine** against *Mycobacterium tuberculosis:* a subtractive proteomics and reverse vaccinology based immunoinformatics approach.
Nayak SS, Sethi G, Ramadas K. J Biomol Struct Dyn. 2023 Feb 12:1-19. doi: 10.1080/07391102.2023.2178511. Online ahead of print. PMID: 36775659

Update From the September 2022 Meeting of the Advisory Committee on Immunization Practices.
Gaviria-Agudelo C, Yonts AB, O'Leary ST, Anderson EJ. J Pediatric Infect Dis Soc. 2023 Feb 9;12(1):1-5. doi: 10.1093/jpids/piac114. PMID: 36309881

LSDV126 gene based molecular assays for specific detection and characterization of emerging Lumpy Skin Disease virus.
Nandi S, Mahajan S, Mishra R, Nautiyal S, Agrawal RK, Singh M, Biswas SK, Chander V, Singh KP, Sharma GK. J Virol Methods. 2023 Feb;312:114665. doi: 10.1016/j.jviromet.2022.114665. Epub 2022 Dec 9. PMID: 36509247

Safety, tolerability, and immunogenicity of inactivated poliovirus **vaccine** with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.
Erdem R, De Coster I, Withanage K, Mercer LD, Marchant A, Taton M, Cools N, Lion E, Cassels F, Higgins D, Ivinson K, Locke E, Mahmood K, Wright PF, Gast C, White JA, Ackerman ME, Konopka-Anstadt JL, Mainou BA, Van Damme P. Vaccine. 2023 Feb 4:S0264-410X(23)00078-6. doi: 10.1016/j.vaccine.2023.01.048. Online ahead of print. PMID: 36746739

Sustained Within-season **Vaccine** Effectiveness Against Influenza-associated Hospitalization in Children: Evidence From the New **Vaccine** Surveillance Network, 2015-2016 Through 2019-2020.
Sahni LC, Naioti EA, Olson SM, Campbell AP, Michaels MG, Williams JV, Staat MA, Schlaudecker EP, McNeal MM, Halasa NB, Stewart LS, Chappell JD, Englund JA, Klein EJ, Szilagyi PG, Weinberg GA, Harrison CJ, Selvarangan R, Schuster JE, Azimi PH, Singer MN, Avadhanula V, Piedra PA, Munoz FM, Patel MM, Boom JA. Clin Infect Dis. 2023 Feb 8;76(3):e1031-e1039. doi: 10.1093/cid/ciac577. PMID: 35867698

Do unbiased people act more rationally?-The case of comparative realism and **vaccine** intention.
Izydorczak K, Dolinski D, Genschow O, Kulesza W, Muniak P, Casara BGS, Suitner C. R Soc Open Sci. 2023 Feb 1;10(2):220775. doi: 10.1098/rsos.220775. eCollection 2023 Feb. PMID: 36756056

A Case of Neuroretinitis following Inactivated Virion COVID-19 Vaccination.
Nair GS, Khan IA, Rizvi SWA, Shahid S. Ocul Immunol Inflamm. 2023 Feb 13:1-4. doi: 10.1080/09273948.2023.2173244. Online ahead of print. PMID: 36780589

Evaluation of the effectiveness of maternal immunization against pertussis in Alberta using agent-based modeling: A Canadian immunization research network study.
Hempel K, McDonald W, Osgood ND, Fisman D, Halperin SA, Crowcroft N, Klein NP, Rohani P, Doroshenko A. Vaccine. 2023 Feb 10:S0264-410X(23)00080-4. doi: 10.1016/j.vaccine.2022.12.071. Online ahead of print. PMID: 36775775

Co-VAN study: COVID-19 **vaccine** associated neurological diseases- an experience from an apex neurosciences centre and review of the literature.
Samim MM, Dhar D, Arshad F, Anudeep DDS, Patel VG, Neeharika SR, Dhamija K, Ravindranath CM, Yadav R, Raja P, Netravathi M, Menon D, Holla VV, Kamble NL, Pal PK, Nalini A, Vengalil S. J Clin Neurosci. 2023 Feb;108:37-75. doi: 10.1016/j.jocn.2022.12.015. Epub 2022 Dec 23. PMID: 36586226

Cluster analysis of adults unvaccinated for COVID-19 based on behavioral and social factors, National Immunization Survey-Adult COVID Module, United States.
Meng L, Masters NB, Lu PJ, Singleton JA, Kriss JL, Zhou T, Weiss D, Black CL. Prev Med. 2023 Feb;167:107415. doi: 10.1016/j.ypmed.2022.107415. Epub 2022 Dec 31. PMID: 36596324

Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022.
Wu N, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, Yip D, Bacon SL. Lancet Respir Med. 2023 Feb 10:S2213-2600(23)00015-2. doi: 10.1016/S2213-2600(23)00015-2. Online ahead of print. PMID: 36780914

Quantifying the effect of delaying the second COVID-19 **vaccine** dose in England: a mathematical modelling study.
Imai N, Rawson T, Knock ES, Sonabend R, Elmaci Y, Perez-Guzman PN, Whittles LK, Kanapram DT, Gaythorpe KAM, Hinsley W, Djaafara BA, Wang H, Fraser K, FitzJohn RG, Hogan AB, Doohan P, Ghani AC, Ferguson NM, Baguelin M, Cori A. Lancet Public Health. 2023 Feb 9:S2468-2667(22)00337-1. doi: 10.1016/S2468-2667(22)00337-1. Online ahead of print. PMID: 36774945

Acquired Thrombotic Thrombocytopenic Purpura: A Rare Coincidence after COVID-19 mRNA **Vaccine**?
Tso ACY, Ong KH, Sum CLL, Fan BE, Chan GYL, Christopher D, Howe HS, Lai YW, Lim XR, Leung BPL. Semin Thromb Hemost. 2023 Feb;49(1):89-91. doi: 10.1055/s-0042-1744301. Epub 2022 Jun 27. PMID: 35760332

Erythema nodosum induced by Covid-19 Pfizer-BioNTech mRNA **vaccine**: A case report and brief literature review.
Chahed F, Ben Fadhel N, Ben Romdhane H, Youssef M, Ben Hammouda S, Chaabane A, Aouam K, Ben Fredj N. Br J Clin Pharmacol. 2023 Feb;89(2):536-540. doi: 10.1111/bcp.15351. Epub 2022 Apr 27. PMID: 35434826

Humoral and cellular responses to the third COVID-19 BNT162b2 **vaccine** dose in research institute workers in Japan.

Nishikimi A, Nakagawa T, Fujiwara M, Watanabe K, Watanabe A, Komatsu A, Yasuoka M, Watanabe R, Naya M, Oshima H, Kitagawa Y, Tokuda H, Kondo I, Niida S, Sakurai T, Kojima M, Arai H. J Infect. 2023 Feb;86(2):e33-e35. doi: 10.1016/j.jinf.2022.10.026. Epub 2022 Oct 21. PMID: 36273645

Monovalent Rotavirus **Vaccine** Efficacy Against Different Rotavirus Genotypes: A Pooled Analysis of Phase II and III Trial Data.
Amin AB, Tate JE, Waller LA, Lash TL, Lopman BA. Clin Infect Dis. 2023 Feb 8;76(3):e1150-e1156. doi: 10.1093/cid/ciac699. PMID: 36031386

Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease.
Kwon JY, Daoud ND, Hashash JG, Picco MF, Farraye FA. Inflamm Bowel Dis. 2023 Feb 1;29(2):254-259. doi: 10.1093/ibd/izac079. PMID: 35468183

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Odera DO, Tuju J, Mwai K, Nkumama IN, Fürle K, Chege T, Kimathi R, Diehl S, Musasia FK, Rosenkranz M, Njuguna P, Hamaluba M, Kapulu MC, Frank R; CHMI-SIKA Study Team; Osier FHA, Abdi AI, Chi PC, de Laurent Z, Jao I, Kamuya D, Kamuyu G, Makale J, Murungi L, Musyoki J, Muthui M, Mwacharo J, Kariuki S, Mwanga D, Mwongeli J, Ndungu F, Njue M, Nyangweso G, Kimani D, Ngoi JM, Musembi J, Ngoto O, Otieno E, Ooko M, Shangala J, Wambua J, Mohammed KS, Omuoyo D, Mosobo M, Kibinge N, Kinyanjui S, Bejon P, Lowe B, Marsh K, Marsh V, Abebe Y, Billingsley PF, Sim BKL, Hoffman SL, James ER, Richie TL, Audi A, Olewe F, Oloo J, Ongecha J, Ongas MO, Koskei N, Bull PC, Hodgson SH, Kivisi C, Imwong M, Murphy SC, Ogutu B, Tarning J, Winterberg M, Williams TN. Sci Transl Med. 2023 Feb 8;15(682):eabn5993. doi: 10.1126/scitranslmed.abn5993. Epub 2023 Feb 8. PMID: 36753561

Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 **Vaccine**.
Liu Z, Alexander JL, Lin KW; VIP Study Investigators; Ahmad T, Pollock KM, Powell N. Gastroenterology. 2023 Feb;164(2):300-303.e3. doi: 10.1053/j.gastro.2022.10.010. Epub 2022 Oct 19. PMID: 36270334

An open letter to Gavi: hepatitis B birth dose **vaccine** can't wait.
CDA Foundation; Coalition for Global Hepatitis Elimination, Hepatitis Australia; Hepatitis Fund; Hepatitis B Foundation, Médecins Sans Frontières Access Campaign; PATH, TREAT Asia/amfAR, The Foundation for AIDS Research, Union for International Cancer Control; World Hepatitis Alliance. Electronic address: contact@worldhepatitisalliance.org. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):115-116. doi: 10.1016/S2468-1253(22)00422-8. Epub 2022 Dec 5. PMID: 36481044

Detection of SARS-CoV-2-Specific Antibodies in Human Breast Milk and Their Neutralizing Capacity after COVID-19 Vaccination: A Systematic Review.
Nicolaidou V, Georgiou R, Christofidou M, Felekkis K, Pieri M, Papaneophytou C. Int J Mol Sci. 2023 Feb 3;24(3):2957. doi: 10.3390/ijms24032957. PMID: 36769279

Maternal mRNA covid-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study.
Jorgensen SCJ, Hernandez A, Fell DB, Austin PC, D'Souza R, Guttmann A, Brown KA, Buchan SA, Gubbay JB, Nasreen S, Schwartz KL, Tadrous M, Wilson K, Kwong JC; Canadian Immunization Research

Network (CIRN) Provincial Collaborative Network (PCN) Investigators. BMJ. 2023 Feb 8;380:e074035. doi: 10.1136/bmj-2022-074035. PMID: 36754426

Effectiveness of a Second Dose of an mRNA **Vaccine** Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants.
Monge S, Rojas-Benedicto A, Olmedo C, Martín-Merino E, Mazagatos C, Limia A, Sierra MJ, Larrauri A, Hernán MA; IBERCovid. Clin Infect Dis. 2023 Feb 8;76(3):e367-e374. doi: 10.1093/cid/ciac429. PMID: 35687580

The AuTOMATIC trial: a study protocol for a multi-arm Bayesian adaptive randomised controlled trial of text messaging to improve childhood immunisation coverage.
Currie GE, Totterdell J, Bowland G, Leeb A, Peters I, Blyth CC, Waddington C, Marsh JA, Snelling TL. Trials. 2023 Feb 7;24(1):97. doi: 10.1186/s13063-023-07097-3. PMID: 36750833

Is partisan conflict over COVID-19 vaccination eroding support for childhood **vaccine** mandates?
Motta M. NPJ Vaccines. 2023 Feb 2;8(1):5. doi: 10.1038/s41541-023-00611-3. PMID: 36732345

Serotype 19A and 6C Account for One-Third of Pneumococcal Carriage Among Belgian Day-Care Children Four Years After a Shift to a Lower-Valent PCV.
Ekinci E, Van Heirstraeten L, Willen L, Desmet S, Wouters I, Vermeulen H, Lammens C, Goossens H, Van Damme P, Verhaegen J, Beutels P, Theeten H, Malhotra-Kumar S; NP Carriage Study Group. J Pediatric Infect Dis Soc. 2023 Feb 9;12(1):36-42. doi: 10.1093/jpids/piac117. PMID: 36377804

Correction: Optimized protocol for double **vaccine** immunization against classical swine fever and porcine reproductive and respiratory syndrome.
Liu Z, Shan B, Ni C, Feng S, Liu W, Wang X, Wu H, ZuofengYang, Liu J, Wei S, Wu C, Liu L, Chen Z. BMC Vet Res. 2023 Feb 9;19(1):38. doi: 10.1186/s12917-023-03595-3. PMID: 36759813

The Association of Time of Day of ChAdOx1 nCoV-19 **Vaccine** Administration With SARS-CoV-2 Anti-Spike IgG Antibody Levels: An Exploratory Observational Study.
Erber AC, Wagner A, Karachaliou M, Jeleff M, Kalafatis P, Kogevinas M, Pepłońska B, Santonja I, Schernhammer E, Stockinger H, Straif K, Wiedermann U, Waldhör T, Papantoniou K. J Biol Rhythms. 2023 Feb;38(1):98-108. doi: 10.1177/07487304221132355. Epub 2022 Nov 11. PMID: 36367167

Effectiveness of fourth dose of COVID-19 **vaccine** against the Omicron variant compared with no vaccination.
Zeng J, Szanyi J, Blakely T. Int J Epidemiol. 2023 Feb 8;52(1):321-328. doi: 10.1093/ije/dyac231. PMID: 36525399

Risk and characteristics of Bell's palsy in adults as an adverse event following COVID-19 vaccination: a retrospective study.
Kim S, Kang M, Park JS, Seok HY. Acta Neurol Belg. 2023 Feb 12. doi: 10.1007/s13760-023-02204-2. Online ahead of print. PMID: 36781626

A study on the design of an *in silico* self-amplifying mRNA **vaccine** against Nipah virus using immunoinformatics.

Rangacharya O, Parab A, Adkine S, Nagargoje R. J Biomol Struct Dyn. 2023 Feb 6:1-12. doi: 10.1080/07391102.2023.2175256. Online ahead of print. PMID: 36744525

The Italian policy of mandating SARS-CoV-2 vaccination for healthcare workers: Analysis of the policy processes and preliminary outcomes.
Vicentini C, Garzaro G, Cornio AR, Bosio D, Bergamaschi E, Parravicini GP, Zotti CM. Health Policy. 2023 Feb;128:49-54. doi: 10.1016/j.healthpol.2022.11.006. Epub 2022 Nov 18. PMID: 36414469

Off-label prescription of BNT162b2 mRNA COVID-19 **vaccine** to <5-year-old children in the European Union.
Dal-Ré R, Calvo C, Neth O. Acta Paediatr. 2023 Feb;112(2):183-185. doi: 10.1111/apa.16442. Epub 2022 Jun 26. PMID: 35657672

The effect of SARS-CoV-2 double vaccination on the outcomes of hemodialysis patients with COVID-19: A meta-analysis.
Ao G, Li A, Wang Y, Tran C, Gao M, Chen M. J Infect. 2023 Feb;86(2):e43-e45. doi: 10.1016/j.jinf.2022.09.022. Epub 2022 Sep 26. PMID: 36174838

Adverse Reactions and Attitudes Toward the BNT162b2 COVID-19 **Vaccine** in Children 5 to 11 Years of Age in Japan.
Matsumoto N, Shimizu J, Yokoyama Y, Tsukahara H, Yorifuji T. J Epidemiol. 2023 Feb 5;33(2):110-111. doi: 10.2188/jea.JE20220265. Epub 2022 Nov 30. PMID: 36310061

Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) **Vaccine** Booster Dosing in Brazilian Healthcare Workers, 2021.
Marra AR, Miraglia JL, Malheiros DT, Guozhang Y, Teich VD, da Silva Victor E, Rebello Pinho JR, Cypriano A, Vieira LW, Polonio M, Ornelas RH, de Oliveira SM, Borges Junior FA, Oler SCC, Schettino GPP, de Oliveira KG, Ferraz Santana RA, de Mello Malta F, Amgarten D, Boechat AL, Trecenti NMZ, Kobayashi T, Salinas JL, Edmond MB, Rizzo LV. Clin Infect Dis. 2023 Feb 8;76(3):e360-e366. doi: 10.1093/cid/ciac430. PMID: 35639918

Antibody response to 2- and 3-dose SARS-CoV-2 mRNA vaccination in pediatric and adolescent kidney transplant recipients.
Crane C, Phebus E, Ingulli E. Pediatr Nephrol. 2023 Feb;38(2):611-614. doi: 10.1007/s00467-022-05661-8. Epub 2022 Jun 27. PMID: 35759003

Global inequity creates local insufficiency: A qualitative study of COVID-19 **vaccine** implementation challenges in low-and-middle-income countries.
Haldane V, Ariyarajah A, Berry I, Loutet M, Salamanca-Buentello F, Upshur REG. PLoS One. 2023 Feb 13;18(2):e0281358. doi: 10.1371/journal.pone.0281358. eCollection 2023. PMID: 36780502

The percentage of hesitation and factors associated with acceptance or refusal for COVID-19 **vaccine**: Does training about vaccines by allergist affect personal decision?
Sayaca N, Aşık Cansız K, Yıldırım E, Öztürk B, Kırmaz C. Rev Fr Allergol (2009). 2023 Feb;63(1):103256. doi: 10.1016/j.reval.2022.09.004. Epub 2022 Oct 3. PMID: 36213873

Philip Morris ejected from Canadian **vaccine** collaboration.

Kirby T. Lancet Respir Med. 2023 Feb 8:S2213-2600(23)00053-X. doi: 10.1016/S2213-2600(23)00053-X. Online ahead of print. PMID: 36773624

Assessing pregnancy outcomes in cow-calf operations after administration of modified-live or killed virus vaccinations at the initiation of synchronization for fixed-time AI.
Stewart JL, Currin J, Clark SG, Redifer T, Givens MD, Mercadante VRG. Theriogenology. 2023 Feb 1;200:43-48. doi: 10.1016/j.theriogenology.2023.01.027. Online ahead of print. PMID: 36753795

Persons with HIV Develop Spike-Specific Lymph Node Germinal Center Responses following SARS-CoV-2 Vaccination.
Quinn M, Parra-Rodriguez L, Alsoussi WB, Ayres C, Klebert MK, Liu C, Suessen T, Scheaffer SM, Middleton WD, Teefey SA, Powderly WG, Diamond MS, Presti RM, Ellebedy AH, Turner JS, O'Halloran JA, Mudd PA. J Immunol. 2023 Feb 13:ji2200920. doi: 10.4049/jimmunol.2200920. Online ahead of print. PMID: 36779802

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 **Vaccine** at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove CA, Galloway J, Goodman AL, Heer A, Higham A, Iyengar S, Jeanes C, Kalra PA, Kyriakidou C, Bradley JM, Munthali C, Minassian AM, McGill F, Moore P, Munsoor I, Nicholls H, Osanlou O, Packham J, Pretswell CH, San Francisco Ramos A, Saralaya D, Sheridan RP, Smith R, Soiza RL, Swift PA, Thomson EC, Turner J, Viljoen ME, Fries L, Cho I, McKnight I, Glenn G, Rivers EJ, Robertson A, Alves K, Smith K, Toback S. Clin Infect Dis. 2023 Feb 8;76(3):398-407. doi: 10.1093/cid/ciac803. PMID: 36210481

Evaluation of the Efficacy of BBIBP-CorV Inactivated **Vaccine** Combined with BNT62b2 mRNA Booster **Vaccine**.
Rákóczi É, Magócs G, Kovács S, Nagy B Jr, Szűcs G, Szekanecz Z. Diagnostics (Basel). 2023 Feb 2;13(3):556. doi: 10.3390/diagnostics13030556. PMID: 36766663

Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein **vaccine**: a phase 3 randomized placebo-controlled trial.
Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, Kafi H, Fallah N, Ebrahimi A, Taheri A, Petrovsky N, Barati S. Clin Microbiol Infect. 2023 Feb;29(2):215-220. doi: 10.1016/j.cmi.2022.09.001. Epub 2022 Sep 10. PMID: 36096430

Estimating the Effectiveness of First Dose of COVID-19 **Vaccine** Against Mortality in England: A Quasi-Experimental Study.
Bermingham C, Morgan J, Ayoubkhani D, Glickman M, Islam N, Sheikh A, Sterne J, Walker AS, Nafilyan V. Am J Epidemiol. 2023 Feb 1;192(2):267-275. doi: 10.1093/aje/kwac157. PMID: 36065824

Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 **Vaccine** against HPV Genome-Positive C3 Cancers in Mice.
Boilesen DR, Neckermann P, Willert T, Müller MD, Schrödel S, Pertl C, Thirion C, Asbach B, Wagner R, Holst PJ. Cancer Immunol Res. 2023 Feb 3;11(2):261-275. doi: 10.1158/2326-6066.CIR-22-0174. PMID: 36534088

Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit **vaccine** (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.
Buntinx E, Brochado L, Borja-Tabora C, Yu CY, Alberto ER, Montellano MEB, Carlos JC, Toloza LB, Hites M, Siber G, Clemens R, Ambrosino D, Qin H, Chen HL, Han HH, Hu B, Li P, Baccarini C, Smolenov I. Vaccine. 2023 Feb 9:S0264-410X(23)00143-3. doi: 10.1016/j.vaccine.2023.02.017. Online ahead of print. PMID: 36781334

Correspondence on acceptability of COVID-19 vaccination with bronchopulmonary dysplasia.
Kleebayoon A, Wiwanitkit V. Pediatr Pulmonol. 2023 Feb 8. doi: 10.1002/ppul.26347. Online ahead of print. PMID: 36751970

Selective suppression of de novo SARS-CoV2 **vaccine** antibody responses in cancer patients on B cell-targeted therapy.
Azar JH, Evans JP, Sikorski MH, Chakravarthy KB, McKenney S, Carmody I, Zeng C, Teodorescu R, Song NJ, Hamon JL, Bucci D, Velegraki M, Bolyard C, Weller KP, Reisinger SA, Bhat SA, Maddocks KJ, Denlinger N, Epperla N, Gumina R, Vlasova AN, Oltz E, Saif L, Chung D, Woyach JA, Shields PG, Liu SL, Li Z, Rubinstein MP. JCI Insight. 2023 Feb 7:e163434. doi: 10.1172/jci.insight.163434. Online ahead of print. PMID: 36749632

Incidence of Chronic Spontaneous Urticaria Following Receipt of the COVID-19 **Vaccine** Booster in Switzerland.
Duperrex O, Tommasini F, Muller YD. JAMA Netw Open. 2023 Feb 1;6(2):e2254298. doi: 10.1001/jamanetworkopen.2022.54298. PMID: 36723944

Tough Talks COVID-19 Digital Health Intervention for **Vaccine** Hesitancy Among Black Young Adults: Protocol for a Hybrid Type 1 Effectiveness Implementation Randomized Controlled Trial.
Budhwani H, Maragh-Bass AC, Tolley EE, Comello MLG, Stoner MCD, Adams Larsen M, Brambilla D, Muessig KE, Pettifor A, Bond CL, Toval C, Hightow-Weidman LB. JMIR Res Protoc. 2023 Feb 13;12:e41240. doi: 10.2196/41240. PMID: 36689557

Gadolinium changes detected on cardiovascular magnetic resonance imaging following COVID-19 **vaccine**-related myocarditis in adolescents.
Kleebayoon A, Wiwanitkit V. Pediatr Radiol. 2023 Feb 9:1. doi: 10.1007/s00247-023-05613-w. Online ahead of print. PMID: 36757489

Effectiveness of Three Doses of mRNA COVID-19 Vaccines in the Hemodialysis Population during the Omicron Period.
Wing S, Thomas D, Balamchi S, Ip J, Naylor K, Dixon SN, McArthur E, Kwong JC, Perl J, Atiquzzaman M, Yeung A, Yau K, Hladunewich MA, Leis JA, Levin A, Blake PG, Oliver MJ. Clin J Am Soc Nephrol. 2023 Feb 1. doi: 10.2215/CJN.0000000000000108. Online ahead of print. PMID: 36723290

Extreme poverty first: An argument on the equitable distribution of the COVID-19 **vaccine** in Peru.
Yabar CA. Dev World Bioeth. 2023 Feb 3. doi: 10.1111/dewb.12391. Online ahead of print. PMID: 36735901

Identification of a Novel Keto Sugar Component in Streptococcus pneumoniae Serotype 12F Capsular Polysaccharide and Impact on **Vaccine** Immunogenicity.

Sackett K, Brown P, Dutta K, Scully IL, Gangolli S, Looi K, Nemani S, Yu AYH, Kleven M, Xie J, Moran J, Pride MW, Anderson AS, Lotvin J. J Immunol. 2023 Feb 1:ji2100849. doi: 10.4049/jimmunol.2100849. Online ahead of print. PMID: 36723033

Evaluation of patients with antiphospholipid syndrome subsequently COVID-19 vaccinations: A retrospective cohort study.
Karakaş Ö, Erden A, Armağan B, Güven SC, Atalar E, Polat B, Omma A, Küçükşahin O. Int J Rheum Dis. 2023 Feb;26(2):292-297. doi: 10.1111/1756-185X.14490. Epub 2022 Nov 12. PMID: 36371485

Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees.
Inoue T, Shinnakasu R, Kawai C, Yamamoto H, Sakakibara S, Ono C, Itoh Y, Terooatea T, Yamashita K, Okamoto T, Hashii N, Ishii-Watabe A, Butler NS, Matsuura Y, Matsumoto H, Otsuka S, Hiraoka K, Teshima T, Murakami M, Kurosaki T. J Exp Med. 2023 Feb 6;220(2):e20221786. doi: 10.1084/jem.20221786. Epub 2022 Dec 13. PMID: 36512034

Durability of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Booster **Vaccine** Protection Against Omicron Among Healthcare Workers With a **Vaccine** Mandate.
Richterman A, Behrman A, Brennan PJ, O'Donnell JA, Snider CK, Chaiyachati KH. Clin Infect Dis. 2023 Feb 8;76(3):e319-e326. doi: 10.1093/cid/ciac454. PMID: 35666508

Exploring the Role of GMMA Components in the Immunogenicity of a 4-Valent **Vaccine** against *Shigella*.
Mancini F, Alfini R, Caradonna V, Monaci V, Carducci M, Gasperini G, Piccioli D, Biagini M, Giannelli C, Rossi O, Pizza M, Micoli F. Int J Mol Sci. 2023 Feb 1;24(3):2742. doi: 10.3390/ijms24032742. PMID: 36769063

First Booster of SARS-COV-2 mRNA **Vaccine** Is Not Associated With Alloimmunization and Subclinical Injury of Kidney Allograft.
Petr V, Zahradka I, Modos I, Roder M, Prewett A, Fialova M, Machkova J, Hruba P, Magicova M, Slavcev A, Striz I, Viklicky O. Transplantation. 2023 Feb 1;107(2):e62-e64. doi: 10.1097/TP.0000000000004421. Epub 2022 Oct 29. PMID: 36314999

Humoral COVID-19 **vaccine** response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies.
Schwake C, Pakeerathan T, Kleiter I, Ringelstein M, Aktas O, Korporal-Kuhnke M, Wildemann B, Jarius S, Bayas A, Pul R, Ceylan U, Faissner S, Hellwig K, Ayroza Galvao Ribeiro Gomes AB, Lipps P, Pröbstel AK, Kümpfel T, Oswald E, Then Bergh F, Gödel C, Hümmert MW, Trebst C, Gold R, Ayzenberg I. Mult Scler. 2023 Feb 7:13524585221151124. doi: 10.1177/13524585221151124. Online ahead of print. PMID: 36748649

Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment.
Ngonghala CN, Taboe HB, Safdar S, Gumel AB. Appl Math Model. 2023 Feb;114:447-465. doi: 10.1016/j.apm.2022.09.017. Epub 2022 Sep 30. PMID: 36281307

Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentration.

Estrada MR, Bzami A, Norton EB, White JA. Vaccine. 2023 Feb 10;41(7):1362-1367. doi: 10.1016/j.vaccine.2023.01.005. Epub 2023 Jan 17. PMID: 36658044

Effect of a SARS-CoV-2 booster **vaccine** dose on the immune response of adults with Down syndrome.
Yarci-Carrión A, Esparcia-Pinedo L, Mateo-Jiménez G, Alfranca A, Real de Asúa D, Gutiérrez-Cobos A. J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.014. Epub 2022 Nov 20. PMID: 36417985

Optimization of Timing of Maternal Pertussis Immunization From 6 Years of Postimplementation Surveillance Data in England.
Amirthalingam G, Campbell H, Ribeiro S, Stowe J, Tessier E, Litt D, Fry NK, Andrews N. Clin Infect Dis. 2023 Feb 8;76(3):e1129-e1139. doi: 10.1093/cid/ciac651. PMID: 35959786

Functional Characterization of Extracellular Vesicles from Baker's Yeast Saccharomyces Cerevisiae as a Novel **Vaccine** Material for Immune Cell Maturation.
Higuchi A, Morishita M, Nagata R, Maruoka K, Katsumi H, Yamamoto A. J Pharm Sci. 2023 Feb;112(2):525-534. doi: 10.1016/j.xphs.2022.08.032. Epub 2022 Aug 31. PMID: 36057319

Major locus on ECA18 influences effectiveness of GonaCon **vaccine** in feral horses.
Thompson MA, McCann BE, Simmons RB, Rhen T. J Reprod Immunol. 2023 Feb;155:103779. doi: 10.1016/j.jri.2022.103779. Epub 2022 Nov 28. PMID: 36462462

New onset of Susac syndrome after mRNA COVID-19 **vaccine**: a case report.
Bianco A, Colò F, Falso S, Russo R, Carlà MM, Minucci A, Cadoni G, Lucchini M, Cicia A, Calabresi P, Mirabella M. J Neurol. 2023 Feb;270(2):614-617. doi: 10.1007/s00415-022-11406-2. Epub 2022 Oct 12. PMID: 36222903

"Why is it so necessary?": African American Parents' Perspectives on Delaying and Refusing HPV Vaccination.
Washington A, Chabaan J, Fakih A, Ford S, Rutledge L, Lilly J, Herrera MY, Kim Y, Thompson HS. J Pediatr Health Care. 2023 Feb 8:S0891-5245(23)00002-0. doi: 10.1016/j.pedhc.2023.01.002. Online ahead of print. PMID: 36764888

Safety of mRNA COVID-19 Vaccines in Patients with Inborn Errors of Immunity: an Italian Multicentric Study.
Milito C, Cinetto F, Garzi G, Palladino A, Puca M, Brambilla E, De Vitis C, Costanzo G, Scarpa R, Punziano A, Lagnese G, Del Giacco S, Spadaro G, Quinti I, Firinu D. J Clin Immunol. 2023 Feb;43(2):299-307. doi: 10.1007/s10875-022-01402-6. Epub 2022 Nov 14. PMID: 36374363

Sexual Behaviors and Human Papillomavirus Vaccination in a Heterosexually Active Adult Population at Increased Risk for HIV Infection.
Amboree TL, Wermuth PP, Montealegre JR, Fujimoto K, Mgbere O, Darkoh C. Arch Sex Behav. 2023 Feb;52(2):793-801. doi: 10.1007/s10508-022-02438-w. Epub 2022 Oct 18. PMID: 36255610

COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI, Lopez-Olivo MA, Geng Y, Suarez-Almazor ME. J Immunother Cancer. 2023 Feb;11(2):e006246. doi: 10.1136/jitc-2022-006246. PMID: 36746512

Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein **vaccine**, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial.
Wang G, Zhao K, Han J, Hu Z, Zhang T, Wang Y, Shi R, Li Y, Song Q, Du H, He P, Xu S, Yang X, Fu Y, Cui Y, Xie L. J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.008. Epub 2022 Nov 17. PMID: 36403700

Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal.
Kislaya I, Casaca P, Borges V, Sousa C, Ferreira BI, Fonte A, Fernandes E, Dias CM, Duarte S, Almeida JP, Grenho I, Coelho L, Ferreira R, Ferreira PP, Borges CM, Isidro J, Pinto M, Menezes L, Sobral D, Nunes A, Santos D, Gonçalves AM, Vieira L, Gomes JP, Leite PP, Nunes B, Machado A, Peralta-Santos A. Emerg Infect Dis. 2023 Feb 3;29(3). doi: 10.3201/eid2903.221367. Online ahead of print. PMID: 36737101

Identification of protein biomarkers of attenuation and immunogenicity of centrin or p27 gene deleted live **vaccine** candidates of Leishmania against visceral leishmaniasis.
Tandon R, Reyaz E, Roshanara, Jadhav M, Gandhi M, Dey R, Salotra P, Nakhasi HL, Selvapandiyan A. Parasitol Int. 2023 Feb;92:102661. doi: 10.1016/j.parint.2022.102661. Epub 2022 Aug 29. PMID: 36049661

Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated **Vaccine**.
Leung NHL, Cheng SMS, Martín-Sánchez M, Au NYM, Ng YY, Luk LLH, Chan KCK, Li JKC, Leung YWY, Tsang LCH, Chaothai S, Kwan KKH, Ip DKM, Poon LLM, Leung GM, Peiris JSM, Cowling BJ. Clin Infect Dis. 2023 Feb 8;76(3):e299-e307. doi: 10.1093/cid/ciac458. PMID: 35675370

Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA **vaccine** with homologous or heterologous schedules: An observational study.
Kang JM, Lee J, Huh KH, Joo DJ, Lee JG, Kim HY, Lee M, Jung I, Kim MY, Kim S, Park Y, Kim MS. J Clin Virol. 2023 Feb;159:105374. doi: 10.1016/j.jcv.2022.105374. Epub 2022 Dec 30. PMID: 36592547

Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to **vaccine** uptake: a modeling analysis.
Choi HCW, Leung K, Chan KKL, Bai Y, Jit M, Wu JT. BMC Med. 2023 Feb 10;21(1):48. doi: 10.1186/s12916-023-02748-3. PMID: 36765349

A long-term retrospective analysis of the haemorrhagic fever with renal syndrome epidemic from 2005 to 2021 in Jiangxi Province, China.
Liu S, Zhang T. Sci Rep. 2023 Feb 8;13(1):2268. doi: 10.1038/s41598-023-29330-4. PMID: 36755085

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials.
Voysey M, Flaxman A, Aboagye J, Aley PK, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Charlton S, Clutterbuck EA, Davies S, Dold C, Edwards NJ, Ewer KJ, Faust SN, Folegatti PM, Fowler J, Gilbride C, Gilbert SC, Godfrey L, Hallis B, Humphries HE, Jenkin D, Kerridge S, Mujadidi YF, Plested E, Ramasamy MN, Robinson H, Sanders H, Snape MD, Song R, Thomas KM, Ulaszewska M, Woods D,

Wright D, Pollard AJ, Lambe T. Clin Exp Immunol. 2023 Feb 2:uxad013. doi: 10.1093/cei/uxad013. Online ahead of print. PMID: 36729167

Invasive pneumococcal infections in France: Changes from 2009 to 2021 in antibiotic resistance and serotype distribution of Streptococcus pneumoniae based on data from the French Regional Pneumococcal Observatories network.
Plainvert C, Varon E, Viriot D, Kempf M; French Regional Pneumococcal Observatories (ORP) network. Infect Dis Now. 2023 Feb;53(1):104632. doi: 10.1016/j.idnow.2022.11.001. Epub 2022 Nov 12. PMID: 36375765

Immunogenicity analysis of the E. coli expressed structural protein VP1 of persistent infection foot-and-mouth disease virus.
Tang H, Wang H, Yang L, Chen H, Kong L, Xin X. Virology. 2023 Feb;579:111-118. doi: 10.1016/j.virol.2023.01.004. Epub 2023 Jan 6. PMID: 36634474

Exacerbation of psoriasis following vaccination with the Pfizer-BioNTech BTN162b2 mRNA COVID-19 **vaccine** during risankizumab treatment.
Tsunoda K, Watabe D, Amano H. J Dermatol. 2023 Feb;50(2):e79-e80. doi: 10.1111/1346-8138.16505. Epub 2022 Jul 7. PMID: 35795974

Developing new COVID-19 **vaccine** against the variants is urgently needed rather than boosters: A longitudinal cohort study.
Xu QY, Zheng XQ, Jia ZJ, Wu MJ, Liu YY, Liu LL, Lin LR, Yang TC. J Infect. 2023 Feb;86(2):e55-e57. doi: 10.1016/j.jinf.2022.09.008. Epub 2022 Sep 13. PMID: 36108784

Impact of vaccination on SARS-CoV-2 seroprevalence rate in French blood donors: An assessment as of July 2021.
Gallian P, Slimani A, Malard L, Morel P, de Lamballerie X. Transfus Clin Biol. 2023 Feb;30(1):25-26. doi: 10.1016/j.tracli.2022.08.002. Epub 2022 Aug 5. PMID: 35934226

Why I Have Not Taken the COVID-19 **Vaccine**" a Descriptive Qualitative Study of Older Adults' Perceived Views of COVID-19 **Vaccine** Uptake in Nigeria.
Iwuagwu AO, Rayner D, Ngwu CN, Kalu ME. J Popul Ageing. 2023 Feb 2:1-21. doi: 10.1007/s12062-023-09410-z. Online ahead of print. PMID: 36747959

Associations Between Routine Adolescent Vaccination Status and Parental Intent to Get a COVID-19 **Vaccine** for Their Adolescent.
Pingali C, Zhang F, Santibanez TA, Elam-Evans LD, Hill HA, Valier MR, Singleton JA. JAMA Pediatr. 2023 Feb 1;177(2):208-210. doi: 10.1001/jamapediatrics.2022.4877. PMID: 36508203

Regression of common viral warts in an immunocompetent child and an immunosuppressed adult relative after mRNA BNT162b2 COVID-19 **vaccine**.
Dalamaga M, Tsilingiris D, Katoulis A. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e125-e126. doi: 10.1111/jdv.18577. Epub 2022 Oct 12. PMID: 36148591

Phase I/II study of multipeptide cancer **vaccine** IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.

Hongo F, Ueda T, Takaha N, Tamada S, Nakatani T, Miki T, Ukimura O. Int J Urol. 2023 Feb;30(2):176-180. doi: 10.1111/iju.15077. Epub 2022 Oct 28. PMID: 36305687

Reduction in Herpes Zoster Antiviral Use Since the Introduction of the Live-Attenuated Zoster **Vaccine** on Australia's National Immunisation Program: A Population-Based Study from 1994 to 2019.
Phakey S, Rogers SL, Hall AJ, Lim LL. Infect Dis Ther. 2023 Feb;12(2):711-726. doi: 10.1007/s40121-022-00749-y. Epub 2023 Jan 10. PMID: 36626109

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate **vaccine**, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
Platt H, Omole T, Cardona J, Fraser NJ, Mularski RA, Andrews C, Daboul N, Gallagher N, Sapre A, Li J, Polis A, Fernsler D, Tamms G, Xu W, Murphy R, Skinner J, Joyce J, Musey L. Lancet Infect Dis. 2023 Feb;23(2):233-246. doi: 10.1016/S1473-3099(22)00526-6. Epub 2022 Sep 15. PMID: 36116461

Robust induction of functional humoral response by a plant-derived Coronavirus-like particle **vaccine** candidate for COVID-19.
Kaplonek P, Cizmeci D, Lee JS, Shin SA, Fischinger S, Gobeil P, Pillet S, Charland N, Ward BJ, Alter G. NPJ Vaccines. 2023 Feb 13;8(1):13. doi: 10.1038/s41541-023-00612-2. PMID: 36781879

Engineered Norovirus-Derived Nanoparticles as a Plug-and-Play Cancer **Vaccine** Platform.
Zheng P, Yang Y, Fu Y, He J, Hu Y, Zheng X, Duan B, Wang M, Liu Q, Li W, Li D, Yang Y, Yang Z, Yang X, Huang W, Ma Y. ACS Nano. 2023 Feb 13. doi: 10.1021/acsnano.2c08840. Online ahead of print. PMID: 36779845

Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study.
Mohr NM, Plumb ID, Harland KK, Pilishvili T, Fleming-Dutra KE, Krishnadasan A, Hoth KF, Saydah SH, Mankoff Z, Haran JP, Briggs-Hagen M, León ES, Talan DA; Project PREVENT Network. BMJ Open. 2023 Feb 2;13(2):e063141. doi: 10.1136/bmjopen-2022-063141. PMID: 36731936

Chronic medical conditions associated with invasive pneumococcal diseases in inpatients in teaching hospitals in São Paulo city: Estimating antimicrobial susceptibility and serotype-coverage of pneumococcal vaccines.
Kfouri RA, Brandileone MC, Sáfadi MAP, Richtmann R, Gilio AE, Rossi F, Guimarães T, Bierrenbach AL, Moraes JC; São Paulo Study Group for IPD. Braz J Infect Dis. 2023 Feb 6;27(2):102746. doi: 10.1016/j.bjid.2023.102746. Online ahead of print. PMID: 36758625

An immunoinformatics analysis: design of a multi-epitope **vaccine** against *Cryptosporidium hominis* by employing heat shock protein triggers the innate and adaptive immune responses.
Pandya N, Kumar A. J Biomol Struct Dyn. 2023 Feb 10:1-17. doi: 10.1080/07391102.2023.2175373. Online ahead of print. PMID: 36764824

Immunogenicity, Reactogenicity, and Reinfection After 2 Doses of the Inactivated Whole-virion CoronaVac **Vaccine** in Kidney Transplant Recipients Convalescents From COVID-19.
Amorim LVP, Cristelli MP, Viana LA, Dreige YC, Requião-Moura LR, Nakamura MR, Foresto RD, Medina-Pestana J, Tedesco-Silva H. Transplantation. 2023 Feb 1;107(2):e72-e73. doi: 10.1097/TP.0000000000004439. Epub 2022 Nov 2. PMID: 36319616

Acute appendicitis in a patient immunised with COVID-19 **vaccine**: A case report with morphological analysis.
Marconi E, Crescioli G, Bonaiuti R, Pugliese L, Santi R, Nesi G, Cerbai E, Vannacci A, Lombardi N. Br J Clin Pharmacol. 2023 Feb;89(2):551-555. doi: 10.1111/bcp.15421. Epub 2022 Jun 7. PMID: 35633085

A Multicenter, Prospective, Randomized, Parallel-Group Trial on the Effects of Temporary Methotrexate Discontinuation for One Week Versus Two Weeks on Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis.
Park JK, Lee YJ, Shin K, Kang EH, Ha YJ, Park JW, Kim MJ, Kim MH, Choi SR, Jung Y, Lee JH, In Jung J, Kim JY, Winthrop KL, Lee EB. Arthritis Rheumatol. 2023 Feb;75(2):171-177. doi: 10.1002/art.42318. Epub 2022 Dec 7. PMID: 35930728

Vaccine hesitancy decreases, long term concerns remain in myositis, rheumatic disease patients: A comparative analysis of the COVAD surveys.
Sen P, Naveen R, Houshmand N, Moghadam Kia S, Joshi M, Saha S, Jagtap K, Agarwal V, Nune A, Nikiphorou E, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Parodis I, Edgar Gracia-Ramos A, Cavagna L, Kuwana M, Knitza J, Makol A, Patel A, Pauling JD, Wincup C, Barman B, Zamora Tehozol EA, Rojas Serrano J, La Torre IG, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Goo PA, Shumnalieva R, Chen YM, Hoff LS, El Kibbi L, Halabi H, Vaidya B, Sazliyana Shaharir S, Hasan ATMT, Dey D, Gutiérrez CET, Caballero-Uribe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Distler O, Saavedra MA, Day J, Chinoy H; COVAD study group; Agarwal V, Aggarwal R, Gupta L. Rheumatology (Oxford). 2023 Feb 3:kead057. doi: 10.1093/rheumatology/kead057. Online ahead of print. PMID: 36734536

Time for change? A systematic review with meta-analysis of leptospires infecting dogs to assess **vaccine** compatibility in Brazil.
Esteves SB, Santos CM, Silva BCS, Salgado FF, Guilloux AGA, Cortez A, Lucco RC, Miotto BA. Prev Vet Med. 2023 Feb 3;213:105869. doi: 10.1016/j.prevetmed.2023.105869. Online ahead of print. PMID: 36773375

Letter to the editor: A case of functional isolated tongue tremor-like dyskinesia after COVID-19 **vaccine**.
Demartini B, Wiedenmann F, Baccara A, Nisticò V, Gambini O, Elia AE, Grisoli M, Romito LM. Psychiatry Clin Neurosci. 2023 Feb;77(2):122-123. doi: 10.1111/pcn.13477. Epub 2022 Oct 17. PMID: 36098902

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial.
Gaglani M, Kim SS, Naleway AL, Levine MZ, Edwards L, Murthy K, Dunnigan K, Zunie T, Groom H, Ball S, Jeddy Z, Hunt D, Wesley MG, Sambhara S, Gangappa S, Grant L, Cao W, Gross FL, Mishina M, Fry AM, Thompson MG, Dawood FS, Flannery B. Clin Infect Dis. 2023 Feb 8;76(3):e1168-e1176. doi: 10.1093/cid/ciac683. PMID: 36031405

Anti-glomerular Basement Membrane Disease Concomitant with MPO-ANCA Positivity Concurrent with High Serum Levels of Interleukin-26 Following Coronavirus Disease 2019 Vaccination.
Kobayashi S, Fugo K, Hatano R, Yamazaki K, Morimoto C, Terawaki H. Intern Med. 2023 Feb 1. doi: 10.2169/internalmedicine.1027-22. Online ahead of print. PMID: 36725042

Evaluation of a point of care lateral flow assay for antibody detection following SARS CoV-2 mRNA **vaccine** series.
Lee W, Kurien P. J Immunol Methods. 2023 Feb;513:113410. doi: 10.1016/j.jim.2022.113410. Epub 2022 Dec 29. PMID: 36586509

Assessing the adverse effects of COVID-19 **vaccine** in different scenarios in Saudi Arabia: A cross-sectional study.
Alsaiari AA, Allahyani M, Aljuaid A, Shafie A, Al-Hazmi A, Dahlawi HA, Abdulaziz O, Alosimi E, Alzaidi A, Almehmadi M. Saudi Med J. 2023 Feb;44(2):194-201. doi: 10.15537/smj.2023.44.2.20220680. PMID: 36773975

Correction to: Prevention of Neisseria gonorrhoeae With Meningococcal B **Vaccine**: A Matched Cohort Study in Southern California.
[No authors listed] Clin Infect Dis. 2023 Feb 8;76(3):561. doi: 10.1093/cid/ciac936. PMID: 36630313

Effectiveness and feasibility of three types of parent reminders to increase adolescent human papillomavirus (HPV) vaccination.
Glenn BA, Crespi CM, Herrmann AK, Nonzee NJ, Debra L Rosen RN, Park CL, Gina Johnson MD, L Cindy Chang MS, Singhal R, Taylor VM, Bastani R. Prev Med. 2023 Feb 9:107448. doi: 10.1016/j.ypmed.2023.107448. Online ahead of print. PMID: 36773962

Association of infant Rib and Alp1 surface protein N-terminal domain immunoglobulin G and invasive Group B Streptococcal disease in young infants.
Dangor Z, Kwatra G, Pawlowski A, Fisher PB, Izu A, Lala SG, Johansson-Lindbom B, Madhi SA. Vaccine. 2023 Feb 6:S0264-410X(23)00113-5. doi: 10.1016/j.vaccine.2023.01.071. Online ahead of print. PMID: 36754766

Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based **Vaccine**: Part II- Real-time and Accelerated Stability Studies.
Sharma N, Jerajani K, Wan Y, Kumru OS, Pullagurla SR, Ogun O, Mapari S, Brendle S, Christensen ND, Batwal S, Mahedvi M, Rao H, Dogar V, Chandrasekharan R, Shaligram U, Volkin DB, Joshi SB. J Pharm Sci. 2023 Feb;112(2):458-470. doi: 10.1016/j.xphs.2022.11.021. Epub 2022 Dec 1. PMID: 36462710

Correction to "Cuban Abdala **vaccine**: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study" [The Lancet Regional Health - Americas 2022; 16: 100366] https://doi.org/10.1016/j.lana.2022.100366.
Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, Galbán-García E, Olivera-Nodarse Y, Morgado-Vega I, Dueñas-Carrera S, Pujol M, Hernández-Bernal F, Limonta-Fernández M, Guillén-Nieto G, Muzio-González VL, Ayala-Ávila M. Lancet Reg Health Am. 2023 Feb;18:100422. doi: 10.1016/j.lana.2022.100422. Epub 2022 Dec 29. PMID: 36593764

Efficacy of an unmodified bivalent mRNA **vaccine** against SARS-CoV-2 variants in female small animal models.
Corleis B, Hoffmann D, Rauch S, Fricke C, Roth N, Gergen J, Kovacikova K, Schlottau K, Halwe NJ, Ulrich L, Schön J, Wernike K, Widera M, Ciesek S, Mueller SO, Mettenleiter TC, Maione D, Petsch B, Beer M, Dorhoi A. Nat Commun. 2023 Feb 13;14(1):816. doi: 10.1038/s41467-023-36110-1. PMID: 36781853

Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses.
Hasegawa A, Murata M, Fujikawa T, Katagiri K, Nagano Y, Masuda T, Kuramitsu M, Nakajima S, Fujisawa JI, Okuma K, Grover P, Kidiga M, Akari H, Kannagi M. PLoS Pathog. 2023 Feb 2;19(2):e1011104. doi: 10.1371/journal.ppat.1011104. Online ahead of print. PMID: 36730466

Decision-making in childhood vaccination: **vaccine** hesitancy among caregivers of under-5 children from a tertiary care institution in Eastern India.
Sahoo SS, Parida SP, Singh AK, Palepu S, Sahoo DP, Bhatia V. Ther Adv Vaccines Immunother. 2023 Feb 3;11:25151355231152650. doi: 10.1177/25151355231152650. eCollection 2023. PMID: 36756042

Recombinant fiber-1 protein of fowl adenovirus serotype 4 induces high levels of neutralizing antibodies in immunized chickens.
Watanabe S, Yamamoto Y, Kurokawa A, Iseki H, Tanikawa T, Mase M. Arch Virol. 2023 Feb 9;168(3):84. doi: 10.1007/s00705-023-05709-6. PMID: 36757474

Longitudinal age differences in humoral responses to the COVID-19 **vaccine** in the elderly are lost after the third dose.
Pozo-Balado MDM, Bulnes-Ramos Á, Garrido-Rodríguez V, Olivas-Martínez I, Lozano C, González-Escribano MF, Leal M, Pacheco YM. J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.12.002. Epub 2022 Dec 8. PMID: 36503017

Immunization of Mice with Virus-Like Vesicles of Kaposi Sarcoma-Associated Herpesvirus Reveals a Role for Antibodies Targeting ORF4 in Activating Complement-Mediated Neutralization.
Lam AK, Roshan R, Miley W, Labo N, Zhen J, Kurland AP, Cheng C, Huang H, Teng PL, Harelson C, Gong D, Tam YK, Radu CG, Epeldegui M, Johnson JR, Zhou ZH, Whitby D, Wu TT. J Virol. 2023 Feb 9:e0160022. doi: 10.1128/jvi.01600-22. Online ahead of print. PMID: 36757205

Effects of adjuvants in a rabies-vectored Ebola virus **vaccine** on protection from surrogate challenge.
Yankowski C, Kurup D, Wirblich C, Schnell MJ. NPJ Vaccines. 2023 Feb 8;8(1):10. doi: 10.1038/s41541-023-00615-z. PMID: 36754965

Evaluation of cross-protection between S. Pneumoniae serotypes 35B and 29 in a mouse model.
Kim E, He J, Kaufhold RM, McGuinness D, McHugh P, Nawrocki D, Xie J, Skinner JM. Vaccine. 2023 Feb 11:S0264-410X(23)00127-5. doi: 10.1016/j.vaccine.2023.02.001. Online ahead of print. PMID: 36781335

Genetic stability of SIV Gag/Tat gene inserted into Del-II in modified vaccinia virus ankara after serial passage of recombinant vector in pCEFs cells.
Faqih L, Vallely P, Klapper P. J Virol Methods. 2023 Feb;312:114651. doi: 10.1016/j.jviromet.2022.114651. Epub 2022 Nov 9. PMID: 36370896

Regarding: Factors associated with severe or fatal clinical manifestations of SARS-CoV-2 infection after receiving the third dose of **vaccine**.
Jolobe O. J Intern Med. 2023 Feb;293(2):269-270. doi: 10.1111/joim.13591. Epub 2022 Nov 27. PMID: 36437497

Environmental surveillance detected type 3 **vaccine**-derived polioviruses in increasing frequency at multiple sites prior to detection of a poliomyelitis case.
Weil M, Sofer D, Shulman LM, Weiss L, Levi N, Aguvaev I, Cohen Z, Kestin K, Vasserman R, Elul M, Fratty IS, Zuckerman NS, Erster O, Yishai R, Hecht L, Alroy-Preis S, Mendelson E, Bar-Or I. Sci Total Environ. 2023 Feb 3;871:161985. doi: 10.1016/j.scitotenv.2023.161985. Online ahead of print. PMID: 36739034

Development of PIVOT with MI: A motivational Interviewing-Based **vaccine** communication training for pediatric clinicians.
O'Leary ST, Spina CI, Spielvogle H, Robinson JD, Garrett K, Perreira C, Pahud B, Dempsey AF, Opel DJ. Vaccine. 2023 Feb 10:S0264-410X(23)00136-6. doi: 10.1016/j.vaccine.2023.02.010. Online ahead of print. PMID: 36775776

Impact of Seasonal Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 **Vaccine** Responses in Solid Organ Transplant Recipients.
Karaba AH, Zhou W, Li S, Aytenfisu TY, Johnston TS, Akinde O, Eby Y, Abedon AT, Alejo JL, Qin CX, Thompson EA, Garonzik-Wang JM, Blankson JN, Cox AL, Bailey JR, Klein SL, Pekosz A, Segev DL, Tobian AAR, Werbel WA. Clin Infect Dis. 2023 Feb 8;76(3):e495-e498. doi: 10.1093/cid/ciac652. PMID: 35959783

A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide **vaccine** for the treatment of advanced soft tissue sarcoma.
Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, Harada N, Miyahara Y, Seo N, Hattori H, Takada K, Emori M, Kakunaga S, Endo M, Matsumoto Y, Sasada T, Sato E, Yamada T, Matsumine A, Nagata Y, Watanabe T, Kageyama S, Shiku H. Int J Cancer. 2023 Feb 2. doi: 10.1002/ijc.34453. Online ahead of print. PMID: 36727538

Mistrust in government and COVID-19 vaccination acceptance in Nigeria: investigating the indirect roles of attitudes towards vaccination.
Olawa B, Lawal A, Odoh I, Azikiwe J, Olawole A, Odusina E, Ayodele I, Ajayi O. J Egypt Public Health Assoc. 2023 Feb 6;98(1):1. doi: 10.1186/s42506-023-00129-5. PMID: 36745270

Development of cell culture based peste des petits ruminants (PPR) virus **vaccine** candidate from BANGLADESHI ISOLATES.
Siddiqui M, Globig A, Hoffmann B, Rahman MM, Islam MR, Chowdhury EH. J Virol Methods. 2023 Feb 10:114690. doi: 10.1016/j.jviromet.2023.114690. Online ahead of print. PMID: 36775141

Development and validation of a mass spectrometry based analytical method to quantify the ratios in hemagglutinin trimers in quadrivalent influenza nanoparticle **vaccine** - FluMos-v1.
Shajahan A, Cai CX, Wolff J, Yang RS, Ivleva VB, Gowetski DB, Gall JGD, Lei QP. Anal Methods. 2023 Feb 1. doi: 10.1039/d2ay01890j. Online ahead of print. PMID: 36723411

A Phase II/III, Multicenter, Observer-blinded, Randomized, Non-inferiority and Safety, study of typhoid conjugate **vaccine** (EuTCV) compared to Typbar-TCV® in healthy 6 Months-45 years aged participants.
Ok Baik Y, Lee Y, Lee C, Kyung Kim S, Park J, Sun M, Jung D, Young Jang J, Jun Yong T, Woo Park J, Jeong S, Lim S, Hyun Han S, Keun Choi S. Vaccine. 2023 Feb 9:S0264-410X(22)01524-9. doi: 10.1016/j.vaccine.2022.12.007. Online ahead of print. PMID: 36774331

Editorial Comment to Phase I/II study of multipeptide cancer **vaccine** IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.
Obara W, Kato R. Int J Urol. 2023 Feb;30(2):181. doi: 10.1111/iju.15093. Epub 2022 Nov 7. PMID: 36345128

Evaluation of Newcastle disease virus LaSota strain attenuated by codon pair deoptimization of the HN and F genes for in ovo vaccination.
Eldemery F, Ou C, Kim T, Spatz S, Dunn J, Silva R, Yu Q. Vet Microbiol. 2023 Feb;277:109625. doi: 10.1016/j.vetmic.2022.109625. Epub 2022 Dec 6. PMID: 36563582

Corrigendum to To clot or not to clot? Ad is the question-Insights on mechanisms related to **vaccine**-induced thrombotic thrombocytopenia [J Thromb Haemost. 2021 Nov;19(11):2845-2856. doi: 10.1111/jth.15485].
Othman M, Baker AT, Gupalo E, Elsebaie A, Bliss CM, Rondina MT, Lillicrap D, Parker AL. J Thromb Haemost. 2023 Feb 1:S1538-7836(23)00065-X. doi: 10.1016/j.jtha.2023.01.022. Online ahead of print. PMID: 36737373

Correction to: Longitudinal Immune Response to 3 Doses of Messenger RNA **Vaccine** Against Coronavirus Disease (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer.
[No authors listed] Clin Infect Dis. 2023 Feb 8;76(3):560-561. doi: 10.1093/cid/ciac964. PMID: 36617214

The COVID-19 curtain: Can past communist regimes explain the vaccination divide in Europe?
Pronkina E, Berniell I, Fawaz Y, Laferrère A, Mira P. Soc Sci Med. 2023 Feb 6;321:115759. doi: 10.1016/j.socscimed.2023.115759. Online ahead of print. PMID: 36774703

Longitudinal Immune Response to 3 Doses of Messenger RNA **Vaccine** Against Coronavirus Disease 2019 (COVID-19) in Pediatric Patients Receiving Chemotherapy for Cancer.
Lehrnbecher T, Sack U, Speckmann C, Groll AH, Boldt A, Siebald B, Hettmer S, Demmerath EM, Reemtsma J, Schenk B, Ciesek S, Klusmann JH, Jassoy C, Hoehl S. Clin Infect Dis. 2023 Feb 8;76(3):e510-e513. doi: 10.1093/cid/ciac570. PMID: 35901198

An oral NoV-rAd5 **vaccine** with built-in dsRNA adjuvant elicits systemic immune responses in mice.
Wang J, Ma Y, Li J, Peng R, Mao T, Sun X, Duan Z. Int Immunopharmacol. 2023 Feb 11;116:109801. doi: 10.1016/j.intimp.2023.109801. Online ahead of print. PMID: 36780828

Adolescents Who Have Undergone Human Papillomavirus Vaccination Are More Likely to Get a COVID-19 **Vaccine**.
Coronado GD, Petrik AF, Slaughter M, Kepka D, Naleway AL. J Adolesc Health. 2023 Feb 11:S1054-139X(23)00013-7. doi: 10.1016/j.jadohealth.2022.12.022. Online ahead of print. PMID: 36781325

Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based **vaccine**.
O'Donnell KL, Feldmann F, Kaza B, Clancy CS, Hanley PW, Fletcher P, Marzi A. EBioMedicine. 2023 Feb 10;89:104463. doi: 10.1016/j.ebiom.2023.104463. Online ahead of print. PMID: 36774693

Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based **Vaccine**: Part I - Screening of Preservative Combinations.

Jerajani K, Wan Y, Kumru OS, Pullagurla SR, Kumar P, Sharma N, Ogun O, Mapari S, Brendle S, Christensen ND, Batwal S, Mahedvi M, Rao H, Dogar V, Chandrasekharan R, Shaligram U, Joshi SB, Volkin DB. J Pharm Sci. 2023 Feb;112(2):446-457. doi: 10.1016/j.xphs.2022.09.001. Epub 2022 Sep 9. PMID: 36096284

Use of the improvement index to evaluate equitable COVID-19 **vaccine** allocation in the San Francisco Bay Area.
Jumamil RB, Rutherford G. AJPM Focus. 2023 Feb 4:100075. doi: 10.1016/j.focus.2023.100075. Online ahead of print. PMID: 36776788

Thrombotic events following the BNT162b2 mRNA COVID-19 **vaccine** (Pfizer-BioNTech) in Aotearoa New Zealand: A self-controlled case series study.
Walton M, Tomkies R, Teunissen T, Lumley T, Hanlon T. Thromb Res. 2023 Feb;222:102-108. doi: 10.1016/j.thromres.2022.12.012. Epub 2022 Dec 28. PMID: 36634464

SARS-CoV-2 **vaccine**-triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors-associated bullous pemphigoid.
Nakahara Y, Yamane M, Sunada M, Aoyama Y. J Dermatol. 2023 Feb;50(2):162-165. doi: 10.1111/1346-8138.16687. Epub 2022 Dec 28. PMID: 36578130

Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern.
Zhang T, Wang Z, Yang J, Xu X. J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28563. Online ahead of print. PMID: 36755368

Immune-mediated necrotizing myopathy following vaccination with the AstraZeneca (AZD1222) COVID-19 **vaccine**: A case report and brief review.
Ansari B, Najafi MA, Kheradmand M, Najafi F, Najafi MR. Rev Neurol (Paris). 2023 Feb 1:S0035-3787(23)00757-9. doi: 10.1016/j.neurol.2022.11.009. Online ahead of print. PMID: 36754672

A cross-sectional analysis of the association between social capital and willingness to get COVID-19 **vaccine** in Ontario, Canada.
Grignon M, Bai Y. Can J Public Health. 2023 Feb 8:1-10. doi: 10.17269/s41997-023-00746-9. Online ahead of print. PMID: 36752981

Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination.
Rujkorakarn P, Patamatamkul S. J Fr Ophtalmol. 2023 Feb 10:S0181-5512(23)00009-8. doi: 10.1016/j.jfo.2022.09.017. Online ahead of print. PMID: 36775731

A multivalent polyomavirus **vaccine** elicits durable neutralizing antibody responses in macaques.
Peretti A, Scorpio DG, Kong WP, Pang YS, McCarthy MP, Ren K, Jackson M, Graham BS, Buck CB, McTamney PM, Pastrana DV. Vaccine. 2023 Feb 8:S0264-410X(23)00128-7. doi: 10.1016/j.vaccine.2023.02.002. Online ahead of print. PMID: 36764908

The impact of SARS-CoV-2 vaccination and infection on neutralising antibodies: a nation-wide cross-sectional analysis.

Althaus T, Landier J, Zhu F, Raps H, Dejoux O, Costantini A, Lavagna C, Rampal P, Mattiuzzo G, Xu S, Wang LF, Voiglio E. J Infect Dis. 2023 Feb 14:jiad030. doi: 10.1093/infdis/jiad030. Online ahead of print. PMID: 36780397

Anti-SARS-CoV-2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated **vaccine** dose to the onset of illness is prolonged in breakthrough infection patients.
Xu CC, He ZS, Lei W, Zhu JZ, Zhao DG, Kong JD, Wei Y, Xu Y, Huang JA. Clin Respir J. 2023 Feb 9. doi: 10.1111/crj.13590. Online ahead of print. PMID: 36759335

Reply to 'A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 **vaccine**'.
Martora F, Fabbrocini G, Guerrasio G, Potestio L. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e141-e142. doi: 10.1111/jdv.18646. Epub 2022 Oct 19. PMID: 36227123

A simulation approach for COVID-19 pandemic assessment based on **vaccine** logistics, SARS-CoV-2 variants, and spread rate.
Erkayman B, Ak F, Çodur S. Simulation. 2023 Feb;99(2):127-135. doi: 10.1177/00375497221120018. PMID: 36751401

Acute bilateral central serous chorioretinopathy in a young male after the first dose of Oxford/AstraZeneca AZD1222 (Covishield) **vaccine**.
Sindhu M, Bamotra RK, Singh S. Indian J Ophthalmol. 2023 Feb;71(2):666-668. doi: 10.4103/ijo.IJO_1629_22. PMID: 36727385

Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern.
Azevedo PO, Hojo-Souza NS, Faustino LP, Fumagalli MJ, Hirako IC, Oliveira ER, Figueiredo MM, Carvalho AF, Doro D, Benevides L, Durigon E, Fonseca F, Machado AM, Fernandes AP, Teixeira SR, Silva JS, Gazzinelli RT. NPJ Vaccines. 2023 Feb 13;8(1):15. doi: 10.1038/s41541-023-00616-y. PMID: 36781862

General practitioner phone calls to improve COVID-19 **vaccine** uptake among patients at increased risk of severe COVID-19: A randomised trial.
Tuv M, Elgersma IH, Furuseth E, Holst C, Helleve A, Fretheim A. BJGP Open. 2023 Feb 8:BJGPO.2022.0175. doi: 10.3399/BJGPO.2022.0175. Online ahead of print. PMID: 36754551

Letter to the Editor on "New-Onset Myasthenia Gravis Confirmed by Electrodiagnostic Studies After a Third Dose of SARS-CoV-2 mRNA-1273 **Vaccine**".
Kim S, Eun MY, Seok HY. Am J Phys Med Rehabil. 2023 Feb 8. doi: 10.1097/PHM.0000000000002208. Online ahead of print. PMID: 36762834

Research progress on substitution of *in vivo* method(s) by *in vitro* method(s) for human **vaccine** potency assays.
Zhang X, Wu X, He Q, Wang J, Mao Q, Liang Z, Xu M. Expert Rev Vaccines. 2023 Feb 13. doi: 10.1080/14760584.2023.2178421. Online ahead of print. PMID: 36779650

Immunogenicity of a quadrivalent human papillomavirus **vaccine** in pediatric kidney and liver transplant recipients.
Kitano T, Schwartz KL, Abdulnoor M, Garfield H, Booran NK, Avitzur Y, Teoh CW, Hébert D, Allen U. Pediatr Transplant. 2023 Feb 5:e14476. doi: 10.1111/petr.14476. Online ahead of print. PMID: 36740761

Association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case-control study.
Collie S, Saggers RT, Bandini R, Steenkamp L, Champion J, Gray G, Bekker LG, Goga A, Garrett N, Patricios J. Br J Sports Med. 2023 Feb;57(4):205-211. doi: 10.1136/bjsports-2022-105734. Epub 2022 Oct 24. PMID: 36280289

COVID-19 Clusters and Outbreaks among Non-Healthcare, Non-Congregate Workers in Chicago, Illinois: Surveillance through the First Omicron Wave.
Lendacki FR, Forst L, Weber E, Mehta SD, Kerins JL. J Occup Environ Med. 2023 Feb 13. doi: 10.1097/JOM.0000000000002782. Online ahead of print. PMID: 36781304

Cancer and COVID-19 vaccines on Twitter: The voice and **vaccine** attitude of cancer community.
Jun J, Wickersham K, Zain A, Ford R, Zhang N, Ciccarelli C, Kim SH, Liang C. J Health Commun. 2023 Feb 8:1-14. doi: 10.1080/10810730.2023.2168800. Online ahead of print. PMID: 36755484

Seroconversion and persistence of neutralizing antibody response after yellow fever vaccination in patients with perinatally acquired HIV infection.
Martin C, Domingo C, Hainaut M, Delforge M, De Wit S, Dauby N. AIDS. 2023 Feb 1;37(2):341-346. doi: 10.1097/QAD.0000000000003433. Epub 2022 Nov 10. PMID: 36541645

Cross-Reactive Profile Against Two Conserved Coronavirus Antigens in Sera from SARS-CoV-2 Hybrid and Vaccinated Immune Donors.
Lobaina Y, Chen R, Ai P, Yang L, Alvarez-Lajonchere L, Suzarte E, Tan C, Silva R, Jiang Z, Yang K, Perera Y, Hermida L. Viral Immunol. 2023 Feb 3. doi: 10.1089/vim.2022.0186. Online ahead of print. PMID: 36735580

Surface functionalization of PLGA nanoparticles for potential oral **vaccine** delivery targeting intestinal immune cells.
Amin MK, Boateng J. Colloids Surf B Biointerfaces. 2023 Feb;222:113121. doi: 10.1016/j.colsurfb.2022.113121. Epub 2022 Dec 29. PMID: 36599187

Mining the vaccination willingness of China using social media data.
Ding J, Wang A, Zhang Q. Int J Med Inform. 2023 Feb;170:104941. doi: 10.1016/j.ijmedinf.2022.104941. Epub 2022 Dec 6. PMID: 36502742

Analysis of LruC lipoprotein and identification of peptides candidates for **vaccine** development and diagnosis of leptospirosis.
Mariano IHM, Silva BF, Machado MDS, Blanco RM, Romero EC, Andrade SA, Ho PL, Martins EAL, da Silva JB. PLoS One. 2023 Feb 6;18(2):e0281344. doi: 10.1371/journal.pone.0281344. eCollection 2023. PMID: 36745643

Recent insights into reverse genetics of norovirus.
Zhang Q, Zhu S, Zhang X, Su L, Ni J, Zhang Y, Fang L. Virus Res. 2023 Feb;325:199046. doi: 10.1016/j.virusres.2023.199046. Epub 2023 Jan 16. PMID: 36657615

A non-toxic recombinant bivalent chimeric protein rETX$_{m3}$CSA$_{m4/TMD}$ as a potential **vaccine** candidate against enterotoxemia and braxy.
Du J, Liu B, Wang T, Zhu Z, Yin C, Luo Y, Liu Y, Chen X. Vaccine. 2023 Feb 3;41(6):1232-1238. doi: 10.1016/j.vaccine.2022.11.021. Epub 2023 Jan 10. PMID: 36635138

Minimal mRNA uptake and inflammatory response to COVID-19 mRNA **vaccine** exposure in human placental explants.
Gonzalez V, Li L, Buarpung S, Prahl M, Robinson JF, Gaw SL. medRxiv. 2023 Feb 2:2023.02.01.23285349. doi: 10.1101/2023.02.01.23285349. Preprint. PMID: 36778281

The impacts of SARS-CoV-2 **vaccine** dose separation and targeting on the COVID-19 epidemic in England.
Keeling MJ, Moore S, Penman BS, Hill EM. Nat Commun. 2023 Feb 10;14(1):740. doi: 10.1038/s41467-023-35943-0. PMID: 36765050

Maternal vaccination-current status, challenges, and opportunities.
Kurasawa K. J Obstet Gynaecol Res. 2023 Feb;49(2):493-509. doi: 10.1111/jog.15503. Epub 2022 Nov 28. PMID: 36444417

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate **vaccine**, in children with SCD: a V114-023 (PNEU-SICKLE) study.
Quinn CT, Wiedmann RT, Jarovsky D, Lopez-Medina E, Rodriguez HM, Papa M, Boggio G, Shou Q, Dagan R, Richmond P, Feemster K, McFetridge R, Tamms G, Lupinacci R, Musey L, Bickham K. Blood Adv. 2023 Feb 14;7(3):414-421. doi: 10.1182/bloodadvances.2022008037. PMID: 36383730

Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16.
Melief CJM, van der Gracht E, Wiekmeijer AS. Semin Immunopathol. 2023 Feb 13. doi: 10.1007/s00281-023-00986-4. Online ahead of print. PMID: 36780000

Increased Stroke Risk Following Herpes Zoster Infection and Protection With Zoster **Vaccine**.
Parameswaran GI, Wattengel BA, Chua HC, Swiderek J, Fuchs T, Carter MT, Goode L, Doyle K, Mergenhagen KA. Clin Infect Dis. 2023 Feb 8;76(3):e1335-e1340. doi: 10.1093/cid/ciac549. PMID: 35796546

Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases.
Van den Steen P, Cheuvart B, Deraedt Q, Valdes Verelst L, Shamarina D. Hum Vaccin Immunother. 2023 Feb 6:2159731. doi: 10.1080/21645515.2022.2159731. Online ahead of print. PMID: 36746754

Risk of reinfection, **vaccine** protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.

Hansen CH, Friis NU, Bager P, Stegger M, Fonager J, Fomsgaard A, Gram MA, Christiansen LE, Ethelberg S, Legarth R, Krause TG, Ullum H, Valentiner-Branth P. Lancet Infect Dis. 2023 Feb;23(2):167-176. doi: 10.1016/S1473-3099(22)00595-3. Epub 2022 Oct 18. PMID: 36270311

First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA **vaccine** BNT162b2.
Umezawa S, Ioka K, Aizawa S, Tashiro Y, Yoshizawa K. Neurol Sci. 2023 Feb;44(2):451-455. doi: 10.1007/s10072-022-06465-2. Epub 2022 Oct 27. PMID: 36289118 Free PMC article.

Vaccination status in patients at risk for invasive disease with encapsulated bacteria at a children's hospital in the City of Buenos Aires.
Del Pino M, Castellano VE, Pacchiotti AC, Lamy P, Bazán V, Diana Menéndez S, Gentile Á. Arch Argent Pediatr. 2023 Feb 1;121(1):e202202648. doi: 10.5546/aap.2022-02648.eng. Epub 2022 Oct 27. PMID: 36287171

Investigating Tetanus, Diphtheria, Acellular Pertussis Vaccination During Pregnancy and Risk of Congenital Anomalies.
Florea A, Sy LS, Ackerson BK, Qian L, Luo Y, Becerra-Culqui T, Lee GS, Tian Y, Zheng C, Bathala R, Tartof SY, Campora L, Ceregido MA, Kuznetsova A, Poirrier JE, Rosillon D, Valdes L, Cheuvart B, Mesaros N, Meyer N, Guignard A, Tseng HF. Infect Dis Ther. 2023 Feb;12(2):411-423. doi: 10.1007/s40121-022-00731-8. Epub 2022 Dec 15. PMID: 36520325

Antibody, cell-mediated response and infection susceptibility in allogeneic hematopoietic stem cell recipients after COVID-19 mRNA vaccination.
Pizzano U, Facchin G, Marcon C, Fabris M, Battista ML, Cerno M, Geromin A, Pucillo M, Petruzzellis G, Vianello G, Battaglia G, Peressutti R, Grillone L, Tascini C, Curcio F, Fanin R, Patriarca F. Transpl Infect Dis. 2023 Feb 7:e14003. doi: 10.1111/tid.14003. Online ahead of print. PMID: 36748718

Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in 2023.
Tervaert JWC, Martinez-Lavin M, Jara LJ, Halpert G, Watad A, Amital H, Shoenfeld Y. Autoimmun Rev. 2023 Feb 2:103287. doi: 10.1016/j.autrev.2023.103287. Online ahead of print. PMID: 36738954

A prospective multicenter study on cutaneous reactions reported after Sinopharm COVID-19 vaccination.
Shawky A, Elrewiny EM, Gharib K, Sallam M, Mansour M, Rageh MA. Int J Dermatol. 2023 Feb;62(2):221-224. doi: 10.1111/ijd.16391. Epub 2022 Aug 12. PMID: 35959522

Hospitalized Patients With Severe Coronavirus Disease 2019 During the Omicron Wave in Israel: Benefits of a Fourth **Vaccine** Dose.
Brosh-Nissimov T, Hussein K, Wiener-Well Y, Orenbuch-Harroch E, Elbaz M, Lipman-Arens S, Maor Y, Yagel Y, Chazan B, Hershman-Sarafov M, Rahav G, Zimhony O, Zaidman Shimshovitz A, Chowers M. Clin Infect Dis. 2023 Feb 8;76(3):e234-e239. doi: 10.1093/cid/ciac501. PMID: 35724127

Willingness to get vaccinated against influenza, pneumococcal disease, pertussis, and herpes zoster - A pre-COVID-19 exploration among the older adult population.
Maertzdorf KM, Rietman ML, Lambooij MS, Verschuren WMM, Picavet HSJ. Vaccine. 2023 Feb 3;41(6):1254-1264. doi: 10.1016/j.vaccine.2023.01.001. Epub 2023 Jan 4. PMID: 36639273

Assessment of psychological distress pattern & its correlates among people receiving COVID-19 vaccination during the COVID-19 pandemic: A cross-sectional study.
Singh S, Parija PP, Verma R, Kumar P, Chadda RK. Indian J Med Res. 2023 Feb 1. doi: 10.4103/ijmr.ijmr_3613_21. Online ahead of print. PMID: 36722548

Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster **Vaccine** Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years.
Leidner AJ, Anderson TC, Hong K, Ortega-Sanchez IR, Guo A, Pike J, Prosser LA, Dooling KL. Value Health. 2023 Feb;26(2):204-215. doi: 10.1016/j.jval.2022.08.003. Epub 2022 Oct 13. PMID: 36243666

Is hepatitis-B immunization effective during chronic liver fibrosis? Investigation of secretory and cellular immune responses on an experimental model.
Kayhan B, Karaca ZM, Canpolat E, Ersan V, Gül M, Yologlu S, Yılmaz S. Immunopharmacol Immunotoxicol. 2023 Feb;45(1):102-113. doi: 10.1080/08923973.2022.2121925. Epub 2022 Sep 14. PMID: 36066099

Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper.
Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, González Del Castillo J, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Bouza E. Rev Esp Quimioter. 2023 Feb 8:molero08feb2023. doi: 10.37201/req/004.2023. Online ahead of print. PMID: 36752132

Immunological correlates of protection following vaccination with glucan particles containing Cryptococcus neoformans chitin deacetylases.
Wang R, Oliveira LVN, Lourenco D, Gomez CL, Lee CK, Hester MM, Mou Z, Ostroff GR, Specht CA, Levitz SM. NPJ Vaccines. 2023 Feb 2;8(1):6. doi: 10.1038/s41541-023-00606-0. PMID: 36732332

Mixed Origins: HIV gp120-specific memory develops from pre-existing memory and naïve B cells following vaccination in humans.
Basu M, Fucile C, Piepenbrink M, Bunce C, Man LX, Liesveld J, Rosenberg A, Keefer M, Kobie JJ. AIDS Res Hum Retroviruses. 2023 Feb 10. doi: 10.1089/AID.2022.0104. Online ahead of print. PMID: 36762930

Development of a personalized dendritic cell **vaccine** and single-cell RNA sequencing-guided assessment of its cell type composition.
Li Q, Yang C, Tian H, Jiang J, Li P, Zhu X, Lei T, Yin R, Ding P, Bai P, Li Q. Cytotherapy. 2023 Feb;25(2):210-219. doi: 10.1016/j.jcyt.2022.10.013. Epub 2022 Nov 25. PMID: 36443171

Eosinophils Recruited during Pulmonary Vaccination Regulate Mucosal Antibody Production.
Prince L, Martín-Faivre L, Villeret B, Sanchez-Guzman D, Le Guen P, Sallenave JM, Garcia-Verdugo I. Am J Respir Cell Mol Biol. 2023 Feb;68(2):186-200. doi: 10.1165/rcmb.2022-0236OC. PMID: 36194580

Effectiveness of SARS-CoV-2 vaccines on hemodialysis patients in Japan: A nationwide cohort study.
Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Yoshihiro O, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Wakino S, Nakamoto H, Takemoto Y, Akizawa T; COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephrology. Ther Apher Dial. 2023 Feb;27(1):19-23. doi: 10.1111/1744-9987.13887. Epub 2022 Jun 14. PMID: 35610734

Vaccines on demand, part II: future reality.
Geall AJ, Kis Z, Ulmer JB. Expert Opin Drug Discov. 2023 Feb;18(2):119-127. doi: 10.1080/17460441.2022.2147501. Epub 2022 Nov 23. PMID: 36384351

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 **vaccine** (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald TJ, Lamb CA, Sebastian S, Kok K, Lees CW, Hart AL, Pollok RC, Boyton RJ, Altmann DM, Pollock KM, Goodhand JR, Kennedy NA, Ahmad T, Powell N; CLARITY study investigators. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):145-156. doi: 10.1016/S2468-1253(22)00389-2. Epub 2022 Dec 5. PMID: 36481043

Poly(I:C) and CpG improve the assembly of foot-and-mouth disease virus-like particles and immune response in mice.
Liu H, Teng Z, Dong H, Li J, Waheed Abdullah S, Zhang Y, Wu J, Guo H, Sun S. Virology. 2023 Feb;579:94-100. doi: 10.1016/j.virol.2022.12.016. Epub 2022 Dec 30. PMID: 36623353

Sero-prevalence of hepatitis B virus and compliance with hepatitis B vaccination schedules among outpatient clinic attendees in Nairobi.
Langat B, Muge EK, Night D, Okoth F, Ochwedo KO, Songok EM. PLoS One. 2023 Feb 2;18(2):e0281256. doi: 10.1371/journal.pone.0281256. eCollection 2023. PMID: 36730277

Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination.
Alidjinou EK, Demaret J, Corroyer-Simovic B, Vuotto F, Miczek S, Labreuche J, Goffard A, Trauet J, Lupau D, Dendooven A, Huvent-Grelle D, Podvin J, Dreuil D, Faure K, Deplanque D, Bocket L, Duhamel A, Sobaszek A, Hober D, Hisbergues M, Puisieux F, Autran B, Yazdanpanah Y, Labalette M, Lefèvre G. Clin Microbiol Infect. 2023 Feb;29(2):258.e1-258.e4. doi: 10.1016/j.cmi.2022.10.014. Epub 2022 Oct 17. PMID: 36257549

Demographic diversity of US-based participants in GSK-sponsored interventional clinical trials.
Reid MM, Davis SP, Henry ON, Mathew AA, McCallister S, Nero TT, Rabheru SA, Sampson SH, Vanderslice TF, Williams DT. Clin Trials. 2023 Feb 6:17407745221149118. doi: 10.1177/17407745221149118. Online ahead of print. PMID: 36744680

Serum Neutralizing Antibody Titers 12 Months After Coronavirus Disease 2019 Messenger RNA Vaccination: Correlation to Clinical Variables in an Adult, US Population.
Zhao M, Slotkin R, Sheth AH, Pischel L, Kyriakides TC, Emu B, McNamara C, Shi Q, Delgobbo J, Xu J, Marhoffer E, Mercer-Falkoff A, Holleck J, Ardito D, Sutton RE, Gupta S. Clin Infect Dis. 2023 Feb 8;76(3):e391-e399. doi: 10.1093/cid/ciac416. PMID: 35639598

Effectiveness of COVID-19 vaccines in people living with HIV in British Columbia and comparisons with a matched HIV-negative cohort: a test-negative design.
Fowokan A, Samji H, Puyat JH, Janjua NZ, Wilton J, Wong J, Grennan T, Chambers C, Kroch A, Costiniuk CT, Cooper CL, Burchell AN, Anis A; COVAXHIV study team. Int J Infect Dis. 2023 Feb;127:162-170. doi: 10.1016/j.ijid.2022.11.035. Epub 2022 Dec 1. PMID: 36462571

Clinical Phenotypes of Immediate First-Dose Reactions to mRNA COVID-19: A Multicenter Latent Class Analysis.
Stone CA Jr, Robinson LB, Li L, Krantz MS, Kwah JH, Ortega G, Mancini C, Wolfson AR, Saff RR, Samarakoon U, Hong DI, Koo G, Chow TG, Gruchalla R, Liao JX, Kuster JK, Price C, Ahola C, Khan DA, Phillips EJ, Banerji A, Blumenthal KG. J Allergy Clin Immunol Pract. 2023 Feb;11(2):458-465.e1. doi: 10.1016/j.jaip.2022.08.048. Epub 2022 Sep 13. PMID: 36108922

Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar.
Tayar E, Abdeen S, Abed Alah M, Chemaitelly H, Bougmiza I, Ayoub HH, Kaleeckal AH, Latif AN, Shaik RM, Al-Romaihi HE, Al-Thani MH, Bertollini R, Abu-Raddad LJ, Al-Khal A. J Infect Public Health. 2023 Feb;16(2):250-256. doi: 10.1016/j.jiph.2022.12.016. Epub 2022 Dec 26. PMID: 36603377

Lower T cell response against SARS-CoV-2 variants of concern after mRNA **vaccine** and risk of breakthrough infections in people living with HIV.
Casado JL, Vizcarra P, Martín-Colmenarejo S, Del Pino J, Gomez-Maldonado S, Martín-Hondarza A, Vallejo A. AIDS. 2023 Feb 8. doi: 10.1097/QAD.0000000000003504. Online ahead of print. PMID: 36779501

Spatial and temporal analysis of invasive pneumococcal disease due to erythromycinresistant serotypes.
Fernández Chávez AC, García Comas L, Gómez Barroso D, Ramis Prieto R, López Fresneña N, Bishofberguer Valdes C, Aranaz Andrés JM. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Feb;41(2):92-98. doi: 10.1016/j.eimce.2022.07.001. Epub 2022 Jul 27. PMID: 35907773

Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States.
Tenforde MW, Self WH, Zhu Y, Naioti EA, Gaglani M, Ginde AA, Jensen K, Talbot HK, Casey JD, Mohr NM, Zepeski A, McNeal T, Ghamande S, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, Busse LW, Lohuis CT, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Exline MC, Botros MM, Lauring AS, Shapiro NI, Halasa N, Chappell JD, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Rhoads JP, Lindsell CJ, Hart KW, Turbyfill C, Olson S, Murray N, Adams K, Patel MM; Influenza and Other Viruses in the Acutely Ill (IVY) Network. Clin Infect Dis. 2023 Feb 8;76(3):e460-e468. doi: 10.1093/cid/ciac381. PMID: 35580849

Predisposing, Enabling, and Need-Related Factors Associated with Human Papillomavirus Vaccination Intentions and Uptake Among Black and Hispanic Sexual and Gender Diverse Adults in the USA.
Wheldon CW, Eaton LA, Watson RJ. J Racial Ethn Health Disparities. 2023 Feb;10(1):237-243. doi: 10.1007/s40615-021-01214-1. Epub 2022 Jan 3. PMID: 34981465

The "humanized" N-glycosylation pathway in CRISPR/Cas9-edited Nicotiana benthamiana significantly enhances the immunogenicity of a S/preS1 Hepatitis B Virus antigen and the virus-neutralizing antibody response in vaccinated mice.
Pantazica AM, van Eerde A, Dobrica MO, Caras I, Ionescu I, Costache A, Tucureanu C, Steen H, Lazar C, Heldal I, Haugslien S, Onu A, Stavaru C, Branza-Nichita N, Liu Clarke J. Plant Biotechnol J. 2023 Feb 13. doi: 10.1111/pbi.14028. Online ahead of print. PMID: 36779605

Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S **vaccine** candidate.
Villadiego J, García-Arriaza J, Ramírez-Lorca R, García-Swinburn R, Cabello-Rivera D, Rosales-Nieves AE, Álvarez-Vergara MI, Cala-Fernández F, García-Roldán E, López-Ogáyar JL, Zamora C, Astorgano D, Albericio G, Pérez P, Muñoz-Cabello AM, Pascual A, Esteban M, López-Barneo J, Toledo-Aral JJ. Nat Neurosci. 2023 Feb;26(2):226-238. doi: 10.1038/s41593-022-01242-y. Epub 2023 Jan 9. PMID: 36624276

Personalized tumor **vaccine** for pancreatic cancer.
Orr S, Huang L, Moser J, Stroopinsky D, Gandarilla O, DeCicco C, Liegel J, Tacettin C, Ephraim A, Cheloni G, Torres D, Kufe D, Rosenblatt J, Hidalgo M, Muthuswamy SK, Avigan D. Cancer Immunol Immunother. 2023 Feb;72(2):301-313. doi: 10.1007/s00262-022-03237-x. Epub 2022 Jul 14. PMID: 35834008

Anti-SARS-CoV-2 **vaccine**-induced myocarditis - real but, in general, rare and mild: A consensus statement from the Studies Committee of the Portuguese Society of Cardiology.
Sousa JP, Roque D, Guerreiro C, Teixeira R; Studies Committee of the Portuguese Society of Cardiology. Rev Port Cardiol. 2023 Feb;42(2):161-167. doi: 10.1016/j.repc.2023.01.003. Epub 2023 Jan 5. PMID: 36621565

Surveillance of invasive meningococcal disease in southern Brazil: considerations of an immunization programme.
Silveira MM, Crespo da Silva PA, Conrad NL, Oliveira TL, Hartwig DD, Trotter C. J Med Microbiol. 2023 Feb;72(2). doi: 10.1099/jmm.0.001658. PMID: 36753430

Host immunity to Plasmodium infection: Contribution of Plasmodium berghei to our understanding of T cell-related immune response to blood-stage malaria.
Ibraheem Y, Bayarsaikhan G, Inoue SI. Parasitol Int. 2023 Feb;92:102646. doi: 10.1016/j.parint.2022.102646. Epub 2022 Aug 23. PMID: 35998816

Expert consensus on vaccination in patients with inflammatory bowel disease in Japan.
Ishige T, Shimizu T, Watanabe K, Arai K, Kamei K, Kudo T, Kunisaki R, Tokuhara D, Naganuma M, Mizuochi T, Murashima A, Inoki Y, Iwata N, Iwama I, Koinuma S, Shimizu H, Jimbo K, Takaki Y, Takahashi S, Cho Y, Nambu R, Nishida D, Hagiwara SI, Hikita N, Fujikawa H, Hosoi K, Hosomi S, Mikami Y, Miyoshi J, Yagi R, Yokoyama Y, Hisamatsu T. J Gastroenterol. 2023 Feb;58(2):135-157. doi: 10.1007/s00535-022-01953-w. Epub 2023 Jan 11. PMID: 36629948

Inexpensive High-Throughput Multiplexed Biomarker Detection Using Enzymatic Metallization with Cellphone-Based Computer Vision.
Rafat N, Brewer L, Das N, Trivedi DJ, Kaszala BK, Sarkar A. ACS Sens. 2023 Feb 8. doi: 10.1021/acssensors.2c01429. Online ahead of print. PMID: 36753573

Therapies against chronic hepatitis B infections: The times they are a-changin', but the changing is slow!
Durantel D. Antiviral Res. 2023 Feb;210:105515. doi: 10.1016/j.antiviral.2022.105515. Epub 2023 Jan 2. PMID: 36603773

The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case.

Oude Blenke E, Örnskov E, Schöneich C, Nilsson GA, Volkin DB, Mastrobattista E, Almarsson Ö, Crommelin DJA. J Pharm Sci. 2023 Feb;112(2):386-403. doi: 10.1016/j.xphs.2022.11.001. Epub 2022 Nov 16. PMID: 36351479

[Recurrent laryngeal papillomatosis].
Coordes A, Grund D, Mainka A, Olze H, Hanitsch L, von Bernuth H, Dommerich S. HNO. 2023 Feb;71(2):77-82. doi: 10.1007/s00106-022-01250-1. Epub 2022 Dec 7. PMID: 36477391

Production of antigenically stable enterovirus A71 virus-like particles in *Pichia pastoris* as a **vaccine** candidate.
Kingston NJ, Snowden JS, Martyna A, Shegdar M, Grehan K, Tedcastle A, Pegg E, Fox H, Macadam AJ, Martin J, Hogle JM, Rowlands DJ, Stonehouse NJ. bioRxiv. 2023 Feb 2:2023.01.30.526315. doi: 10.1101/2023.01.30.526315. Preprint. PMID: 36778240

Mycobacterium bovis BCG Given at Birth Followed by Inactivated Respiratory Syncytial Virus **Vaccine** Prevents **Vaccine**-Enhanced Disease by Promoting Trained Macrophages and Resident Memory T Cells.
Wang Y, Ge F, Wang J, Li H, Zheng B, Li W, Chen S, Zheng X, Deng Y, Wang Y, Zeng R. J Virol. 2023 Feb 13:e0176422. doi: 10.1128/jvi.01764-22. Online ahead of print. PMID: 36779760

COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database.
Keh RYS, Scanlon S, Datta-Nemdharry P, Donegan K, Cavanagh S, Foster M, Skelland D, Palmer J, Machado PM, Keddie S, Carr AS, Lunn MP; BPNS/ABN COVID-19 Vaccine GBS Study Group. Brain. 2023 Feb 13;146(2):739-748. doi: 10.1093/brain/awac067. PMID: 35180300

Fourth Dose of BNT162b2 **Vaccine** for Patients with Autoimmune Rheumatic Diseases in a Nationwide Setting.
Bieber A, Brikman S, Novack L, Abuhasira R, Fawaz A, Abu-Shakra M, Zeller L, Ling E, Mader R, Sagy I. Rheumatology (Oxford). 2023 Feb 10:kead064. doi: 10.1093/rheumatology/kead064. Online ahead of print. PMID: 36762825

Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents.
Wang H, Yuan Y, Wu B, Xiao M, Wang Z, Diao T, Zeng R, Chen L, Lei Y, Long P, Guo Y, Lai X, Wen Y, Li W, Cai H, Song L, Ni W, Zhao Y, Ouyang K, Wang J, Wang Q, Liu L, Wang C, Pan A, Li X, Gong R, Wu T. Front Med. 2023 Feb 4:1-11. doi: 10.1007/s11684-022-0954-x. Online ahead of print. PMID: 36738428

Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities.
Alam MS. Heliyon. 2023 Feb;9(2):e13285. doi: 10.1016/j.heliyon.2023.e13285. Epub 2023 Jan 31. PMID: 36744070

New-onset inflammatory arthritis after COVID-19 vaccination: A systematic review.
Chen CC, Chen CJ. Int J Rheum Dis. 2023 Feb;26(2):267-277. doi: 10.1111/1756-185X.14482. Epub 2022 Nov 12. PMID: 36371629

Prevalence, clinical course and outcomes of COVID-19 in peritoneal dialysis (PD) patients: a single-center experience.
Alfano G, Fontana F, Giovanella S, Morisi N, Amurri A, Ligabue G, Guaraldi G, Ferrari A, Cappelli G, Magistroni R, Gregorini M, Donati G. Clin Exp Nephrol. 2023 Feb;27(2):171-178. doi: 10.1007/s10157-022-02283-0. Epub 2022 Nov 3. PMID: 36326942

Changes in Older Adults' Frequency of Going Outside between 2020 and 2021: Associations with Health Status and Environmental Factors.
Choi NG, Choi BY, Marti CN. Clin Gerontol. 2023 Feb 9:1-14. doi: 10.1080/07317115.2023.2177573. Online ahead of print. PMID: 36760067

Management and Control Issues Related to Two Mumps Outbreaks in Houston: Future Implications.
Schulte J, Short K, Persse D. Clin Infect Dis. 2023 Feb 8;76(3):e1416-e1420. doi: 10.1093/cid/ciac650. PMID: 35959718

COVID-19 in Latin America: A Snapshot in Time and the Road Ahead.
LaRotta J, Escobar O, Ávila-Aguero ML, Torres JP, Sini de Almeida R, Morales GDC, Srivastava A. Infect Dis Ther. 2023 Feb;12(2):389-410. doi: 10.1007/s40121-022-00748-z. Epub 2023 Jan 12. PMID: 36633818

Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation.
Komatsuda H, Wakisaka R, Kono M, Kumai T, Hayashi R, Yamaki H, Sato R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Takahara M, Katada A, Kobayashi H. Cancer Sci. 2023 Feb;114(2):399-409. doi: 10.1111/cas.15619. Epub 2022 Nov 28. PMID: 36285482

IgA vasculitis with transient glomerular hematuria, diarrhea, and pericarditis following COVID-19 mRNA vaccination in a young patient with possible pre-existing ulcerative colitis.
Ito C, Odajima K, Niimura Y, Fujii M, Sone M, Asakawa S, Arai S, Yamazaki O, Tamura Y, Saito K, Tada Y, Yamamoto T, Kozuma K, Shibata S, Fujigaki Y. CEN Case Rep. 2023 Feb;12(1):84-90. doi: 10.1007/s13730-022-00727-w. Epub 2022 Aug 4. PMID: 35927545

Extracellular Vesicles derived from Plasmodium-infected Hosts as Stimuli of "Trained" Innate Immunity.
Chen JG, Du YT, Guan CH, Fan HY, Liu YA, Wang T, Li X, Chen G. Curr Med Chem. 2023 Feb 7. doi: 10.2174/0929867330666230207115157. Online ahead of print. PMID: 36748809

Disparities among Japanese municipalities in recommendations for routine and catch-up HPV vaccinations.
Watanabe Y, Ueda Y, Yagi A, Ikeda S, Oka E, Kakuda M, Nakagawa S, Hiramatsu K, Miyoshi A, Kobayashi E, Kimura T, Kimura T. Cancer Sci. 2023 Feb 6. doi: 10.1111/cas.15748. Online ahead of print. PMID: 36747329

Bioinformatics design of recombinant chimeric protein containing SipD and LptD immunogens and evaluation of its immunogenicity against Salmonella Typhimurium.
Aghaie SM, Tabatabaei M, Nazarian S. Microb Pathog. 2023 Feb;175:105959. doi: 10.1016/j.micpath.2022.105959. Epub 2022 Dec 26. PMID: 36581307

Evaluation of the immune protective effects of rEmMIC2 and rEmMIC3 from Eimeria magna in rabbits.
Chen H, Pu J, Xiao J, Bai X, Zheng R, Gu X, Xie Y, He R, Xu J, Jing B, Peng X, Ren Y, Yang G. Parasitol Res. 2023 Feb;122(2):661-669. doi: 10.1007/s00436-022-07774-3. Epub 2022 Dec 27. PMID: 36572833

Immune responses to SARS-CoV-2 vaccines in celiac disease.
Ibsen JH, Chopra A, Vaage EB, Vaage JT, Lund-Johansen F, Lundin KEA. Scand J Gastroenterol. 2023 Feb;58(2):142-147. doi: 10.1080/00365521.2022.2114809. Epub 2022 Sep 1. PMID: 36049123

Co-existence of two Yersinia ruckeri biotypes and serotype O1a retrieved from rainbow trout (Oncorhynchus mykiss) farmed in Puno, Peru.
Fernandez-Espinel C, Medina-Morillo M, Irgang R, Sotil G, Araya-León H, Flores-Dominick V, Romalde JL, Avendaño-Herrera R, Yunis-Aguinaga J. J Fish Dis. 2023 Feb;46(2):157-163. doi: 10.1111/jfd.13730. Epub 2022 Nov 20. PMID: 36404601

Consumption and tax gains attributable to Covid-19 vaccinations in 12 EU countries with low vaccination rates.
Cylus J, Walters J, McKee M, Cowley P. Eur J Public Health. 2023 Feb 13:ckad023. doi: 10.1093/eurpub/ckad023. Online ahead of print. PMID: 36780609

Effect of maternal immunisation with multivalent vaccines containing inactivated poliovirus **vaccine** (IPV) on infant IPV immune response: A phase 4, multi-centre randomised trial.
Grassly NC, Andrews N, Cooper G, Stephens L, Waight P, Jones CE, Heath PT, Calvert A, Southern J, Martin J, Miller E. Vaccine. 2023 Feb 10;41(7):1299-1302. doi: 10.1016/j.vaccine.2023.01.035. Epub 2023 Jan 21. PMID: 36690561

SARS-CoV-2 antibodies among health care workers from a children's hospital.
Svartz A, Rial MJ, Insúa C, Stedile G, Haleblian E, Peverini A, Brunetto O. Arch Argent Pediatr. 2023 Feb 1;121(1):e202202595. doi: 10.5546/aap.2022-02595.eng. Epub 2022 Aug 19. PMID: 35984671

Intracellular Experimental Evolution of *Francisella tularensis* Subsp. *holarctica* Live **Vaccine** Strain (LVS) to Antimicrobial Resistance.
Mehta HH, Song X, Shamoo Y. ACS Infect Dis. 2023 Feb 10;9(2):308-321. doi: 10.1021/acsinfecdis.2c00483. Epub 2023 Jan 20. PMID: 36662533

Effects of SARS-CoV-2 **vaccine** (Vero cells) on disease activity in patients with inflammatory bowel disease in China: a multicenter study.
Zhang M, Huang Q, Shi C, Feng Y, Duan T, Lin T, Zhu Y, Liu G, Li H, Liu Y, Jiang B. Int J Colorectal Dis. 2023 Feb 9;38(1):31. doi: 10.1007/s00384-023-04315-x. PMID: 36757427

It Can't Be a Coincidence: A Comparison of Cases of Autoimmune Hepatitis After Vaccination Against COVID-19.
Gips JR, Woreta TA. ACG Case Rep J. 2023 Feb 1;10(1):e00965. doi: 10.14309/crj.0000000000000965. eCollection 2023 Jan. PMID: 36743330

Supporting healthcare workers in vaccination efforts.
Ramot S, Tal O. Hum Vaccin Immunother. 2023 Feb 2:2172882. doi: 10.1080/21645515.2023.2172882. Online ahead of print. PMID: 36728864

20 million pregnant women with group B streptococcus carriage: consequences, challenges, and opportunities for prevention.
Paul P, Gonçalves BP, Le Doare K, Lawn JE. Curr Opin Pediatr. 2023 Feb 8. doi: 10.1097/MOP.0000000000001223. Online ahead of print. PMID: 36749143

Evaluation and mechanism of immune enhancement effects of Pleurotus ferulae polysaccharides-gold nanoparticles.
Yuan P, Liu L, Aipire A, Zhao Y, Cai S, Wu L, Yang X, Aimaier A, Lu J, Li J. Int J Biol Macromol. 2023 Feb 1;227:1015-1026. doi: 10.1016/j.ijbiomac.2022.11.277. Epub 2022 Nov 30. PMID: 36460244

Transmission Pattern of Measles Virus Circulating in China During 1993-2021: Genotyping Evidence Supports That China Is Approaching Measles Elimination.
Wang H, Zhu Z, Duan X, Song J, Mao N, Cui A, Wang C, Du H, Wang Y, Li F, Zhou S, Feng D, Li C, Gao H, He J, Li L, Lei Y, Zheng H, Gong T, Hu Y, Xu C, Zhao H, Sun Z, Chen Y, Tang X, Chen M, Deng L, Wang S, Tian X, Zhang T, Si Y, Yuan F, Fan L, Mahemutijiang K, Chen Z, Chen H, Xu W, Zhang Y. Clin Infect Dis. 2023 Feb 8;76(3):e1140-e1149. doi: 10.1093/cid/ciac674. PMID: 36037029

A C2 domain containing plasma membrane protein of Plasmodium falciparum merozoites mediates calcium-dependent binding and invasion to host erythrocytes.
Munjal A, Kannan D, Singh S. J Microbiol Immunol Infect. 2023 Feb;56(1):139-149. doi: 10.1016/j.jmii.2022.07.008. Epub 2022 Aug 6. PMID: 35995671

Development of an Effective Immune Response in Adults With Down Syndrome After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination.
Esparcia-Pinedo L, Yarci-Carrión A, Mateo-Jiménez G, Ropero N, Gómez-Cabañas L, Lancho-Sánchez Á, Almendro-Vázquez P, Martín-Gayo E, Paz-Artal E, Sanchez-Madrid F, Moldenhauer F, Gutiérrez-Cobos A, Real de Asúa D, Alfranca A. Clin Infect Dis. 2023 Feb 8;76(3):e155-e162. doi: 10.1093/cid/ciac590. PMID: 35869848

Acute myocardial infarction complicated by severe left ventricle systolic dysfunction in a young patient after Covid 19 vaccination: a case report.
Boudihi A, El-Azrak M, Doudouh O, Ismaili N, El Ouafi N. Radiol Case Rep. 2022 Nov 23;18(2):435-440. doi: 10.1016/j.radcr.2022.09.053. eCollection 2023 Feb. PMID: 36439930

Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIV.
Hansen SG, Womack JL, Perez W, Schmidt KA, Marshall E, Iyer RF, Cleveland-Rubeor H, Otero CE, Taher H, Vande Burgt NH, Barfield R, Randall KT, Morrow D, Hughes CM, Selseth AN, Gilbride RM, Ford JC, Caposio P, Tarantal A, Chan C, Malouli D, Barry PA, Permar SR, Picker LJ, Frueh K. JCI Insight. 2023 Feb 7:e164692. doi: 10.1172/jci.insight.164692. Online ahead of print. PMID: 36749635

A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.
Schmierer K, Wiendl H, Oreja-Guevara C, Centonze D, Chudecka A, Roy S, Boschert U. Neurodegener Dis Manag. 2023 Feb;13(1):15-21. doi: 10.2217/nmt-2022-0026. Epub 2022 Dec 22. PMID: 36545912

Protein Nanoparticle-Mediated Delivery of Recombinant Influenza Hemagglutinin Enhances Immunogenicity and Breadth of the Antibody Response.
Badten AJ, Ramirez A, Hernandez-Davies JE, Albin TJ, Jain A, Nakajima R, Felgner J, Davies DH, Wang SW. ACS Infect Dis. 2023 Feb 10;9(2):239-252. doi: 10.1021/acsinfecdis.2c00362. Epub 2023 Jan 6. PMID: 36607269

Impact of the COVID-19 pandemic on human papillomavirus (HPV) vaccination among a national sample of United States adults ages 18-45: A cross-sectional study.
Turner K, Brownstein NC, Whiting J, Arevalo M, Vadaparampil S, Giuliano AR, Islam JY, Meade CD, Gwede CK, Kasting ML, Head KJ, Christy SM. Prev Med Rep. 2022 Nov 21;31:102067. doi: 10.1016/j.pmedr.2022.102067. eCollection 2023 Feb. PMID: 36439896

Association between a low response to rubella vaccination and reduced anti-severe acute respiratory syndrome coronavirus 2 immune response after vaccination with BNT162b2: a cross-sectional study.
Nakaharai K, Nakazawa Y, Mishima Y, Saito M, Shinozaki Y, Yoshida M. Clin Microbiol Infect. 2023 Feb;29(2):253.e1-253.e5. doi: 10.1016/j.cmi.2022.09.007. Epub 2022 Sep 20. PMID: 36150670

Assessment of humoral and cellular immunity after bivalent BNT162b2 vaccination and potential association with reactogenicity.
Salvagno GL, Pighi L, Henry BM, Valentini M, Tonin B, Bragantini D, Gianfilippi G, De Nitto S, Plebani M, Lippi G. Clin Chem Lab Med. 2023 Feb 2. doi: 10.1515/cclm-2023-0055. Online ahead of print. PMID: 36722026

COVID-19 Vaccination Responses with Different **Vaccine** Platforms in Patients with Inborn Errors of Immunity.
Erra L, Uriarte I, Colado A, Paolini MV, Seminario G, Fernández JB, Tau L, Bernatowiez J, Moreira I, Vishnopolska S, Rumbo M, Cassarino C, Vijoditz G, López AL, Curciarello R, Rodríguez D, Rizzo G, Ferreyra M, Ferreyra Mufarregue LR, Badano MN, Pérez Millán MI, Quiroga MF, Baré P, Ibañez I, Pozner R, Borge M, Docena G, Bezrodnik L, Almejun MB. J Clin Immunol. 2023 Feb;43(2):271-285. doi: 10.1007/s10875-022-01382-7. Epub 2022 Oct 17. PMID: 36251205

COVID-19 booster vaccination uptake and infection breakthrough amongst health care workers in Wales: A national prospective cohort study.
Bedston S, Lowthian E, Jarvis CI, Akbari A, Beggs J, Bradley D, de Lusignan S, Griffiths R, Herbert L, Hobbs R, Kerr S, Lyons J, Midgley W, Owen RK, Quint JK, Tsang R, Torabi F, Sheikh A, Lyons RA. Vaccine. 2023 Feb 10;41(7):1378-1389. doi: 10.1016/j.vaccine.2023.01.023. Epub 2023 Jan 13. PMID: 36669966

Applications of Social Media and Digital Technologies in COVID-19 Vaccination: Scoping Review.
Zang S, Zhang X, Xing Y, Chen J, Lin L, Hou Z. J Med Internet Res. 2023 Feb 10;25:e40057. doi: 10.2196/40057. PMID: 36649235

Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
Abara WE, Gee J, Marquez P, Woo J, Myers TR, DeSantis A, Baumblatt JAG, Woo EJ, Thompson D, Nair N, Su JR, Shimabukuro TT, Shay DK. JAMA Netw Open. 2023 Feb 1;6(2):e2253845. doi: 10.1001/jamanetworkopen.2022.53845. PMID: 36723942

O-GalNAc glycosylation affects the immunogenicity of the receptor-binding domain (RBD) of SARS-CoV-2 spike protein.
Rong Y, Wang X, Mao W, Chen M, Wang S, Wang PG, He Y, Kong Y. Chem Commun (Camb). 2023 Feb 9;59(13):1797-1800. doi: 10.1039/d2cc06583e. PMID: 36722411

Sudden Hearing Loss Following Vaccination Against COVID-19.
Nieminen TA, Kivekäs I, Artama M, Nohynek H, Kujansivu J, Hovi P. JAMA Otolaryngol Head Neck Surg. 2023 Feb 1;149(2):133-140. doi: 10.1001/jamaoto.2022.4154. PMID: 36520464

Imprecision in adverse event reports following immunization against HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of **vaccine** hesitancy and government policy.
Inokuma Y, Kneller R. Eur J Clin Pharmacol. 2023 Feb;79(2):269-278. doi: 10.1007/s00228-022-03412-0. Epub 2022 Dec 17. PMID: 36527455

Low Response to the COVID-19 **Vaccine** Among the Arab Population in Israel: Is It a Cultural Background, or a Systemic Failure, or Maybe Both?
Ali-Saleh O, Bord S, Basis F. J Racial Ethn Health Disparities. 2023 Feb;10(1):296-305. doi: 10.1007/s40615-021-01220-3. Epub 2022 Jan 4. PMID: 34984653

Modeling the impact of combined use of COVID Alert SA app and vaccination to curb COVID-19 infections in South Africa.
Kinyili M, Munyakazi JB, Mukhtar AYA. PLoS One. 2023 Feb 3;18(2):e0264863. doi: 10.1371/journal.pone.0264863. eCollection 2023. PMID: 36735664

Prevention of fatal equine herpesvirus type 1 encephalitis in mice by immunization with a limited-replication cycle virus.
Fukushi N, Fukushi H. Vet Microbiol. 2023 Feb;277:109633. doi: 10.1016/j.vetmic.2022.109633. Epub 2022 Dec 9. PMID: 36543092

Risk of, and risk factors for, vasculopathy associated with acute herpes zoster.
Yawn BP, Lindsay AC, Yousefi M, Wang C. J Stroke Cerebrovasc Dis. 2023 Feb;32(2):106891. doi: 10.1016/j.jstrokecerebrovasdis.2022.106891. Epub 2022 Dec 5. PMID: 36473399

Detection of Influenza in Managed Quarantine in Australia and the Estimated Risk of Importation.
Peck H, Anbumurali N, McMahon K, Freeman K, Aziz A, Gillespie L, Yang B, Moselen J, Deng YM, Cowling BJ, Barr IG, Subbarao K, Sullivan SG. Clin Infect Dis. 2023 Feb 8;76(3):e1328-e1334. doi: 10.1093/cid/ciac648. PMID: 35959938 F
Interventions to Increase Uptake of Influenza Vaccination in Pregnancy: A Systematic Review and Meta-analysis.
Brillo E, Tosto V, Buonomo E. Int J Gynaecol Obstet. 2023 Feb 6. doi: 10.1002/ijgo.14714. Online ahead of print. PMID: 36748179

The COVID-19 **vaccine** did not affect the basal immune response and menstruation in female athletes.
Chiang MR, Shih LC, Lu CC, Fang SH. Physiol Rep. 2023 Feb;11(3):e15556. doi: 10.14814/phy2.15556. PMID: 36750121

Genotypic characterization of Japanese encephalitis virus circulating in swine population of India: Genotype-III still in dominance.
Mote AB, Mehta D, Kumar MS, Gupta M, Hussain M, Patel SM, Gandham RK, Dhanze H. Virus Genes. 2023 Feb;59(1):67-78. doi: 10.1007/s11262-022-01953-1. Epub 2022 Nov 10. PMID: 36357764

Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: A multicenter observational study.
Aydin MA, Janapatla RP, Chen CL, Li HC, Su LH, Chiu CH. J Microbiol Immunol Infect. 2023 Feb 2:S1684-1182(23)00013-0. doi: 10.1016/j.jmii.2023.01.013. Online ahead of print. PMID: 36774315

Clonal composition and persistence of antigen-specific circulating T follicular helper cells.
Hu M, Notarbartolo S, Foglierini M, Jovic S, Mele F, Jarrossay D, Lanzavecchia A, Cassotta A, Sallusto F. Eur J Immunol. 2023 Feb;53(2):e2250190. doi: 10.1002/eji.202250190. Epub 2022 Dec 25. PMID: 36480793

Effects of a video-based positive side-effect information framing: An online experiment.
Bender FL, Rief W, Brück J, Wilhelm M. Health Psychol. 2023 Feb 13. doi: 10.1037/hea0001263. Online ahead of print. PMID: 36780276

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.
Kemlin D, Gemander N, Depickère S, Olislagers V, Georges D, Waegemans A, Pannus P, Lemy A, Goossens ME, Desombere I, Michiels J, Vandevenne M, Heyndrickx L, Ariën KK, Matagne A, Ackerman ME, Le Moine A, Marchant A. Am J Transplant. 2023 Feb 9:S1600-6135(23)00300-3. doi: 10.1016/j.ajt.2023.02.015. Online ahead of print. PMID: 36773936

Syncope after COVID-19 Vaccination in a Young Man with Unmasking Brugada Syndrome.
Okuyama T, Kabutoya T, Gonda Y, Kubota Kashihara K, Imai Y, Morisawa Y, Kario K. Intern Med. 2023 Feb 8. doi: 10.2169/internalmedicine.1250-22. Online ahead of print. PMID: 36754404

Development of a porous layer-by-layer microsphere with branched aliphatic hydrocarbon porogens.
Shahjin F, Patel M, Hasan M, Cohen JD, Islam F, Ashaduzzaman M, Nayan MU, Subramaniam M, Zhou Y, Andreu I, Gendelman HE, Kevadiya BD. Nanomedicine. 2023 Feb;48:102644. doi: 10.1016/j.nano.2022.102644. Epub 2022 Dec 20. PMID: 36549555

ViralVacDB: a manually curated repository of viral vaccines.
Tripathi S, Sharma N, Leimarembi Devi N, Raghava GPS. Drug Discov Today. 2023 Feb 8:103523. doi: 10.1016/j.drudis.2023.103523. Online ahead of print. PMID: 36764575

Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
Stefanou MI, Palaiodimou L, Theodorou A, Christodoulou MV, Tzartos JS, Tzanetakos D, Kitsos D, Chondrogianni M, Zouvelou V, Dardiotis E, Tzavellas E, Syrigou E, Benetou V, Paraskevas GP, Tsiodras S, Tsivgoulis G, Giannopoulos S. Mult Scler. 2023 Feb 1:13524585221150881. doi: 10.1177/13524585221150881. Online ahead of print. PMID: 36722184

Associations of health literacy with missed free influenza immunization in people with chronic diseases.
Arsenović S, Trajković G, Pekmezović T, Gazibara T. Health Promot Int. 2023 Feb 1;38(1):daac180. doi: 10.1093/heapro/daac180. PMID: 36617290

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer **vaccine**.
Tran CA, Lynch KT, Meneveau MO, Katyal P, Olson WC, Slingluff CL Jr. J Immunother Cancer. 2023 Feb;11(2):e005952. doi: 10.1136/jitc-2022-005952. PMID: 36746511

Inactivated whole-virion SARS-CoV-2 vaccines and long-term clinical outcomes in patients with coronary atherosclerosis disease in China: a prospective cohort study.
Xu H, Zheng J, Zhao X, Zhou Q, Fan B, Wu H, Zhang S, Ge J. Cardiovasc Res. 2023 Feb 9:cvad031. doi: 10.1093/cvr/cvad031. Online ahead of print. PMID: 36756815

The relation between digital literacy, cyberchondria, and parents' attitudes to childhood vaccines.
Ustuner Top F, Çevik C, Bora Güneş N. J Pediatr Nurs. 2023 Feb 6;70:12-19. doi: 10.1016/j.pedn.2023.01.006. Online ahead of print. PMID: 36753874

Adolescent Self-Consent for COVID-19 Vaccination: Views of Healthcare Workers and Their Adolescent Children on Vaccination Autonomy.
Delgado JR, Mansfield LN, Bruxvoort K, Macias M, Grotts J, Lewin B, Bronstein D, Munoz-Plaza C, Szilagyi P, Chang J, Choi K. J Adolesc Health. 2023 Feb 10:S1054-139X(23)00009-5. doi: 10.1016/j.jadohealth.2022.12.018. Online ahead of print. PMID: 36775750

A prospective randomized controlled study of Mycobacterium Indicus Pranii **vaccine**, Measles Mumps Rubella **vaccine** and Vitamin D3 in extragenital cutaneous warts.
Lahoria U, Singh S, Bhardwaj A, Budania A, Chhajed N, Rajagopal SV, Singh S. J Cosmet Dermatol. 2023 Feb 9. doi: 10.1111/jocd.15564. Online ahead of print. PMID: 36762385

Impact of healthcare capacity disparities on the COVID-19 vaccination coverage in the United States: A cross-sectional study.
Cuadros DF, Gutierrez JD, Moreno CM, Escobar S, Miller FD, Musuka G, Omori R, Coule P, MacKinnon NJ. Lancet Reg Health Am. 2023 Feb;18:100409. doi: 10.1016/j.lana.2022.100409. Epub 2022 Dec 14. PMID: 36536782

Immunization status of children at kindergarten entry in Alberta, Canada.
Dhungana M, Hoben M, O'Brien C, MacDonald SE. Can J Public Health. 2023 Feb;114(1):82-92. doi: 10.17269/s41997-022-00663-3. Epub 2022 Jul 21. PMID: 35864307

Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis.
Monti S, Fornara C, Delvino P, Bartoletti A, Bergami F, Comolli G, Sammartino JC, Biglia A, Bozzalla Cassione E, Cassaniti I, Baldanti F, Lilleri D, Montecucco C. Rheumatology (Oxford). 2023 Feb 1;62(2):726-734. doi: 10.1093/rheumatology/keac365. PMID: 35736379

Mapping the delivery of interventions for **vaccine**-preventable infections in pregnancy in Victoria, Australia.
Yussf N, Allard N, Romero N, Wilson A, Wallace J, Perrier M, Rowe S, Morey R, Aykut N, Cowie B. Aust J Prim Health. 2023 Feb 6. doi: 10.1071/PY22158. Online ahead of print. PMID: 36740448

An appraisal of gene targets for phylogenetic classification of canine distemper virus: Is the hemagglutinin the best candidate?

Becker AS, Silva Júnior JVJ, Weiblen R, Flores EF. Virus Res. 2023 Feb;325:199043. doi: 10.1016/j.virusres.2023.199043. Epub 2023 Jan 10. PMID: 36634899

Pulmonary Administration of the Liposome-Based Adjuvant CAF01: Effect of Surface Charge on Mucosal Adjuvant Function.
Müllertz OAO, Andersen P, Christensen D, Foged C, Thakur A. Mol Pharm. 2023 Feb 6;20(2):953-970. doi: 10.1021/acs.molpharmaceut.2c00634. Epub 2022 Dec 30. PMID: 36583936

DEC-205 receptor targeted poly(lactic-co-glycolic acid) nanoparticles containing Eucommia ulmoides polysaccharide enhances the immune response of foot-and-mouth disease **vaccine** in mice.
Feng Y, Fan J, Wu D, Liu Q, Li H, Zhang X, Li S, Tang F, Liu Z, Zhang L, Feng H. Int J Biol Macromol. 2023 Feb 1;227:576-589. doi: 10.1016/j.ijbiomac.2022.12.158. Epub 2022 Dec 19. PMID: 36549613

Chicken genome editing for investigating poultry pathogens.
Mitchell E, Tellez G Jr, McGrew MJ. Avian Pathol. 2023 Feb;52(1):1-11. doi: 10.1080/03079457.2022.2130173. Epub 2022 Oct 24. PMID: 36278430

COVID-19 Vaccines-All You Want to Know.
Shishido AA, Barnes AH, Narayanan S, Chua JV. Semin Respir Crit Care Med. 2023 Feb;44(1):143-172. doi: 10.1055/s-0042-1759779. Epub 2023 Jan 16. PMID: 36646092

Intravesical bacillus Calmette-Guérin-induced myopathy presenting as rhabdomyolysis: a case report.
Lee CH, Choi BJ, Kim JH, Yang TW, Kim GJ, Shin HY, Kim SH, Kim SW. J Yeungnam Med Sci. 2023 Feb 13. doi: 10.12701/jyms.2022.00850. Online ahead of print. PMID: 36775925

Fulminant Myocarditis and Acute Appendicitis after COVID-19 Vaccination.
Kawano H, Yamamoto N, Kurohama H, Okano S, Kurobe M, Honda T, Akashi R, Yonekura T, Ikeda S, Izumikawa K, Maemura K. Intern Med. 2023 Feb 1;62(3):411-417. doi: 10.2169/internalmedicine.0680-22. Epub 2022 Nov 23. PMID: 36418095

Understanding the Roles of Host Defense Peptides in Immune Modulation: From Antimicrobial Action to Potential as Adjuvants.
Kim J, Cho BH, Jang YS. J Microbiol Biotechnol. 2023 Feb 10;33(3):1-11. doi: 10.4014/jmb.2301.01005. Online ahead of print. PMID: 36775853

Pregnancy Outcomes in Patients After Completion of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Compared With Unvaccinated Patients.
Morgan JA, Biggio JR Jr, Martin JK, Mussarat N, Elmayan A, Chawla HK, Kandalaft S, Magalski GR, Puri P, Williams FB. Obstet Gynecol. 2023 Feb 2. doi: 10.1097/AOG.0000000000005072. Online ahead of print. PMID: 36735413

Coronavirus Disease 19 (COVID-19) **Vaccine** Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, Arioka H, Yanai H, Kuramochi J, Ihara G, Chubachi K, Yanagisawa N, Nagura Y, Kato Y, Ueda A, Numata A, Kato H, Ishii K, Ooki T, Oka H, Nishida

Y, Stucky A, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. doi: 10.1093/cid/ciac635. PMID: 35918782

Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer **vaccine** with the potential to turn up the heat on non-immunoreactive tumors.
Suginobe N, Nakamura M, Takanashi Y, Ban H, Gotoh M. Clin Transl Oncol. 2023 Feb;25(2):396-407. doi: 10.1007/s12094-022-02946-0. Epub 2022 Sep 23. PMID: 36138335

Reduced humoral response to two doses of COVID-19 **vaccine** in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study.
Macaluso FS, Principi M, Facciotti F, Contaldo A, Todeschini A, Saibeni S, Bezzio C, Castiglione F, Nardone OM, Spagnuolo R, Fantini MC, Riguccio G, Caprioli F, Viganò C, Felice C, Fiorino G, Correale C, Bodini G, Milla M, Scardino G, Vernero M, Desideri F, Mannino M, Rizzo G, Orlando A; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2023 Feb;55(2):154-159. doi: 10.1016/j.dld.2022.08.027. Epub 2022 Aug 29. PMID: 36127228

Arrayed Imaging Reflectometry monitoring of anti-viral antibody production throughout vaccination and breakthrough Covid-19.
Klose AM, Kosoy G, Miller BL. PLoS One. 2023 Feb 7;18(2):e0277846. doi: 10.1371/journal.pone.0277846. eCollection 2023. PMID: 36749755

Prevalence and epidemiological trends in mortality due to COVID-19 in Saudi Arabia.
Alissa DA, Aburas W, Almasuood R, Almudaiheem HY, Al Aseri Z, Alrabiah F, Ezzat H, Moulana AA, Alawi MM, Al-Mutairy E, Alaama T, Alamri MS, Bamousa MS, Alshehri AA, Alosaimi MH, Alali A, Nori R, Devol EB, Mohamed G, Al-Jedai AH. Public Health. 2023 Feb;215:31-38. doi: 10.1016/j.puhe.2022.07.014. Epub 2023 Jan 10. PMID: 36634404

Development of real-time RT-PCR assays to detect measles virus on the Hologic Panther Fusion® System.
Grant J, Atapattu N, Dilcher M, Tan CE, Elvy J, Ussher JE. J Clin Virol. 2023 Feb;159:105355. doi: 10.1016/j.jcv.2022.105355. Epub 2022 Dec 16. PMID: 36603330

Dynamics of Humoral and Cellular Responses in Renal Transplant Recipients Receiving 3 Doses of SARS-CoV-2 mRNA **Vaccine**.
Arias-Cabrales C, Folgueiras M, Faura A, Eguia J, Padilla E, Hurtado S, Ribera L, Echeverria-Esnal D, Pérez-Sáez MJ, Redondo-Pachón D, Burballa C, Buxeda A, Llinàs-Mallol L, Cao H, Barbosa F, Rovira X, Cima F, Pascual J, Crespo M. Transplantation. 2023 Feb 1;107(2):457-465. doi: 10.1097/TP.0000000000004433. Epub 2022 Nov 2. PMID: 36584381

Evaluation of retinal and optic disc vascular structures in individuals before and after Pfizer-BioNTech vaccination.
Gedik B, Erol MK, Suren E, Yavuz S, Kucuk MF, Bozdogan YC, Ekinci R, Akidan M. Microvasc Res. 2023 Feb 4;147:104500. doi: 10.1016/j.mvr.2023.104500. Online ahead of print. PMID: 36746365

Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.
Kim S, Seok HY. Neurol Sci. 2023 Feb 13. doi: 10.1007/s10072-023-06676-1. Online ahead of print. PMID: 36781562

Burden of all-cause and organism-specific parapneumonic empyema hospitalization rates prior to the SARS-CoV-2 pandemic in the United States.
Wiese AD, Grijalva CG. Respir Med. 2023 Feb;207:107111. doi: 10.1016/j.rmed.2022.107111. Epub 2022 Dec 31. PMID: 36592639

Tick-borne encephalitis epidemic in Hungary 1951-2021: The story and lessons learned.
Egyed L, Nagy A, Lakos A, Zöldi V, Lang Z. Zoonoses Public Health. 2023 Feb;70(1):81-92. doi: 10.1111/zph.13003. Epub 2022 Oct 7. PMID: 36205381

Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer.
Rajan A, Gray JE, Devarakonda S, Birhiray R, Korchin B, Menius E, Donahue RN, Schlom J, Gulley JL. Int J Cancer. 2023 Feb 1;152(3):447-457. doi: 10.1002/ijc.34267. Epub 2022 Sep 9. PMID: 36054490

The hybrid protein BTH2 suppresses allergic airway inflammation in a murine model of HDM-specific immunotherapy.
da Silva ES, de Santana MBR, Silveira EF, Torres RT, Silva RC, Fernandes AMS, Belitardo EMMA, Garcés LFS, Santiago LF, Urrego JR, Vilas-Bôas DS, de Freitas LAR, Zakzuk J, Pacheco LGC, Cruz ÁA, Ferreira F, Cooper P, Caraballo L, Pinheiro CDS, Alcantara-Neves NM. Clin Exp Allergy. 2023 Feb 13. doi: 10.1111/cea.14293. Online ahead of print. PMID: 36779555

Scarcity nationalism during COVID-19: Identifying the impact on trade costs.
Egger PH, Masllorens G, Rocha N, Ruta M. Econ Lett. 2023 Feb;223:110973. doi: 10.1016/j.econlet.2022.110973. Epub 2023 Jan 16. PMID: 36714269

The second HPV serology meeting: Progress and challenges in standardization of human papillomavirus serology assays.
Park I, Unger ER, Kemp TJ, Pinto LA. Vaccine. 2023 Feb 3;41(6):1177-1181. doi: 10.1016/j.vaccine.2023.01.008. Epub 2023 Jan 13. PMID: 36642631

Nasal vaccines: solutions for respiratory infectious diseases.
Nakahashi-Ouchida R, Fujihashi K, Kurashima Y, Yuki Y, Kiyono H. Trends Mol Med. 2023 Feb;29(2):124-140. doi: 10.1016/j.molmed.2022.10.009. Epub 2022 Nov 23. PMID: 36435633

Coronavirus Disease-2019 and Implications on the Liver.
Campbell PT, Fix OK. Clin Liver Dis. 2023 Feb;27(1):27-45. doi: 10.1016/j.cld.2022.08.003. Epub 2022 Aug 18. PMID: 36400465

Vaccines against monkeypox.
Reina J, Iglesias C. Med Clin (Barc). 2023 Feb 10:S0025-7753(23)00002-7. doi: 10.1016/j.medcli.2023.01.001. Online ahead of print. PMID: 36775782

Repeated Biting by a Mediterranean Loggerhead Sea Turtle.
Boga B, Asma S. Wilderness Environ Med. 2023 Feb 1:S1080-6032(22)00215-0. doi: 10.1016/j.wem.2022.11.006. Online ahead of print. PMID: 36737309

Reduced COVID-19 **vaccine** response in patient treated with dupilumab for IgG4-related disease.

Abadeh A, Lee JK. J Allergy Clin Immunol Glob. 2023 Feb;2(1):118-119. doi: 10.1016/j.jacig.2022.08.007. Epub 2022 Oct 26. PMID: 36313899

Comparison of influenza and COVID-19 hospitalisations in British Columbia, Canada: a population-based study.
Setayeshgar S, Wilton J, Sbihi H, Zandy M, Janjua N, Choi A, Smolina K. BMJ Open Respir Res. 2023 Feb;10(1):e001567. doi: 10.1136/bmjresp-2022-001567. PMID: 36731922

Characteristics associated with influenza vaccination uptake in pregnancy: a retrospective cohort study.
Woodcock T, Novov V, Skirrow H, Butler J, Lovett D, Adeleke Y, Blair M, Saxena S, Majeed A, Aylin P. Br J Gen Pract. 2023 Jan 26;73(727):e148-e155. doi: 10.3399/BJGP.2022.0078. Print 2023 Feb. PMID: 36702602

Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021-November 2021.
Levin-Rector A, Firestein L, McGibbon E, Sell J, Lim S, Lee EH, Weiss D, Geevarughese A, Zucker JR, Greene SK. Clin Infect Dis. 2023 Feb 8;76(3):e469-e476. doi: 10.1093/cid/ciac380. PMID: 35594552

Racial Discrimination, Social Disadvantage, and Racial-Ethnic Disparities in COVID-19 **Vaccine** Uptake.
Haro-Ramos AY, Bacong AM, Rodriguez HP. AJPM Focus. 2023 Feb 1:100072. doi: 10.1016/j.focus.2023.100072. Online ahead of print. PMID: 36744154

A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases.
Chanprapaph K, Seree-Aphinan C, Rattanakaemakorn P, Pomsoong C, Ratanapokasatit Y, Setthaudom C, Thitithanyanont A, Suriyo A, Suangtamai T, Suchonwanit P; COVIDVAC-DERM study group. Br J Dermatol. 2023 Feb 10;188(2):268-277. doi: 10.1093/bjd/ljac045. PMID: 36637102

Assessing the Self-reported After Events Following Immunization of COVID-19 Vaccines in Turkey and Bangladesh.
Sultana A, Mim SR, Saha A, Yesmin F, Tahsin MR, Bahar NB, Fatema KR, Shahriar S, Prattay KMR, Rabbi F, Noushin F, Samodder M, Sadia QA, Ferdous J, Mamun MAH, Uddin MI, Akter T, Rahman MM, Sarker MMR, Kuddus MR, Aktar F, Chowdhury JA, Chowdhury AA, Kabir S, Büyüker SM, Rahman MS, Rahman MH, Amran MS. Environ Sci Pollut Res Int. 2023 Feb 4:1-13. doi: 10.1007/s11356-023-25527-2. Online ahead of print. PMID: 36738411

Impaired long-term anti-HBs responses in choronic hepatitis C patients: Results from a five-year follow-up study with healthy control.
Yan B, Lu J, Jia L, Feng Y, Wang J, Meng X, Liang X, Wang F, Wan Y, Xu A, Zhang L. Hum Vaccin Immunother. 2023 Feb 6:2168432. doi: 10.1080/21645515.2023.2168432. Online ahead of print. PMID: 36747308

Attitudes to COVID-19 Vaccines Among Australians During the Delta Variant Wave: A Qualitative Interview Study.
Lupton D. Health Promot Int. 2023 Feb 1;38(1):daac192. doi: 10.1093/heapro/daac192. PMID: 36738451

Higher Troponin Levels on Admission are associated With Persistent Cardiac Magnetic Resonance Lesions in Children Developing Myocarditis After mRNA-Based COVID-19 Vaccination.
Manno EC, Amodio D, Cotugno N, Rossetti C, Giancotta C, Santilli V, Zangari P, Rotulo GA, Villani A, Giglioni E, Turchetta A, Cafiero G, Franceschini A, Chinali M, Porzio O, Secinaro A, Palma P. Pediatr Infect Dis J. 2023 Feb 1;42(2):166-171. doi: 10.1097/INF.0000000000003762. Epub 2022 Oct 31. PMID: 36638405

Antibody and T-cell responses to COVID-19 Vaccination in Common Variable Immunodeficiency and Specific Antibody Deficiency.
Rosenthal JA, Papa MP, Sanz M, Nicholes S, Stower C, Bosque A, Keswani A, Amdur R, Lynch RM, Soriano-Sarabia N, Ein D. Ann Allergy Asthma Immunol. 2023 Feb 1:S1081-1206(23)00077-7. doi: 10.1016/j.anai.2023.01.025. Online ahead of print. PMID: 36736722

Increase in SARS-CoV-2 RBD-Specific IgA and IgG Antibodies in Human Milk From Lactating Women Following the COVID-19 Booster Vaccination.
Henle AM. J Hum Lact. 2023 Feb;39(1):51-58. doi: 10.1177/08903344221134631. Epub 2022 Nov 18. PMID: 36398916

Effectiveness of vaccination on influenza-related critical illnesses in the elderly population.
Aso S, Ono S, Michihata N, Uemura K, Yasunaga H. J Infect Chemother. 2023 Feb 6:S1341-321X(23)00037-5. doi: 10.1016/j.jiac.2023.02.002. Online ahead of print. PMID: 36754256

Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.
Davies MA, Morden E, Rousseau P, Arendse J, Bam JL, Boloko L, Cloete K, Cohen C, Chetty N, Dane P, Heekes A, Hsiao NY, Hunter M, Hussey H, Jacobs T, Jassat W, Kariem S, Kassanjee R, Laenen I, Roux SL, Lessells R, Mahomed H, Maughan D, Meintjes G, Mendelson M, Mnguni A, Moodley M, Murie K, Naude J, Ntusi NAB, Paleker M, Parker A, Pienaar D, Preiser W, Prozesky H, Raubenheimer P, Rossouw L, Schrueder N, Smith B, Smith M, Solomon W, Symons G, Taljaard J, Wasserman S, Wilkinson RJ, Wolmarans M, Wolter N, Boulle A. Int J Infect Dis. 2023 Feb;127:63-68. doi: 10.1016/j.ijid.2022.11.024. Epub 2022 Nov 24. PMID: 36436752

Quantifying Antibody Persistence After a Single Dose of COVID-19 **Vaccine** Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach.
Dari A, Boulton M, Neyens M, Le Gars M, Valenzuela B, Shukarev G, Cárdenas V, Ruiz-Guiñazú J, Sadoff J, Hoetelmans RMW, Ruixo JJP. Clin Pharmacol Ther. 2023 Feb;113(2):380-389. doi: 10.1002/cpt.2796. Epub 2022 Dec 9. PMID: 36377532

Community pharmacists' participation in adult vaccination: A cross-sectional survey based on the theoretical domains framework.
El Hajj MS, Al-Ziftawi N, Stewart D, Al-Khater DMAY. Br J Clin Pharmacol. 2023 Feb;89(2):773-786. doi: 10.1111/bcp.15529. Epub 2022 Oct 4. PMID: 36098619

Risk of adverse events following CoronaVac's COVID-19 vaccination in women with and without autoimmunity.
Sumantri S, Haryanto MA, Widyastuti ESA. Clin Epidemiol Glob Health. 2023 Mar-Apr;20:101249. doi: 10.1016/j.cegh.2023.101249. Epub 2023 Feb 8. PMID: 36778061

Decompressive surgery in cerebral venous sinus thrombosis due to **vaccine**-induced immune thrombotic thrombocytopenia.
Krzywicka K, Aguiar de Sousa D, Cordonnier C, Bode FJ, Field TS, Michalski D, Pelz J, Skjelland M, Wiedmann M, Zimmermann J, Wittstock M, Zanotti B, Ciccone A, Bandettini di Poggio M, Borhani-Haghighi A, Chatterton S, Aujayeb A, Devroye A, Dizonno V, Geeraerts T, Giammello F, Günther A, Ichaporia NR, Kleinig T, Kristoffersen ES, Lemmens R, De Maistre E, Mirzaasgari Z, Payen JF, Putaala J, Petruzzellis M, Raposo N, Sadeghi-Hokmabadi E, Schoenenberger S, Umaiorubahan M, Sylaja PN, van de Munckhof A, Sánchez van Kammen M, Lindgren E, Jood K, Scutelnic A, Heldner MR, Poli S, Kruip MJHA, Arauz A, Conforto AB, Aaron S, Middeldorp S, Tatlisumak T, Arnold M, Coutinho JM, Ferro JM; Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group. Eur J Neurol. 2023 Feb 11. doi: 10.1111/ene.15735. Online ahead of print. PMID: 36773014

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
Baek YJ, Kim WJ, Ko JH, Lee YJ, Ahn JY, Kim JH, Jang HC, Jeong HW, Kim YC, Park YS, Kim SH, Peck KR, Shin EC, Choi JY. Vaccine. 2023 Feb 6:S0264-410X(23)00094-4. doi: 10.1016/j.vaccine.2023.01.063. Online ahead of print. PMID: 36754764

Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine.
Abdellatif AAH, Younis MA, Alsowinea AF, Abdallah EM, Abdel-Bakky MS, Al-Subaiyel A, Hassan YAH, Tawfeek HM. Colloids Surf B Biointerfaces. 2023 Feb;222:113111. doi: 10.1016/j.colsurfb.2022.113111. Epub 2022 Dec 20. PMID: 36586237

Interferon-induced restriction of Chikungunya virus infection.
Suzuki Y. Antiviral Res. 2023 Feb;210:105487. doi: 10.1016/j.antiviral.2022.105487. Epub 2022 Dec 22. PMID: 36657882

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
Md Yusof MY, Arnold J, Saleem B, Vandevelde C, Dass S, Savic S, Vital EM, Emery P. Lancet Rheumatol. 2023 Feb;5(2):e88-e98. doi: 10.1016/S2665-9913(23)00004-8. Epub 2023 Jan 10. PMID: 36712951

Molecular Bottlebrushes for Immunostimulatory CpG ODN Delivery: Relationship among Cation Density, Complex Formation Ability, and Cytotoxicity.
Takano S, Miyashima Y, Fujii S, Sakurai K. Biomacromolecules. 2023 Feb 10. doi: 10.1021/acs.biomac.2c01348. Online ahead of print. PMID: 36762890

Emerging peptide-based nanovaccines: From design synthesis to defense against cancer and infection.
Xu F, Yuan Y, Wang Y, Yin Q. Biomed Pharmacother. 2023 Feb;158:114117. doi: 10.1016/j.biopha.2022.114117. Epub 2022 Dec 16. PMID: 36528914

Biocatalytic cascade transformations for the synthesis of C-nucleosides and N-nucleoside analogs.
Pfeiffer M, Nidetzky B. Curr Opin Biotechnol. 2023 Feb;79:102873. doi: 10.1016/j.copbio.2022.102873. Epub 2023 Jan 9. PMID: 36630750

Multisystem Inflammatory Syndrome in Adults (MIS-A) After COVID-19 Infection and Recent Vaccination with Recombinant Adenoviral Vector Encoding the Spike Protein Antigen of SARS-CoV-2 (ChAdOx1 nCoV-19, Vaxzevria).
Ehikhametalor K, Deans-Minott J, Duncan JP. J Intensive Care Med. 2023 Feb;38(2):232-237. doi: 10.1177/08850666221121589. Epub 2022 Aug 17. PMID: 35979616

Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response.
Brala D, Thevathasan T, Grahl S, Barrow S, Violano M, Bergs H, Golpour A, Suwalski P, Poller W, Skurk C, Landmesser U, Heidecker B. J Am Heart Assoc. 2023 Feb 6:e027619. doi: 10.1161/JAHA.122.027619. Online ahead of print. PMID: 36744683

Optimal control of the coronavirus pandemic with both pharmaceutical and non-pharmaceutical interventions.
Oke SI, Ekum MI, Akintande OJ, Adeniyi MO, Adekiya TA, Achadu OJ, Matadi MB, Iyiola OS, Salawu SO. Int J Dyn Control. 2023 Feb 1:1-25. doi: 10.1007/s40435-022-01112-2. Online ahead of print. PMID: 36743263

Effectiveness of a nation-wide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data.
Bello-Chavolla OY, Antonio-Villa NE, Valdés-Ferrer SI, Fermín-Martínez CA, Fernández-Chirino L, Vargas-Vázquez A, Ramírez-García D, Mancilla-Galindo J, Kammar-García A, Ávila-Funes JA, Zúñiga-Gil CH, García-Grimshaw M, Ceballos-Liceaga SE, Carbajal-Sandoval G, Montes-González JA, Zaragoza-Jiménez CA, García-Rodríguez G, Cortés-Alcalá R, Reyes-Terán G, López-Gatell H, Gutiérrez-Robledo LM. Int J Infect Dis. 2023 Feb 10:S1201-9712(23)00042-5. doi: 10.1016/j.ijid.2023.01.040. Online ahead of print. PMID: 36775188

Aerosol delivered irradiated Escherichia coli confers serotype-independent protection and prevents colibacillosis in young chickens.
Paudel S, Hess C, Kamal Abdelhamid M, Lyrakis M, Wijewardana V, Thiga Kangethe R, Cattoli G, Hess M. Vaccine. 2023 Feb 10;41(7):1342-1353. doi: 10.1016/j.vaccine.2022.12.002. Epub 2023 Jan 13. PMID: 36642629

Humoral immunogenicity of COVID-19 vaccines in patients with coeliac disease and other noncoeliac enteropathies compared to healthy controls.
Scalvini D, Schiepatti A, Maimaris S, Cosentini E, Muscia R, Gregorio V, Roda E, Fassio F, Baiardi P, Locatelli CA, Biagi F. Eur J Gastroenterol Hepatol. 2023 Feb 1;35(2):167-173. doi: 10.1097/MEG.0000000000002484. Epub 2022 Nov 29. PMID: 36574307

African Swine Fever Virus L83L Negatively Regulates the cGAS-STING-Mediated IFN-I Pathway by Recruiting Tollip To Promote STING Autophagic Degradation.
Cheng M, Kanyema MM, Sun Y, Zhao W, Lu Y, Wang J, Li X, Shi C, Wang J, Wang N, Yang W, Jiang Y, Huang H, Yang G, Zeng Y, Wang C, Cao X. J Virol. 2023 Feb 13:e0192322. doi: 10.1128/jvi.01923-22. Online ahead of print. PMID: 36779759

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease.

Huang L, McDade CL, Perdrizet JE, Wilson MR, Warren SA, Nzenze S, Sewdas R. Infect Dis Ther. 2023 Feb 12:1-18. doi: 10.1007/s40121-023-00767-4. Online ahead of print. PMID: 36774428

The Pregnancy, Arsenic, and Immune Response (PAIR) Study in rural northern Bangladesh.
Avolio LN, Smith TJS, Navas-Acien A, Kruczynski K, Pisanic N, Randad PR, Detrick B, Fry RC, van Geen A, Goessler W, Karron RA, Klein SL, Ogburn EL, Wills-Karp M, Alland K, Ayesha K, Dyer B, Islam MT, Oguntade HA, Rahman MH, Ali H, Haque R, Shaikh S, Schulze KJ, Muraduzzaman AKM, Alamgir ASM, Flora MS, West KP Jr, Labrique AB, Heaney CD; JiVitA Maternal and Child Health and Nutrition Research Project. Paediatr Perinat Epidemiol. 2023 Feb;37(2):165-178. doi: 10.1111/ppe.12949. Epub 2023 Feb 9. PMID: 36756808

Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
Debie Y, Van Audenaerde JRM, Vandamme T, Croes L, Teuwen LA, Verbruggen L, Vanhoutte G, Marcq E, Verheggen L, Le Blon D, Peeters B, Goossens ME, Pannus P, Ariën KK, Anguille S, Janssens A, Prenen H, Smits ELJ, Vulsteke C, Lion E, Peeters M, van Dam PA. Clin Cancer Res. 2023 Feb 1;29(3):635-646. doi: 10.1158/1078-0432.CCR-22-2185. PMID: 36341493

Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry.
Zacharopoulou E, Orfanoudaki E, Tzouvala M, Tribonias G, Kokkotis G, Kitsou V, Almpani F, Christidou A, Viazis N, Mantzaris GJ, Tsafaridou M, Karmiris K, Theodoropoulou A, Papathanasiou E, Zampeli E, Michopoulos S, Tigkas S, Michalopoulos G, Laoudi E, Karatzas P, Mylonas I, Kyriakos N, Liatsos C, Kafetzi T, Theocharis G, Taka S, Panagiotopoulou K, Koutroubakis IE, Bamias G. Inflamm Bowel Dis. 2023 Feb 1;29(2):228-237. doi: 10.1093/ibd/izac068. PMID: 35394529

A method for mapping the linear epitopes targeted by the natural antibody response to Zika virus infection using a VLP platform technology.
Fowler A, Ye C, Clarke EC, Pascale JM, Peabody DS, Bradfute SB, Frietze KM, Chackerian B. Virology. 2023 Feb;579:101-110. doi: 10.1016/j.virol.2023.01.001. Epub 2023 Jan 4. PMID: 36623351

New Glucosamine-Based TLR4 Agonists: Design, Synthesis, Mechanism of Action, and In Vivo Activity as **Vaccine** Adjuvants.
Romerio A, Gotri N, Franco AR, Artusa V, Shaik MM, Pasco ST, Atxabal U, Matamoros-Recio A, Mínguez-Toral M, Zalamea JD, Franconetti A, Abrescia NGA, Jimenez-Barbero J, Anguita J, Martín-Santamaría S, Peri F. J Med Chem. 2023 Feb 2. doi: 10.1021/acs.jmedchem.2c01998. Online ahead of print. PMID: 36728697

History and impact of the mouse-adapted Ebola virus model.
Bradfute SB. Antiviral Res. 2023 Feb;210:105493. doi: 10.1016/j.antiviral.2022.105493. Epub 2022 Dec 23. PMID: 36567023

COVID-19 vaccination in individuals with inflammatory rheumatic diseases.
Skapenko A, Schulze-Koops H. Nat Rev Rheumatol. 2023 Feb;19(2):76-77. doi: 10.1038/s41584-022-00892-3. PMID: 36517627

A dynamic causal modeling of the second outbreak of COVID-19 in Italy.

Bilancia M, Vitale D, Manca F, Perchinunno P, Santacroce L. Adv Stat Anal. 2023 Feb 7:1-30. doi: 10.1007/s10182-023-00469-9. Online ahead of print. PMID: 36776481

Bacillus subtilis spores displaying RBD domain of SARS-CoV-2 spike protein.
Vetráková A, Chovanová RK, Rechtoríková R, Krajčíková D, Barák I. Comput Struct Biotechnol J. 2023 Feb 8. doi: 10.1016/j.csbj.2023.02.007. Online ahead of print. PMID: 36778063

In praise of Prais-Winsten: An evaluation of methods used to account for autocorrelation in interrupted time series.
Bottomley C, Ooko M, Gasparrini A, Keogh RH. Stat Med. 2023 Feb 1. doi: 10.1002/sim.9669. Online ahead of print. PMID: 36722328

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma.
Dibajnia P, Cardenas LM, Lalani AA. Hum Vaccin Immunother. 2023 Feb 12:2178217. doi: 10.1080/21645515.2023.2178217. Online ahead of print. PMID: 36775257

Process Evaluation of a Collaborative Social Media Health Campaign: An Analysis of Partner and User Engagement.
Hether HJ, O'Connor-Coates E, Crittendon R. Health Promot Pract. 2023 Feb 1:15248399231152469. doi: 10.1177/15248399231152469. Online ahead of print. PMID: 36722287

Pandemics, infodemics and health promotion.
White B, Phuong L, Roach J, Teggelove N, Wallace H. Health Promot J Austr. 2023 Feb;34(1):169-172. doi: 10.1002/hpja.644. Epub 2022 Aug 21. PMID: 35906964

A Single Dose, Thermostable, Trivalent Human Papillomavirus **Vaccine** Formulated Using Atomic Layer Deposition.
Witeof AE, Meinerz NM, Walker KD, Funke HH, Garcea RL, Randolph TW. J Pharm Sci. 2023 Feb 11:S0022-3549(23)00061-8. doi: 10.1016/j.xphs.2023.02.007. Online ahead of print. PMID: 36780987

BCG-induced trained immunity: history, mechanisms and potential applications.
Chen J, Gao L, Wu X, Fan Y, Liu M, Peng L, Song J, Li B, Liu A, Bao F. J Transl Med. 2023 Feb 10;21(1):106. doi: 10.1186/s12967-023-03944-8. PMID: 36765373

Durability of **Vaccine**-Induced and Natural Immunity Against COVID-19: A Narrative Review.
Pooley N, Abdool Karim SS, Combadière B, Ooi EE, Harris RC, El Guerche Seblain C, Kisomi M, Shaikh N. Infect Dis Ther. 2023 Feb;12(2):367-387. doi: 10.1007/s40121-022-00753-2. Epub 2023 Jan 9. PMID: 36622633

Seroprevalence of Chikungunya in an Asymptomatic Adult Population in North and South Sulawesi, Indonesia.
A Jalloh M, Artika IM, P Dewi Y, Syafruddin D, Idris I, B B Bernadus J, Telew A, S Purwanto D, D Rosita Y, Antonjaya U, S A Myint K. Am J Trop Med Hyg. 2022 Dec 19;108(2):359-362. doi: 10.4269/ajtmh.22-0328. Print 2023 Feb 1. PMID: 36535254

mRNA vaccines: The future of prevention of viral infections?

Rzymski P, Szuster-Ciesielska A, Dzieciątkowski T, Gwenzi W, Fal A. J Med Virol. 2023 Feb 10. doi: 10.1002/jmv.28572. Online ahead of print. PMID: 36762592

[Severity, susceptibility and social norms perceived as antecedents of the intention to be vaccinated against COVID-19].
Cavazos-Arroyo J, Pérez de Celis-Herrero C. Rev Salud Publica (Bogota). 2023 Feb 6;22(2):178-184. doi: 10.15446/rsap.V22n2.86877. PMID: 36753108

Polymeric nanoparticle-based nanovaccines for cancer immunotherapy.
Zhang Y, Chen J, Shi L, Ma F. Mater Horiz. 2023 Feb 6;10(2):361-392. doi: 10.1039/d2mh01358d. PMID: 36541078

A single dose of genetically-attenuated malaria blood-stage parasites protects against two Plasmodium species infections.
Deveci G, Kamil M, Aly ASI. Vaccine. 2023 Feb 10;41(7):1281-1285. doi: 10.1016/j.vaccine.2023.01.004. Epub 2023 Jan 16. PMID: 36653222

[EDP-938, a new antiviral with inhibitory activity against the nucleoprotein of the respiratory syncytial virus].
Reina J, Iglesias C. Rev Esp Quimioter. 2023 Feb;36(1):26-29. doi: 10.37201/req/096.2022. Epub 2022 Nov 21. PMID: 36401806

The importance of pediatric trauma prevention: The work of Criança Segura - Safe Kids Brazil.
Vieira Abib SC. J Pediatr Surg. 2023 Feb;58(2):198-203. doi: 10.1016/j.jpedsurg.2022.10.011. Epub 2022 Oct 21. PMID: 36376125

Religious Doctrine and Attitudes Toward Vaccination in Jewish Law.
Muravsky NL, Betesh GM, McCoy RG. J Relig Health. 2023 Feb;62(1):373-388. doi: 10.1007/s10943-021-01447-8. Epub 2021 Oct 27. PMID: 34708328

High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India.
Kante B, Vuyyuru SK, Gupta R, Dwivedi T, Kumar P, Mundhra S, Golla R, Virmani S, Verma M, Makharia G, Ahuja V, Kedia S. Indian J Gastroenterol. 2023 Feb 4:1-9. doi: 10.1007/s12664-022-01310-y. Online ahead of print. PMID: 36738383

Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022.
Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, Casado I, Navascués A, Burgui C, Ezpeleta C, Castilla J, Guevara M; Working Group for the Study of COVID-19 in Navarra; Members of the Working Group for the Study of COVID-19 in Navarra. Euro Surveill. 2023 Feb;28(5):2200337. doi: 10.2807/1560-7917.ES.2023.28.5.2200337. PMID: 36729113

Temporal metabolic profiling of erythrocytes in mice infected with Babesia microti.
Gong H, Rahman SU, Zhou K, Lin Z, Mi R, Huang Y, Zhang Y, Zhang Y, Jia H, Tang W, Xia C, Pandey K, Chen Z. Microb Pathog. 2023 Feb;175:105954. doi: 10.1016/j.micpath.2022.105954. Epub 2022 Dec 24. PMID: 36574865

Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A follow-up study.
Doubrovinskaia S, Mooshage CM, Seliger C, Lorenz HM, Nagel S, Lehnert P, Purrucker J, Wildemann B, Bendszus M, Wick W, Schönenberger S, Kaulen LD. Eur J Neurol. 2023 Feb;30(2):463-473. doi: 10.1111/ene.15602. Epub 2022 Nov 2. PMID: 36259114

VaccinateLA: Protocol for a Community-based Public Health Vaccination Campaign in Los Angeles' Black and Latino Communities.
Kipke M, Karimipour N, Wolfe N, Orechwa A, Stoddard L, Rubio-Diaz M, North G, Dezfuli G, Murphy S, Phelps A, Kagan J, De La Haye K, Perry C, Baezconde-Garbanati L. JMIR Res Protoc. 2023 Feb 7. doi: 10.2196/40161. Online ahead of print. PMID: 36757953

COVID-19 Mortality and Progress Toward Vaccinating Older Adults - World Health Organization, Worldwide, 2020-2022.
Wong MK, Brooks DJ, Ikejezie J, Gacic-Dobo M, Dumolard L, Nedelec Y, Steulet C, Kassamali Z, Acma A, Ajong BN, Adele S, Allan M, Cohen HA, Awofisayo-Okuyelu A, Campbell F, Cristea V, De Barros S, Edward NV, Waeber AREC, Guinko TN, Laurenson-Schafer H, Mahran M, Carrera RM, Mesfin S, Meyer E, Miglietta A, Mirembe BB, Mitri M, Nezu IH, Ngai S, Ejoh OO, Parikh SR, Peron E, Sklenovská N, Stoitsova S, Shimizu K, Togami E, Jin YW, Pavlin BI, Novak RT, Le Polain O, Fuller JA, Mahamud AR, Lindstrand A, Hersh BS, O'Brien K, Van Kerkhove MD. MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):113-118. doi: 10.15585/mmwr.mm7205a1. PMID: 36730046

Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece.
Maltezou HC, Basoulis D, Bonelis K, Gamaletsou MN, Giannouchos TV, Karantoni E, Karapanou A, Kounouklas K, Livanou ME, Zotou M, Rapti V, Stamou P, Loulakis D, Souliotis K, Chini M, Panagopoulos P, Poulakou G, Syrigos KN, Hatzigeorgiou D, Sipsas NV. Vaccine. 2023 Feb 2:S0264-410X(23)00109-3. doi: 10.1016/j.vaccine.2023.01.067. Online ahead of print. PMID: 36740558

Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021.
Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, Salomon JA, Menzies NA. Clin Infect Dis. 2023 Feb 8;76(3):e350-e359. doi: 10.1093/cid/ciac438. PMID: 35717642

Baculovirus displaying SARS-CoV-2 spike RBD promotes neutralizing antibody production in a mouse model.
Wahba MA, Mofed D, Ghareeb DA, Omran JI, Salem TZ. J Genet Eng Biotechnol. 2023 Feb 9;21(1):16. doi: 10.1186/s43141-023-00472-2. PMID: 36759349

Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of IFNγ-releasing cells: An exploratory study.
Garofalo E, Biamonte F, Palmieri C, Battaglia AM, Sacco A, Biamonte E, Neri G, Antico GC, Mancuso S, Foti G, Torti C, Costanzo FS, Longhini F, Bruni A. PLoS One. 2023 Feb 9;18(2):e0281444. doi: 10.1371/journal.pone.0281444. eCollection 2023. PMID: 36757971

Severity of influenza illness by seasonal influenza vaccination status among hospitalised patients in four South American countries, 2013-19: a surveillance-based cohort study.

Regan AK, Arriola CS, Couto P, Duca L, Loayza S, Nogareda F, de Almeida WAF, Antman J, Araya S, Avendaño Vigueras MA, Battaglia Paredes SC, Brstilo IF, Bustos P, Fandiño ME, Fasce R, Giovacchini CM, González Caro CI, von Horoch M, Del Valle Juarez M, Katz N, Olivares MF, da Silva DA, da Silva ET, Sotomayor V, Vergara N, Azziz-Baumgartner E, Ropero AM. Lancet Infect Dis. 2023 Feb;23(2):222-232. doi: 10.1016/S1473-3099(22)00493-5. Epub 2022 Oct 4. PMID: 36206790

The gut microbiota and metabolome are associated with diminished COVID-19 **vaccine**-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
Alexander JL, Mullish BH, Danckert NP, Liu Z, Olbei ML, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Roberts LA, Bewshea CM, Nice R, Lin S, Prabhudev H, Sands C, Horneffer-van der Sluis V, Lewis M, Sebastian S, Lees CW, Teare JP, Hart A, Goodhand JR, Kennedy NA, Korcsmaros T, Marchesi JR, Ahmad T, Powell N. EBioMedicine. 2023 Feb;88:104430. doi: 10.1016/j.ebiom.2022.104430. Epub 2023 Jan 10. PMID: 36634565

Immunotherapeutic strategies for treating opioid use disorder and overdose.
Luba R, Martinez S, Jones J, Pravetoni M, Comer SD. Expert Opin Investig Drugs. 2023 Feb 12:1-11. doi: 10.1080/13543784.2023.2173062. Online ahead of print. PMID: 36696567

ORFV can carry TRAP gene expression via intracellular CRISPR/Cas9 gene editing technology.
Yu Y, Zhang F, Duan X, Yang C, Cui Y, Yu L. J Virol Methods. 2023 Feb;312:114652. doi: 10.1016/j.jviromet.2022.114652. Epub 2022 Dec 6. PMID: 36493528

Rapid upskilling about COVID-19 vaccines: an evaluation of a novel interprofessional education workshop.
Hemingway S, Sam-Okerenta C, Kittrick A, Hanson V, Holden S, Stephenson J, Gorton H. Br J Nurs. 2023 Feb 9;32(3):118-124. doi: 10.12968/bjon.2023.32.3.118. PMID: 36763472

Spike Gene Target Amplification in a Diagnostic Assay as a Marker for Public Health Monitoring of Emerging SARS-CoV-2 Variants - United States, November 2021-January 2023.
Scobie HM, Ali AR, Shirk P, Smith ZR, Paul P, Paden CR, Hassell N, Zheng XY, Lambrou AS, Kondor R, MacCannell D, Thornburg NJ, Miller J, Wentworth D, Silk BJ. MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):125-127. doi: 10.15585/mmwr.mm7205e2. PMID: 36730050

The Relationship Between Anti-Spike SARS-CoV-2 Antibody Levels and Risk of Breakthrough COVID-19 Among Fully Vaccinated Adults.
Asamoah-Boaheng M, Goldfarb DM, Karim ME, OBrien SF, Wall N, Drews SJ, Barakauskas V, Jassem AN, Grunau B. J Infect Dis. 2023 Feb 1;227(3):339-343. doi: 10.1093/infdis/jiac403. PMID: 36197948

Preliminary evaluation of an inter-professional e-consultation on vaccines.
Fernández-Prada M, Cano-García P, Alonso-Penanes P, Zapico-Baragaño MJ, Giménez-Gómez P, Lana A. J Telemed Telecare. 2023 Feb;29(2):111-116. doi: 10.1177/1357633X20970077. Epub 2020 Nov 11. PMID: 33176541

Community Health, Health Care Access, And COVID-19 Booster Uptake In Massachusetts.
Gaffney A, Woolhandler S, Bor J, McCormick D, Himmelstein DU. Health Aff (Millwood). 2023 Feb;42(2):268-276. doi: 10.1377/hlthaff.2022.00835. PMID: 36745834

Vaccination against poliomyelitis in Brazil from 2011 to 2021: successes, setbacks, and challenges ahead.

Donalisio MR, Boing AC, Sato APS, Martinez EZ, Xavier MO, Almeida RLF, Moreira RDS, Queiroz RCS, Matijasevich A. Cien Saude Colet. 2023 Feb;28(2):337. doi: 10.1590/1413-81232023282.17842022. Epub 2022 Nov 19. PMID: 36651390

Diagnostic and management strategies for chronic hepatitis E infection.
Abravanel F, Lhomme S, Marion O, Péron JM, Kamar N, Izopet J. Expert Rev Anti Infect Ther. 2023 Feb;21(2):143-148. doi: 10.1080/14787210.2023.2166932. Epub 2023 Jan 13. PMID: 36625025

Recovery of Siniperca chuatsi rhabdovirus from cloned cDNA.
Liu X, Zhang X, Xu Z, Huang Z, Zhong J, Zhu Y, Wei Y. J Fish Dis. 2023 Feb;46(2):127-135. doi: 10.1111/jfd.13726. Epub 2022 Nov 2. PMID: 36321410

Application of codon pair deoptimization for ORF7-induced attenuation of type I porcine reproductive and respiratory syndrome virus without reduced immune responses.
Cha SH, You SH, Lee MA, Baek JH, Cho SH, Jeong J, Park CJ, Lee MS, Park C. Virology. 2023 Feb;579:119-127. doi: 10.1016/j.virol.2023.01.009. Epub 2023 Jan 14. PMID: 36669328

Antitumor effect of invasive Lactobacillus plantarum delivering associated antigen gene sHSP between Trichinella spiralis and Lewis lung cancer cells.
Yue T, Zhang X, Gong P, Li J, Wang X, Li X, Ma Y, Chen X, Zhang X, Cheng S, Zhang H, Zhang N. Int Immunopharmacol. 2023 Feb;115:109708. doi: 10.1016/j.intimp.2023.109708. Epub 2023 Jan 11. PMID: 36638662

Emerging strategies and challenges of molecular therapeutics in antileishmanial drug development.
Gupta D, Singh PK, Yadav PK, Narender T, Patil UK, Jain SK, Chourasia MK. Int Immunopharmacol. 2023 Feb;115:109649. doi: 10.1016/j.intimp.2022.109649. Epub 2023 Jan 3. PMID: 36603357

Isolation and characterization of a duck reovirus strain from mature ducks in China.
Huang C, Huang Y, Liu Z, Li J, Han J, Liu Y, Liu J, Chen H, Chen Z. Poult Sci. 2023 Feb;102(2):102345. doi: 10.1016/j.psj.2022.102345. Epub 2022 Nov 25. PMID: 36571873

Cerebral toxoplasmosis in HIV-infected patients: a review.
Dian S, Ganiem AR, Ekawardhani S. Pathog Glob Health. 2023 Feb;117(1):14-23. doi: 10.1080/20477724.2022.2083977. Epub 2022 Jun 11. PMID: 35694771

Postvaccination Immunogenicity of BNT162b2 SARS-CoV-2 **Vaccine** and Its Predictors in Pediatric Inflammatory Bowel Disease.
Bronsky J, Copova I, Durilova M, Kazeka D, Kubat M, Lerchova T, Vlckova E, Mitrova K, Rataj M, Klocperk A, Sediva A, Hradsky O. J Pediatr Gastroenterol Nutr. 2023 Feb 1;76(2):e36-e44. doi: 10.1097/MPG.0000000000003661. Epub 2022 Nov 23. PMID: 36705698

Outcomes following severe acute respiratory syndrome coronavirus 2 infection among individuals with and without HIV in Denmark.
Rasmussen LD, Cowan S, Gerstoft J, Kronborg G, Johansen IS, Larsen CS, Weise L, Dalager-Pedersen M, Leth S, Nielsen LN, Lunding S, Omland LH, Obel N. AIDS. 2023 Feb 1;37(2):311-321. doi: 10.1097/QAD.0000000000003393. Epub 2022 Sep 19. PMID: 36129108

Streptolysin O Deficiency in Streptococcus pyogenes M1T1 *covR/S* Mutant Strain Attenuates Virulence in *In Vitro* and *In Vivo* Infection Models.
Langshaw EL, Reynolds S, Ozberk V, Dooley J, Calcutt A, Zaman M, Walker MJ, Batzloff MR, Davies MR, Good MF, Pandey M. mBio. 2023 Feb 6:e0348822. doi: 10.1128/mbio.03488-22. Online ahead of print. PMID: 36744883

Systematic review on the impact of the pneumococcal conjugate **vaccine** ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old.
Reyburn R, Tsatsaronis A, von Mollendorf C, Mulholland K, Russell FM; ARI Review group. J Glob Health. 2023 Feb 3;13:05002. doi: 10.7189/jgoh.13.05002. PMID: 36734192

Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case-control study.
Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, Kinney J, Clout M, Maskell N, Oliver J, Danon L, Finn A; Avon CAP Research Group. Lancet Reg Health Eur. 2022 Dec 7;25:100552. doi: 10.1016/j.lanepe.2022.100552. eCollection 2023 Feb. PMID: 36506791

Molecular characterization and antimicrobial susceptibility profiles of Thai Mycoplasma synoviae isolates.
Limpavithayakul K, Sasipreeyajan J, Pakpinyo S. Sci Rep. 2023 Feb 3;13(1):2002. doi: 10.1038/s41598-023-29266-9. PMID: 36737453

A Cluster Randomized Phase 3 Trial of Bovine Vaccination to Enhance Control of Human Schistosomiasis in Asia.
Ross AG, Harn DA, Chy D, Inobaya M, Guevarra JR, Shollenberger L, Li Y, McManus DP, Gray DJ, Williams GM. Int J Infect Dis. 2023 Feb 1:S1201-9712(23)00038-3. doi: 10.1016/j.ijid.2023.01.037. Online ahead of print. PMID: 36736992

Current and Emerging Knowledge in COVID-19.
Jeong YJ, Wi YM, Park H, Lee JE, Kim SH, Lee KS. Radiology. 2023 Feb;306(2):e222462. doi: 10.1148/radiol.222462. Epub 2023 Jan 10. PMID: 36625747

An extended picture fuzzy multicriteria group decision analysis with different weights: A case study of COVID-19 **vaccine** allocation.
Almulhim T, Barahona I. Socioecon Plann Sci. 2023 Feb;85:101435. doi: 10.1016/j.seps.2022.101435. Epub 2022 Sep 24. PMID: 36187871

Executive summary. Diagnosis, treatment and prophylaxis of influenza virus infection. Consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Society of Pediatric Infectious Diseases (SEIP), the Spanish Association of Vaccinology (AEV), the Spanish Society of Family and Community Medicine (SEMFYC) and the Spanish Society of Preventive Medicine, Public Health and Health Management (SEMPSPGS).
López-Medrano F, Alfayate S, Carratalà J, Chamorro-Camazón J, Cordero E, Cruz-Cañete M, Fernández-Prada M, García-Cenoz M, Marcos MÁ, Melón S, Moreno-Millán N, Onieva-García MÁ, Lejarazu RO, Pérez-Martín JJ, Rodríguez-García J, Schwarz-Chavarri G, Tagarro-García A, van Esso-Arbolave D,

Viasus D, Pumarola T. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Feb;41(2):111-122. doi: 10.1016/j.eimce.2022.10.013. PMID: 36759049

PRRSV infection activates NLRP3 inflammasome through inducing cytosolic mitochondrial DNA stress.
Li H, Yang X, Song Y, Zhu Q, Liao Z, Liang Y, Guo J, Wan B, Bao D. Vet Microbiol. 2023 Feb 3;279:109673. doi: 10.1016/j.vetmic.2023.109673. Online ahead of print. PMID: 36764219

Effect of delayed mating on reproductive performance and life-history parameters of dengue vector *Aedes aegypti*.
Gunathilaka RAKM, Jayatunga DPW, Ganehiarachchi GASM. Bull Entomol Res. 2023 Feb;113(1):126-132. doi: 10.1017/S0007485322000396. Epub 2022 Sep 6. PMID: 36065760

Thimerosal, a competitive thioredoxin reductase 1 (TrxR1) inhibitor discovered via high-throughput screening.
Ni Y, Luo Z, Lv Y, Ma S, Luo C, Du D. Biochem Biophys Res Commun. 2023 Feb 7;650:117-122. doi: 10.1016/j.bbrc.2023.02.014. Online ahead of print. PMID: 36780763

An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies.
Quraish RU, Hirahata T, Quraish AU, Ul Quraish S. Cancer Inform. 2023 Feb 1;22:11769351221150772. doi: 10.1177/11769351221150772. eCollection 2023. PMID: 36762284

Increase in Colorado Tick Fever Virus Disease Cases and Effect of COVID-19 Pandemic on Behaviors and Testing Practices, Montana, 2020.
Soto RA, Baldry E, Vahey GM, Lehman J, Silver M, Panella A, Brault AC, Hughes HR, Fitzpatrick KA, Velez J, Biggerstaff BJ, Wolff B, Randolph J, Ruth LJ, Staples JE, Gould CV. Emerg Infect Dis. 2023 Feb 2;29(3). doi: 10.3201/eid2903.221240. Online ahead of print. PMID: 36732081

Estimating the global impact of coronavirus disease 2019 on people living with HIV.
Thornhill J, Orkin C, Cevik M. Curr Opin Infect Dis. 2023 Feb 1;36(1):20-25. doi: 10.1097/QCO.0000000000000898. Epub 2022 Dec 8. PMID: 36729763

Research Note: Oxidative stress and immune response following the administration of live attenuated Mycoplasma gallisepticum vaccination in backyard chicken.
Iemmi T, Basini G, Ramoni R, Bussolati S, Heredero AMC, Grasselli F, Grolli S, Serventi P, Bertini S. Poult Sci. 2023 Feb;102(2):102400. doi: 10.1016/j.psj.2022.102400. Epub 2022 Dec 8. PMID: 36565636

Roles of Bothrops jararacussu toxins I and II: Antiviral findings against Zika virus.
Cassani NM, Santos IA, Grosche VR, Ferreira GM, Guevara-Vega M, Rosa RB, Pena LJ, Nicolau-Junior N, Cintra ACO, Mineo TP, Sabino-Silva R, Sampaio SV, Jardim ACG. Int J Biol Macromol. 2023 Feb 1;227:630-640. doi: 10.1016/j.ijbiomac.2022.12.102. Epub 2022 Dec 15. PMID: 36529220

The Omicron variant wave: Where are we now and what are the prospects?
Wang ML, Lin Y, Hou JF, Yang YP, Chien Y, Sun YC, Liang KH, Yang DM, Chang TJ, Wu CH, Kao SY, Hung KF. J Chin Med Assoc. 2023 Feb 1;86(2):135-137. doi: 10.1097/JCMA.0000000000000863. Epub 2022 Dec 13. PMID: 36524941

PLGA nanoparticle with *Amomum longiligulare* polysaccharide 1 increased the immunogenicity of infectious bursal disease virus VP2 protein.
Zhang C, Liu J, Xing Z, Chen Y, Chen H, Zhu Y, Wu H. Br Poult Sci. 2023 Feb 8:1-9. doi: 10.1080/00071668.2022.2154639. Online ahead of print. PMID: 36469700

The current Monkeypox outbreak: Updates and concerns.
Najeeb A, Eltalkhawy YM, Reda O. J Taibah Univ Med Sci. 2023 Feb;18(1):137-139. doi: 10.1016/j.jtumed.2022.08.001. Epub 2022 Aug 26. PMID: 36345424

Vaccination control measures of an epidemic model with long-term memristive effect.
G M V, P RB. J Comput Appl Math. 2023 Feb;419:114738. doi: 10.1016/j.cam.2022.114738. Epub 2022 Aug 19. PMID: 36000087

Zona pellucida glycoproteins: Relevance in fertility and development of contraceptive vaccines.
Gupta SK. Am J Reprod Immunol. 2023 Feb;89(2):e13535. doi: 10.1111/aji.13535. Epub 2022 Mar 15. PMID: 35249246

Genetic engineering of bacteriophages: Key concepts, strategies, and applications.
Hussain W, Yang X, Ullah M, Wang H, Aziz A, Xu F, Asif M, Ullah MW, Wang S. Biotechnol Adv. 2023 Feb 9:108116. doi: 10.1016/j.biotechadv.2023.108116. Online ahead of print. PMID: 36773707

Unveiling New Druggable Pockets in Influenza Non-Structural Protein 1: NS1-Host Interactions as Antiviral Targets for Flu.
Cunha AES, Loureiro RJS, Simões CJV, Brito RMM. Int J Mol Sci. 2023 Feb 3;24(3):2977. doi: 10.3390/ijms24032977. PMID: 36769298

Lessons from the coronavirus disease 2019 pandemic in schizophrenia: a review.
Fond G, Boyer L. Curr Opin Psychiatry. 2023 Feb 13. doi: 10.1097/YCO.0000000000000855. Online ahead of print. PMID: 36762657

An overview of current accomplishments and gaps of COVID-19 **vaccine** platforms and considerations for next generation vaccines.
Kale A, Gaur A, Menon I, Chirmule N, Bagwe P, Jawa R, Vijayanand S, Patil S, Suresh S, Jawa V. J Pharm Sci. 2023 Feb 1:S0022-3549(23)00021-7. doi: 10.1016/j.xphs.2023.01.019. Online ahead of print. PMID: 36736775

BIRCH: An Automated Workflow for Evaluation, Correction, and Visualization of Batch Effect in Bottom-Up Mass Spectrometry-Based Proteomics Data.
Sundararaman N, Bhat A, Venkatraman V, Binek A, Dwight Z, Ariyasinghe NR, Escopete S, Joung SY, Cheng S, Parker SJ, Fert-Bober J, Van Eyk JE. J Proteome Res. 2023 Feb 3;22(2):471-481. doi: 10.1021/acs.jproteome.2c00671. Epub 2023 Jan 25. PMID: 36695565

The Trend of CRISPR-Based Technologies in COVID-19 Disease: Beyond Genome Editing.
Najafabadi ZY, Fanuel S, Falak R, Kaboli S, Kardar GA. Mol Biotechnol. 2023 Feb;65(2):146-161. doi: 10.1007/s12033-021-00431-7. Epub 2022 Jan 29. PMID: 35091986

Conservation, abundance, glycosylation profile, and localization of the TSP protein family in Cryptosporidium parvum.
John A, Bader SM, Madiedo Soler N, Wiradiputri K, Tichkule S, Smyth ST, Ralph SA, Jex AR, Scott NE, Tonkin CJ, Goddard-Borger ED. J Biol Chem. 2023 Feb 10:103006. doi: 10.1016/j.jbc.2023.103006. Online ahead of print. PMID: 36775128

Pregnancy Care during the COVID-19 Pandemic in Germany: A Public Health Lens.
Leiße A, Dötzer J, Ruhnau A, Aschentrup L, Fischer F, Wrona KJ. Int J Environ Res Public Health. 2023 Feb 3;20(3):2721. doi: 10.3390/ijerph20032721. PMID: 36768087

Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients.
Rouet R, Henry JY, Johansen MD, Sobti M, Balachandran H, Langley DB, Walker GJ, Lenthall H, Jackson J, Ubiparipovic S, Mazigi O, Schofield P, Burnett DL, Brown SHJ, Martinello M, Hudson B, Gilroy N, Post JJ, Kelleher A, Jäck HM, Goodnow CC, Turville SG, Rawlinson WD, Bull RA, Stewart AG, Hansbro PM, Christ D. Nat Commun. 2023 Feb 8;14(1):687. doi: 10.1038/s41467-023-36295-5. PMID: 36755042

[Long COVID-A New Challenge in Medicine: Focus on Pregnancy and Breastfeeding].
Han E, Gyöngyösi M. J Gynakol Endokrinol. 2023 Feb 2:1-6. doi: 10.1007/s41974-023-00250-5. Online ahead of print. PMID: 36747883

Investigation of the effects of *N*-Acetylglucosamine on the stability of the spike protein in SARS-CoV-2 by molecular dynamics simulations.
Deniz Tekin E. Comput Theor Chem. 2023 Apr;1222:114049. doi: 10.1016/j.comptc.2023.114049. Epub 2023 Feb 1. PMID: 36743995

Safety of primary immunization using inactivated SARS-CoV-2 **vaccine** (CoronaVac®) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China.
Yang H, Li Z, Zhang R, Guo S, Wang B, Fang X, Zhang D, Zhang X, Tong Y, Wang Q, Deng Q, Sun Z, Liu X, Gao Y. Vaccine. 2023 Feb 10;41(7):1354-1361. doi: 10.1016/j.vaccine.2023.01.020. Epub 2023 Jan 13. PMID: 36658045

Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.
Kuriakose Gift S, Wieczorek L, Sanders-Buell E, Zemil M, Molnar S, Donofrio G, Townsley S, Chenine AL, Bose M, Trinh HV, Barrows BM, Sriplienchan S, Kitsiripornchai S, Nitayapan S, Eller LA, Rao M, Ferrari G, Michael NL, Ake JA, Krebs SJ, Robb ML, Tovanabutra S, Polonis VR. J Virol. 2023 Feb 7:e0163522. doi: 10.1128/jvi.01635-22. Online ahead of print. PMID: 36749076

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 **vaccine**.
Azzi L, Dalla Gasperina D, Veronesi G, Shallak M, Maurino V, Baj A, Gianfagna F, Cavallo P, Dentali F, Tettamanti L, Maggi F, Maffioli LS, Tagliabue A, Accolla RS, Forlani G. EBioMedicine. 2023 Feb;88:104435. doi: 10.1016/j.ebiom.2022.104435. Epub 2023 Jan 9. PMID: 36628844

Evaluation of an Audio-Visual Novela to Improve COVID-19 Knowledge and Safe Practices Among Spanish-Speaking Individuals with Schizophrenia.
Kopelowicz A, Lopez SR, Molina GB, Baron M, Franco R, Mayer D. J Immigr Minor Health. 2023 Feb 4:1-10. doi: 10.1007/s10903-023-01456-7. Online ahead of print. PMID: 36738379

An Exploratory Study of the Mpox Media Consumption, Attitudes, and Preferences of Sexual and Gender Minority People Assigned Male at Birth in the United States.
Owens C, Hubach RD. LGBT Health. 2023 Feb 3. doi: 10.1089/lgbt.2022.0251. Online ahead of print. PMID: 36735618

COVID-19 in Assisted Living: Protecting a Critical Long-Term Care Resource.
Schwartz LB, Lieblich C, Laxton CE, Kaes L, Barnett DP, Port C, Pace DD. J Am Med Dir Assoc. 2023 Feb;24(2):134-139. doi: 10.1016/j.jamda.2022.12.012. Epub 2022 Dec 30. PMID: 36592942

Dynamic planning of a two-dose vaccination campaign with uncertain supplies.
Calafiore GC, Parino F, Zino L, Rizzo A. Eur J Oper Res. 2023 Feb 1;304(3):1269-1278. doi: 10.1016/j.ejor.2022.05.009. Epub 2022 May 13. PMID: 35582705

Induction of transmucosal protection by oral vaccination with an attenuated *Chlamydia*.
Wang Y, He R, Winner H, Gauduin MC, Zhang N, He C, Zhong G. bioRxiv. 2023 Feb 2:2023.01.30.526385. doi: 10.1101/2023.01.30.526385. Preprint. PMID: 36778293

Vaccination Upregulates Th1 Cytokines in the Lung of Pigs Experimentally Infected with *Mycoplasma hyopneumoniae*.
Rodríguez F, Rosales RS, Ramírez AS, Poveda JB. Animals (Basel). 2023 Feb 1;13(3):520. doi: 10.3390/ani13030520. PMID: 36766408

Genome-wide exploration reveals distinctive northern and southern variants of Clonorchis sinensis in the Far East.
Kinkar L, Korhonen PK, Saarma U, Wang T, Zhu XQ, Harliwong I, Yang B, Fink JL, Wang D, Chang BCH, Chelomina GN, Koehler AV, Young ND, Gasser RB. Mol Ecol Resour. 2023 Feb 2. doi: 10.1111/1755-0998.13760. Online ahead of print. PMID: 36727564

Analysis of tumor-immune functional responses in a mathematical model of neoantigen cancer vaccines.
Han L, Rodriguez Messan M, Yogurtcu ON, Nukala U, Yang H. Math Biosci. 2023 Feb;356:108966. doi: 10.1016/j.mbs.2023.108966. Epub 2023 Jan 13. PMID: 36642160

Lung Resident Memory T Cells Activated by Oral Vaccination Afford Comprehensive Protection against Pneumonic Yersinia pestis Infection.
Singh AK, Majumder S, Wang X, Song R, Sun W. J Immunol. 2023 Feb 1;210(3):259-270. doi: 10.4049/jimmunol.2200487. PMID: 36480265

The effect of emotion regulation strategies on decision-making about the maternal pertussis vaccination among pregnant women in the Netherlands: an experimental study.
Buursma P, Anraad C, van Empelen P, Ruiter RAC, van Keulen HM. Patient Educ Couns. 2023 Feb;107:107566. doi: 10.1016/j.pec.2022.11.008. Epub 2022 Nov 11. PMID: 36459828

Global dynamics of two-strain epidemic model with single-strain vaccination in complex networks.
Li CL, Cheng CY, Li CH. Nonlinear Anal Real World Appl. 2023 Feb;69:103738. doi: 10.1016/j.nonrwa.2022.103738. Epub 2022 Aug 26. PMID: 36042914

In silico study of potential immunonutrient-based sports supplements against COVID-19 via targeting ACE2 inhibition using molecular docking and molecular dynamics simulations.
Banitalebi E, Abdizadeh T, Khademi Dehkordi M, Saghaei E, Mardaniyan Ghahfarrokhi M. J Biomol Struct Dyn. 2023 Feb;41(3):1041-1061. doi: 10.1080/07391102.2021.2016489. Epub 2021 Dec 21. PMID: 34931597

Identification and genome sequencing of an influenza H3N2 variant in wastewater from elementary schools during a surge of influenza A cases in Las Vegas, Nevada.
Vo V, Harrington A, Chang CL, Baker H, Moshi M, Ghani N, Itorralba JY, Tillett RL, Dahlmann E, Basazinew N, Gu R, Familara T, Boss S, Vanderford F, Ghani M, Tang A, Matthews A, Papp K, Khan E, Koutras C, Kan HY, Lockett C, Gerrity D, Oh EC. Sci Total Environ. 2023 Feb 7:162058. doi: 10.1016/j.scitotenv.2023.162058. Online ahead of print. PMID: 36758698

High-throughput saturation mutagenesis generates a high-affinity antibody against SARS-CoV-2 variants using protein surface display assay on a human cell.
Yang Y, Liu S, Luo Y, Wang B, Wang J, Li J, Li J, Ye B, Wang Y, Xi JJ. PLoS Pathog. 2023 Feb 1;19(2):e1011119. doi: 10.1371/journal.ppat.1011119. eCollection 2023 Feb. PMID: 36724179

Modelling Aotearoa New Zealand's COVID-19 protection framework and the transition away from the elimination strategy.
Vattiato G, Lustig A, Maclaren O, Binny RN, Hendy SC, Harvey E, O'Neale D, Plank MJ. R Soc Open Sci. 2023 Feb 1;10(2):220766. doi: 10.1098/rsos.220766. eCollection 2023 Feb. PMID: 36756071

CXCR5^{+}PD-1^{++} CD4^{+} T cells colonize infant intestines early in life and promote B cell maturation.
Jordan-Paiz A, Martrus G, Steinert FL, Kaufmann M, Sagebiel AF, Schreurs RRCE, Rechtien A, Baumdick ME, Jung JM, Möller KJ, Wegner L, Grüttner C, Richert L, Thünauer R, Schroeder-Schwarz J, van Goudoever JB, Geijtenbeek TBH, Altfeld M, Pals ST, Perez D, Klarenbeek PL, Tomuschat C, Sauter G, Königs I, Schumacher U, Friese MA, Melling N, Reinshagen K, Bunders MJ. Cell Mol Immunol. 2023 Feb;20(2):201-213. doi: 10.1038/s41423-022-00944-4. Epub 2023 Jan 5. PMID: 36600048

Weighted gene co-expression network-based identification of genetic effect of mRNA vaccination and previous infection on SARS-CoV-2 infection.
He Y, Sun M, Xu Y, Hu C, Wang Y, Zhang Y, Fang J, Jin L. Cell Immunol. 2023 Feb 10;385:104689. doi: 10.1016/j.cellimm.2023.104689. Online ahead of print. PMID: 36780771

Nationwide Measles and Rubella Outbreaks in South Sudan, 2019.
Peck ME, Maleghemi S, Kayembe L, Hercules M, Anyuon A, Bunga S, McFarland J, Olu O. Open Forum Infect Dis. 2023 Feb 8;10(2):ofad032. doi: 10.1093/ofid/ofad032. eCollection 2023 Feb. PMID: 36776776

Structural and genomic analysis of single nucleotide polymorphisms in human host factor endothelial protein C receptor (EPCR) reveals complex interplay with malaria parasites.
Gill J, Sharma A. Infect Genet Evol. 2023 Feb 10:105413. doi: 10.1016/j.meegid.2023.105413. Online ahead of print. PMID: 36775045

Epidemiology of bacteremia in a pediatric population - A 10-year study.
Ferreira M, Santos M, Rodrigues J, Diogo C, Resende C, Baptista C, Faria C. Enferm Infecc Microbiol Clin (Engl Ed). 2023 Feb;41(2):85-91. doi: 10.1016/j.eimce.2021.06.006. PMID: 36759058

Are you vaccinated? COVID-19 vaccination rates and the effect of a vaccination program in a metropolitan mental health inpatient population in Australia.
Hooper K, Hooper M, Nguyen J, Fukutomi A. Australas Psychiatry. 2023 Feb;31(1):38-42. doi: 10.1177/10398562221136756. Epub 2022 Nov 6. PMID: 36337038

Parents' Willingness to Vaccinate Children for COVID-19: Conspiracy Theories, Information Sources, and Perceived Responsibility.
Allen JD, Fu Q, Nguyen KH, Rose R, Silva D, Corlin L. J Health Commun. 2023 Feb 8:1-13. doi: 10.1080/10810730.2023.2172107. Online ahead of print. PMID: 36755480

Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity.
Chen WH, Hajduczki A, Martinez EJ, Bai H, Matz H, Hill TM, Lewitus E, Chang WC, Dawit L, Peterson CE, Rees PA, Ajayi AB, Golub ES, Swafford I, Dussupt V, David S, Mayer SV, Soman S, Kuklis C, Corbitt C, King J, Choe M, Sankhala RS, Thomas PV, Zemil M, Wieczorek L, Hart T, Duso D, Kummer L, Yan L, Sterling SL, Laing ED, Broder CC, Williams JK, Davidson E, Doranz BJ, Krebs SJ, Polonis VR, Paquin-Proulx D, Rolland M, Reiley WW, Gromowski GD, Modjarrad K, Dooley H, Joyce MG. Nat Commun. 2023 Feb 3;14(1):580. doi: 10.1038/s41467-023-36106-x. PMID: 36737435

Predicting COVID-19 vaccination intentions: the roles of threat appraisal, coping appraisal, subjective norms, and negative affect.
Zou X, Chen Q, Zhang Y, Evans R. BMC Public Health. 2023 Feb 2;23(1):230. doi: 10.1186/s12889-023-15169-x. PMID: 36732695

Modelling the impact of the Omicron BA.5 subvariant in New Zealand.
Lustig A, Vattiato G, Maclaren O, Watson LM, Datta S, Plank MJ. J R Soc Interface. 2023 Feb;20(199):20220698. doi: 10.1098/rsif.2022.0698. Epub 2023 Feb 1. PMID: 36722072

Human papillomavirus vaccination in Africa: An airway perspective.
McGuire JK, Kabagenyi F, Peer S. Int J Pediatr Otorhinolaryngol. 2023 Feb;165:111423. doi: 10.1016/j.ijporl.2022.111423. Epub 2023 Jan 5. PMID: 36681046

Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction.
Crespo J, Cabezas J, Aguilera A, Berenguer M, Buti M, Forns X, García F, García-Samaniego J, Hernández-Guerra M, Jorquera F, Lazarus JV, Lens S, Martró E, Pineda JA, Prieto M, Rodríguez-Frías F, Rodríguez M, Serra MÁ, Turnes J, Domínguez-Hernández R, Casado MÁ, Calleja JL. Gastroenterol Hepatol. 2023 Feb;46(2):150-162. doi: 10.1016/j.gastrohep.2022.09.009. Epub 2022 Oct 17. PMID: 36257502

A mass vaccination site selection problem: An application of GIS and entropy-based MAUT approach.
Çetinkaya C, Erbaş M, Kabak M, Özceylan E. Socioecon Plann Sci. 2023 Feb;85:101376. doi: 10.1016/j.seps.2022.101376. Epub 2022 Jun 20. PMID: 35755637

Cellular and Humoral Responses to Recombinant and Inactivated SARS-CoV-2 Vaccines in CKD Patients: An Observational Study.
Zhang S, He J, Tang B, Zhou Q, Hu Y, Yu Y, Chen J, Liu Y, Li C, Ren H, Liao X. J Clin Med. 2023 Feb 3;12(3):1225. doi: 10.3390/jcm12031225. PMID: 36769873

Modeling the spread dynamics of multiple-variant coronavirus disease under public health interventions: A general framework.
Zhan C, Zheng Y, Shao L, Chen G, Zhang H. Inf Sci (N Y). 2023 May;628:469-487. doi: 10.1016/j.ins.2023.02.001. Epub 2023 Feb 6. PMID: 36777698

Comparison of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in Nigeria.
Iriemenam NC, Ige FA, Greby SM, Okunoye OO, Uwandu M, Aniedobe M, Nwaiwu SO, Mba N, Okoli M, William NE, Ehoche A, Mpamugo A, Mitchell A, Stafford KA, Thomas AN, Olaleye T, Akinmulero OO, Agala NP, Abubakar AG, Owens A, Gwyn SE, Rogier E, Udhayakumar V, Steinhardt LC, Martin DL, Okoye MI, Audu R. J Clin Virol Plus. 2023 Feb;3(1):100139. doi: 10.1016/j.jcvp.2023.100139. Epub 2023 Jan 13. PMID: 36683611

Granuloma annulare after SARS-CoV-2 vaccination: A case report and a literature review.
Russo D, Accarino R, Varricchio S, Franca RA, Potestio L, Patruno C, Napolitano M, Mascolo M. Pathol Res Pract. 2023 Feb;242:154300. doi: 10.1016/j.prp.2022.154300. Epub 2022 Dec 31. PMID: 36638589

Genetic characterization of dengue virus from patients presenting multi-serotypic infections in the Northern West Bengal, India.
Roy SK, Goswami BK, Bhattacharjee S. Virus Genes. 2023 Feb;59(1):45-54. doi: 10.1007/s11262-022-01950-4. Epub 2022 Nov 3. PMID: 36327057

Reverse genetic systems of SARS-CoV-2 for antiviral research.
Kurhade C, Xie X, Shi PY. Antiviral Res. 2023 Feb;210:105486. doi: 10.1016/j.antiviral.2022.105486. Epub 2022 Dec 22. PMID: 36657881

A potential host and virus targeting tool against COVID-19: Chemical characterization, antiviral, cytoprotective, antioxidant, respiratory smooth muscle relaxant effects of Paulownia tomentosa Steud.
Magurano F, Micucci M, Nuzzo D, Baggieri M, Picone P, Gioacchini S, Fioravanti R, Bucci P, Kojouri M, Mari M, Retini M, Budriesi R, Mattioli LB, Corazza I, Di Liberto V, Todaro L, Giuseppetti R, D'Ugo E, Marchi A, Mecca M, D'Auria M. Biomed Pharmacother. 2023 Feb;158:114083. doi: 10.1016/j.biopha.2022.114083. Epub 2022 Dec 5. PMID: 36495668

Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants.
Junker D, Becker M, Wagner TR, Kaiser PD, Maier S, Grimm TM, Griesbaum J, Marsall P, Gruber J, Traenkle B, Heinzel C, Pinilla YT, Held J, Fendel R, Kreidenweiss A, Nelde A, Maringer Y, Schroeder S, Walz JS, Althaus K, Uzun G, Mikus M, Bakchoul T, Schenke-Layland K, Bunk S, Haeberle H, Göpel S, Bitzer M, Renk H, Remppis J, Engel C, Franz AR, Harries M, Kessel B, Lange B, Strengert M, Krause G, Zeck A, Rothbauer U, Dulovic A, Schneiderhan-Marra N. Clin Infect Dis. 2023 Feb 8;76(3):e240-e249. doi: 10.1093/cid/ciac498. PMID: 35717657

An Insight into Modern Targeted Genome-Editing Technologies with a Special Focus on CRISPR/Cas9 and its Applications.
Akram F, Sahreen S, Aamir F, Haq IU, Malik K, Imtiaz M, Naseem W, Nasir N, Waheed HM. Mol Biotechnol. 2023 Feb;65(2):227-242. doi: 10.1007/s12033-022-00501-4. Epub 2022 Apr 26. PMID: 35474409

Antibody-based protection against respiratory syncytial virus in mice and their offspring through vectored immunoprophylaxis.
Rghei AD, Yates JGE, Lopes JA, Zhan X, Guilleman MM, Pei Y, van Lieshout LP, Santry LA, Bridle BW, Karimi K, Thompson B, Susta L, Crowe JE Jr, Wootton SK. Gene Ther. 2023 Feb 2. doi: 10.1038/s41434-023-00385-2. Online ahead of print. PMID: 36732618

Helicobacter pylori World Gastroenterology Organization Global Guideline.
Katelaris P, Hunt R, Bazzoli F, Cohen H, Fock KM, Gemilyan M, Malfertheiner P, Mégraud F, Piscoya A, Quach D, Vakil N, Vaz Coelho LG, LeMair A, Melberg J. J Clin Gastroenterol. 2023 Feb 1;57(2):111-126. doi: 10.1097/MCG.0000000000001719. PMID: 36598803

Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective virus replication and CD8+ T cell-dependent immune response.
Liu J, Hu YY, Zhang QY, Zhang YN, Li N, Zhang ZR, Zhan SL, Gao L, Deng CL, Li XD, Yuan SP, He YQ, Ye HQ, Zhang B. Biomed Pharmacother. 2023 Feb;158:114094. doi: 10.1016/j.biopha.2022.114094. Epub 2022 Dec 8. PMID: 36502755

Long COVID: An inevitable sequela of SARS-CoV-2 infection.
Lai CC, Hsu CK, Yen MY, Lee PI, Ko WC, Hsueh PR. J Microbiol Immunol Infect. 2023 Feb;56(1):1-9. doi: 10.1016/j.jmii.2022.10.003. Epub 2022 Oct 15. PMID: 36283919

Elucidating the role of N440K mutation in SARS-CoV-2 spike - ACE-2 binding affinity and COVID-19 severity by virtual screening, molecular docking and dynamics approach.
Kullappan M, Mary U, Ambrose JM, Veeraraghavan VP, Surapaneni KM. J Biomol Struct Dyn. 2023 Feb;41(3):912-929. doi: 10.1080/07391102.2021.2014973. Epub 2021 Dec 14. PMID: 34904526

Photothermal-triggered dendrimer nanovaccines boost systemic antitumor immunity.
Shen S, Gao Y, Ouyang Z, Jia B, Shen M, Shi X. J Control Release. 2023 Feb 6;355:171-183. doi: 10.1016/j.jconrel.2023.01.076. Online ahead of print. PMID: 36736909

Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model.
Wang J, Sud S, Qu Y, Li L, Zhang J, Marron D, Knape NM, Kim IJ, Wagner KT, Zhang T, Zhao Y, Guo G, Wang AZ. Neoplasia. 2023 Feb;36:100864. doi: 10.1016/j.neo.2022.100864. Epub 2022 Dec 24. PMID: 36571944

Economic Burden of Cervical Cancer in Bulgaria.
Lebanova H, Stoev S, Naseva E, Getova V, Wang W, Sabale U, Petrova E. Int J Environ Res Public Health. 2023 Feb 3;20(3):2746. doi: 10.3390/ijerph20032746. PMID: 36768109

Effects of Sirolimus treatment on patients with β-Thalassemia: Lymphocyte immunophenotype and biological activity of memory $CD4^+$ and $CD8^+$ T cells.
Zurlo M, Nicoli F, Proietto D, Dallan B, Zuccato C, Cosenza LC, Gasparello J, Papi C, d'Aversa E, Borgatti M, Scapoli C, Finotti A, Gambari R. J Cell Mol Med. 2023 Feb;27(3):353-364. doi: 10.1111/jcmm.17655. Epub 2023 Jan 10. PMID: 36625233

Molecular genotyping of Echinococcus granulosus sensu stricto from human Echinococcal cysts in Hatay, Türkiye.
Hamamcı B, Açıkgöz G, Çetinkaya Ü, Kılıç E, Koçal S, Karaaslan K, Durgun Yetim T, Yetim İ. Exp Parasitol. 2023 Feb;245:108454. doi: 10.1016/j.exppara.2022.108454. Epub 2022 Dec 29. PMID: 36587835

OX40L enhances the immunogenicity of dendritic cells and inhibits tumor metastasis in mice.
Zhao L, Zhang W, Liu M, Jia R, Wang J, Wang F, Xu Y. Microbiol Immunol. 2023 Feb;67(2):79-89. doi: 10.1111/1348-0421.13037. Epub 2022 Nov 30. PMID: 36345699

Large yellow croaker (Lrimichthys crocea) IL-2 modulates humoral immunity via the conserved JAK-STAT5 signal pathway.
Mu P, Teng Y, Wu H, Li X, Huo J, Ao J, Chen X. Fish Shellfish Immunol. 2023 Feb;133:108519. doi: 10.1016/j.fsi.2023.108519. Epub 2023 Jan 3. PMID: 36608811

A questionnaire study on disparity of cervical cancer prevention programs in Asia-Oceania.
Oncology Committee, Asia and Oceania Federation of Obstetrics and Gynecology; Tse KY, Ushijima K, Tan AL, Intasorn P, Pariyar J, Chang CL, Domingo EJ, Konar H, Kumarasamy S, Tjokroprawiro BA, Wilailak S. J Obstet Gynaecol Res. 2023 Feb 1. doi: 10.1111/jog.15566. Online ahead of print. PMID: 36726190

Nonlysosomal Route of mRNA Delivery and Combining with Epigenetic Regulation Optimized Antitumor Immunoprophylactic Efficacy.
Liu Y, Liu X, Huang J, Shi Y, Luo Z, Zhang J, Guo X, Jiang M, Li X, Yin H, Qin B, Guan G, Luo L, Zhou Y, You J. Adv Healthc Mater. 2023 Feb;12(4):e2202460. doi: 10.1002/adhm.202202460. Epub 2022 Nov 24. PMID: 36366890

Estimating the excess burden of pertussis disease in Australia within the first year of life, that might have been prevented through timely vaccination.
Jayasundara D, Randall D, Sheridan S, Sheppeard V, Liu B, Richmond PC, Blyth CC, Wood JG, Moore HC, McIntyre PB, Gidding HF. Int J Epidemiol. 2023 Feb 8;52(1):250-259. doi: 10.1093/ije/dyac175. PMID: 36099159

Epidemiology of invasive Haemophilus influenzae disease in Northwestern Ontario: comparison of invasive and non-invasive H. influenzae clinical isolates.
Ulanova M, Tsang RSW, Nix EB, Kelly L, Shuel M, Lance B. Can J Microbiol. 2023 Feb 8. doi: 10.1139/cjm-2022-0208. Online ahead of print. PMID: 36753721

Up-to-Date Colonoscopy Use in Asian and Hispanic Subgroups in New York City, 2003-2016.
Liang PS, Dubner R, Xia Y, Glenn M, Lin K, Nagpal N, Ng S, Trinh-Shevrin C, Troxel AB, Kwon SC. J Clin Gastroenterol. 2023 Feb 3. doi: 10.1097/MCG.0000000000001835. Online ahead of print. PMID: 36753456

Investigating the effects of various control measures on economy and spread of COVID-19 in Turkey: a system dynamics approach.
Alım M, Kesen SE. Simulation. 2023 Feb;99(2):113-125. doi: 10.1177/00375497221116641. PMID: 36751402

Role of Noroviruses in Sporadic Acute Gastroenteritis Cases from Children Attending a Large Referral Children's Hospital in Buenos Aires City, Argentina.
Gentile Á, Areso MS, Degiuseppe JI, Orqueda A, Turco M, Sabbaj L, Rodrigo A, Juárez MDV, Stupka JA. Pediatr Infect Dis J. 2023 Feb 1;42(2):94-98. doi: 10.1097/INF.0000000000003775. Epub 2022 Jan 11. PMID: 36638391

Nonclinical safety assessments of a novel synthetic toll-like receptor 4 agonist and saponin based adjuvant.
Syntin P, Piras-Douce F, Dalençon F, Garinot M, Haensler J. Toxicol Appl Pharmacol. 2023 Feb 1;460:116358. doi: 10.1016/j.taap.2022.116358. Epub 2022 Dec 23. PMID: 36572229

5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death.
Sun Z, Zhao M, Wang W, Hong L, Wu Z, Luo G, Lu S, Tang Y, Li J, Wang J, Zhang Y, Zhang L. Cancer Lett. 2023 Feb 1;554:216032. doi: 10.1016/j.canlet.2022.216032. Epub 2022 Dec 6. PMID: 36493899

Prospective cohort study of Cryptosporidium infection and shedding in infants and their households.
Korpe P, Ni Z, Kabir M, Alam M, Ferdous T, Ara R, Munday RM, Haque R, Duggal P. Clin Infect Dis. 2023 Feb 8:ciad059. doi: 10.1093/cid/ciad059. Online ahead of print. PMID: 36750491

IgG antibody response to pneumococcal-conjugated **vaccine** (Prevenar®13) in children with immunodeficiency disorders.
Garrido-Jareño M, Sahuquillo-Arce JM, Rodríguez-Vega H, Lloret-Sos C, Gil-Brusola A, López-Hontangas JL, Nuñez-Beltran M, Tortosa-Carreres J, García-García JÁ, Cordón L, Puchades-Carrasco L, de Santivañes CC, Pineda-Lucena A, Pemán-García J. Med Microbiol Immunol. 2023 Feb;212(1):93-102. doi: 10.1007/s00430-022-00759-0. Epub 2023 Jan 3. PMID: 36595027

Development of a reporter gene assay for antibody dependent cellular cytotoxicity activity determination of anti-rabies virus glycoprotein antibodies.
Wang W, Yu C, Cui Y, Liu C, Yang Y, Xu G, Wu G, Du J, Fu Z, Guo L, Long C, Xia X, Li Y, Wang L, Wang Y. Microbiol Immunol. 2023 Feb;67(2):69-78. doi: 10.1111/1348-0421.13036. Epub 2022 Nov 27. PMID: 36346082

Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination.
Grant LR, Slack MPE, Theilacker C, Vojicic J, Dion S, Reinert RR, Jodar L, Gessner BD. Clin Infect Dis. 2023 Feb 8;76(3):e1062-e1070. doi: 10.1093/cid/ciac475. PMID: 35789262

In silico screening and covalent binding of phytochemicals of *Ocimum sanctum* against SARS-CoV-2 (COVID 19) main protease.
Mohapatra PK, Chopdar KS, Dash GC, Mohanty AK, Raval MK. J Biomol Struct Dyn. 2023 Feb;41(2):435-444. doi: 10.1080/07391102.2021.2007170. Epub 2021 Nov 25. PMID: 34821198

Evolving Trends for the Clinical Presentation of Primary Rhegmatogenous Retinal Detachments From Early to Late Phases of the COVID-19 Pandemic.
Mundae R, Haq Z, Adams OE, Parke DW 3rd, Tang PH. Ophthalmic Surg Lasers Imaging Retina. 2023 Feb;54(2):78-83. doi: 10.3928/23258160-20230117-01. Epub 2023 Feb 1. PMID: 36780637

Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi.
Mseka UL, Mandolo J, Nyoni K, Divala O, Kambalame D, Mapemba D, Kamzati M, Chibwe I, Henrion MYR, Manda K, Thindwa D, Mvula M, Odala B, Kamng'ona R, Dzinza N, Jere KC, Feasey N, Ho A, Amoah AS, Gordon M, Swarthout TD, Crampin A, Heyderman RS, Kagoli M, Chitsa-Banda E, Mitambo C, Phuka J, Chilima B, Kasambara W, Jambo KC, Chauma-Mwale A. EClinicalMedicine. 2023 Feb;56:101800. doi: 10.1016/j.eclinm.2022.101800. Epub 2022 Dec 30. PMID: 36600885 Free PMC article.

US Infant Pertussis Incidence Trends Before and After Implementation of the Maternal Tetanus, Diphtheria, and Pertussis **Vaccine**.
Skoff TH, Deng L, Bozio CH, Hariri S. JAMA Pediatr. 2023 Feb 6. doi: 10.1001/jamapediatrics.2022.5689. Online ahead of print. PMID: 36745442

Evaluating the effects of a global pandemic on the operation of an investigational drug service.
Coulter C, Thorne A, Amerine L. Am J Health Syst Pharm. 2023 Feb 6:zxad039. doi: 10.1093/ajhp/zxad039. Online ahead of print. PMID: 36745616

Effect of the incremental protection of previous infection against Omicron infection among individuals with a hybrid of infection- and **vaccine**-induced immunity: a population-based cohort study in Canada.
Wu S, Li Y, Mishra S, Bodner K, Baral S, Kwong JC, Wei X. Int J Infect Dis. 2023 Feb;127:69-76. doi: 10.1016/j.ijid.2022.11.028. Epub 2022 Nov 28. PMID: 36455812

Global Distribution of O Serotypes and Antibiotic Resistance in Extraintestinal Pathogenic Escherichia coli Collected From the Blood of Patients With Bacteremia Across Multiple Surveillance Studies.
Weerdenburg E, Davies T, Morrow B, Zomer AL, Hermans P, Go O, Spiessens B, van den Hoven T, van Geet G, Aitabi M, DebRoy C, Dudley EG, Bonten M, Poolman J, Geurtsen J. Clin Infect Dis. 2023 Feb 8;76(3):e1236-e1243. doi: 10.1093/cid/ciac421. PMID: 35684979

Clinical differences in symptomology, characteristics, and risk factors in patients with post-acute sequelae of COVID-19: an experience from a tertiary-care academic center.
Munipalli B, Paul S, Mohabbat A, Siddiqui H, Li Z, Abu Dabrh AM. J Investig Med. 2023 Feb 9:10815589231153604. doi: 10.1177/10815589231153604. Online ahead of print. PMID: 36760093

NHP BurkPx: A multiplex serodiagnostic bead assay to monitor Burkholderia pseudomallei exposures in non-human primates.
Celona KR, Shannon AB, Sonderegger D, Yi J, Monroy FP, Allender C, Hornstra H, Barnes MB, Didier ES, Bohm RP, Phillippi-Falkenstein K, Sanford D, Keim P, Settles EW. PLoS Negl Trop Dis. 2023 Feb 8;17(2):e0011067. doi: 10.1371/journal.pntd.0011067. eCollection 2023 Feb. PMID: 36753522

QM/MM study of N501 involved intermolecular interaction between SARS-CoV-2 receptor binding domain and antibody of human origin.
Liu Y, Sulaiman HF, Johnson BR, Ma R, Gao Y, Fernando H, Amarasekara A, Ashley-Oyewole A, Fan H, Ingram HN, Briggs JM. Comput Biol Chem. 2023 Feb;102:107810. doi: 10.1016/j.compbiolchem.2023.107810. Epub 2023 Jan 4. PMID: 36610304

Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.
Chiu W, Schepers J, Francken T, Vangeel L, Abbasi K, Jochmans D, De Jonghe S, Thibaut HJ, Thiel V, Neyts J, Laporte M, Leyssen P. Antiviral Res. 2023 Feb;210:105506. doi: 10.1016/j.antiviral.2022.105506. Epub 2022 Dec 21. PMID: 36565756

Vaccine Coverage Associated With Ending a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Wave: A Retrospective Longitudinal Analysis.
Glatman-Freedman A, Feldman SF, Hershkovitz Y, Kaufman Z, Dichtiar R, Keinan-Boker L, Bromberg M. Clin Infect Dis. 2023 Feb 8;76(3):e207-e215. doi: 10.1093/cid/ciac524. PMID: 35762838

Different Interventions for COVID-19 Primary and Booster Vaccination? Effects of Psychological Factors and Health Policies on **Vaccine** Uptake.
Sprengholz P, Henkel L, Böhm R, Betsch C. Med Decis Making. 2023 Feb;43(2):239-251. doi: 10.1177/0272989X221138111. Epub 2022 Nov 19. PMID: 36404766

Interaction mode of hydroxypropyl-β-cyclodextrin with **vaccine** adjuvant components Tween 80 and Triton X-100 revealed by fluorescence increasing-quenching analysis.
Kurosawa Y, Goto S, Mitsuya K, Otsuka Y, Yokoyama H. Phys Chem Chem Phys. 2023 Feb 8. doi: 10.1039/d3cp00094j. Online ahead of print. PMID: 36753064

Factors Associated With Airline Cabin Crews' Influenza Vaccination Intention in the Workplace-based Setting.
Kim L, Kim GS, Lee KH, Kim J. Workplace Health Saf. 2023 Feb 1:21650799221151153. doi: 10.1177/21650799221151153. Online ahead of print. PMID: 36726296

Deletion of gene OV132 attenuates Orf virus more effectively than gene OV112.
Yamada Y, Chuang ST, Tseng CY, Liao GR, Liu SW, Tseng YY, Lin FY, Hsu WL. Appl Microbiol Biotechnol. 2023 Feb;107(2-3):835-851. doi: 10.1007/s00253-022-12323-0. Epub 2022 Dec 9. PMID: 36484827

Influence of deoxynivalenol-contaminated feed on the immune response of pigs after PRRSV vaccination and infection.
Pierron A, Vatzia E, Stadler M, Mair KH, Schmidt S, Stas MR, Dürlinger S, Kreutzmann H, Knecht C, Balka G, Lagler J, Zaruba M, Rümenapf T, Saalmüller A, Mayer E, Ladinig A, Gerner W. Arch Toxicol. 2023 Feb 13. doi: 10.1007/s00204-023-03449-9. Online ahead of print. PMID: 36781434

PI3K-Akt pathway-independent PIK3AP1 identified as a replication inhibitor of the African swine fever virus based on iTRAQ proteomic analysis.
Yang B, Yu H, Yang J, Zhang D, Shi X, Yang X, Zhao D, Yan W, Chen L, Chen G, Bie X, Liu X, Zheng H, Zhang K. Virus Res. 2023 Feb 10:199052. doi: 10.1016/j.virusres.2023.199052. Online ahead of print. PMID: 36775023

Uptake of HPV vaccination among boys after the introduction of gender-neutral HPV vaccination in Germany before and during the COVID-19 pandemic.
Wähner C, Hübner J, Meisel D, Schelling J, Zingel R, Mihm S, Wölle R, Reuschenbach M. Infection. 2023 Feb 10:1-12. doi: 10.1007/s15010-023-01978-0. Online ahead of print. PMID: 36763286

An algorithm to estimate the real time secondary infections in sub-urban bus travel: COVID-19 epidemic experience at Chennai Metropolitan city India.
Arumugam GR, Ambikapathy B, Krishnamurthy K, Kumar A, De Britto L. Virusdisease. 2023 Feb 2:1-11. doi: 10.1007/s13337-022-00804-9. Online ahead of print. PMID: 36747967

Outreach to the Veterans Crisis Line During the COVID-19 Pandemic: A Mixed-Methods Analysis.
Krishnamurti LS, Agha A, Iverson KM, Monteith LL, Dichter ME. Psychiatr Serv. 2023 Feb 1;74(2):142-147. doi: 10.1176/appi.ps.202200044. Epub 2022 Sep 6. PMID: 36065583

Suboptimal Serologic Immunity Against Poliomyelitis Among New Migrant Children in Greece Calls for Organized Action.
Ioannidou C, Galanis P, Voulgari-Kokota A, Dikalioti SK, Papachristidou S, Bozas E, Mentis A, Tsoumakas K, Pavlopoulou ID. J Immigr Minor Health. 2023 Feb;25(1):96-103. doi: 10.1007/s10903-022-01363-3. Epub 2022 Apr 20. PMID: 35441972

The Structural Basis of African Swine Fever Virus pS273R Protease Binding to E64 through Molecular Dynamics Simulations.
Lu G, Ou K, Jing Y, Zhang H, Feng S, Yang Z, Shen G, Liu J, Wu C, Wei S. Molecules. 2023 Feb 2;28(3):1435. doi: 10.3390/molecules28031435. PMID: 36771101

Efficacy of BCG Vaccination against COVID-19: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wen J, Liu Q, Tang D, He JQ. J Clin Med. 2023 Feb 1;12(3):1154. doi: 10.3390/jcm12031154. PMID: 36769802

Cryo-EM reveals binding of linoleic acid to SARS-CoV-2 spike glycoprotein, suggesting an antiviral treatment strategy.
Toelzer C, Gupta K, Berger I, Schaffitzel C. Acta Crystallogr D Struct Biol. 2023 Feb 1;79(Pt 2):111-121. doi: 10.1107/S2059798323000049. Epub 2023 Jan 20. PMID: 36762857

COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.
Gong X, Khan A, Wani MY, Ahmad A, Duse A. J Infect Public Health. 2023 Feb;16(2):233-249. doi: 10.1016/j.jiph.2022.12.019. Epub 2022 Dec 29. PMID: 36603376

Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls.
Kartnig F, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Hommer N, Mayer M, Hofer P, Hummel T, Deimel T, Geßl I, Puchner A, Kerschbaumer A, Thalhammer R, Handisurya A, Kain R, Winkler S, Smolen JS, Stiasny K, Perkmann T, Haslacher H, Aberle JH, Aletaha D, Heinz LX, Sieghart D, Bonelli M. Ann Rheum Dis. 2023 Feb;82(2):292-300. doi: 10.1136/ard-2022-222682. Epub 2022 Sep 15. PMID: 36109141

Vaccination against SARS-CoV-2 and risk of hospital admission and death among infected cancer patients: A population-based study in northern Italy.
Gobbato M, Clagnan E, Toffolutti F, Del Zotto S, Burba I, Tosolini F, Polimeni J, Serraino D, Taborelli M. Cancer Epidemiol. 2023 Feb;82:102318. doi: 10.1016/j.canep.2022.102318. Epub 2022 Dec 19. PMID: 36566579

Immunodominant T cell peptides from four candidate malarial antigens as biomarkers of protective immunity against malaria.
Belmonte M, Ganeshan H, Huang J, Belmonte A, Inoue S, Velasco R, Acheampong N, Ofori EA, Akyea-Mensah K, Frimpong A, Ennuson NA, Frempong AF, Kyei-Baafour E, Amoah LE, Edgel K, Peters B, Villasante E, Kusi KA, Sedegah M. Vaccine. 2023 Feb 3;41(6):1265-1273. doi: 10.1016/j.vaccine.2023.01.016. Epub 2023 Jan 13. PMID: 36642628

Anti-varicella-zoster virus antibody titers and seroprotection status from before the first dose of varicella vaccination to before entering elementary school in one region in Japan.
Ozaki T, Nishimura N, Gotoh K, Takemoto K. Vaccine. 2023 Feb 3;41(6):1274-1279. doi: 10.1016/j.vaccine.2023.01.010. Epub 2023 Jan 9. PMID: 36631357

Attenuated humoral response against SARS-CoV-2 mRNA vaccination in allogeneic stem cell transplantation recipients.
Toya T, Atsuta Y, Sanada T, Honda T, Sadato D, Sekiya N, Kogure H, Takakuwa S, Onai D, Shingai N, Shimizu H, Najima Y, Kobayashi T, Ohashi K, Harada Y, Kohara M, Doki N. Cancer Sci. 2023 Feb;114(2):586-595. doi: 10.1111/cas.15603. Epub 2022 Oct 9. PMID: 36161681

HPV Knowledge Retention and Concurrent Increase in Vaccination Rates 1.5 Years After a Novel HPV Workshop in Medical School.
Sutton S, Azar SS, Evans LK, Murtagh A, McCarthy C, John MS. J Cancer Educ. 2023 Feb;38(1):240-247. doi: 10.1007/s13187-021-02106-y. Epub 2021 Oct 20. PMID: 34669178

Concurrence of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura: a case report and review of the literature.
Lin HC, Huang J, Huang J, Zhang LJ, Yin XW, Yang JC, Huang XY. J Med Case Rep. 2023 Feb 8;17(1):38. doi: 10.1186/s13256-023-03762-y. PMID: 36750960

Incidence and predictors of breakthrough and severe breakthrough infections of SARS-CoV-2 after primary series vaccination in adults: A population-based survey of 22,575 participants.
DeSantis SM, Yaseen A, Hao T, León-Novelo L, Talebi Y, Valerio-Shewmaker MA, Pinzon Gomez CL, Messiah SE, Kohl HW, Kelder SH, Ross JA, Padilla LN, Silberman M, Tuzo S, Lakey D, Shuford JA, Pont SJ, Boerwinkle E, Swartz MD. J Infect Dis. 2023 Feb 2:jiad020. doi: 10.1093/infdis/jiad020. Online ahead of print. PMID: 36729177

Preparation of chitosan nanoparticle containing recombinant CD44v antigen and evaluation of its immunization capacity against breast cancer in BALB/c mice.
Gheybi E, Asoodeh A, Amani J. BMC Cancer. 2023 Feb 9;23(1):134. doi: 10.1186/s12885-023-10614-x. PMID: 36759786

Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches.
Khan A, Imran K, Zhu G, Ji J, Zhang Y, Guan X, Ge G, Heng W, Wei DQ. J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28542. Online ahead of print. PMID: 36727647

Relative Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Vaccinated and Unvaccinated Individuals Hospitalized With SARS-CoV-2.

Grima AA, Murison KR, Simmons AE, Tuite AR, Fisman DN. Clin Infect Dis. 2023 Feb 8;76(3):e409-e415. doi: 10.1093/cid/ciac412. PMID: 35616115

The use of representative community samples to assess SARS-CoV-2 lineage competition: Alpha outcompetes Beta and wild-type in England from January to March 2021.
Eales O, Page AJ, Tang SN, Walters CE, Wang H, Haw D, Trotter AJ, Le Viet T, Foster-Nyarko E, Prosolek S, Atchison C, Ashby D, Cooke G, Barclay W, Donnelly CA, O'Grady J, Volz E, The Covid-Genomics Uk Cog-Uk Consortium, Darzi A, Ward H, Elliott P, Riley S. Microb Genom. 2023 Feb;9(2). doi: 10.1099/mgen.0.000887. PMID: 36745545

Perceptions and Cues to Action as Predictors of Nurses' Vaccination Intentions at Two Primary Health Care Facilities in Ghana.
Tagbor S, Ohene LA, Adjei CA, Kyei J. Am J Trop Med Hyg. 2022 Dec 19;108(2):433-440. doi: 10.4269/ajtmh.21-1335. Print 2023 Feb 1. PMID: 36535250

Experiences, risk perceptions, and COVID-19 vaccination outcomes among hospital workers.
Wagner AL, Moniz MH, Stout MJ, Townsel C, Hawley ST, Zikmund-Fisher BJ. Vaccine. 2023 Feb 3;41(6):1247-1253. doi: 10.1016/j.vaccine.2023.01.012. Epub 2023 Jan 9. PMID: 36639271

Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study.
Singh A, De A, Singh MP, Rathi S, Verma N, Premkumar M, Taneja S, Duseja A, Singh V. Dig Dis Sci. 2023 Feb;68(2):676-684. doi: 10.1007/s10620-022-07641-2. Epub 2022 Sep 25. PMID: 36156752

Viral Dynamics of Omicron and Delta Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants With Implications for Timing of Release from Isolation: A Longitudinal Cohort Study.
Bouton TC, Atarere J, Turcinovic J, Seitz S, Sher-Jan C, Gilbert M, White L, Zhou Z, Hossain MM, Overbeck V, Doucette-Stamm L, Platt J, Landsberg HE, Hamer DH, Klapperich C, Jacobson KR, Connor JH. Clin Infect Dis. 2023 Feb 8;76(3):e227-e233. doi: 10.1093/cid/ciac510. PMID: 35737948

SARS-CoV-2 BA.2 (Omicron) variant infection in pediatric liver transplanted recipients and cohabitants during 2022 Shanghai outbreak: a prospective cohort.
Zhu XY, Lu YF, Xue F, Luo Y, Feng MX, Qiu BJ, Zhou T, Zhu JJ, Zhang JJ, Wan P, Xia Q. Virol J. 2023 Feb 11;20(1):28. doi: 10.1186/s12985-023-01978-4. PMID: 36774503

Safety Profiles of mRNA COVID-19 Vaccines Using World Health Organization Global Scale Database (VigiBase): A Latent Class Analysis.
Lee MT, Choi W, You SH, Park S, Kim JY, Nam DR, Lee JW, Jung SY. Infect Dis Ther. 2023 Feb;12(2):443-458. doi: 10.1007/s40121-022-00742-5. Epub 2022 Dec 15. PMID: 36520333

Co-creation of information materials within the assent process: From theory to practice.
Fons-Martinez J, Ferrer-Albero C, Diez-Domingo J. Health Expect. 2023 Feb;26(1):429-439. doi: 10.1111/hex.13675. Epub 2022 Nov 23. PMID: 36416386

Demographic and Clinical Predictors of Pharmacist-Administered Pediatric Influenza Immunization.
Gates DM, Cohen SA, Orr K, Caffrey AR. J Pharm Pract. 2023 Feb 1:8971900231155223. doi: 10.1177/08971900231155223. Online ahead of print. PMID: 36724433

Vaccine target and carrier molecule nontypeable Haemophilus influenzae protein D dimerizes like the close Escherichia coli GlpQ homolog but unlike other known homolog dimers.
Jones SP, Cook KH, Holmquist ML, Almekinder LJ, Delaney AM, Charles R, Labbe N, Perdue J, Jackson N, Pichichero ME, Kaur R, Michel LV, Gleghorn ML. Proteins. 2023 Feb;91(2):161-170. doi: 10.1002/prot.26418. Epub 2022 Sep 16. PMID: 36065600

COVID-19 Associated Fulminant Myocarditis in a Fully-Vaccinated Female: A Case Report with Clinical Follow-up.
Samimisedeh P, Sehati F, Jafari Afshar E. Clin Med Insights Case Rep. 2023 Feb 8;16:11795476221147238. doi: 10.1177/11795476221147238. eCollection 2023. PMID: 36776728

School immunization coverage in adolescents during the COVID-19 pandemic: A retrospective cohort study.
Sell H, Raj Paudel Y, Voaklander D, MacDonald SE. Vaccine. 2023 Feb 10;41(7):1333-1341. doi: 10.1016/j.vaccine.2023.01.011. Epub 2023 Jan 9. PMID: 36642632

Field investigation of high reported non-neonatal tetanus burden in Uganda, 2016-2017.
Casey RM, Nguna J, Opar B, Ampaire I, Lubwama J, Tanifum P, Zhu BP, Kisakye A, Kabwongera E, Tohme RA, Dahl BA, Ridpath AD, Scobie HM. Int J Epidemiol. 2023 Feb 10:dyad005. doi: 10.1093/ije/dyad005. Online ahead of print. PMID: 36762894

Expression of TIGIT, PD-1 and HLA-DR/CD38 markers on CD8-T cells of children and adolescents infected with HIV and uninfected controls.
Pereira-Manfro WF, Silva GPD, Costa PR, Costa DA, Ferreira BDS, Barreto DM, Frota ACC, Hofer CB, Kallas EG, Milagres LG. Rev Inst Med Trop Sao Paulo. 2023 Feb 6;65:e14. doi: 10.1590/S1678-9946202365014. eCollection 2023. PMID: 36753067

In vitro culture of the zoonotic nematode Anisakis pegreffii (Nematoda, Anisakidae).
Mladineo I, Charouli A, Jelić F, Chakroborty A, Hrabar J. Parasit Vectors. 2023 Feb 2;16(1):51. doi: 10.1186/s13071-022-05629-5. PMID: 36732837

Persistent short nighttime sleep duration is associated with a greater post-COVID risk in fully mRNA-vaccinated individuals.
Xue P, Merikanto I, Chung F, Morin CM, Espie C, Bjorvatn B, Cedernaes J, Landtblom AM, Penzel T, De Gennaro L, Holzinger B, Matsui K, Hrubos-Strøm H, Korman M, Leger D, Mota-Rolim S, Bolstad CJ, Nadorff M, Plazzi G, Reis C, Chan RNY, Wing YK, Yordanova J, Bjelajac AK, Inoue Y, Partinen M, Dauvilliers Y, Benedict C. Transl Psychiatry. 2023 Feb 1;13(1):32. doi: 10.1038/s41398-023-02334-4. PMID: 36726008

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study.
Iavarone M, Tosetti G, Facchetti F, Topa M, Er JM, Hang SK, Licari D, Lombardi A, D'Ambrosio R, Degasperi E, Loglio A, Oggioni C, Perbellini R, Caccia R, Bandera A, Gori A, Ceriotti F, Scudeller L, Bertoletti A, Lampertico P. Dig Liver Dis. 2023 Feb;55(2):160-168. doi: 10.1016/j.dld.2022.09.010. Epub 2022 Oct 17. PMID: 36266209

Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccination During Pregnancy: Impact on Infant Anti-Pertussis Antibody Concentrations by Maternal Pertussis Priming Series.
Havers FP, Skoff TH, Rench MA, Epperson M, Rajam G, Schiffer J, Hariri S, Swaim LS, Baker CJ, Healy CM. Clin Infect Dis. 2023 Feb 8;76(3):e1087-e1093. doi: 10.1093/cid/ciac432. PMID: 35642525

Estimating the prevalence of Epstein-Barr virus in primary gastric lymphoma: a systematic review and meta-analysis.
Hirabayashi M, Traverse-Glehen A, Combes JD, Clifford GM, de Martel C. Infect Agent Cancer. 2023 Feb 10;18(1):8. doi: 10.1186/s13027-023-00482-2. PMID: 36765388

Creating a Comprehensive Pandemic Response to Decrease Hospitalist Burnout During COVID-19: Intervention vs Control Results in 2 Comparable Hospitals (HOSP-CPR).
James TT, Hudon R, Merrick T, Olson L, Hanes D, Scanlan JM. J Gen Intern Med. 2023 Feb 10:1-8. doi: 10.1007/s11606-023-08041-6. Online ahead of print. PMID: 36764984

The Incidence of Myocarditis Following an Influenza Vaccination: A Population-Based Observational Study.
Wang WH, Wei KC, Huang YT, Huang KH, Tsai TH, Chang YC. Drugs Aging. 2023 Feb;40(2):145-151. doi: 10.1007/s40266-022-00997-0. Epub 2023 Jan 10. PMID: 36626028

The Nicaraguan Pediatric Influenza Cohort Study, 2011-2019: Influenza Incidence, Seasonality, and Transmission.
Maier HE, Kuan G, Gresh L, Chowell G, Bakker K, Lopez R, Sanchez N, Lopez B, Schiller A, Ojeda S, Harris E, Balmaseda A, Gordon A. Clin Infect Dis. 2023 Feb 8;76(3):e1094-e1103. doi: 10.1093/cid/ciac420. PMID: 35639580

Immunisation rates and predictors of undervaccination in infants with CHD.
Murray AM, Lee GM, Brown DW, Saia TA, Gongwer R, Nakamura MM. Cardiol Young. 2023 Feb;33(2):242-247. doi: 10.1017/S104795112200052X. Epub 2022 Apr 12. PMID: 35411845

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study.
Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordoni V, Sacchi A, Matusali G, Salvarani C, Zinzani PL, Mantegazza R, Tagliavini F, Lupo-Stanghellini MT, Ciceri F, Damian S, Uccelli A, Fenoglio D, Silvestris N, Baldanti F, Piaggio G, Ciliberto G, Morrone A, Locatelli F, Sinno V, Rescigno M, Costantini M; VAX4FRAIL Study Group. Clin Infect Dis. 2023 Feb 8;76(3):e426-e438. doi: 10.1093/cid/ciac404. PMID: 35607769

Mortality risk model validation in a prospective cohort of patients from the sixth wave of the COVID-19 pandemic in a hospital emergency department.
Fresco L, Osorio G, Marco DN, Artajona L, Sempertegui D, Piñango D, Demidenoka N, García-Gozalbes J, Carbó M, Perea M, Ortega Romero MDM; Grupo de Trabajo sobre la atención de la COVID-19 en Urgencias (COVID19-URG). Emergencias. 2023 Feb;35(1):15-24. PMID: 36756912

Exploring monitoring strategies for population surveillance of HPV **vaccine** impact using primary HPV screening.

Velentzis LS, Hawkes D, Caruana M, Brotherton JM, Smith MA, Roeske L, Karim KA, Garland SM, Wrede CD, Tan J, Wheeler C, Castle PE, Saville M, Canfell K. Tumour Virus Res. 2023 Feb 1;15:200255. doi: 10.1016/j.tvr.2023.200255. Online ahead of print. PMID: 36736490

Using *Entamoeba muris* To Model Fecal-Oral Transmission of *Entamoeba* in Mice.
Mendoza Cavazos C, Heredia MY, Owens LA, Knoll LJ. mBio. 2023 Feb 6:e0300822. doi: 10.1128/mbio.03008-22. Online ahead of print. PMID: 36744962

Cost-effectiveness of monoclonal antibody and maternal immunization against respiratory syncytial virus (RSV) in infants: Evaluation for six European countries.
Getaneh AM, Li X, Mao Z, Johannesen CK, Barbieri E, van Summeren J, Wang X, Tong S, Baraldi E, Phijffer E, Rizzo C, van Wijhe M, Heikkinen T, Bont L, Willem L, Jit M, Beutels P, Bilcke J; for Respiratory Syncytial Virus Consortium in Europe (RESCEU) investigators. Vaccine. 2023 Feb 1:S0264-410X(23)00092-0. doi: 10.1016/j.vaccine.2023.01.058. Online ahead of print. PMID: 36737318

Social and demographic patterns of influenza vaccination coverage in Norway, influenza seasons 2014/15 to 2020/21.
Klüwer B, Margrethe Rydland K, Nybru Gleditsch R, Mamelund SE, Laake I. Vaccine. 2023 Feb 3;41(6):1239-1246. doi: 10.1016/j.vaccine.2023.01.013. Epub 2023 Jan 11. PMID: 36639272

Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study.
Patel NJ, Wang X, Fu X, Kawano Y, Cook C, Vanni KMM, Qian G, Banasiak E, Kowalski E, Zhang Y, Sparks JA, Wallace ZS. Semin Arthritis Rheum. 2023 Feb;58:152108. doi: 10.1016/j.semarthrit.2022.152108. Epub 2022 Oct 26. PMID: 36347211

Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis.
Li P, Wang W, Tao Y, Tan X, Li Y, Mao Y, Gao L, Feng L, Zhan S, Sun F. Chin Med J (Engl). 2023 Feb 2. doi: 10.1097/CM9.0000000000002567. Online ahead of print. PMID: 36723872

Effects of Aluminum Oxide Nanoparticles in the Cerebrum, Hippocampus, and Cerebellum of Male Wistar Rats and Potential Ameliorative Role of Melatonin.
Abdelhameed NG, Ahmed YH, Yasin NAE, Mahmoud MY, El-Sakhawy MA. ACS Chem Neurosci. 2023 Feb 1;14(3):359-369. doi: 10.1021/acschemneuro.2c00406. Epub 2023 Jan 23. PMID: 36689351

Group A streptococcal disease in paediatric inpatients: a European perspective.
Boeddha NP, Atkins L, de Groot R, Driessen G, Hazelzet J, Zenz W, Carrol ED, Anderson ST, Martinon-Torres F, Agyeman PKA, Galassini R, Herberg J, Levin M, Schlapbach LJ, Emonts M; EUCLIDS consortium. Eur J Pediatr. 2023 Feb;182(2):697-706. doi: 10.1007/s00431-022-04718-y. Epub 2022 Nov 30. PMID: 36449079

Risk factors associated with self-reported Q fever in Australian wildlife rehabilitators: Findings from an online survey.
Mathews KO, Savage C, Norris JM, Phalen D, Malikides N, Sheehy PA, Bosward KL. Zoonoses Public Health. 2023 Feb;70(1):69-80. doi: 10.1111/zph.13002. Epub 2022 Oct 12. PMID: 36225093

Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis.

Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein LH, Saliba W. Clin Infect Dis. 2023 Feb 8;76(3):453-460. doi: 10.1093/cid/ciac781. PMID: 36130189

Effects of anti-stress agents on the growth performance and immune function in broiler chickens with vaccination-induced stress.
Wang X, Liu X, Liu S, Qu J, Ye M, Wang J, Li X, Yuan Z, Wu J, Yi J, Wen L, Li R. Avian Pathol. 2023 Feb;52(1):12-24. doi: 10.1080/03079457.2022.2114874. Epub 2022 Dec 6. PMID: 35980124

Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant.
Sanders JF, Messchendorp AL, de Vries RD, Baan CC, van Baarle D, van Binnendijk R, Diavatopoulos DA, Geers D, Schmitz KS, GeurtsvanKessel CH, den Hartog G, Kho MML, Koopmans MPG, van der Molen RG, Remmerswaal EBM, Rots N, Gansevoort RT, Bemelman FJ, Hilbrands LB, Reinders MEJ; VACcination Immune Response Study (RECOVAC) Collaborators. Clin Infect Dis. 2023 Feb 8;76(3):e188-e199. doi: 10.1093/cid/ciac557. PMID: 35796536

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients.
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein LH, Saliba W. Clin Infect Dis. 2023 Feb 8;76(3):e342-e349. doi: 10.1093/cid/ciac443. PMID: 35653428

Relationship between asthma and severe COVID-19: a national cohort study.
Dolby T, Nafilyan V, Morgan A, Kallis C, Sheikh A, Quint JK. Thorax. 2023 Feb;78(2):120-127. doi: 10.1136/thoraxjnl-2021-218629. Epub 2022 Mar 30. PMID: 35354646

Association of sleep duration and quality with immunological response after vaccination against severe acute respiratory syndrome coronavirus-2 infection.
Athanasiou N, Baou K, Papandreou E, Varsou G, Amfilochiou A, Kontou E, Pataka A, Porpodis K, Tsiouprou I, Kaimakamis E, Kotoulas SC, Katsibourlia E, Alexopoulou C, Bouloukaki I, Panagiotarakou M, Dermitzaki A, Charokopos N, Pagdatoglou K, Lamprou K, Pouriki S, Chatzivasiloglou F, Nouvaki Z, Tsirogianni A, Kalomenidis I, Katsaounou P, Vagiakis E. J Sleep Res. 2023 Feb;32(1):e13656. doi: 10.1111/jsr.13656. Epub 2022 Jun 7. PMID: 35670298

Increased COVID-19 Infection Risk Drives Racial and Ethnic Disparities in Severe COVID-19 Outcomes.
Shortreed SM, Gray R, Akosile MA, Walker RL, Fuller S, Temposky L, Fortmann SP, Albertson-Junkans L, Floyd JS, Bayliss EA, Harrington LB, Lee MH, Dublin S. J Racial Ethn Health Disparities. 2023 Feb;10(1):149-159. doi: 10.1007/s40615-021-01205-2. Epub 2022 Jan 24. PMID: 35072944

No association of malignant B-cell non-Hodgkin lymphomas with ipsilateral SARS-CoV-2 vaccination.
Claaß LV, Mayr P, Paschold L, Weber T, Terziev D, Jehs B, Brill R, Dober J, Märkl B, Wickenhauser C, Czapiewski P, Trepel M, Claus R, Binder M. Cancer Med. 2023 Feb 12. doi: 10.1002/cam4.5687. Online ahead of print. PMID: 36775947

Does prior vaccination affect the immune response to seasonal influenza vaccination among older adults? Findings from a prospective cohort study in a Northeastern Province of Thailand.

Praphasiri P, Prasert K, Shrestha M, Ditsungnoen D, Chittaganpich M, Chawalchitiporn S, Dawood FS, Sirilak S, Mott JA. PLoS One. 2023 Feb 3;18(2):e0279962. doi: 10.1371/journal.pone.0279962. eCollection 2023. PMID: 36735691

Validation of ASCL1 and LHX8 Methylation Analysis as Primary Cervical Cancer Screening Strategy in South African Women with Human Immunodeficiency Virus.
Vink FJ, Meijer CJLM, Lissenberg-Witte BI, Visser C, Duin S, Snyman LC, Richter KL, van der Merwe FH, Botha MH, Steenbergen RDM, Dreyer G. Clin Infect Dis. 2023 Feb 8;76(3):416-423. doi: 10.1093/cid/ciac801. PMID: 36366827

The association of neonatal SARS-CoV-2 anti-spike protein receptor-binding domain antibodies at delivery with infant COVID-19 infection under age 6 months: a prospective cohort study.
Oz-Alkalay L, Elron E, Davidovits R, Chodick G, Osovsky M, Chen R, Ashkenazi-Hoffnung L. Clin Microbiol Infect. 2023 Feb 3:S1198-743X(23)00048-4. doi: 10.1016/j.cmi.2023.01.023. Online ahead of print. PMID: 36739973

Evaluation of SARS-CoV-2 antibody persistence and viral spread in stool: a long-term care experience before COVID-19 vaccination.
Eren-Kutsoylu OO, Appak O, Nazli-Zeka A, Omeroglu-Simsek G, Tekin N, Bayram B, Sayiner AA, Tanglay N, Avkan-Oguz V. Ir J Med Sci. 2023 Feb;192(1):263-268. doi: 10.1007/s11845-022-03095-7. Epub 2022 Jul 12. PMID: 35829907

Unmasking Pneumococcal Carriage in a High Human Immunodeficiency Virus (HIV) Prevalence Population in two Community Cohorts in South Africa, 2016-2018: The PHIRST Study.
Carrim M, Tempia S, Thindwa D, Martinson NA, Kahn K, Flasche S, Hellferscee O, Treurnicht FK, McMorrow ML, Moyes J, Mkhencele T, Mathunjwa A, Kleynhans J, Lebina L, Mothlaoleng K, Wafawanaka F, Gómez-Olivé FX, Cohen C, von Gottberg A, Wolter N; PHIRST group. Clin Infect Dis. 2023 Feb 8;76(3):e710-e717. doi: 10.1093/cid/ciac499. PMID: 35717655

Recent developments in the immunopathology of COVID-19.
Zhang HP, Sun YL, Wang YF, Yazici D, Azkur D, Ogulur I, Azkur AK, Yang ZW, Chen XX, Zhang AZ, Hu JQ, Liu GH, Akdis M, Akdis CA, Gao YD. Allergy. 2023 Feb;78(2):369-388. doi: 10.1111/all.15593. Epub 2022 Dec 5. PMID: 36420736

Rates of and Factors Associated With Primary and Booster COVID-19 **Vaccine** Receipt by US Veterans, December 2020 to June 2022.
Bajema KL, Rowneki M, Berry K, Bohnert A, Bowling CB, Boyko EJ, Iwashyna TJ, Maciejewski ML, O'Hare AM, Osborne TF, Viglianti EM, Hynes DM, Ioannou GN. JAMA Netw Open. 2023 Feb 1;6(2):e2254387. doi: 10.1001/jamanetworkopen.2022.54387. PMID: 36729454

Prospective study of loss of health-related quality adjusted life years in children and their families due to uncomplicated and hospitalised varicella.
Rodrigues F, Marlow R, Gouveia C, Correia P, Brett A, Silva C, Gameiro I, Rua I, Dias J, Martins M, Diogo R, Lopes T, Hipólito E, Moreira D, Costa Alves M, Prata F, Labrusco M, Gomes S, Fernandes A, Andrade A, Granjo Morais C, João Virtuoso M, Manuel Zarcos M, Teresa Raposo A, Boon A, Finn A. Vaccine. 2023 Feb 3;41(6):1182-1189. doi: 10.1016/j.vaccine.2022.12.011. Epub 2022 Dec 13. PMID: 36522267

Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus-Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Aggarwal C, Saba NF, Algazi A, Sukari A, Seiwert TY, Haigentz M, Porosnicu M, Bonomi M, Boyer J, Esser MT, Cheng LI, Agrawal S, Jennings EC, Durham NM, Fraser K, Lissa D, Gong M, Ceaicovscaia N, Gascó Hernández A, Kumar R. Clin Cancer Res. 2023 Feb 1;29(3):560-570. doi: 10.1158/1078-0432.CCR-22-1987. PMID: 36455147

COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
Johnson AG, Linde L, Ali AR, DeSantis A, Shi M, Adam C, Armstrong B, Armstrong B, Asbell M, Auche S, Bayoumi NS, Bingay B, Chasse M, Christofferson S, Cima M, Cueto K, Cunningham S, Delgadillo J, Dorabawila V, Drenzek C, Dupervil B, Durant T, Fleischauer A, Hamilton R, Harrington P, Hicks L, Hodis JD, Hoefer D, Horrocks S, Hoskins M, Husain S, Ingram LA, Jara A, Jones A, Kanishka FNU, Kaur R, Khan SI, Kirkendall S, Lauro P, Lyons S, Mansfield J, Markelz A, Masarik J 3rd, McCormick D, Mendoza E, Morris KJ, Omoike E, Patel K, Pike MA, Pilishvili T, Praetorius K, Reed IG, Severson RL, Sigalo N, Stanislawski E, Stich S, Tilakaratne BP, Turner KA, Wiedeman C, Zaldivar A, Silk BJ, Scobie HM. MMWR Morb Mortal Wkly Rep. 2023 Feb 10;72(6):145-152. doi: 10.15585/mmwr.mm7206a3. PMID: 36757865

Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2-18 years: an updated systematic review and meta-analysis.
Gao P, Kang LY, Liu J, Liu M. World J Pediatr. 2023 Feb 1:1-14. doi: 10.1007/s12519-022-00680-9. Online ahead of print. PMID: 36723827

Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: Onset Following Acute COVID-19 Infection, a Case Series.
Avila M, Tan Y, Hernandez R, Zuberi H, Rivera VM. Neurol Ther. 2023 Feb;12(1):319-327. doi: 10.1007/s40120-022-00418-9. Epub 2022 Nov 18. PMID: 36399224

Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: Real world data analysis from Thailand.
Srisubat A, Thanasitthichai S, Kongsaengdao S, Maneeton N, Maneeton B, Akksilp S. Lancet Reg Health Southeast Asia. 2023 Feb 7:100166. doi: 10.1016/j.lansea.2023.100166. Online ahead of print. PMID: 36776761

Effects of Medicare eligibility and enrollment at age 65 years on the use of high-value and low-value care.
Park S, Wadhera RK, Jung J. Health Serv Res. 2023 Feb;58(1):174-185. doi: 10.1111/1475-6773.14065. Epub 2022 Sep 23. PMID: 36106508

Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis.
Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Vaccine. 2023 Feb 8:S0264-410X(23)00134-2. doi: 10.1016/j.vaccine.2023.02.008. Online ahead of print. PMID: 36774332

Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022.

Wiegand RE, Deng Y, Deng X, Lee A, Meyer WA 3rd, Letovsky S, Charles MD, Gundlapalli AV, MacNeil A, Hall AJ, Thornburg NJ, Jones J, Iachan R, Clarke KEN. Lancet Reg Health Am. 2023 Feb;18:100403. doi: 10.1016/j.lana.2022.100403. Epub 2022 Dec 2. PMID: 36479424

Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis.
Guo Y, Cao XS, Yang HT, Zhou MG, Yu B. J Glob Health. 2023 Feb 10;13:06008. doi: 10.7189/jogh.13.06008. PMID: 36757823

Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study.
Evans A, Qi C, Adebayo JO, Underwood J, Coulson J, Bailey R, Lyons R, Edwards A, Cooper A, John G, Akbari A. J Infect. 2023 Feb 9:S0163-4453(23)00082-8. doi: 10.1016/j.jinf.2023.02.012. Online ahead of print. PMID: 36773891

Engagement With and Acceptability of Digital Media Platforms for Use in Improving Health Behaviors Among Vulnerable Families: Systematic Review.
Eppes EV, Augustyn M, Gross SM, Vernon P, Caulfield LE, Paige DM. J Med Internet Res. 2023 Feb 3;25:e40934. doi: 10.2196/40934. PMID: 36735286

Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Macedo Silva V, Lima Capela T, Freitas M, Cúrdia Gonçalves T, Boal Carvalho P, Dias de Castro F, João Moreira M, Cotter J. Inflamm Bowel Dis. 2023 Feb 1;29(2):268-273. doi: 10.1093/ibd/izac187. PMID: 36099059

Patterns in the Prevalence of Unvaccinated Children Across 36 States and Union Territories in India, 1993-2021.
Rajpal S, Kumar A, Johri M, Kim R, Subramanian SV. JAMA Netw Open. 2023 Feb 1;6(2):e2254919. doi: 10.1001/jamanetworkopen.2022.54919. PMID: 36763362

Circulation of Rhinoviruses and/or Enteroviruses in Pediatric Patients With Acute Respiratory Illness Before and During the COVID-19 Pandemic in the US.
Rankin DA, Spieker AJ, Perez A, Stahl AL, Rahman HK, Stewart LS, Schuster JE, Lively JY, Haddadin Z, Probst V, Michaels MG, Williams JV, Boom JA, Sahni LC, Staat MA, Schlaudecker EP, McNeal MM, Harrison CJ, Weinberg GA, Szilagyi PG, Englund JA, Klein EJ, Gerber SI, McMorrow M, Rha B, Chappell JD, Selvarangan R, Midgley CM, Halasa NB; NVSN Network Investigators. JAMA Netw Open. 2023 Feb 1;6(2):e2254909. doi: 10.1001/jamanetworkopen.2022.54909. PMID: 36749589

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Khoo SH, FitzGerald R, Saunders G, Middleton C, Ahmad S, Edwards CJ, Hadjiyiannakis D, Walker L, Lyon R, Shaw V, Mozgunov P, Periselneris J, Woods C, Bullock K, Hale C, Reynolds H, Downs N, Ewings S, Buadi A, Cameron D, Edwards T, Knox E, Donovan-Banfield I, Greenhalf W, Chiong J, Lavelle-Langham L, Jacobs M, Northey J, Painter W, Holman W, Lalloo DG, Tetlow M, Hiscox JA, Jaki T, Fletcher T, Griffiths G; AGILE CST-2 Study Group. Lancet Infect Dis. 2023 Feb;23(2):183-195. doi: 10.1016/S1473-3099(22)00644-2. Epub 2022 Oct 19. PMID: 36272432

Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis.
Hamada Y, Gupta RK, Quartagno M, Izzard A, Acuna-Villaorduna C, Altet N, Diel R, Dominguez J, Floyd S, Gupta A, Huerga H, Jones-López EC, Kinikar A, Lange C, van Leth F, Liu Q, Lu W, Lu P, Rueda IL, Martinez L, Mbandi SK, Muñoz L, Padilla ES, Paradkar M, Scriba T, Sester M, Shanaube K, Sharma SK, Sloot R, Sotgiu G, Thiruvengadam K, Vashishtha R, Abubakar I, Rangaka MX. EClinicalMedicine. 2023 Jan 5;56:101815. doi: 10.1016/j.eclinm.2022.101815. eCollection 2023 Feb. PMID: 36636295

Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-*O*-gallate (EGCG) in SARS-CoV-2 infection: Major interactions with host/virus proteases.
Dinda B, Dinda S, Dinda M. Phytomed Plus. 2023 Feb;3(1):100402. doi: 10.1016/j.phyplu.2022.100402. Epub 2022 Dec 30. PMID: 36597465

COVID-19-related uncertainty: fertility staff experiences of its sources, processing, responses, and consequences.
Gameiro S, Armstrong K, Carluke N, Baccino G, Zegers-Hochschild F, Boivin J. Hum Reprod. 2023 Feb 1;38(2):247-255. doi: 10.1093/humrep/deac262. PMID: 36534892

Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20230201:20230214 as the publication date 73 records*

1.4129326REKOMBINANTES PROTEIN KASTRIEREN ODER STERILISIEREN VON TIEREN UND DIESE ENTHALTENDE IMPFSTOFFZUSAMMENSETZUNG
EP - 08.02.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 21775220 Solicitante BIOAPPLICATIONS INC Inventor/a SOHN EUN-JU
The present invention relates to a vaccine composition which is form neutering or spaying an animal and comprises a recombinant protein in which cholera toxin B subunit (CTB) and gonadotropin-releasing hormone (GnRH) are fused. More specifically, provided are: a recombinant protein for neutering or spaying an animal and for inducing antibodies against GnRH; a recombinant vector for producing the recombinant protein; a vaccine composition for neutering or spaying an animal, the vaccine composition comprising the recombinant protein; and a method for neutering or spaying an animal by using the vaccine composition. The vaccine composition according to the present invention induces antibodies against GnRH in an individual, thereby atrophying the ovaries or testes thereof. Therefore, the present invention can, at low cost, a high level of safety, and with minimal side effects, replace surgical procedures for neutering and spaying, and be beneficially used to neuter or spay an animal.

2.WO/2023/0107843D-PRINTED TUMOR VACCINE COMPOSITION, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
WO - 09.02.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/CN2021/141918 Solicitante SOOCHOW UNIVERSITY Inventor/a WANG, Chao
Disclosed in the present invention are a 3D-printed tumor vaccine composition, a preparation method therefor, and an application thereof. According to the tumor vaccine composition of the present invention,

a vaccine preparation containing a tumor antigen and a biosafety macromolecular material are prepared into 3D printing ink, and the tumor vaccine composition of a porous structure is prepared by means of 3D printing, wherein the porous structure is that a plurality of pores having the pore diameter of 1-10 μm are formed in the surface and the interior of the tumor vaccine composition.

3.WO/2023/005486EBV COMPOSITE ANTIGEN, DENDRITIC CELL VACCINE AND USE THEREOF
WO - 02.02.2023
Clasificación Internacional A61K 39/245 Nº de solicitud PCT/CN2022/099296 Solicitante SHANGHAI HENGSAI BIOLOGICAL TECHNOLOGY CO., LTD. Inventor/a LIU, Helen
Provided are an EBV composite antigen, a dendritic cell vaccine and the use thereof for preparing an EBV-related infectious disease drug, which belong to the technical field of biomedicine. A dendritic cell of a patient is stimulated in vitro, loaded with a variety of EBV infected cell lysates with super-strong immunogenicity against EBV-associated infectious diseases, and induced to be mature under the conditions of a variety of cytokines and a specific agonist, so as to form a complete dendritic cell vaccine with a corresponding antigen; and the complete dendritic cell vaccine is transported back to a human body to activate the immune system, so as to generate a cytotoxic T cell and kill EBV infected cells. The dendritic cell vaccine exerts an immunological effect and improves the life quality of a patient. The preparation period thereof is about 1 week, and therefore the dendritic cell vaccine is short in time, low in cost, safe, and almost completely free of side effects.

4.WO/2023/013755CANCER PEPTIDE VACCINE COCKTAIL FORMULATION AMD METHOD FOR PRODUCING SAME
WO - 09.02.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/JP2022/030039 Solicitante BRIGHTPATH BIOTHERAPEUTICS CO., LTD. Inventor/a YOSHIMORI, Takayuki
The present invention addresses the problem of providing a cancer peptide vaccine cocktail formulation, from which a vaccine administration solution can be easily prepared while reducing wasteful disposal of a peptide-containing solution during the preparation of the vaccine administration solution and in which the solubilities of peptides in a solvent are improved, a method for producing the same, etc. A method for producing a cancer peptide vaccine cocktail formulation, said method comprising step (A) for adding a solvent with pH 2.5-4 to a composition containing a peptide of SEQ ID NO: 1, a peptide of SEQ ID NO: 2, a peptide of SEQ ID NO: 3 and a peptide of SEQ ID NO. 4.

5.WO/2023/007456A METHOD FOR PRODUCING COMPLEXES OF PROTEINS WITH BACTERIAL LIPOPOLYSACCHARIDES, THE USE THEREOF, A VACCINE COMPRISING AN LPS/PROTEIN IMMUNOGENIC COMPLEX AND A METHOD FOR PRODUCING THE VACCINE
WO - 02.02.2023
Clasificación Internacional A61K 39/02 Nº de solicitud PCT/IB2022/057067 Solicitante BIOVETIKA SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ Inventor/a LIPIŃSKI, Tomasz
The object of the invention is a method for producing bacterial lipopolysaccharide (LPS)/protein immune complexes, the use of the LPS/protein complex to induce an immune response, a method for producing a veterinary vaccine comprising the LPS/protein immune complex and a veterinary vaccine produced by this method.

6.4126039BEHANDLUNG MIT NICHTIMMUNOGENER RNA ZUR ANTIGENIMPFUNG
EP - 08.02.2023
Clasificación Internacional A61K 39/39 Nº de solicitud 21715268 Solicitante BIONTECH SE Inventor/a SAHIN UGUR
The present disclosure relates to methods and agents for antigen vaccination and inducing effective antigen-specific immune effector cell responses such as T cell responses. Specifically, the present

disclosure relates to methods comprising administering to a subject (i) non-immunogenic RNA encoding a peptide or protein comprising an epitope for inducing an immune response against an antigen in the subject, i.e., non-immunogenic RNA encoding vaccine antigen; and (ii) an immune stimulant or RNA encoding an immunostimulant. Administering to the subject non-immunogenic RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for stimulation, priming and/or expansion of immune effector cells and, thus, may induce an immune response against vaccine antigen (and disease-associated antigen) in the subject.

7.WO/2023/014853HPV VACCINE
WO - 09.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/US2022/039371 Solicitante MERCK SHARP & DOHME LLC Inventor/a BETT, Andrew
The present disclosure provides, among other things, a single-dose vaccine composition that includes a chitosan adjuvant and HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82, where the single-dose vaccine composition provides enhanced or comparable HPV vaccine response in comparison to a similar multiple-dose vaccine formulated without such chitosan adjuvant.

8.WO/2023/015145MULTIVALENT PAN-INFLUENZA VACCINE
WO - 09.02.2023
Clasificación Internacional A61K 39/145 Nº de solicitud PCT/US2022/074356 Solicitante NAJIT TECHNOLOGIES, INC. Inventor/a AMANNA, Ian J.
Provided are highly immunogenic multivalent pan-influenza vaccines, comprising a viral haemagglutinin (HA) protein, or HA1-containing portion thereof, of/corresponding to a virus strain from each of any three of, or from all four of component virus strain groups (H1-CVG1 - H1-CVG-4) as defined herein. Additionally provided are highly immunogenic multivalent pan-influenza vaccine, comprising a viral haemagglutinin (HA) protein, or HA1-containing portion thereof, of/corresponding to a virus strain from each of any three of, or from all four of component virus strain groups (H3-CVG-1 – H3-CVG-4) as defined herein. Further provided are highly immunogenic multivalent pan-influenza vaccine, comprising a viral haemagglutinin (HA) protein, or HA1-containing portion thereof, of/corresponding to a virus strain from each of two component virus strain groups Influenza B-CVG-1 and Influenza B-CVG-2 as defined herein. Yet further provided are methods for making the immunogenic vaccine compositions, and methods for eliciting an immune response, comprising administering the immunogenic vaccine compositions.

9.WO/2023/015277CLOSTRIDIUM CHAUVOEI VACCINE AND METHOD OF MAKING
WO - 09.02.2023
Clasificación Internacional A61K 39/08 Nº de solicitud PCT/US2022/074574 Solicitante ZOETIS SERVICES LLC Inventor/a CAMERON, Anthony James
The invention provides a vaccine against C chauvoei, the vaccine comprising a C chauvoei component and additional cctA protein. The methods of making and using said vaccine are also provided.

10.20230031287METHOD AND COMPOSITION FOR ENHANCING THE IMMUNE RESPONSE
US - 02.02.2023
Clasificación Internacional A61K 39/395 Nº de solicitud 17784891 Solicitante Northwestern University Inventor/a Pablo Penaloza-MacMaster
Disclosed herein are methods, compositions, and kits useful to enhance an immune response against an antigen and to improve vaccine efficacy. The disclosed methods, compositions, and kits may be utilized to improve vaccine immunogenicity and enhance immune protection following subsequent antigen

challenges. In some embodiments, the methods include co-administering a blocker of the IFN-I pathway with an antigen that is used as part of a vaccine, such as a viral vaccine.

11.WO/2023/008988MULTI-SUBUNIT SARS-COV-2 VACCINE
WO - 02.02.2023
Clasificación Internacional A61K 47/42 Nº de solicitud PCT/KZ2022/000010 Solicitante AUTONOMOUS ORGANIZATION OF EDUCATION "NAZARBAYEV UNIVERSITY" Inventor/a SYED, Ali
Claimed is a vaccine that combines evolutionarily conserved B and T cell epitopes of human coronaviruses, inter alia SARS-CoV-2, to provide both humoral and cellular immunity. The high degree of sequence similarity between SARS-CoV-2 and other human coronaviruses (HCoVs) opens possibilities for the development of vaccines that will provide protection against SARS-CoV-2 and its current and future new variants, together with cross protection against other HCoVs. A bioinformatics analysis identifying T cell and B cell epitopes originating from spike, membrane, nucleocapsid or envelope protein sequences has shown that said epitopes are evolutionarily conserved among the seven main HCoVs. The evolutionary conservation of these epitopes indicates that they may play a crucial role in viral fitness and thus are unlikely to mutate during viral replication, which makes them attractive candidates for a vaccine. The proposed vaccine construct comprises 12 T cell and 6 B cell epitopes that are conserved among HCoVs.

12.20230033133VACCINE CONJUGATES
US - 02.02.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17781826 Solicitante ULTIMOVACS AB Inventor/a Sara MANGSBO
The present invention relates to conjugates comprising B- and T-cell epitopes, vaccine compositions comprising said conjugates, their use in the prevention and treatment of cancer, such as prostate cancer, as well as kits comprising the conjugates and/or vaccine compositions. Also claimed are particular T-cell epitope-containing antigenic peptides, and nucleic acids encoding them and constructs and vectors comprising such nucleic acids.

13.4126022NEUARTIGER CORONAVIRUSIMPFSTOFF AUF SALMONELLENBASIS
EP - 08.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21714916 Solicitante NEC ONCOIMMUNITY AS Inventor/a LUBENAU HEINZ
The present invention relates to a DNA vaccine comprising a *Salmonella typhi* Ty21a strain comprising a DNA molecule comprising a eukaryotic expression cassette encoding at least a COVID-19 coronavirus (SARS-CoV-2) spike (S) protein or a portion thereof. In particular, the present invention relates to the DNA vaccine for use in the prevention and/ or the treatment of coronavirus disease 2019 (COVID-19) or a SARS-CoV-2 infection.

14.WO/2023/009171OPTIMIZED MULTIDIMENSIONAL BIOLOGICAL ACTIVITY OF POLY-ICLC WITH CONTROLLED COMPONENT SIZE AND FORMULATION
WO - 02.02.2023
Clasificación Internacional Nº de solicitud PCT/US2022/000015 Solicitante ONCOVIR, INC. Inventor/a SALAZAR, Andres
Poly-ICLC molecules and methods for producing them, including certain specific molecular weight molecules having improved activity in certain applications. These molecules may be incorporated in pharmaceutically or veterinary acceptable excipients and carriers for a number of uses in humans, in domestic animals and in wild animals. Such uses include (but are not limited to) prophylaxis pre-exposure prophylaxis, treatment and/or inflammatory symptom attenuation of viral or microbial infections; immunomodulating, vaccine adjuvant, antiviral, and/or anti-inflammatory effects mediated through

activation of the MDA5, TLR3 and other dsRNA dependent enzyme systems; antineoplastic effects either alone or when combined with therapeutic vaccine or other anticancer immunologic agents; preventive cancer vaccine adjuvant effects in patients at risk for cancer. The molecules may be of particular use against SARS-CoV-2 infection or a cytokine storm caused by a SARS-CoV-2 infection. While dosage may be adjusted depending on the specific target and the specific patient, the dose should be sufficient to activate the MDA5 and TLR3 enzyme systems in the patient. For humans the dose is between approximately 0.5 and 50 micrograms per kilogram body weight. The nature of the molecule does not demand any specific route of administration. Therefore, the route can be selected based on the specific target and the specific patient, and could include (but not be limited to) IM, SC, IT, IV or IN. Preferably, administration would comprise two or three repeated dose cycles spaced 24 to 96 hours apart. Depending on the target and the patient's response, dose cycles may be repeated 2 to 4 times per month.

15.4126023STABILISIERTE IMPFSTOFFZUSAMMENSETZUNGEN
EP - 08.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21714920 Solicitante JANSSEN VACCINES & PREVENTION BV Inventor/a RITSCHEL TINA
The present invention relates to vaccine composition comprising an immunologically effective amount of a viral fusion protein antigen, such as an RSV pre-fusion F protein, and a stabilizing amount of an antiviral compound, and to methods for preparing such vaccine compositions.

16.WO/2023/008815HER2 VACCINE COMPOSITION
WO - 02.02.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/KR2022/010597 Solicitante ASTON SCI. INC. Inventor/a JUNG, Hun
The present invention relates to an HER2-ICD DNA vaccine composition. The vaccine composition according to the present invention can effectively suppress the growth of gastric cancer without adverse side effects in a human gastric cancer cell line transplant animal model expressing HER2, and thus can be useful for treating gastric cancer.

17.WO/2023/011812A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS OF VARIOUS SEROTYPES
WO - 09.02.2023
Clasificación Internacional A61K 39/09 Nº de solicitud PCT/EP2022/067892 Solicitante INTERVET INTERNATIONAL B.V. Inventor/a JACOBS, Antonius, Arnoldus, Christiaan
The present invention pertains to a vaccine for protection against a pathogenic infection with Streptococcus suis, the vaccine comprising a whole IgM protease antigen of Streptococcus suis, the antigen comprising in its amino acid sequence less than four repeats, and a pharmaceutically acceptable carrier. The invention also pertains to this antigen for use in a method to protect a pig against such an infection, and to a method to protect such a pig.

18.4126024VERFAHREN ZUR BEREITSTELLUNG EINES VAKZINS GEGEN CORONAVIREN
EP - 08.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21715228 Solicitante WUERFEL WOLFGANG Inventor/a WÜRFEL WOLFGANG
Verfahren zur Bereitstellung eines Vakzins zur Immunisierung eines Individuums gegen eine durch einen Virus der Familie der Coronaviren verursachte Erkrankung sind offenbart. Das Verfahren umfasst ein Erhalten einer Probe des Virus; ein Inaktivieren des Virus, indem Nukleinsäuren mit genetischer Information des Virus zerstört oder entfernt werden; und ein Aufbereiten des inaktivierten Virus um ein darreichungsfähiges Vakzin zur Darreichung als inhalationsfähiges Aerosol oder als gurgelfähige Lösung zu erhalten. Dergestalt bereitgestellte Vakzine sowie deren Verwendung sind ebenfalls offenbart.

19.202300299 48MYCOPLASMA VACCINE COMPOSITION AND METHODS
US - 02.02.2023
Clasificación Internacional A61K 39/02 Nº de solicitud 17782447 Solicitante UNIVERSITY OF CONNECTICUT Inventor/a Steven M. Szczepanek
Described are vaccine compositions, methods of manufacture thereof, and methods of treating or preventing certain bacterial infections in humans and other mammals. For example, described are compositions comprising bacterial cell extracts that have undergone pretreatment such that lipid moieties have been cleaved from bacterial lipoproteins, thereby forming a vaccine composition that can stimulate a desired mammalian immune response while avoiding unwanted negative effects.

20.4127130VERFAHREN UND SYSTEME ZUR IMPFSTOFFHERSTELLUNG
EP - 08.02.2023
Clasificación Internacional C12M 3/00 Nº de solicitud 21779112 Solicitante ADVA BIOTECHNOLOGY LTD Inventor/a KARNIELI OHAD
A decentralized distributed vaccine manufacturing systems and methods thereof provide a cost effective, simple to operate, automated, and small-scale development and manufacturing process by automated computer-controlled devices. The devices and methods disclosed that allows localized vaccine development and manufacture. The bioreactor systems can include at least one bioreactor chamber, at least one reservoir, a plurality of sensors, and a fluid circuit. The operational methods disclosed herein are directed towards growing cells or tissue while measuring various parameters, and a controlled operation of the various parameters during the operation of the bioreactor systems.

21.20230034467Engineered HCV E2 Immunogens and Related Vaccine Compositions
US - 02.02.2023
Clasificación Internacional C07K 14/005 Nº de solicitud 17554907 Solicitante THE SCRIPPS RESEARCH INSTITUTE Inventor/a Linling He
The present invention provides novel engineered HCV E2 polypeptide immunogens and related vaccine compositions that display the engineered E2 polypeptides. The invention also provides methods of using such immunogens and vaccine compositions in various therapeutic applications, e.g., for preventing or treating HCV infections.

22.202347005704IMMUNOTHERAPY
IN - 03.02.2023
Clasificación Internacional A61K 35/15 Nº de solicitud 202347005704 Solicitante TCER ONCOLOGY AB Inventor/a GRÖNLUND, Hans
The present invention provides an in vitro method for the manufacture of a dendritic cell (DC) cancer vaccine, said method comprising the steps of: (i) providing a plurality of phagocytosable particles, wherein each phagocytosable particle comprises a core and an antigenic construct tightly associated to the core, wherein the antigenic construct comprises at least one epitope peptide having an amino acid sequence corresponding to an amino acid sequence of a part of a protein or peptide known or suspected to be expressed by a cancer cell in a subject; (ii) providing a sample of DCs; and (iii) contacting the sample of DCs with the plurality of phagocytosable particles in vitro and under conditions allowing for the phagocytosis of at least one phagocytosable particle by a DC. The present invention also provides a DC cancer vaccine produced by the method of the invention, and the use a DC cancer vaccine of the invention as a medicament and for the ex vivo expansion of anticancer T-cells.

23.20230041112METHOD OF COMPACT PEPTIDE VACCINES USING RESIDUE OPTIMIZATION
US - 09.02.2023
Clasificación Internacional C07K 14/74 Nº de solicitud 17863603 Solicitante Think Therapeutics, Inc. Inventor/a David Kenneth GIFFORD

A system for selecting an immunogenic peptide composition comprising a processor and a memory storing processor-executable instructions that, when executed by the processor, cause the processor to create a first peptide set by selecting a plurality of base peptides, wherein at least one peptide of the plurality of base peptides is associated with a disease, create a second peptide set by adding to the first peptide set a modified peptide, wherein the modified peptide comprises a substitution of at least one residue of a base peptide selected from the plurality of base peptides, and create a third peptide set by selecting a subset of the second peptide set, wherein the selected subset of the second peptide set has a predicted vaccine performance, wherein the predicted vaccine performance has a population coverage above a predetermined threshold, and wherein the subset comprises at least one peptide of the second peptide set.

24.WO/2023/012824SYNERGISM OF IMMUNOGENICITY VIA COMBINED PARENTAL AND MUCOSAL IMMUNIZATION AGAINST COVID-19
WO - 09.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/IN2022/050694 Solicitante BHARAT BIOTECH INTERNATIONAL LIMITED Inventor/a ELLA, Raches
The present invention discloses a system and method of generating robust immune response in mammals against SARS-CoV-2 antigen by administering two or more doses of same or different COVID-19 vaccines through same or different routes, wherein at least one vaccine is selected from a primary series of vaccines and at least one vaccine is selected from a secondary series of vaccines and wherein vaccines of primary and secondary series are administered through homologous or heterologous routes. The homologous route of administration comprises administering primary and secondary series of vaccines through same route. The heterologous route of administration comprises administering primary and secondary series vaccines through different routes. The system and method of the invention induces superior cross protection against SARS-CoV-2 variants including against Delta and Omicron variants.

25.4126029CORONAVIRUS-IMPFSTOFFZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG DAVON
EP - 08.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21719005 Solicitante UNIV LOYOLA CHICAGO Inventor/a BAKER SUSAN
The present disclosure provides compositions, for example vaccine compositions comprising live, attenuated coronavirus. The disclosure also provides methods of using coronavirus vaccines, including methods of treating and/or preventing coronavirus infections, and provides methods of preparing coronavirus vaccines.

26.202217063128METHODS TO GENERATE VACCINE COMPOSITIONS THAT PRIME HUMAN LEUKOCYTE ANTIGEN CLASS I RESTRICTED CD8 T-CELL RESPONSES AGAINST VIRAL NON-VIRION-INTEGRAL DERIVED EPITOPES
IN - 03.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 202217063128 Solicitante GENOVIE AB Inventor/a JARVIS, Reagan Micheal
Method for providing a vaccine composition capable of effectively inducing a systemic immune response and/or a localised immune response upon administration, wherein the composition comprises human leukocyte antigen class I (HLAI) -restricted epitopes selected from viral pathogen non-virion-integral proteins (non-VIP) and thus prime a CD8 T-cell response specifically directed against virally infected cells.

27.4126020MALARIAÜBERTRAGUNGSBLOCKIERENDE IMPFSTOFFE
EP - 08.02.2023

Clasificación Internacional A61K 39/015 Nº de solicitud 20927675 Solicitante PATH Inventor/a KING C RICHTER
Malaria transmission-blocking vaccines with good preservation stability and immunostimulatory action are provided. According the present invention, combination use of a pharmaceutical composition comprising (4E,8E,12E,16E,20E)-N-{2-[{4-[(2-amino-4-{[(3S)-1-hydroxyhexan-3-yl]amino}-6-methylpyrimidin-5-yl)methyl]benzyl}(methyl)amino]ethyl}-4,8,12,17,21,25-hexamethylhexacosa-4,8,12,16,20,24-hexaeneamide, or a pharmaceutically acceptable salt thereof, as a vaccine adjuvant with enhanced specific immune response against antigens and good preservation stability and a malaria vaccine with non-glycosylation, homogeneity, and biological activity allow for the provision of malaria transmission-blocking vaccines with good preservation stability and immunostimulatory action.

28.4129325TRANSPORTSYSTEM FÜR GANZZELLBESTANDTEILE UND ANWENDUNG DAVON
EP - 08.02.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 20927430 Solicitante SUZHOU ERSHENG BIOPHARMACEUTICAL CO LTD Inventor/a LIU MI
A transport system which utilizes nanoscale size or microscale size particles to deliver whole-cell constituent water soluble components and water insoluble components, and is used in an application for preparing a vaccine that prevents and treats cancer. The whole-cell constituent transport system consists of nanoscale size or microscale size particles and whole-cell constituents loaded onto said particles, the whole-cell constituents being whole-cell water soluble components and water insoluble components among cells or tissues. Among cell constituents, mutated proteins or polypeptides produced due to cancer are loaded onto the nanoparticles or micronparticles. Among whole-cell constituents, these substances, which possess immunogenicity and which are produced due to illness and mutation, can be used for the treatment and prevention of cancer, and can be used to prepare a vaccine for the prevention and/or treatment of cancer.

29.WO/2023/011810A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS OF VARIOUS SEROTYPES
WO - 09.02.2023
Clasificación Internacional A61K 39/09 Nº de solicitud PCT/EP2022/067890 Solicitante INTERVET INTERNATIONAL B.V. Inventor/a JACOBS, Antonius, Arnoldus, Christiaan
The present invention pertains to a vaccine comprising in combination an IgM protease antigen of Streptococcus suis serotype (7), a Streptococcus suis bacterin serotype (9), sequence type (16), and a pharmaceutically acceptable carrier. The invention also pertains to a combination of an IgM protease antigen of Streptococcus suis serotype (7), and a Streptococcus suis bacterin serotype (9), sequence type (16), for use in a method to protect a pig against a pathogenic infection with Streptococcus suis and to a method for protecting pigs against a pathogenic infection with Streptococcus suis, by administering to the pigs an IgM protease antigen of Streptococcus suis serotype (7) and a Streptococcus suis bacterin serotype (9), sequence type (16).

30.WO/2023/008814NUCLEIC ACID-BASED IMMUNOADJUVANT, AND VACCINE COMPOSITION COMPRISING SAME
WO - 02.02.2023
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/KR2022/010584 Solicitante SML BIOPHARM CO., LTD. Inventor/a NAM, Jae Hwan
Disclosed is an immunoadjuvant which is a nucleic acid molecule comprising: an expression control sequence including a nucleotide sequence having internal ribosomal entry site (IRES) activity against the encephalomyocarditis virus; and a coding region that is operably linked to the expression control sequence and encodes at least one peptide selected from among interferon-alpha (IFN-α), interferon-

gamma (IFN-γ), and granulocyte-macrophage colony-stimulating factor (GM-CSF), or a fragment thereof. Also disclosed is a vaccine composition comprising the immunoadjuvant.

31.4126025CORONAVIRUS-IMPFSTOFF
EP - 08.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21716828 Solicitante IMPERIAL COLLEGE INNOVATIONS LTD Inventor/a SHATTOCK ROBIN
The invention relates to vaccines, and in particular, to vaccines for preventing, treating or ameliorating coronavirus infections, such as severe acute respiratory syndrome coronavirus (SARS), SARS-CoV-2 and Middle East respiratory syndrome-related coronavirus (MERS). The invention is especially concerned with self-amplifying RNA replicons and genetic constructs or vectors encoding such RNA replicons, and their use in vaccine delivery for preventing infections of coronavirus. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.

32.4126037ATTENUIERTER POXVIRUSVEKTORBASIERTER IMPFSTOFF ZUM SCHUTZ GEGEN COVID-19
EP - 08.02.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 21779614 Solicitante SEMENTIS LTD Inventor/a PROW NATALIE
The present invention relates to a composition for raising an immune response in an animal which prevents or decreases the risk of a coronavirus infection and decreases severity of disease. In particular, the invention relates to vaccines and/or immunogenic compositions for raising an immune response in an animal which prevents or decreases the risk of the SARS-CoV-2 disease named COVID-19 by the World Health Organization. The composition comprises an attenuated poxvirus, and especially a vaccinia virus, wherein the attenuated poxvirus genome comprises a coronavirus SARS-CoV-2 nucleic acid sequence encoding the spike protein polypeptide and or the membrane protein polypeptide and or nucleocapsid protein polypeptide and or envelope protein polypeptide or an immunogenic or functional part of any of these.

33.WO/2023/006131ANTIGENO RECOMBINANTE PARA LA INDUCCION DE RESPUESTA INMUNE CONTRA EL VIRUS ZIKA
WO - 02.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/CU2022/050008 Solicitante CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA Inventor/a VALDÉS PRADO, Iris
Antígeno quimérico recombinante que comprende en su cadena polipeptídica un polipéptido correspondiente a los aminoácidos 2 al 104 de la proteína de la cápsida del virus zika o un polipéptido con una secuencia de aminoácidos con al menos 90% de identidad con dicha región de la proteína de la cápsida. Composición vacunal que comprende dicho antígeno quimérico recombinante y un adyuvante vacunal farmacéuticamente aceptable. Uso del antígeno quimérico recombinante que comprende en su cadena polipeptídica un polipéptido correspondiente a los aminoácidos 2 al 104 de la proteína de la cápsida o una secuencia de aminoácidos con al menos 90% de identidad con dicho segmento para la fabricación de un medicamento para la inducción de respuesta inmune contra el virus zika. La invención también revela un método para la inducción de respuesta inmune contra el virus zika, donde se administra dicho antígeno quimérico recombinante.

34.20230045688CUSTOMMUNE: A WEB TOOL FOR DESIGNING PERSONALIZED AND POPULATION-TARGETED PEPTIDE VACCINES
US - 09.02.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17901094 Solicitante Tarek Mohammad Inventor/a Tarek Mohammad

Computational prediction of immunogenic epitopes is a promising platform for designing therapeutic and preventive vaccines. A potential target is, for example, the human immunodeficiency virus (HIV-1) for which, despite decades of efforts, no vaccine is available. Indeed, due to the enormous variability of the virus, a single formulation effective against all or most HIV strains might not be achievable. Moreover, upon infecting host cells, HIV-1 can integrate in the host genome and form long lasting latent reservoirs that are not susceptible to common antiretroviral treatments. Therefore, a therapeutic vaccine designed to eliminate infected cells might represent a key component of strategies aimed at curing the infection. We herein introduce an automated algorithm to produce personalized and population-based vaccines.

35.20230031097MULTIVALENT HVT VECTOR VACCINE
US - 02.02.2023
Clasificación Internacional A61K 39/295 Nº de solicitud 17784838 Solicitante Intervet Inc. Inventor/a Martijn Alexander Langereis
The present invention describes a recombinant herpesvirus of turkeys (rHVT) that can be used as a vector vaccine for poultry against infection and disease from multiple poultry pathogens. Specifically the rHVT expresses an infectious bursal disease virus (IBDV) viral protein 2 (VP2) gene and a Newcastle disease virus (NDV) fusion (F) protein gene from a first and a second expression cassette inserted in the unique small (Us) region, and expresses an avian influenza vims (AIV) haemagglutinin (HA) gene from a third expression cassette inserted in the unique long (UL) region of the genome of said rHVT either between the UL40 and UL41 genes, or between the UL44 and UL45 genes. This rHVT can be used to vaccinate poultry against MDV, IBDV, NDV and AIV.

36.WO/2023/014245VACCINE COMPOSITION AGAINST COVID-19
WO - 09.02.2023
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/RU2022/050154 Solicitante FEDERALNOE GOSUDARSTVENNOE UNITARNOE PREDPRIIATIE "SANKT-PETERBURGSKII NAUCHNO-ISSLEDOVATELSKII INSTITUT VAKTSIN I SYVOROTOK I PREDPRIIATIE PO PROIZVODSTVU BAKTERIINYKH PREPARATOV" FEDERALNOGO MEDIKO-BIOLOGICHESKOGO AGENTSTVA Inventor/a BELOZEROVA, Natalia Sergeevna
The invention relates to biotechnology, immunology and virology. Proposed is a pharmaceutical composition for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2, said composition containing SARS-CoV-2 nucleocapsid protein N, having the amino acid sequence SEQ ID NO: 1, in an amount of 20 to 100 μg/ml, and pharmaceutically acceptable excipients selected from the group consisting of buffering agents, surfactants, an adjuvant and an isotonic agent in pharmaceutically acceptable amounts.

37.20230043887COMPOSITIONS AND METHODS RELATED TO SURGE-ASSOCIATED SARS-COV-2 MUTANTS
US - 09.02.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17750817 Solicitante Venkataramanan Soundararajan Inventor/a Venkataramanan Soundararajan
Compositions for use as a vaccine against SARS-CoV-2 infection are disclosed, which comprise either a polypeptide that comprises at least one surge-associated mutation (e.g., deletion) in its amino acid sequence or a nucleic acid (e.g., mRNA) that encodes said polypeptide. Also disclosed are formulations that include these compositions, antibodies or their antigen-biding fragments directed to these polypeptides, methods of making such antibodies, methods of vaccinating subjects against SARS-CoV-2 infection, and methods of selecting an antibody, convalescent plasma, or vaccine against SARS-CoV-2 infection.

38.WO/2023/010088NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-COV-2 SPIKE PROTEINS, AND MRNA VACCINE SPIKE PROTEINS
WO - 02.02.2023
Clasificación Internacional A61K 31/192 Nº de solicitud PCT/US2022/074271 Solicitante PONO LIFESTYLE COLORADO, LLC Inventor/a FLUGA, Mark
Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

39.WO/2023/011811A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS OF VARIOUS SEROTYPES
WO - 09.02.2023
Clasificación Internacional A61K 39/09 Nº de solicitud PCT/EP2022/067891 Solicitante INTERVET INTERNATIONAL B.V. Inventor/a JACOBS, Antonius, Arnoldus, Christiaan
The present invention pertains to a vaccine comprising in combination an IgM protease antigen of Streptococcus suis serotype 1, a Streptococcus suis bacterin serotype 9, sequence type 16, and a pharmaceutically acceptable carrier. The invention also pertains to a combination of an IgM protease antigen of Streptococcus suis serotype 1, and a Streptococcus suis bacterin serotype 9, sequence type 16, for use in a method to protect a pig against a pathogenic infection with Streptococcus suis and to a method for protecting pigs against a pathogenic infection with Streptococcus suis, by administering to the pigs an IgM protease antigen of Streptococcus suis serotype 1 and a Streptococcus suis bacterin serotype 9, sequence type 16.

40.WO/2023/015276ADENOVIRAL VECTOR-BASED VACCINE FOR EMERGING VIRUSES
WO - 09.02.2023
Clasificación Internacional C12N 15/861 Nº de solicitud PCT/US2022/074573 Solicitante THERAVAX, INC. Inventor/a MAGGINI, Norberto Julián
Provided herein is an adenoviral vector-based vaccine for inducing immune responses against viruses, such as coronaviruses. The adenoviral vector comprises a hybrid promoter, a nucleic acid sequence encoding a viral antigen operatively linked to the hybrid promoter; a post-transcriptional regulatory element; and a modified fiber protein. Also provided is a method of inducing an immune response against a coronavirus using a composition containing the adenoviral vector.

41.20230038577NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEINS
US - 09.02.2023
Clasificación Internacional A61K 36/73 Nº de solicitud 17815878 Solicitante Pono Lifestyle Colorado, LLC Inventor/a Mark A Fluga
Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins

and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.

42.WO/2023/008881EXPRESSION SYSTEM, AND NUCLEIC ACID-BASED PHARMACEUTICAL COMPOSITION COMPRISING SAME
WO - 02.02.2023
Clasificación Internacional C12N 15/63 Nº de solicitud PCT/KR2022/010978 Solicitante SML BIOPHARM CO., LTD. Inventor/a NAM, Jae Hwan
Disclosed is a nucleic acid molecule comprising: a translational regulatory element having a translation initiation activity; and a coding region, which is operably linked to the translational regulatory element and consists of a nucleotide encoding an immunogen of an influenza virus or a severe fever with thrombocytopenia syndrome virus (SFTSV), or a fragment thereof. The nucleic acid molecule or an expression system in which the nucleic acid molecule is inserted can be used in a pharmaceutical composition for treating or preventing influenza or SFTS, for example, that of an mRNA vaccine or a gene therapy platform.

43.20230038284CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINE
US - 09.02.2023
Clasificación Internacional A61K 39/215 Nº de solicitud 17471904 Solicitante Valneva Austria GmbH Inventor/a Andreas Meinke
Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

44.4125585VORRICHTUNG ZUR ENTNAHME VON KÖRPERFLÜSSIGKEITEN UND VERFAHREN ZUR VERWENDUNG DAVON
EP - 08.02.2023
Clasificación Internacional A61B 5/15 Nº de solicitud 21726964 Solicitante PRECI HEALTH SA Inventor/a VOUILLAMOZ LUCIEN
A fluid sampling device and a method is provided for collecting body fluid samples such as blood without the intervention of medically trained personnel. The body fluid sampling device having a sample containment chamber made of a material having a thermal inertia permitting the maintenance of sample temperature over a known period of time. Optionally an isolating cover or sleeve may slide in place by a mechanism triggered by thermal contraction of an element after the device has reached a sufficiently low temperature in a patients refrigerator. Associated methods are provided to ensure hermetic transport of the collected body fluid sample to an analysis lab. Also disclosed is a device and app combination for drug or vaccine injection, the app including means to allow for verification of the patient's ID and/or the particular device used. The device my be equipped with geo-localization and long-range communication capabilities.

45.WO/2023/007409EAST COAST FEVER ANTIGENIC CONSTRUCTS
WO - 02.02.2023
Clasificación Internacional A61K 39/018 Nº de solicitud PCT/IB2022/056970 Solicitante UNIVERSITY OF CAPE TOWN Inventor/a WILLIAMSON, Anna-Lise
This invention relates to a chimaeric BLV-Gag VLP which contains T. parva p67 and/or gp34 antigens on its surface, the invention also relates to vectors comprising nucleic acids encoding the BLV-Gag proteins; and T. parva p67 and/or T. parva gp34 proteins. The invention specifically relates to the chimaeric BLV-

Gag VLPs described herein, methods of producing the chimaeric BLV-Gag VLPs and pharmaceutical compositions either comprising the chimaeric BLV-Gag VLPs and/or vectors comprising the nucleic acids encoding the recombinant proteins which make up the chimaeric BLV-Gag VLPs. More specifically, the invention relates to a lumpy skin disease virus vaccine encoding the chimaeric BLV-Gag VLPs of the invention.

46.202311003226COMPOSITIONS AND METHODS FOR TREATMENT OF MUCORMYCOSIS
IN - 03.02.2023
Clasificación Internacional A61P / Nº de solicitud 202311003226 Solicitante Prof. (Dr.) Mayadhar Barik Inventor/a Prof. (Dr.) Mayadhar Barik
The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; The invention also provides a method of treating or preventing a fungal condition. The method includes administering to an individual having, or susceptible to having, a fungal condition a therapeutically effective amount of at least one iron chelating compound for a sufficient time to reduce the severity of a fungal condition, wherein the iron chelating compound comprises a non-siderophore or non-xenosiderophore relative to the fungal condition.

47.4129330ZUSAMMENSETZUNGEN UND VERFAHREN FÜR CHIMÄRE DENGUE-VIRUSKONSTRUKTE IN IMPFSTOFFEN
EP - 08.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 22182269 Solicitante TAKEDA VACCINES INC Inventor/a STINCHCOMB DAN T
Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.

48.20230042461NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS
US - 09.02.2023
Clasificación Internacional C07K 14/74 Nº de solicitud 17930914 Solicitante Immatics Biotechnologies GmbH Inventor/a Andrea MAHR
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

49.2022287621PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS
AU - 02.02.2023

Clasificación Internacional A61K 38/17 Nº de solicitud 2022287621 Solicitante Immatics Biotechnologies GmbH Inventor/a Mahr, Andrea
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor associated T-cell peptide epitopes, alone or in combination with other tumor associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

50.4126032UNIVERSELLER INFLUENZAIMPFSTOFF UNTER VERWENDUNG VON NUKLEOSID-MODULFELD-MRNA
EP - 08.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21780181 Solicitante UNIV PENNSYLVANIA Inventor/a PARDI NORBERT
The present invention relates to compositions and methods for inducing an immune response against influenza virus in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding at least one influenza virus antigen, such as a hemagglutinin antigen or a fragment thereof, neuraminidase antigen or a fragment thereof, nucleoprotein antigen or a fragment thereof, matrix protein 1 antigen or a fragment thereof, or matrix-2 ion channel antigen or a fragment thereof.

51.4130273HERSTELLUNG HETEROLOGER POLYPEPTIDE IN MIKROALGEN, EXTRAZELLULÄRE ALGENKÖRPER, ZUSAMMENSETZUNGEN UND VERFAHREN ZUR HERSTELLUNG SOWIE VERWENDUNGEN DAVON
EP - 08.02.2023
Clasificación Internacional C12N 15/44 Nº de solicitud 22181704 Solicitante SANOFI VACCINE TECH S A S Inventor/a BAYNE ANNE-CECILE V
The present invention relates to recombinant microalgal cells and their use in heterologous protein production, methods of production of heterologous polypeptides in microalgal extracellular bodies, microalgal extracellular bodies comprising heterologous polypeptides, and compositions comprising the same.

52.WO/2023/010074VACCINE COMPOSITIONS COMPRISING BRUCELLA STRAINS AND METHODS THEREOF
WO - 02.02.2023
Clasificación Internacional A61K 39/10 Nº de solicitud PCT/US2022/074252 Solicitante THE TEXAS A&M UNIVERSITY SYSTEM Inventor/a DE FIGEIREDO, Paul
The present disclosure provides pharmaceutical compositions comprising a live attenuated bacterial strain of Brucella melitensis, in particular a live attenuated bacterial strain of Brucella melitensis is Brucella melitensis 16M ΔvjbR (BmΔvjbR). Methods of utilizing the live attenuated bacterial strain of Brucella melitensis for treatment of a patient are also provided, including wherein the patient is in need of treatment for cancer, an autoimmune disorder, and/or an inflammatory disorder.

53.4130268CPG-ODN MIT IMMUNREGULATORISCHER FUNKTION UND VERWENDUNG DAVON
EP - 08.02.2023
Clasificación Internacional C12N 15/117 Nº de solicitud 21778756 Solicitante PARR BIOTECHNOLOGY HEBEI CO LTD Inventor/a WANG LIGONG
Provided are an immunomodulatory CpG ODN chemically modified by means of a structure as shown by general formula I and the use thereof. The CpG ODN has an immunostimulatory activity, can stimulate

the proliferation of B cells, and produce specific cytokines. The above-mentioned CpG ODN can be used as a vaccine adjuvant alone or in combination with other adjuvants to exert a synergistic effect, and can also be used in the preparation of drugs for preventing or treating tumors, infections, and allergies.

54.WO/2023/010177SELF-CLEAVING POLYPROTEINS AND USES THEREOF
WO - 09.02.2023
Clasificación Internacional A61K 39/00 Nº de solicitud PCT/AU2022/050844 Solicitante THE UNIVERSITY OF MELBOURNE Inventor/a TORRESI, Joseph
Disclosed herein are vaccine constructs for producing a virus-like particle (VLP) capable of raising an immune response to an immunogen, and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.

55.4126038IMPFSTOFFZUSAMMENSETZUNGEN ZUR BEHANDLUNG DES CORONAVIRUS
EP - 08.02.2023
Clasificación Internacional A61K 39/385 Nº de solicitud 21782275 Solicitante VARIATION BIOTECHNOLOGIES INC Inventor/a ANDERSON DAVID EVANDER
The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.

56.4125973NEOANTIGEN-IMPFSTOFFTHERAPIE
EP - 08.02.2023
Clasificación Internacional A61K 35/76 Nº de solicitud 20883770 Solicitante GRITSTONE BIO INC Inventor/a FERGUSON ANDREW
Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime/boost vaccination strategy.

57.4127190ERHÖHUNG DER PRODUKTION VON GENTRANSFERVEKTOREN AUF ADENOVIRUSBASIS
EP - 08.02.2023
Clasificación Internacional C12N 15/86 Nº de solicitud 21779319 Solicitante GREFFEX INC Inventor/a STAERZ UWE D
In one aspect, the embodiments disclosed herein relate to the production of fully-deleted adenovirus-based gene delivery vectors packaged without the use of an adenoviral helper virus, and more particularly in their use in the transfer of genes and the expression of proteins, vaccine development, and cell engineering. In another aspect, the production of adenoviral vectors deleted of all adenoviral genes is described that carry genes of interest with detrimental or toxic activities to eukaryotic cells.

58.20230029979BROADLY PROTECTIVE BOVINE PARAINFLUENZA 3 VIRUS AND BOVINE VIRAL DIARRHEA VIRUS VACCINE
US - 02.02.2023
Clasificación Internacional C12N 15/86 Nº de solicitud 17755359 Solicitante Kansas State University Research Foundation Inventor/a Waithaka Mwangi

A vector comprising a BPI3Vc backbone and at least one antigenic insert sequence from a pathogen other than BPI3V is provided. The vector is configured to provide protection against BPI3V as well as against the pathogen from which the insert sequence was obtained.

59.4126030MULTILAMELLARER RNA-NANOPARTIKELIMPFSTOFF GEGEN SARS-COV-2
EP - 08.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21720642 Solicitante UNIV FLORIDA Inventor/a SAYOUR ELIAS
The present disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, wherein the nanoparticle comprises RNA molecules encoding a SARS-CoV-2 protein. Methods of making such nanoparticles are further provided herein. Additionally, related cells, populations of cells, pharmaceutical compositions comprising the presently disclosed nanoparticles are provided. Methods of increasing an immune response against a tumor in a subject, methods of delivering RNA molecules to an intra-tumoral microenvironment, lymph node, and/or a reticuloendothelial organ in a subject, and methods of treating a subject with a disease are furthermore provided.

60.20230035702NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
US - 02.02.2023
Clasificación Internacional C07K 14/47 Nº de solicitud 17930891 Solicitante Immatics Biotechnologies GmbH Inventor/a Colette SONG
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

61.20230043654NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
US - 09.02.2023
Clasificación Internacional C07K 14/47 Nº de solicitud 17933298 Solicitante Immatics Biotechnologies GmbH Inventor/a Colette SONG
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

62.4126027CORONAVIRUS-IMPFSTOFF
EP - 08.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud 21717500 Solicitante PEPTC VACCINES LTD Inventor/a CSISZOVSZKI ZSOLT
The disclosure relates to polypeptides, vaccines and pharmaceutical compositions that find use in the prevention or treatment of Coronaviridae or SARS-CoV-2 infection. The disclosure also relates to methods of treating or preventing Coronaviridae or SARS-CoV-2 infection in a subject. The polypeptides

and vaccines comprise B cell epitopes and cytotoxic and helper T cell epitopes that are immunogenic in a high percentage of subjects in the human population.

63.20230042253NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
US - 09.02.2023
Clasificación Internacional C07K 14/47 Nº de solicitud 17934747 Solicitante Immatics Biotechnologies GmbH Inventor/a Colette SONG
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

64.20230040789NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS
US - 09.02.2023
Clasificación Internacional C07K 14/47 Nº de solicitud 17843733 Solicitante Immatics Biotechnologies GmbH Inventor/a Colette SONG
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

65.20230044692HUMAN CYTOMEGALOVIRUS VACCINE
US - 09.02.2023
Clasificación Internacional A61K 39/245 Nº de solicitud 17839401 Solicitante ModernaTX, Inc. Inventor/a Giuseppe Ciaramella
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

66.20230032643CR2 Binding Proteins and their use in Medical Therapy
US - 02.02.2023
Clasificación Internacional C07K 16/28 Nº de solicitud 17639096 Solicitante GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED Inventor/a James Matthew BAILEY
The present invention provides CR2 binding proteins which bind to human CR2, pharmaceutical compositions comprising said CR2 binding proteins and their use in the treatment or prevention of autoimmune and/or inflammatory conditions, infectious diseases and malignancies associated with the Epstein-Barr virus (EBV); and their use as vaccine adjuvants/antigen carriers.

67.20230034802Nant Cancer Vaccine
US - 02.02.2023
Clasificación Internacional A61K 39/00 Nº de solicitud 17880558 Solicitante NantCell, Inc. Inventor/a Patrick Soon-Shiong

Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.

68.WO/2023/011267CLOSTRIDIOIDES DIFFICILE SPECIFIC ANTIGEN PEPTIDE
WO - 09.02.2023
Clasificación Internacional C07K 14/33 Nº de solicitud PCT/CN2022/108065 Solicitante THE SECOND HOSPITAL OF HEBEI MEDICAL UNIVERSITY Inventor/a ZHAO, Jianhong
The present invention relates to a Clostridioides difficile specific antigen peptide, and in particular, a specific antigen peptide for a high-toxin-yield Clostridioides difficile RT027, comprising an amino acid sequence shown in SEQ ID No.1. By using a specific peptide fragment and a specific antibody thereof of the present invention, a new Clostridioides difficile high-toxin-yield strain detection reagent kit and a Clostridioides difficile vaccine can be developed, and the present invention has important significance on the detection and treatment of Clostridioides difficile high-toxin-yield strain infection.

69.202300417381H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US - 09.02.2023
Clasificación Internacional A61K 31/519 Nº de solicitud 17793174 Solicitante BRISTOL-MYERS SQUIBB COMPANY Inventor/a Yam B. POUDEL
Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

70.20230045719SYSTEMS AND METHODS FOR PRE-FILLED MEDICAL DELIVERY DEVICES
US - 09.02.2023
Clasificación Internacional A61M 5/28 Nº de solicitud 17960111 Solicitante Koska Family Limited Inventor/a Marc Andrew Koska
A pre-filled medical delivery assembly assembled and configured to allow delivery of a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) from a Blow-Fill-Seal (BFS) vial to a patient. The delivery assembly generally includes a modular design consisting of separately constructed components cooperatively arranged and coupled to one another.

71.20230043128MULTIVALENT INFLUENZA VACCINES
US - 09.02.2023
Clasificación Internacional A61K 39/145 Nº de solicitud 17843445 Solicitante SANOFI Inventor/a Tim ALEFANTIS
Provided are octavalent influenza vaccine compositions comprising eight mRNA, each mRNA comprising an open reading frame encoding a different influenza antigen. Also provided are lipid nanoparticles (LNPs) for delivering said mRNA.

72.WO/2023/012331VACCINE FOR EQUINE HERPESVIRUS
WO - 09.02.2023
Clasificación Internacional A61K 39/12 Nº de solicitud PCT/EP2022/072079 Solicitante INTERVET INTERNATIONAL B.V. Inventor/a REEMERS, Sylvia
The present invention is directed to an immunogenic composition comprising an antigen of Equine Herpes Virus type 1 (EHV-1) and an antigen of Equine Herpes Virus type 4 (EHV-4). The immunogenic composition reduces viremia and other clinical reactions in horses infected with EHV-1 when compared to non-treated horses but also when compared to EHV-1 vaccinated horses.

73.WO/2023/010176VACCINE CONSTRUCT AND USES THEREOF

WO - 09.02.2023
Clasificación Internacional C07K 14/005 Nº de solicitud PCT/AU2022/050843 Solicitante THE UNIVERSITY OF MELBOURNE Inventor/a TORESSI, Joseph
Disclosed herein are nucleic acid constructs for producing a virus-like particle (VLP) capable of raising an immune response against severe acute respiratory syndrome coronavirus (SARS-CoV), and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Irina Crespo Molina icrespo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY EDICIONES